University of Waterloo
REPORT FOR
MASTER OF PHARMACY IN ADVANCED PHARMACY PRACTICE
Submitted to the Ontario Universities Council on Quality Assurance
VOLUME II - CURRICULA VITAE OF THE FACULTY
MAY 2018
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
[This page left intentionally blank]
Page 2 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Contents ALSABBAGH, M. Wasem ...... 5 BARRETT, Brett ...... 11 BEAZELY, Michael, A...... 14 BLAY, Jonathan ...... 20 CHANG, Feng ...... 33 COULSTON, Barb ...... 50 DHAMI, Rita ...... 54 EDGINTON, Andrea N...... 61 EDWARDS, David Jardine ...... 80 FOLDVARI, Marianna...... 84 GAMBLE, John-Michael ...... 106 GRINDROD, Kelly…………………………………………………………………………………………………………………….129 HO, Emmanuel ...... 143 HOULE, Sherilyn ...... 158 JOSEPH, Jamie William ...... 168 MAXWELL, Colleen J...... 180 MCFARLANE, Thomas ...... 211 NAGGE, Jeffrey ...... 222 NAKHLA, Nardine ...... 226 PATEL, Tejal ...... 242 NEKKAR, Praveen Rao ...... 258 RICHARD, Cynthia ...... 271 SIAN, Preet ...... 276 SLAVCEV, Roderick ...... 279 WAITE, Nancy Madeline ...... 287 WETTIG, Shawn David ...... 312 WONG, William W.L...... 324
Page 3 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
[This page left intentionally blank]
Page 4 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
ALSABBAGH, M. Wasem Assistant Professor, tenure track Member of the Graduate Faculty: yes b) DEGREES:
PhD, Pharmacy, University of Saskatchewan, Canada, 2015 BSc, Pharmacy and Pharmaceutical Chemistry, Damascus University, Syria, 2000 c) EMPLOYMENT HISTORY:
2015- Assistant Professor, School of Pharmacy, University of Waterloo d) HONOURS:
None e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2018 DSECT: scholarship application review committee 2018 CARDIOVASCULAR PHARMACISTS HEALTH COACHING PROGRAM/Ontario Pharmacists Association 2018 Review of abstracts for the 34th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management 2018 DSECT OSKTE assessment committee 2017 DSECT: scholarship application review committee 2017 DSECT OSKTE assessment committee 2017 Review of MS #24108 manuscript Title: Incidence of acute cardiovascular event after acute exacerbation of COPD. Journal: Journal of General Internal Medicine 2017 Review of CJD_2017_369 manuscript Title: Healthcare utilization and costs following initiation of metformin therapy: a descriptive cohort study. Journal: Canadian Journal of Diabetes 2017 Review of CPJ-# 17-8 manuscript Title: A Provincial Comparison of Pharmacist Prescribing in Canada Using Alberta’s Model As The Reference Point. Journal: Canadian Pharmacists Journal 2015 Member, Board, Canadian Association for Population Therapeutics 2015 Member, Alberta Strategy for Patient-Oriented Research (SPOR) Graduate Studentship Review Committee
Page 5 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
f) GRADUATE SUPERVISIONS:
Completed: 1 MSc, 0 PhD In Progress: 0 MSc, 0 PhD
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Razan Amoud MSc (2015-2018 ) The impact of affordability on Completed non-adherence to medications of chronic diseases g) GRADUATE COURSES:
601 MSc Thesis Proposal courses 616 PhD Thesis Proposal courses h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Role 2018- CIHR C $359,550 Research Principal Investigator 2020 2018 CSHP F $13,400 Research Co-investigator 2015- CIHR C $1,374,000 Research Co-investigator 2020 *Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** 2015 UW-Starter S $110,000 Research Fund Waterloo’s O $10,000 Research Chronic Disease Prevention Initiative Seed Funding *Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc.
Page 6 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 0 - refereed journal articles ...... 15 - refereed conference proceedings...... 9 - presentations at conferences ...... 5 - technical reports ...... 0 - invited/keynote addresses ...... 0 - others (workshops presented) ...... 0
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Journals:
a) Alsabbagh MW, Wenger L, Raman-Wilms L, Schneider E, Church D, Waite N. Pharmacists as immunizers, their pharmacies and immunization services: A survey of Ontario community pharmacists. Accepted CPJ 2018.
b) Alsabbagh MW, Church D, Wenger L, Papastergiou J, Raman-Wilms L, Schneider E, Waite N. Community pharmacy patrons’ perspective of pharmacist administration of influenza vaccinations. In progress. Res Social Adm Pharm (RSAP_2017_580).
c) Alsabbagh MW, Eurich D, Lix LM, Wilson TW, Blackburn DF. Does the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort study. BMC Med Res Methodol. 2017 Apr 20;17(1):66. doi: 10.1186/s12874-017-0339-z.
d) Kosar L, Alsabbagh MW, Lu X, Lix L, Shevchuk Y, Teare G, Champagne A, Blackburn DF. Self-monitoring Blood Glucose Test Strip Utilization in Saskatchewan. Can J Diabetes. 2017 May 9. pii: S1499-2671(16)30818-8. doi: 10.1016/j.jcjd.2017.01.004. [Epub ahead of print]
e) Grindrod K, Alsabbagh MW. Managing medications during Ramadan fasting. Can Pharm J (Ott). 2017 Apr 3;150(3):146-149. doi: 10.1177/1715163517700840. eCollection 2017 May-Jun.
Page 7 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
f) Barbara Farrell, Lisa Richardson, Lalitha Raman-Wilms, David de Launay, WM Wasem Alsabbagh, James Conklin. Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines. Res Social Adm Pharm. 2017 Jan 28. pii: S1551-7411(17)30055-4. doi: 10.1016/j.sapharm.2017.01.003
g) Ziegler B, Alsabbagh MW, Houle S, Wenger L, Church D, Waite N. Protecting our patients by protecting ourselves: An analysis of the personal influenza immunization rate of Ontario community pharmacists. Can Pharm J. 2016 Jul;149(4):246-55. doi: 10.1177/1715163516651630.
h) Alsabbagh MW, Lix LM, Eurich D, Wilson TW, Blackburn DF. Multiple versus single- domain measurements of socio-economic status (SES) for predicting non-adherence to statin medications: an observational population-based cohort study. Med Care. 2016 Feb;54(2):195-204.
i) Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh MW, Hemmelgarn B, Dormuth CR, Ernst P; and the Canadian Network of Observational Drug Effect Studies (CNODES). Investigators. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis. Clin J Am Soc Nephrol. 2015 Jul 31. pii: CJN.11271114. [Epub ahead of print]
j) Alsabbagh MW, Mansell K, Lix LM, Teare G, Shevchuk Y, Lu X, Champagne A, Blackburn DF.Trends in prevalence, incidence and pharmacologic management of diabetes among seniors newly admitted to long-term care facilities in Saskatchewan between 2003 and 2011 CJD. 2015 Apr;39(2):138-45.
k) Alsabbagh MW, Lemstra M, Eurich D, Lix LM, Wilson TW, Watson E, Blackburn DF. Socioeconomic status and nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Value Health. 2014;17(2):288-296.
l) Lemstra M, Alsabbagh MW. Proportion and risk indicators of nonadherence to antihypertensive therapy: a meta-analysis. Patient Prefer Adherence. 2014 Feb 13;8:211- 8.
m) Alsabbagh MW, Dagenais J, Yan L, Lu X, Lix LM, Shevchuk Y, Teare GF, Blackburn DF. Use and misuse of ezetimibe: analysis of use and cost in Saskatchewan, a Canadian jurisdiction with broad access. Can J Cardiol. 2014 Feb;30(2):237-43.
n) Lemstra M, Alsabbagh MW, Rajakumar RJ, Rogers MR, Blackburn DF. Neighbourhood Income and Cardiac Rehabilitation Access as Determinants of Non-Attendance and Non- Completion. Can J Cardiol. 2013 Dec;29(12):1599-603. Page 8 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
o) Alsabbagh MW, Lemstra M, Eurich D, Wilson TW, Robertson P, Blackburn DF. Pharmacist intervention in cardiac rehabilitation: a randomized controlled trial. J Cardiopulm Rehabil Prev. 2012 Nov-Dec;32(6):394-9
Papers in Refereed Conference Proceedings
1. Amoud R*, Grindrod K, Cooke M, Alsabbagh W. The Impact of Prescription Medication Cost Coverage on Optimal Adherence to Hypertension and Diabetes Medications: A Repeated Cross-Sectional Population-Based Study. J Popul Ther Clin Pharmacol Vol 24(3):e51-e78; October 26, 2017. (Poster: National)
2. Waite N, Alsabbagh MW, Cadarette S, Cook K, Cook M, Elliott S, Johnson P, Milne E. Mapping Health Geography Data and Pharmacy Access: What is the degree to which the geographic distribution of community pharmacies is aligned with the residential concentrations of vulnerable populations? 2016 OPEN Summit. Toronto, Ontario. January 20, 2016 (Oral: provincial)
3. Farrell B, Sunstrum L, Conklin J, Raman-Wilms L, Irving H, de Launay D, Alsabbagh MW. The Impact of a PPI deprescribing guideline on clinician self-efficacy for deprescribing tasks. 2016 OPEN Summit. Toronto, Ontario. January 20, 2016 (Poster: provincial)
4. Alsabbagh MW, Eurich D, Lix LM, Wilson TW, Blackburn DF. Does The Association Between Adherence To Statin Medications And Mortality Depend On The Measurement Approach? A Retrospective Cohort Study. The American Heart Association's Scientific Sessions November, 2015 in Orlando, Florida, USA.
5. Alsabbagh MW, Wenger L, Papastergiou J, Pojskic N, Raman-Wilms L, Schneider E, Waite N. Facilitators and barriers of Ontario pharmacists as providers of influenza vaccination: Surveys of pharmacists and patrons of community pharmacies. Canadian Pharmacists Association conference Aug 2015 in Ottawa, ON.
6. Alsabbagh MW, Wenger L, Papastergiou J, Pojskic N, Raman-Wilms L, Schneider E, Waite N. Effect of age on Ontario community pharmacy patrons’ perspective of pharmacists as influenza immunizers. Canadian pharmacists association conference Aug 2015 in Ottawa, ON.
7. Mansell K, Alsabbagh MW, Lu X, Lix LM, Teare G, Shevchuk Y, Blackburn DF. Incidence and Prevalence of Diabetes in Residents of Saskatchewan Long-term Care Facilities between 2003 and 2011. Canadian Diabetes Association (CDA) 2013. Montreal, QC.
Page 9 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
8. Mansell K, Alsabbagh MW, Lu X , Lix LM, Shevchuk Y, Teare G, Blackburn DF Pharmacologic Management of Diabetes among Seniors Newly Admitted to Long-term Care Facilities in Saskatchewan. Canadian Diabetes Association (CDA) 2013. Montreal, QC.
9. Alsabbagh MW, Lamb D, Blackburn DF. Survival with adherence to beta-blocker medications in heart failure: the 'unhealthy-adherer' effect? J Popul Ther Clin Pharmacol Vol 19(2):e113-e149; May 1, 2012.
DATE: April 2018
Page 10 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
BARRETT, Brett Adjunct Clinical Assistant Professor, Contract Member of the Graduate Faculty: no b) DEGREES:
Bachelor of Science in Pharmacy, University of Toronto, Toronto ON, 2003 Bachelor of Science (Honours), Queen’s University, Kingston ON, 1999 c) EMPLOYMENT HISTORY:
2012 – present Adjunct Clinical Assistant Professor, University of Waterloo School of Pharmacy, Waterloo ON 2012 – present Infectious Disease Pharmacist, Grand River Hospital, Kitchener ON 2003 – 2011 Clinical Pharmacist, Grand River Hospital, Kitchener ON d) HONOURS: e) SCHOLARLY AND PROFESSIONAL ACTIVITIES: past 7 years only (eg. executive and editorial positions but not memberships in societies)
2016 National Delegate, Canadian Society of Hospital Pharmacists (Ontario Branch) f) GRADUATE SUPERVISIONS:
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion: g) UNDERGRADUATE COURSES: past 7 years, by year
Course Coordinator 2012 – present PHARM 221: Integrated Patient Focused Care 2 2014 – 2017 PHARM 473: Advanced Infectious Disease 2018 PHARM 372: Pediatric Pharmacy
Guest Lecturer 2012 – present PHARM 220: Introduction to the Profession of Pharmacy 2012 – present PHARM 491: Seminars in Pharmacy 3 2013 – present PHARM 422: Integrated Patient Focused Care 9 2015 – present PHARM 229: Professional Practice 4 Page 11 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015 – present PHARM 320: Integrated Patient Focused Care 5 2016 – present PHARM 329: Professional Practice 5 2016 – present PHARM 472: Community Practice in a Changing Environment 2017 – present PHARM 475: Advanced Pharmacotherapeutics in the Ambulatory Care Setting 2013 – 2014 PHARM 367: Pediatric Pharmacy 2013 – 2014 PHARM 420: Integrated Patient Focused Care 7 2012 – 2014 PHARM 320: Integrated Patient Focused Care 6 2012 – 2013 PHARM 220: Integrated Patient Focused Care 1 2012 – 2013 PHARM 232: Medical Microbiology
External Lectures 2016 – present McMaster University Michael G. DeGroote School of Medicine (Waterloo Regional Campus), Kitchener ON h) 1. EXTERNAL RESEARCH FUNDING: past 7 years only, by year, indicating source (granting councils, industry, government, foundations, other); amount; principal investigator; purpose (research, travel, publications, etc...)
Year Source Type* Amount per year Purpose**
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING: This includes university funds, SSHRC minor grants awarded through the University, etc.] Year Source Type* Amount per year Purpose**
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc.
i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... - edited book and monographs ...... - chapters in books and monographs ...... - refereed journal articles ...... - refereed conference proceedings...... - presentations at conferences ...... 7 - technical reports ...... - invited/keynote addresses ...... Page 12 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
- others (workshops presented) ...... 2
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Presentations: 1. Optimizing Antibiotic Prescribing. Communication presented at Update on Geriatric Problems, Freeport Physicians’ Education Committee (Grand River Hospital). Kitchener, ON. 2 May 2012. 2. Sexually Transmitted Infections: An Update. Communication presented at Primary Care Today, University of Toronto. Toronto, ON. 8 May 2014. 3. Rational Use of Antibiotics in Primary Care. Communication presented at Pharmacy Learning and Leadership Symposium, St. Joseph’s Hospital. London, ON. 21 August 2015. 4. Antibiotic Resistance. Communication presented at Public Lecture, University of Waterloo School of Pharmacy. Kitchener, ON. 12 November 2015. 5. Resistance is Not Futile: How You Can Decrease Antimicrobial Resistance. Communication presented at Regional Hospital Pharmacy Technician Conference, Grand River Hospital. Kitchener, ON. 25 March 2017 6. Antimicrobial Stewardship: Opportunity is Everywhere. Communication presented at Fall Education Day, Canadian Society of Hospital Pharmacists. Fredericton, NB. 30 September 2017.
Others: 1. [5in5 app]. (2016, May 9). Antibiotic Stewardship. [Video File]. Retrieved from https://www.youtube.com/watch?v=86N6iu29ynI. 2. Antimicrobial Stewardship in Primary Care. Online Continuing Educational Program at University of Waterloo School of Pharmacy. (in progress)
DATE: May 2018
Page 13 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
BEAZELY, Michael, A. Associate Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
PhD, Pharmacology, Purdue University, 2004 BSP, Pharmacy, University of Saskatchewan, 2000 c) EMPLOYMENT HISTORY:
2015- Associate Professor,* School of Pharmacy, University of Waterloo 2015- Associate Director, Curriculum,* School of Pharmacy, University of Waterloo 2008-2015 Assistant Professor, School of Pharmacy, University of Waterloo 2008-2009 Consultant, Health Professions Regulatory Advisory Council (HPRAC), Non-Physician Prescriber Project 2006-2007 Lecturer, Faculty of Pharmacy, University of Toronto 2006-2008 Adjunct Assistant Professor, School of Pharmacy, University of Waterloo 2004- 2008 Postdoctoral Fellow, Department of Physiology, University of Toronto d) HONOURS:
2016 Best Community Outreach Initiative, Canadian Council for Advancement of Education 2016 Excellent in Science Teaching Award, Faculty of Science 2014 Outstanding Faculty Mentor, Graduate Program 2014 Alumni of Influence, University of Saskatchewan, College of Pharmacy and Nutrition (named one of the top 100 influential Pharmacy alumni) 2006, 2007 Teacher of the Year, Faculty of Pharmacy, University of Toronto e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
Seminars
“Street fentanls: what pharmacists need to know”, Canadian Pharmacists Association Webinar, 2017 Page 14 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
“Opioids, overdose, and naloxone, what parents and caregivers need to know” School of Pharmacy, University of Waterloo, 2017
“Opioid, overdose, and naloxone in community pharmacy practice”, McKesson Showcase, Toronto, 2017
“Opioid overdose and naloxone in primary care”, Primed Conference, Toronto, 2017
“Opioid overdose, naloxone, and opioid prescribing”, Expert Witness in Drug Trials Conference, Toronto, 2017
“The Opioid Crisis”, School of Pharmacy, Univresity of Waterloo, Public Lecture, 2016
“An emerging role for 5-HT7 receptors as a therapeutic target: focus on growth factor receptor cross-talk”, Department of Psychology, Brock University, 2016
“Opioid Overdose and Naloxone”, Ontario Association of Chiefs of Police Conference, Dec 2016
“Opioid Overdose and Fentanyls”, Waterloo Region Fentanyl Symposium, Dec 2016
“Indirect activation of receptor tyrosine kinases (RTKs) in neurodegeneration and psychiatric disease” Soochow University, Suzhou, China, 2016
“Heterologous Desensitization of GPCR-RTK Transactivation” Discovery on Target, Sept 2015, Boston
“Common contaminants of street drugs” Anti-counterfiet drugs week (Canadian Association for Pharmacy Students and Interns) Sept 2015
“A systematic approach to understanding GPCR transactivation of receptor tyrosine kinases” Department of Physiology and Pharmacology, Western University, London ON, Sept 2014
“Research Showcase” Ontario Health Human Resources Research Network (OHHRRN) (with Rishma Walji), Toronto, ON, April 2013
“Pharmacy in Focus – A snapshot” School of Pharmacy Seminar Series, 2013
“Hot Topics in Drug Safety and Effectiveness (with Azita Kouchmeshky) DSECT Conference, Hamilton, ON, April 2013 Page 15 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Online Q&A, “Policy Analysis of Scope of Practice Changes for Pharmacists and Optometrists and Regulation of Pharmacy Technicians”, OHHRRN “Fireside Chat”, 2012
UW Pharmacy Continuing Professional Development Program - Recommendations on Chiropodist competencies for the administration of oxygen and nitrous oxide, ongoing. - Assessment of applications for additions to the parenteral therapy list of approved substances, Board of Directors of Drugless Therapy - Naturopathy Assessment of Pharmacotherapy Competence for Ontario Chiropody Graduates, 2010 - International Optometric Bridging Program, Pharmacology Course, 2010 f) GRADUATE SUPERVISION:
Completed: 4 MSc, 2 PhD In progress: 2 PhD
*PhD students supervised with Jon Heikkila, UW Department of Biology
NAME OF STUDENT supervised within the past seven years, title of thesis of project, year of first registration and year of completion S:
Name of Student Type (years of Title of Thesis or Project Status supervision) Hui (Lucy) Liu MSc (2010-12) Mechanisms of neuroprotection by Completed neurotrophic factors in Alzheimer’s disease Golam Saffi MSc (2011-2013) Inhibition of Growth Factor Signaling by Completed Beta-amyloid (co-supervisor) Azita Kouchmesky MSc (2012-2014) Systematic Examination of Ligand- Completed induced and Transactivated growth factor activity Nawaz Ahmed Msc (2013-2015) Acute 5-HT7 receptor-mediated Completed Neuroprotection Against Excitotoxicity Maryam Vasefi PhD (2009-2014) Regulation of Neuronal PDGF Receptor Completed Expression by Serotonin Type 7 Receptors Jeff Kruk PhD (2010-2014) Regulation of the Neuronal Completed Cytoskeleton in Developed Page 16 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Neurons by Abl kinase Nyasha Gondora PhD (2014-) Receptor Tyrosine Kinase In Progress Transactivation in Models of Early-life Stress Morgan Robinson PhD (2017-) Specific and non-specific interactions In Progress between amyloid beta and the neuronal cell membrane g) GRADUATE COURSES:
Pharm 610, Topics in Drug Development, 2012-2015 Pharm 608A, Special Topics Course: Neuroscience, 2012-present h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type Amount Purpose 2013 NSERC Discovery C $30,000/yr Research 2012 CFI O $79,000 + $2,000/yr for 5 yrs Research 2011 CIHR Catalyst (Principal C $50,000 Research Investigator: Z. Leonenko) 2010 NSERC Discovery C $28,000 Research
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose 2008 UW- Starter Fund O $300,000 Research 2010 UW – Incentive Funds O $8,000 Research 2012 UW – Graduate Research Funds O $24,000 Research
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories - books and monographs ...... 0
Page 17 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
- edited book and monographs ...... 0 - chapters in books and monographs ...... 2 - refereed journal articles ...... 32 - refereed conference proceedings...... 0 - presentations at conferences ...... 1 - technical reports ...... 10 - invited/keynote addresses ...... 0 - others (workshops presented) ...... 0
2) Details on above for past seven years, same categories
Chapters in Books
1. Kruk JS, Kouchmeshky A, Grimburg N, Rezkella M, Beazely MA. Transactivation of receptor tyrosine kinases by dopamine receptors. In: Neuromethods, Dopamine Receptor Technologies. Tiberi M, ed. Humana Press, 2014
Papers in Refereed Journals
1. Liu H, Saffi GT, Vasefi MS, Choi Y, Kruk JS, Ahmed N, Gondora N, Mielke J, Leonenko Z, Beazely MA. Amyloid-beta inhibits PDGFbeta receptor activation and prevents PDGF-BB- induced neuroprotection. Curr Alzheimer Res. 2018 Epub Jan 9 2018
2. Grindrod K and Beazely MA. Fitting Naloxone into community practice. Can Pharm J (Ott). 2016 Nov;149(6):329-331. This article was adapted and reproduced in the Spanish pharmacy journal el Farmaceutico
3. Osman W, Mohamed T, Sit VM, Vasefi SM, Beazely MA, Rao PP. Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9- amines as a mutlitargeting agents to treat Alzheimer’s disease. Chem Biol Drug Des. 2016;88(5):710-23.
4. Bradley RM, Mardian EB, Marvyn PM, Vasefi MS, Beazely MA, Mielke JG, Duncan RE. Data on acylglycerophosphate acyltransferase 4 (AGPAT4) during murine embryogenesis and in embryo-derived cultured primary neurons and glia. Data Brief 2015;6:28-32
5. Kruk JS, Vasefi SM, Gondora N, Ahmed N, Heikkila JJ, Beazely MA. Fluoxetine-induced transactivation of the platelet-derived growth factor type beta receptor reveals a novel heterologous desensitization process. Mol Cell Neurosci 2015;65:45-51
6. Samarajeewa S, Goldemann L, Khanderia C, Vasefi SM, Ahmed N, Gondora N, Mielke J, Beazely MA. 5-HT7 receptor activation promotes an increase in TrkB receptor expression Page 18 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
and phosphorylation. Front Behav Neurosci 2014;8:391. Special issue: “Further Understanding of Serotonin 7 Receptors’ Neuro-Psycho-Pharmacology”.
7. Alqawlaq S, Sivak JM, Huzil JT, Ivanova MV, Flanagan JG, Beazely MA, Foldvari M. Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: Towards non-invasive glaucoma gene therapy. Nanomedicine 2014;10:1637-47.
8. Kruk JS, Vasefi MS, Heikkila JJ, Beazely MA. Reactive oxygen species are required for 5-HT induced transactivation of the neuronal platelet-derived growth factor and TrkB receptors, but not for ERK1/2 activation. PLoS One 2013;8:e77027.
9. Vasefi SM, Yang K, Li J, Kruk JS, Heikkila JJ, Jackson MF, MacDonald JF, Beazely MA. Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons. Mol Brain 2013;6:24.
10. Vasefi SM, Kruk JS, Heikkila JJ, Beazely MA. 5-HT7 receptor neuroprotection against NMDA-induced excitotoxicity is PDGFβ receptor-dependent. J Neurochem 2013;125:26- 36
11. Kruk JS, Vasefi SM, Liu H, Heikkila JJ, Beazely MA. 5-HT(1A) receptors transactivated the platelet-derived growth factor receptor type beta in neuronal cells. Cell Signal 2013;25:133-43
12. Tarek Mohamed, Jacky C. K. Yeung, Maryam S. Vasefi, Michael A. Beazely and Praveen P. N. Rao. Development and Evaluation of Multifunctional Agents for Potential Treatment of Alzheimer’s Disease: Application to a Pyrimidine-2,4-Diamine Template. Bioorg and Med Chem Lett 2012;22:4707-12
13. Vasefi SM, Kruk JS, Liu H, Heikkila JJ, Beazely MA. Activation of 5-HT7 receptors increases neuronal platelet-derived growth factor beta receptor expression. Neurosci Lett 2012;511:65-9
DATE: April 2018
Page 19 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
BLAY, Jonathan Full Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
PhD, Cell Biology, University of Cambridge, UK, 1985 BSc, Medical Sciences, University of Bradford, UK, 1981 ONC, Medical Laboratory Subjects, College of Technology, Bromley, UK, 1977 c) EMPLOYMENT HISTORY:
2012- Professor, School of Pharmacy, University of Waterloo. 2012- Adjunct Professor of Pathology, Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia. 2012-15 Associate Director for Research and Graduate Studies, School of Pharmacy, University of Waterloo. 2009-12 Scientific Director, Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia. 2008-12 Professor of Pathology (cross-appointment), Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia. 2008-12 Professor of Biology (cross-appointment), Department of Biology, Faculty of Science, Dalhousie University, Halifax, Nova Scotia. 2004-12 Professor of Pharmacology, Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia. 2003-04 Acting Assistant Dean, Research (Student Programs and Research Promotion), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia. 1997-04 Associate Professor of Pharmacology, Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia. 1989- 97 Assistant Professor of Pharmacology, Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia. 1985-89 Alberta Heritage Postdoctoral Research Fellow, Department of Pharmacology & Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta. 1981-85 Postgraduate Research Student, Institute of Animal Physiology and Genetics Research; and University of Cambridge, Cambridge, United Kingdom. d) HONOURS: Page 20 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2017 Invited/elected as an overseas Fellow of the Royal Society of Medicine (FRSM). 2016 Chartered Scientist of the Science Council (UK) 2015 Fellow of the Royal Society of Biology (FRSB) 2012 Honorary (Life) Membership of the Beatrice Hunter Cancer Research Institute “In recognition of his long-standing commitment and strong contributions to the goals of the Institute” 2012 Beatrice Hunter Cancer Research Institute (BHCRI) Award from the Board “In grateful recognition of your outstanding leadership and dedication during the initial years of BHCRI. For your diligent efforts toward establishment of a framework for the Institute and insightful guidance for the evolution of future collaborative research in Atlantic Canada” 2010 Canadian Research Knowledge Network (CRKN) Inaugural Ron MacDonald Distinguished Service Award. “The award is intended to recognize an individual within a member institution who has demonstrated vision, dedication and outstanding service in building bridges and collaboration to advance knowledge infrastructure in Canada” 2007 Dalhousie University Faculty of Medicine, Community of Scholars Award of Excellence in Medical Education 2006 Canadian Cancer Society (CCS) Award for Service on Board of Directors of CCS Nova Scotia Division 2003 Dalhousie University Faculty of Medicine, Outstanding Teaching Award in Undergraduate Medical Education 1993 Professor of the Year, Medicine Year 3 1989-93 National Cancer Institute of Canada, Terry Fox Salary Award e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2016- CIHR (Canadian Institutes of Health Research) Project Scheme Review. 2016- Judge, Waterloo-Wellington Science and Engineering Fair. 2016- Contributing Lecturer, Medical Foundation 4, McMaster Medical School. 2016- University of Waterloo Animal Ethics Committee. 2016 Organizing Committee, 6th Asia-Pacific Pharma Congress, July 11-13, 2016, Kuala Lumpur, Malaysia. 2015- Editorial Board, Journal of Pharmacology and Pharmaceutical Sciences. 2014-16 Board of Directors, Centre for Bioengineering & Biotechnology (CBB) 2007-10 Chair, Senate Review Committee for the Library System 2011-12 Member, CARL-CRKN (Canadian Association of Research Libraries – Canadian Research Knowledge Network) Joint Open Access Working Group
Page 21 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011 Invited Session Chair, Anticancer Drugs Targeting Tumor Necrosis Factor (TNF) and Chemokine Receptors, 4th World Cancer Congress (WCC-2011), Dalian, Liaoning Province, China 2010 Regional Steering Committee for the Atlantic Dialogue, Terry Fox Research Institute, Atlantic Node 2009-11 Chair, Research Committee, Beatrice Hunter Cancer Research Institute 2009-10 Member, Canadian Research Knowledge Network Human Resources Task Group 2009-10 Chair, Canadian Research Knowledge Network VITaL Task Group 2008-09 Member, CRKN Working Group on Value and Impact 2008-10 Member, Association of Universities and Colleges of Canada (AUCC) Copyright Working Group 2004-10 Board of Directors, Canadian Research Knowledge Network 2006-10 Member, Executive Committee, Canadian Research Knowledge Network 2004-09 Member, Evaluation Committee, Canadian Research Knowledge Network f) GRADUATE SUPERVISIONS (Waterloo only, since 2013):
Completed: 1 MSc In progress: 3 MSc, 2 PhD
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Spencer Berg MSc (2013- Alterations in Colorectal Cancer Cell- Completed 2015) Extracellular Matrix Interactions Upon Acquisition of Chemotherapy Resistance Deep Patel PhD (2014- ) Cellular Phenotype in Disease Progression In Progress and Metastasis of Colorectal Cancer Alexandra MSc (2015- ) Substrates of Dipeptidyl Peptidase IV and In Progress Durocher Their Role in Cell Population Control Bogdan Diaconu MSc (2015-) Regulation of CD26 and CD13 by Plant In Progress Derived Bioflavonoids Heather Dekker MSc (2016- ) Cell Biology of Epithelial Cell Migration into In Progress an Abnormal Tissue Environment Hayden Huh MSc (2016-) Infiltration of tumour multicell spheroids by In Progress Page 22 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
bacteriophages g) GRADUATE COURSES:
Seminars:
2016- PHARM 608A Cellular and Tissue Considerations in Cancer Treatment 2014- PHARM 613 Principles and Practices in Systemic Treatments for Cancer 2009-2012 PHAC 5575 Pharmacology and Therapeutics of Systemic Cancer Therapy h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Per Purpose** Year 2018- Centre for Bioengineering and O $10,000 Research 2019 Biotechnology “Bioprinter and Bioink formulation for the printing of authentic 3D colorectal tumor models” 2018- McMaster Medical Student Research O $2,000 Student 2019 Excellence Award “Clinical Research Research Elective on techniques to assess the migration and invasion of colorectal cancer cells” 2017- Algae Dynamics Corp “Studies on botanical O $200,000 Research 2020 oils” 2016- Private Investors “Translation of O $12,000 Research 2018 engineered bacteriophage platform to cancer therapy” 2016- Ourotech Inc “Evaluation of bioink for 3- O $32,000 Research 2017 dimensional printing of cells in a biocompatible matrix” 2015- London Regional Cancer Program Quality O $15,498 Research 2017 Improvement Project Fund 2015- R.E.D Research Fund, Medbuy O $5,000 Research 2017 2011- CBCF “Exploring Microenvironmental F $50,000 Research 2014 Regulation of Metastasis Through HSP27” (as PI, with Dr. T. MacRae) 2008- NSERC “Energy-sensing regulation of cell- C $40,101 Research
Page 23 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2013 surface proteins”, Discovery Grant (as PI) 2012- DMRF “BMG Spectrostar Nano Microplate O $25,126 Equipment 2013 Reader”, (with Dr C Sinal [PA] and 8 others) 2010- CBCF“Regulation of the SDF-1α:CXCR4 F $60,000 Research 2011 Pathway of Metastasis through HSP27”, (as PI, with Dr T MacRae). 2009- NSERC “Refrigerated centrifuge”, Research O $18,063 Equipment 2010 Tools and Instruments (Category 1), Equipment grant, “Shared equipment for counting and sizing of cell populations” (as PI). 2007-10 CIHR “CXCR4 and DPPIV in colorectal C $78,338 Research cancer”, Operating Grant (As PI) 2008-10 CBCF “Ion channels and the growth of F $60,000 Research breast cancer cells”, (With Drs P Linsdell [PI] and E Cowley). 2009-10 NSERC “Shared equipment for counting O $74,000 Equipment and sizing of cell populations”, Research Tools and Instruments (Category 1), Equipment grant, (as PI, with Drs M Nachtigal, D Hoskin, P Linsdell, E Cowley and Y Anini). 2008-9 NSERC “HPLC for nucleoside and O $77,981 Equipment metabolite measurement”, Research Tools and Instruments (Category 1), Equipment grant, (as PI). 2008-9 DMRF “Beckman Coulter Z2 Analyzer Cell O $26,000 Equipment Counter”, (as PI, with Drs E Cowley, M Nachtigal, P Linsdell, D Hoskin and Y Anini).
*Type: C-Granting councils; G-government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) **Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Per Year Purpose** 2016-2017 UW-RIF (CIHR) O $8,000 Research 2013-2015 UW-RIF (NSERC) O $7,500 Research 2013-2014 UW-RIF (CIHR) O $8,000 Research
Page 24 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2012 UW Starter Fund S $200,000 Research 2013-2015 UW-RIF (NSERC) O $7,500 Research 2013-2014 UW-RIF (CIHR) O $8,000 Research
*Type: S – Startup, O-Other (eg., UW RIF, UW SSHRC, Internal travel grants) **Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories: - books and monographs...... 0 - edited book and monographs...... 1 - chapters in books and monographs...... 11 - refereed journal articles...... 61 - refereed conference proceedings...... 39 - presentations at conferences...... 136 - technical reports ...... 2 - invited/keynote addresses ...... 40 - others (workshops presented) ...... 1
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Chapters in Books:
1. Blay J (2012). Adenosine and Tumor Microenvironment. In Encyclopedia of Cancer, 3rd edn., (M Schwab, Ed.). Springer Verlag GmbH, Heidelberg.
2. Blay J (2012). CD26/DPPIV in Cancer Progression and Spread. In Encyclopedia of Cancer, 3rd edn., (M Schwab, Ed.). Springer Verlag GmbH, Heidelberg.
3. Blay J (2012). CXCR4 Chemokine Receptor. In Encyclopedia of Cancer, 3rd edn., (M Schwab, Ed.). Springer Verlag GmbH, Heidelberg.
4. Blay J (2016). Adenosine and Tumor Microenvironment. In Encyclopedia of Cancer, 4th edn., (M Schwab, Ed.). Springer Verlag GmbH, Heidelberg.
5. Blay J (2016). CD26/DPPIV in Cancer Progression and Spread. In Encyclopedia of Cancer, 4th edn., (M Schwab, Ed.). Springer Verlag GmbH, Heidelberg.
Page 25 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
6. Blay J (2016). Chemokine Receptor CXCR4. In Encyclopedia of Cancer, 4th edn., (M Schwab, Ed.). Springer Verlag GmbH, Heidelberg.
Papers in Refereed Journals:
Highlighted are postdoctoral, graduate or undergraduate students in my laboratory.
1. Blay J and Price RB (2010). Cellular Inhibition Produced by Dental Curing Lights is a Heating Artifact. J Biomed Mater Res B Appl Biomater, 93, 367-374.
2. Lefort EC and Blay J (2011). The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells. Clin Exp Metastasis, 28, 337-349.
3. Yadav PN, Beveridge RE, Blay J, Boyd AR, Chojnacka MW, Decken A, Deshpande AA, Gardiner MG, Hambley TW, Hughes MJ, Jolly L, Lavangie JA, MacInnis TD, McFarland SA, New EJ and Gossage RA (2011). Platinum-oxazoline complexes as anti-cancer agents: syntheses, characterisation and initial biological studies. Med Chem Commun, 2, 274- 277.
4. Gillies KEA and Blay J (2012). The Use of Aloe Constituents in Self-Administered Cancer Treatment. Proceedings of the Nova Scotian Institute of Science, 47(1), 59-89.
5. Lefort EC and Blay J (2013). Apigenin and its impact on gastrointestinal cancers. Mol NutrFood Res, 57(1) 126-144.
6. Cutler, MJ, Lowthers EL, Richard CL, Hajducek DM, Spagnuolo PA and Blay J (2015). Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26. BMC Cancer 15, 882 (14pp).
7. Spagnuolo P, Rodrigo R, Ma C, Kreinin E, Berg S and Blay J (2017) Knockdown of BNIP3L or SQSTM1 alters cellular response to mitochondria target drugs. Oncotarget, submitted 9 February 2017, paper #: 026799.
8. Malik P, Phipps C, Edginton A and Blay J (2017). Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Pharm Res 34(12), 2579-2595.
Papers in Refereed Conference Proceedings
Page 26 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1. Lefort E and Blay J (2010). Modulation of CD26 by the phytochemical apigenin alone and in combination therapy with chemotherapeutic agents, on human colorectal carcinoma cells. 2nd Annual Scientific Meeting of the Terry Fox Research Institute, Vancouver, BC.
2. Tweel K and Blay J (2010). Factors in the Tumour Microenvironment Regulate Proteins Involved in the Migration and Invasion of Colorectal Carcinoma Cells. 2nd Annual Scientific Meeting of the Terry Fox Research Institute, Vancouver, BC.
3. Lefort E and Blay J (2011). The phytochemical apigenin restores the abundance and function of the anti-metastatic protein CD26 in colorectal carcinoma HT-29 cells. Proceedings of the Keystone Symposium on Stem Cells, Cancer and Metastasis, Keystone, Colorado, USA.
4. Lefort E and Blay J (2011). The possible link between apigenin and chemotherapeutic agents targeting topoisomerases on the anti-metastatic protein CD26 in colorectal carcinoma cells. Proceedings of the Montreal International Symposium on Angiogenesis and Metastasis, Montreal, QC, Canada.
Presentations at Conferences:
1. Tufts J, Douglas R, MacRae TH and Blay J (2010) The Purine Nucleoside Adenosine In Contrast To Hypoxia And Heat Shock Fails To Alter The Abundance Of HSP27, But Stimulates Phosphorylation On Serine-78. Proceedings of the 13th Annual Dalhousie Faculty of Medicine Graduate Student Research Day, Halifax, Nova Scotia.
2. Gillies K, Douglas R and Blay J (2010). The Regulation Of Extracellular Adenosine Levels And Its Implications For The Roles Of CD26 And CXCR4 In Cancer Cell Invasion And Metastasis. Proceedings of the 13th Annual Dalhousie Faculty of Medicine Graduate Student Research Day, Halifax, Nova Scotia.
3. Tweel K and Blay J (2010). A Dual Role for Factors from the Tumour Microenvironment in the Modulation of the Migratory Phenotype of Colorectal Carcinoma Cells: Regulation of CD26 and MMP13. Proceedings of the 13th Annual Dalhousie Faculty of Medicine Graduate Student Research Day, Halifax, Nova Scotia.
4. Tufts J, Douglas R, MacRae TH and Blay J (2010). Changes in the Phosphorylation of Mammalian HSP27 in Response to the Purine Nucleoside Adenosine, and Relationship to the Cellular Migratory Phenotype. Proceedings of the 3rd Annual Dr. Patrick Lett Symposium For Biology Graduate Students, Halifax, Nova Scotia.
5. Tufts J*, Douglas R, MacRae TH and Blay J (2010). Phosphorylation Of The Small Heat Shock Protein 27 Is Stimulated By The Purine Nucleoside Adenosine In Breast Cancer Page 27 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Cells. Proceedings of the 2nd Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia. *Awarded first prize for poster presentation.
6. Lefort E* and Blay J (2010). Exposure to the flavone apigenin restores the abundance and function of the anti-metastatic protein CD26 on colorectal carcinoma cells. Proceedings of the 2nd Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia. *Honorable mention for poster presentation.
7. Gillies K, Douglas R and Blay J (2010). Regulation of the CD26-CXCR4 Protein Complex by Extracellular Adenosine and its Implications for Cancer Cell Invasion and Metastasis. Proceedings of the 2nd Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia.
8. Lefort E and Blay J (2011). The possible link between apigenin and chemotherapeutic agents targeting topoisomerases on the anti-metastatic protein CD26 in colorectal carcinoma cells. Proceedings of the 1st Annual IHRTP Student Research Day, Halifax, Nova Scotia.
9. Gillies KEA and Blay J (2011). Functional consequences of cell-surface CD26 levels and saturation of CD26 with exogenous adenosine deaminase, in relation to cancer metastasis. Proceedings of the 3rd Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia.
10. Cutler MJ, Melanson JE and Blay J (2011). In vitro micro-nodular growth of colorectal cancer cell lines confers SN-38 resistance. Proceedings of the 3rd Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia.
11. Lefort E and Blay J (2011). Potential mechanisms of tumor suppressor protein CD26 enhancement in human colorectal carcinoma cells by the dietary constitutent apigenin. Proceedings of the 3rd Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia.
12. Cutler MJ, Lowthers EL, Lefort EC and Blay J (2012). Low-dose anticancer agents reduce the potential for CXCL12-induced migration of colon cancer cells by simultaneously decreasing CXCR4 and increasing CD26. Proceedings of the 4th Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia.
13. Lefort EC, Cutler MJ and Blay J (2012). The dietary flavonoid apigenin has opposing effects on the multifunctional protein CD26 between SN-38-sensitive and resistant colorectal cancer cells. Proceedings of the 4th Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia. Page 28 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
14. Dawson E, Cutler MJ and Blay J (2012). SN-38-resistant colon cancer cells are less tumorigenic and more differentiated than parental cells. Proceedings of the 4th Annual Cancer Research Symposium of the Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia.
15. Cutler MJ, Lowthers EL, Richard CL, Spagnuolo P and Blay J (2013). Treatment of colon cancer cells with diverse anticancer agents decreases CXCR4 and CD133 and increases CD26 and CD44 while reducing CXCL12-induced migration. Canadian Cancer Research Conference, Toronto, ON. 3-6 November 2013.
16. Berg SIT, Cutler MJ and Blay J (2014). Changes in matrix metalloproteinase expression in SN-38-resistant colorectal cancer cells. Institute for Comparative Cancer Investigation (ICCI) 7th Annual Cancer Research Symposium. Ontario Veterinary College, University of Guelph. 15 May 2014.
17. Cutler, MJ, Lowthers EL, Richard CL, Hajducek DM, Spagnuolo PA and Blay J (2014). Chemotherapeutic agents attenuate subsequent CXCL12-induced migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26. American Association for Cancer Research (AACR) conference on Drug Sensitivity and Resistance: Improving Cancer Therapy conference, Orlando, FL, USA. 18-21 June 2014.
18. Berg SIT, Cutler MJ and Blay J (2014). Changes in matrix metalloproteinase expression in SN-38-resistant colorectal cancer cells. American Association for Cancer Research (AACR) conference on Drug Sensitivity and Resistance: Improving Cancer Therapy conference, Orlando, FL, USA. 18-21 June 2014.
19. Berg SIT, Cutler MJ and Blay J (2015). Colorectal cancer cells rendered resistant to the topoisomerase inhibitor SN-38 display altered interactions with fibronectin. Institute for Comparative Cancer Investigation (ICCI) 8th Annual Cancer Research Symposium. Ontario Veterinary College, University of Guelph. 27 May 2015.
20. Berg SIT, Cutler MJ and Blay J (2015). Acquisition of resistance to the chemotherapeutic agent SN-38 coincides with gain of integrin α 5-mediated adhesion to the extracellular matrix protein fibronectin in colorectal cancer cells. Canadian Cancer Research Conference, Montreal, QC. 8-10 November, 2015
21. Berg, S.I.T., Cutler, M.J., Blay, J. (2016). Colorectal cancer cells resistant to the chemotherapeutic agent SN-38 gain integrin α5β1 expression and signalling. Poster presentation at 9th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation, 17th May 2016, Guelph, ON, Canada.
Page 29 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
22. Dekker, H., Berg, S.I.T., Cutler, M.J., Blay, J. (2016). Colorectal cancer cells resistant to SN- 38 show elevated binding to fibronectin and localize within hepatic epithelial cultures. Poster presentation at 9th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation, 17th May 2016, Guelph, ON, Canada.
23. Diaconu, B., Berg, S.I.T., Cutler, M.J., Blay, J. (2016). SN38-resistant colorectal cancer cells exhibit changes in cell-surface enzymes involved in adenosine-dependent cell regulation. Poster presentation at 9th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation, 17th May 2016, Guelph, ON, Canada.
24. Patel, D., Cutler, M.J., Blay, J. (2016). Development of drug resistance in colorectal cancer cells is associated with changes in the expression of chemokines. Poster presentation at 9th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation, 17th May 2016, Guelph, ON, Canada.
25. Diaconu, B., Lefort, E.C., and Blay, J. (2016). Apigenin regulates the expression of cell- surface components on colon epithelial cells that are implicated in adenosine-dependent cell regulation. Poster presentation at the Annual Conference of the Natural Health Product Research Society of Canada, 17th-20th May 2016, Charlottetown, PEI, Canada.
26. Patel, D., Bahl, M., and Blay, J. (2017). Optimisation Of A Technique For Recovery Of Circulating Tumour Cells From The Peripheral Blood Of Colorectal And Breast Cancer Patients. Conference of the Canadian Association of Pharmacy in Oncology, Banff, AB, Canada, 20-23 April, 2017.
27. Durocher A, and Blay J (2017). Characterizing Changes in Dipeptidyl Peptidase IV on Colon Cancer Cells in Response to Prostaglandin Treatment. Poster presentation at 10th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 25 May, 2017.
28. Dekker H, Cutler M, and Blay J (2017). Behavioural and enzymatic changes in drug- resistant colorectal cancer cells. Poster presentation at 10th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 25 May, 2017.
29. Patel, D., Bahl, M., and Blay, J. (2017). Optimisation Of A Technique For Recovery Of Circulating Tumour Cells From The Peripheral Blood Of Colorectal And Breast Cancer Patients. Poster presentation at 10th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 25 May, 2017.
30. Diaconu B, and Blay J (2017). Inhibitory effects of the plant flavonoid apigenin on the expression and function of CD38 in HT29 colorectal carcinoma cells. Poster presentation Page 30 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
at 10th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 25 May, 2017.
31. Huh H, Blay J, and Slavcev R (2017). Evaluating phage infiltration into solid tumours. Poster presentation at 10th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 25 May, 2017.
32. Patel D, Bahl M, and Blay J (2017). Optimisation Of A Technique For Recovery Of Circulating Tumour Cells From The Peripheral Blood Of Colorectal And Breast Cancer Patients. Poster presentation at University of Waterloo Biotechnology and Bioengineering Conference (BioTEC 2017), Waterloo, ON, 25 November, 2017.
33. Blay J, Fux J, Bentley V, Diaconu B and Lefort E (2018). Actions of the dietary flavone apigenin in the context of human colorectal cancer. Presentation at the NHPRS 2018 Conference: Innovation at the Food/NHP Interface, 14-18 May 2018, Delta Guelph Conference Centre, Guelph, Ontario, Canada.
34. Dekker H, and Blay J (2018). Considerations in fluorescent tagging of colon cancer cells in adhesion assays. Poster presentation at 11th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 30 May, 2018.
35. Patel D, Bahl M, and Blay J (2018). Recovery and analysis of circulating tumour cells from the peripheral blood of stages III and IV colorectal and breast cancer patients. Poster presentation at 11th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 30 May, 2018.
36. Durocher A, and Blay J (2018). Studies of the regulation of dipeptidyl peptidase IV (DPPIV) expression and activity on colorectal carcinoma cells by J-series prostaglandins. Poster presentation at 11th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 30 May, 2018.
37. Huh H, Chen D, Foldvari M, Slavcev R, and Blay J (2018). The use of fibroblast spheroids as a model for assessing the ability of bacteriophages to penetrate tumour stromal tissues. Poster presentation at 11th Annual Cancer Research Symposium of the Institute for Comparative Cancer Investigation (ICCI), Guelph, ON, 30 May, 2018.
38. Patel D, Bahl M and Blay J (2018). Recovery and analysis of circulating tumour cells from the peripheral blood of stages III and IV colorectal and breast cancer patients. Presentation at McMaster University 5th Annual Waterloo-Wellington Clinical Research and Quality Improvement (WWCRQI) Symposium, Kitchener, ON, Canada, 30 May 2018.
Page 31 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
DATE: April 2018
Page 32 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
CHANG, Feng Assistant Professor, tenure-track Member of the Graduate Faculty: yes b) DEGREES:
PharmD, Ohio State University, College of Pharmacy, 2004 BScPhm, University of Toronto, Leslie Dan Faculty of Pharmacy, 1998 c) EMPLOYMENT HISTORY:
2017- Associate Professor, School of Pharmacy, University of Waterloo 2010-2017 Assistant Professor, School of Pharmacy, University of Waterloo 2007-2010 Clinical Pharmacy Practitioner, Elder Care, Interim Clinical Coordinator, Department of Pharmacy, North York General Hospital 2005-2007 Consultant Pharmacist, Specialized Geriatric Services, Clinical Coordinator, Department of Pharmacy, St. Joseph’s Health Care 2004-2005 Fellowship in Geriatric Pharmacotherapy, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University 1999-2003 Clinical Pharmacist, Department of Pharmacy, St. Joseph’s Health Care 1998-1999 Clinical Pharmacist, Department of Pharmacy, The Scarborough Hospital d) HONOURS:
2017 Canadian Association for University Continuing Education (CAUCE) award for non- credit programming under 48 hours 2011 Canadian Society of Hospital Pharmacists Ontario Branch Scott Walker Research Award 2011 Canadian Society of Hospital Pharmacists Ontario Branch Pharmaceutical Care Award 2010 Pharmacy Practice and Drugstore Canada Commitment to Care and Service Awards – Hospital Pharmacy Initiative 2008 Volunteer Award in Professional Guidance, Chinese Professionals Association of Canada 2007 Canadian Society of Hospital Pharmacists Ontario Branch Literary Award – Therapeutic Review or Case Report 2007 Volunteer Award, Chinese Professionals Association of Canada 2006 Canadian Society of Hospital Pharmacists Ontario Branch Pharmaceutical Care Award
Page 33 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2006 First Annual Best Practices in Online Learning Award, RxBriefcase, www.RxBriefcase.com 2003 Clinical Education and Development Award, St. Joseph Health Care 2001 St. Joseph Health Care, Middlesex London Health Unit Heart Health Award
e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2010 - Chair of Rural Pharmacy Chair, Board of Directors (June 2016 – June 2017) First Vice Chair, Board of Directors (June 2015 – June 2016) Gateway Centre of Excellence in Rural Health, Seaforth, ON 2013-2017 University of Waterloo Liaison, Ontario Branch Council, Canadian Society of Hospital Pharmacists 2016 – 2017 Reviewer, Alzheimer’s Association Research Grant (AARG) program 2016 Member, Health Canada Scientific Advisory Panel on Opioids (SAP- OPIOIDS) 2012- Member, Knowledge Generation and Translation Committee and Palliative Care Working Group, SouthWestern Academic Health Network 2011- Executive Committee Member, Hospital Pharmacy Residency Forum of Ontario, University of Waterloo School of Pharmacy Representative 2011-2015 Member, London Health Sciences Centre Pharmacy Residency Advisory Board 2013-2014 Executive Committee, Ontario Pharmacy Research Collaboration 2012-2013 Member, Ontario Branch Awards Committee, Canadian Society of Hospital Pharmacists 2009 Preceptor, Student Exchange Program, International Pharmaceutical Students’ Federation and the Canadian Association of Pharmacy Students and Interns 2008-2009 Mentor, Pharmacist and Physician Mentorship Program, Phase III, Ontario Pharmacists Association and Ontario College of Family Physicians, Sponsored by HealthForce Ontario 2005-2008 Canadian Society of Hospital Pharmacists Representative, 2008 Global Conference on the Future of Hospital Pharmacy, International Pharmaceutical Federation, Hospital Pharmacy Section 2006-2008 Chair / Past-Chair, Geriatric Pharmacy Specialty Network (PSN), Canadian Society of Hospital Pharmacists f) GRADUATE SUPERVISIONS:
Completed: 6 MSc, 0 PhD In Progress: 3 MSc, 0 PhD Page 34 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Tuan Phan (MSc), 2012-2015 Evaluating the usability of a Completed medication organizing tool on home medication management – A proof-of-concept experiment Haya Mukhlef Al- (MSc), 2012-2014 Prevalence of potentially Completed Shamri inappropriate medications use among recently admitted geriatric patients in rural hospital Sara Ibrahim (MSc), 2012-2014 Perceptions of community- Completed dwelling patients on the impact of the discontinuation of Oxycontin on their pain management: A mixed methods study
Mo Chen (MSc) Sept 2014 – An Evaluation of the Effect of In Progress Dec 2016 Community-based Pharmacist Intervention on Patients with Chronic Pain Hamed Tabeefar (MSc) Jan 2015 – Pharmacists experience with In Progress Dec 2016 chronic pain management: A qualitative study
Mira Maximos (MSc) Jan 2015 – “A Picture is Worth a Thousand In Progress Apr 2017 Words” A Randomized Controlled Trial to Assess the Influence of a Pictorial Medication Calendar on Medication Taking Behaviour g) GRADUATE COURSES: past 7 years, by year
2012-2015 Lecturer, Pharm610 Topics in Drug Development
h) 1. EXTERNAL RESEARCH FUNDING
Page 35 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Year Source Type* Amount Purpose** Investigator 2018- Ministry of Senior Affairs G $76,080 Research Co-Principal 2019 Seniors Community Grant investigator: F. Program Chang 2017- Canadian Foundation for F $44,000 Research Principal 2018 Pharmacy Innovation Fund investigator: F. grant Chang 2017 McCall MacBain F $20,000 Research Principal Foundation investigator: F. Chang 2016- Women’s Xchange $15K O $15,020 Research Co-Principal 2017 Challenge Grant investigator: F. Chang 2015- Health Canada Drug G $749,546 Research Principal 2017 Strategy Community investigator: F. Initiatives Fund, Anti-Drug Chang Strategies Initiatives 2015- Women’s Xchange $15K O $14,906 Research Principal 2016 Challenge Grant investigator: T. Patel, Co- investigator: F. Chang 2015- London Regional Cancer O $30,996.62 Research Principal 2017 Program Quality investigator: Improvement Project M. Maximos, Fund Co- investigator: F. Chang 2015- R.E.D Research Fund, O $10,000 Research Principal 2017 Medbuy investigator: M. Maximos, Co- investigator: F. Chang 2014- Employment and Social G $24,322 Research Principal 2015 Development Canada New investigator: F. Horizons for Seniors Chang Program 2013- Ontario Ministry of Health G Direct Research Program 2016 and Long-Term Care, project principal Health Systems Research funds investigator: N.
Page 36 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Fund within the Waite, Project grant: level co- $326,700 principal $142,258 investigator $216,247 and co- investigator: F. Chang 2011 Canadian Society of O $1,000 Research Principal Hospital Pharmacists investigator: F. Ontario Branch Scott Chang Walker Research Award 2011 Huron East/Seaforth O $10,000 Research Principal Community Development investigator: F. Trust Chang 2009 Iris and Dalton Bales F $3,000 Research Principal Research Endowment investigator: F. Fund, North York General Chang Hospital Foundation
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2018- University of Waterloo O $40,000 Research Principal 2019 International Research (with investigator: F. Partnership Grants matching Chang funds) 2014- Canadian Institute of C $4,251 Research Principal 2015 Health Research (CIHR) investigator: F. Health Professional Chang Student Research Award 2013- University of Waterloo O $10,000 Research Principal 2014 Chronic investigator: K. Disease Prevention Grindrod, Co- Initiative Seed Grant investigator: F. Chang 2013- Canadian Institute of C $4,251 Research Principal 2014 Health Research (CIHR) investigator: F.
Page 37 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Health Professional Chang Student Research Award 2012- Canadian Institute of C $4,251 Research Principal 2013 Health Research (CIHR) investigator: F. Health Professional Chang Student Research Award 2011 NSERC General Research C $25,000 Research Principal Funds investigator: N. Waite, Co- investigator: F. Chang 2011 Unrestricted grant, O $20,000 Research Principal AstraZeneca investigator: F. Chang 2011 RBC Retirement O $9,600 Research Principal Research Undergraduate investigator: F. Fellowship, University of Chang Waterloo
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc.
Page 38 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
Chapters in books ...... 2 Papers in refereed journal ...... 24 Abstracts and/or papers read ...... 60
Others - Workshops / presentations presented 30 - Certificate program course developed 6 - Certificate program course presented 6 - Educational program developed 3 - Educational program reviewed 9
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Journals:
1. Fonseca J, Chang A, Chang F. Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in southwestern Ontario. Journal of Rural Health. 2018 Dec;34(1):23-30. Doi: 10.1111/jrh.12264.
2. Cooke M, Waite N, Cook K, Milne E, Chang F, McCarthy L, Sproule B. Incorporating sex, gender and vulnerable populations in a large multisite health research programme: the Ontario Pharmacy Evidence Network as a case study. Health Research Policy and Systems. 2017;15(1):20.
3. Duong S, Patel T, Chang F. Dementia: what pharmacists need to know. Canadian Pharmacists Journal. 2017;150(2):118-29.
4. Maximos M, Chang F, Patel T. Risk of falls associated with antiepileptic drug use in ambulatory elderly populations: a systematic review. Canadian Pharmacists Journal. 2017;150(2):101-11.
5. Chang F, Ibrahim S. Perceptions of community-dwelling patients and their physicians on OxyContin discontinuation and the impact on chronic pain management. Pain Research and Management. 2017;2017:5402915. https://doi.org/10.1155/2017/5402915.
6. Chang F, Paramsothy T, Roche M, Gupta NS. Patient, staff and clinician perspectives on implementing electronic communications in an interdisciplinary rural family health practice. Page 39 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Primary Health Care Research and Development. 2017 Mar;18(2):149-60. Epub 2016 Dec 20. https://doi.org/10.1017/S1463423616000414.
7. McCarthy L, Milne E, Waite N, Cooke M, Cook K, Chang F, Sproule BA. Sex and gender-based analysis in pharmacy practice research: a scoping review. Research in Social and Administrative Pharmacy. 2016 Nov 19. http://dx.doi.org/10.1016/j.sapharm.2016.11.007.
8. Patel T, Chang F, Mohammed HT, Raman-Wilms L, Jurcic J, Khan A, Sproule B. Knowledge, perceptions and attitudes toward chronic pain and its management: a cross sectional survey of frontline pharmacists in Ontario, Canada. PLoS ONE. 2016;11(6):e0157151. doi:10.1371/journal.pone.0157151.
9. Chang F, Yeung KT, Chan G, Identifying mercury heavy-metal poisoning masquerading as dementia and Parkinson’s disease – Recognizing neuropsychiatric manifestations and dietary contributors, Canadian Geriatrics Society Journal of CME, 5(2):1-8, 2015
10. Chang F, Gupta NS, Progress in electronic medical record adoption in Canada, Canadian Family Physician, 61(12):1076-84, 2015
11. O’Connell MB, Chang F, Tocco A, Mills ME, Hwang JM, Garwood CL, Khreizat HS, Gupta NS, Drug-related-problem outcomes and program satisfaction from a comprehensive brown bag medication review, Journal of the American Geriatrics Society, 63(9):1900-5, 2015
12. Chang F, Patel T, Schultz ME, The “Rising Tide” of dementia in Canada: What does it mean for pharmacists and the people they care for? Canadian Pharmacists Journal, 148(4):193-9, 2015
13. Duong S, Yeung KT, Chang F, Intramuscular olanzapine in the management of behavioral and psychological symptoms in hospitalized older adults: A retrospective descriptive study, Journal of Aging Research, 2015;570410. Doi:10.1155/2015/570410.
14. Patel T, Chang F, Practice recommendations for Parkinson’s disease: Assessment and management by community pharmacists, Canadian Pharmacists Journal, 148(3):142-9, 2015
15. Mercer K, Baskerville NB, Burns CM, Chang F, Giangregorio L, Goodwin JT, Rezai LS, Grindrod K, Using a collaborative research approach to develop an interdisciplinary research agenda for the study of mobile health interventions for older adults, Journal of Medical Internet Research mHealth and uHealth, 3(1):e11, 2015. Doi:10.2196/mhealth.3509 16. Chang F, Gupta NS*, Smith L*, Stringer D, The impact of a community pharmacy-based coaching program on patient confidence and lifestyle, Open Journal of Preventive Medicine, 4:499-503, 2014. Doi:10.4236/ojpm.2014.46058.
Page 40 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
17. Patel T, Chang F, Parkinson’s disease guidelines for pharmacists, Canadian Pharmacists Journal, 147(3):161-70, 2014
18. Hu M, Chang F, Pu J, Wu P, Forgione A*, Jiang XH, Status of Pharmacy Administration education in China: A survey of undergraduate curriculum and faculty, Pharmacy Education, 12(1):25-30, 2012
19. Duong, S., Chang, F., A practical approach to the management of chronic non-cancer nociceptive pain in the elderly. Canadian Pharmacists Journal. 144(6):270-7, 2011
Abstracts and / or Papers Read:
ORAL:
1. Chang F, Tabeefar H, Patel T, Pharmacist experience with providing care for patients with chronic pain in the community setting: A qualitative study, Canadian Pharmacists Conference, Quebec City QC, Jun 2-5, 2017.
2. Fonseca J, Chang A, Chang F, Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in Southwestern Ontario, Canadian Pharmacists Conference, Quebec City QC, Jun 2-5, 2017. Previously presented at the Canadian Undergraduate Conference on Healthcare (CUCOH), Kingston ON, Nov 18-20, 2016.
3. McCarthy L, Milne E, Waite N, Cooke M, Cook K, Chang F, Sproule B, Sex and gender based analysis in pharmacy practice research, Canadian Pharmacists Conference, Quebec City QC, Jun 2-5, 2017.
4. Waite N, Cooke M, Cook K, Milne E, Chang F, McCarthy L, Sproule B, Consideration of sex / gender and vulnerable populations in pharmacy practice research, Canadian Pharmacists Conference, Calgary AB, June 26, 2016. Canadian Pharmacists Journal 2016;149(4):S14.
5. Chang F, Chen M, Patel T, Effectiveness of community-based pharmacist-interventions in chronic non-cancer pain: A systematic review, Canadian Pharmacists Conference, Calgary AB, June 26, 2016. Previously presented at the 37th Canadian Pain Society Annual Scientific Meeting, Vancouver BC, May 24-27, 2016. Canadian Pharmacists Journal 2016;149(4):S13. 6. Chang F, Patel T, Killeen R, Kluz A, Pantazi F, Opioid Education Partnership: From blueprint to practice, building opioid education for physicians and pharmacists, Canadian Association for University Continuing Education (CAUCE) – Canadian Network for Innovation in Education (CNIE) Conference, Waterloo ON, May 30 – June 2, 2016.
Page 41 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
7. Chang F, Patel T, Killeen R, Kluz A, Pantazi F, Challenges in designing an online continuing education program for health professionals, University of Waterloo Teaching and Learning Conference: OND 2016, Waterloo ON, April 28, 2016.
8. Dolovich L, Waite N, Farrell B, MacKeigan L, Chang F, Sproule B, Patel T, Winslade N, Development of an evaluation framework for pharmacy services, Ontario Pharmacy Research Collaboration Summit, Toronto ON, Jan 20-21, 2016.
9. Waite N, Cooke M, Milne E, Cook K, Chang F, McCarthy L, Sproule B, Sex / gender and vulnerable populations in OPEN research, Ontario Pharmacy Research Collaboration Summit, Toronto ON, Jan 20-21, 2016.
10. Chang F, Butt K. Retiring Well: Promoting awareness of health-related costs in aging among Southwestern Ontario rural communities. 14th Conference of the Canadian Rural Health Research Society, Edmonton AB, Sept 20-22, 2015.
11. Dolovich L, Babaei-Rad R, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K, Waite NM. Evaluation of pharmacy services: Capturing the patient perspective. Canadian Pharmacists Conference, Ottawa ON, May 28-31, 2015.
12. Chang F, Patel T, Sproule B, Khan A, Coulston B, Jurcic J, Raman-Wilms L, Pharmacist and chronic pain survey: Insight on your attitudes, perceptions and knowledge. Ontario Pharmacy Research Collaboration Summit, Toronto ON, Oct 8, 2014.
13. Chang F, Khan A, Patel T, Grindrod K, Aoki K, Chen K, Milic A, Mercer K, Sproule B, Identification of challenges and opportunities for community pharmacists to manage chronic pain – dialogue exchange by chronic pain stakeholders, Ontario Pharmacy Research Collaboration Summit, Toronto ON, Oct 7, 2014.
14. Chang F, Cook KM, Cooke M, McCarthy L, Sproule B, Waite NM. Developing and implementing inclusive survey questions in pharmacy practice research. Ontario Pharmacy Research Collaboration Summit, Toronto ON, Oct 7-8, 2014.
15. Dolovich L, Akran S, Rietkoetter S, Slonim K, Nainifard A, MacKeigan L, Patel T, Waite N, Chang F, Farrell B. Capturing the perspectives of academics, policy makers, physicians and pharmacists about the evaluation of pharmacy—Preliminary results. Ontario Pharmacy Research Collaboration Summit, Toronto ON, Oct 7-8, 2014.
16. Chang F, Cook KM, Cooke M, McCarthy L, Sproule B, Waite NM, Developing and implementing more inclusive demographic survey questions, Canadian Pharmacists Association National Conference, Saskatoon SK, June 2, 2014. Canadian Pharmacists Journal 2014;147(4):S12. Page 42 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
17. Dolovich L, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K, Waite NM, Capturing the perspectives of academics, policy makers, physicians and pharmacists about the evaluation of pharmacy services – preliminary results, Canadian Pharmacists Association National Conference, Saskatoon SK, June 2, 2014. Canadian Pharmacists Journal 2014;147(4):S11. Previously presented at Trillium Primary Health Care Research Day, Toronto ON, May 28, 2014.
18. Chang F, Seguin J, Gupta NS, Munoz C, Stringer D, Connecting wealth to health for pre- retirement adults in a rural community, 11th Conference of the Canadian Rural Health Research Society: Rural and Remote Health Research: Creative Approaches, Levis QC, Oct 25- 27, 2012.
19. Chang F, Gupta NS, Seguin J, Mirhossseini M, Annis R, Atkinson M, Environmental scan for implementing electronic communication at a Family Health Team in rural Ontario, 11th Conference of the Canadian Rural Health Research Society: Rural and Remote Health Research: Creative Approaches, Levis, QC, Oct 25-27, 2012.
POSTER:
20. Chang F, Mohammed HT, Kluz A, Patel T, Killeen R, Opioid Education Partnership: Pilot test results for an interdisciplinary education initiative targeting prescription opioid, 38th Canadian Pain Society Annual Scientific Meeting, Halifax NS, May 23-26, 2017.
21. Mah G, Chan G, Olanubi T, Lum M, Mandas R, Heitner R, McGeachie ME, Dellaposta F, Lilly S, Hanna M, Chang F, Chu D, McCormack N, Chu P, Interprofessional Geriatric Day Hospital Chronic Pain Management Benefits Sustained, Canadian Geriatrics Society Annual Scientific Meeting, Toronto ON, Apr 20-22, 2017.
22. Chang F, Chen M, Patel T, Kulkarni T, Effectiveness of community-based pharmacist interventions in chronic non-cancer pain: A systematic review, 37th Canadian Pain Society Annual Scientific Meeting, Vancouver BC, May 24-27, 2016.
23. Chang F, Patel T, Kluz A, Killeen R, Opioid Education Partnership: An interdisciplinary initiative to reduce prescription opioid misuse, 37th Canadian Pain Society Annual Scientific Meeting, Vancouver BC, May 24-27, 2016.
24. Chang F, Sproule B, Patel T, Jurcic J, Raman-Wilms L, Opioid management in chronic pain by pharmacists providing care in the community setting in Ontario, 37th Canadian Pain Society Annual Scientific Meeting, Vancouver BC, May 24-27, 2016. Previously presented at the Ontario Pharmacy Research Collaboration Summit, Toronto ON, Jan 20-21, 2016.
Page 43 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
25. Patel T, Hasan S, Chang F, MacFarlane T, Handling and disposal of controlled substances in hospices in Ontario: A cross-sectional survey, Canadian Association for Health Services and Policy Research, Toronto ON, May 10-12, 2016.
26. Patel T, Chang F, Mohammed HT, Lyon J, Expectations and needs assessment of women with epilepsy: Community pharmacist assistance with antiepileptic medications, 19th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs CO, April 17-20, 2016. Journal of Pharmacy Practice 2016;29:307.
27. Chang F, Patel T, Kluz A, Killeen R, Opioid Education Partnership: Pharmacists as collaborators in reducing prescription opioid misuse, Ontario Pharmacy Research Collaboration Summit, Toronto ON, Jan 20-21, 2016.
28. Chang F, Butt K. Understanding rural seniors’ experiences with health-related costs in aging: A qualitative study. 14th Conference of the Canadian Rural Health Research Society, Edmonton AB, Sept 20-22, 2015.
29. Chang F, Devereaux G, Stringer D, The Gateway story: Building and growing a centre of excellence in rural health in Ontario. 14th Conference of the Canadian Rural Health Research Society, Edmonton AB, Sept 20-22, 2015.
30. Chang F, Khan A, Wong K, Patel T. Emerging chronic disease prevention or management programs by community pharmacists: A systematic review. Canadian Pharmacists Conference, Ottawa ON, May 28-31, 2015. Previously presented at Ontario Pharmacy Research Collaboration Summit, Toronto ON, Oct 7-8, 2014.
31. Khan A, Vuong V, Iftikhar N, Patel T, Chang F. Implementation of programs and services by community pharmacists: Barriers, facilitators and operational requirements. Canadian Pharmacists Conference, Ottawa ON, May 28-31, 2015. Previously presented at Ontario Pharmacy Research Collaboration Summit, Toronto ON, Oct 7-8, 2014. 32. Patel T, Chang F, Khan A, Raman-Wilms L, Jurcic J, Coulston B, Sproule B. Survey of community pharmacists: Knowledge, perceptions and practice related to chronic pain. Canadian Pharmacists Conference, Ottawa ON, May 28-31, 2015.
33. Dolovich L, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K, Waite N. Barriers and facilitators to implementing an evaluation framework for pharmacy services, Canadian Pharmacists Conference, Ottawa ON, May 28-31, 2015.
34. Chang F, Cook KM, Cooke M, McCarthy L, Sproule B, Waite NM. Sex and gender based analysis in the pharmacy research literature. Ontario Pharmacy Research Collaboration Summit, Toronto ON, Oct 7-8, 2014.
Page 44 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
35. Chang F, Khan A, Patel T, Grindrod K, Aoki K, Chen K, Milic A, Mercer K, Sproule B, Chronic Pain Stakeholder Engagement Workshop, Canadian Pharmacists Association National Conference, Saskatoon SK, May 31-June 3, 2014.
36. Sayavong S, Pizzey H, Grindrod K, Penny Light T, Schneider E, Chang F, Stakeholder perceptions of warfarin management in a community setting, Canadian Pharmacy Education and Research Conference, Niagara-on-the-Lake ON, June 13, 2013.
37. Chang F, Dalton JM, Rural pharmacist practice, interest and engagement in academic activities, Canadian Association for Health Services and Policy Research Annual Conference, Vancouver BC, May 28, 2013.
38. Chang F, Dalton JM, Direct patient care training for rural pharmacists in medication management, Canadian Society of Hospital Pharmacists Ontario Branch 64th Annual General Meeting Education Sessions and Awards Program, Toronto ON, Nov 17, 2012.
39. Chang F, Dalton JM, Giving rural pharmacists a voice in the Rural Academic Health Network, Canadian Society of Hospital Pharmacists Ontario Branch 64th Annual General Meeting Education Sessions and Awards Program, Toronto ON, Nov 17, 2012.
40. Chang F, Gupta NS, Smith L, Stringer D, Pilot community pharmacy based diabetes program using health coaching principles, 11th Conference of the Canadian Rural Health Research Society: Rural and Remote Health Research: Creative Approaches, Levis, QC, Oct 25-27, 2012. Previously presented at the Canadian Pharmacists Association National Conference, Whistler, BC, June 1-4, 2012. Canadian Pharmacists Journal 2012;145(Suppl 1):S29.
41. Becotte G, Chang F, Stringer D, Munoz C, Devereaux G, A five step model for pharmacist intervention in the detection and management of cognitive impairment in rural Ontario, 8th Congress of the European Union Geriatric Medicine Society, Brussels, Belgium, Sept 26-28, 2012.
42. Chang F, Becotte G, Stringer D, Devereaux G, Munoz C, What pharmacists can do for cognitive impairment in rural Ontario, Canadian Pharmacists Association National Conference, Montreal QC, May 28-31, 2011. Canadian Pharmacists Journal 2011;144(5):e41.
43. Seguin J, Chang F, Yeung KT, Gastrointestinal bleeding as a consequence of bisphosphonate- induced musculoskeletal pain, American Geriatrics Society Annual Scientific Meeting, Seattle WA, May 3-5, 2012.
44. Tocco AM, Chang F, Kleinow ME, Hwang JM, Garwood CL, Khreizat HS, O'Connell MB, Classifications of drug related problems discovered during senior brown bag medication reviews, Canadian Society of Hospital Pharmacists 43rd Annual Professional Practice Page 45 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Conference, Toronto ON, Feb 4-8, 2012. Previously presented at American College of Clinical Pharmacy Annual Meeting, Pittsburgh PA, Oct 16-19, 2011.
45. Gupta NS, Chang F, Kleinow ME, Hwang JM, Garwood CL, Khreizat HS, O'Connell MB, Patient satisfaction and self-perceived knowledge gained during senior brown bag medication reviews, Canadian Society of Hospital Pharmacists 43rd Annual Professional Practice Conference, Toronto ON, Feb 4-8, 2012. Previously presented at American College of Clinical Pharmacy Annual Meeting, Pittsburgh PA, Oct 16-19, 2011.
46. Gupta NS, Chang F, Kleinow ME, Hwang JM, Garwood CL, Khreizat HS, O'Connell MB, Evaluation of patient education on preventive health measures and poison control center awareness during senior brown bag medication reviews, Canadian Society of Hospital Pharmacists 43rd Annual Professional Practice Conference, Toronto ON, Feb 4-8, 2012. Previously presented at American College of Clinical Pharmacy Annual Meeting, Pittsburgh PA, Oct 16-19, 2011.
47. Chang F, Duong S, Yeung KT, Case series of Olanzapine intramuscular use in elderly hospitalized patients, American Geriatrics Society Annual Scientific Meeting, National Harbor MD, May 11-14, 2011.
48. Chang F, Yeung KT, Chan G, Neuropsychiatric manifestations in a suspected case of heavy metal poisoning, Canadian Geriatric Society Annual Scientific Meeting, Ottawa ON, Apr 15- 17, 2010.
49. Chang F, Yeung KT, Case series of Olanzapine intramuscular use in elderly hospitalized patients on a medicine unit, 5th Canadian Conference on Dementia, Toronto ON, Oct 1-3, 2009.
Workshops / Presentations Presented:
1. Developing deprescribing guidelines for opioids, Evidenced Based Deprescribing Guideline Symposium, Ottawa ON, Mar 26, 2018.
2. Safe medication use and falls in older adults, Kitchener-Waterloo Interprofessional Geriatric Skill Day, Kitchener ON, Feb 24, 2018.
3. Rethinking our approach to opioid prescribing, Canadian Pharmacists Conference, Quebec City QC, June 3, 2017.
4. Opioids, Practice Guidelines and Clinical Issues, Expert Witness Symposium, Ontario Association of Chiefs of Police, Toronto ON, May 2, 2017.
Page 46 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
5. Polypharmacy, workshop speaker and panelist, Kitchener-Waterloo Interprofessional Geriatric Skill Day, Kitchener ON, Feb 25, 2017.
6. Patel T, Chang F, Parkinson’s disease: Initiating drug therapy, managing motor complications and more… Markham Pharmacists Association, Markham ON, Nov 10, 2016.
7. Opioid Education Partnership: An interdisciplinary initiative to reduce prescription opioid misuse, School of Pharmacy Alumni Reunion, Kitchener ON, Oct 1, 2016.
8. Thinking about Pharmacy? Further Education Boot Camp, Centre for Career Action, University of Waterloo, Waterloo ON, Sept 24, 2016.
9. Keynote speaker and panelist: Polypharmacy in the Older Adult: 15 plus drugs in 15 plus minutes? Kitchener-Waterloo Interprofessional Geriatric Skill Day, Kitchener ON, Feb 27, 2016.
10. Putting the design to practice: Building meaningful exposure for rural and underserved populations, Canadian Pharmacy Education and Research Conference, Niagara-on-the-Lake ON, June 13, 2013.
11. How Innovative technology can be used to support the prevention and management of chronic diseases, Witness to the House of Commons Standing Committee on Health, Ottawa ON, April 30, 2013.
12. Panelist: Pharmacists in rural primary care, Refining Pharma Marketing Conference, Toronto ON, May 3, 2011.
13. Common infections in the elderly, Kitchener-Waterloo Interprofessional Geriatric Skill Day, Kitchener ON, Jan 22, 2011.
14. Clinical pharmacy practice in Canada, West China School of Pharmacy, SiChuan University, SiChuan China, Sept 29, 2010.
15. Back to the basics II: Medication management in the elderly, Pan Northern Geriatric Care Conference, Sault Ste Marie ON, Oct 30, 2009.
16. Medications and geriatric failure to thrive, Southwestern Ontario Geriatric Assessment Network Annual Exchange Day, London ON, Mar 27, 2009.
17. Key papers that may influence your practice in geriatrics, CSHP 40th Annual Professional Practice Conference, Toronto ON, Feb 2, 2009.
Page 47 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Certificate program course developed / presented:
1. Online: Chang F, Kluz A, Patel T, Killeen R, Opioid Education Partnership, www.opioidpartnership.org, 2016. (An 8-Module interprofessional training program for physicians and pharmacists on prescription opioid misuse. Accredited by the College of Family Physicians of Canada for 8 Mainpro credits)
2. Online: Benign prostatic hyperplasia and erectile dysfunction, Certified Geriatric Pharmacist (CGP) Preparation Course – Medication Therapy Management for Older Adults, Ontario Pharmacists Association, 2016, updated 2018.
3. Genitourinary Therapeutics: Benign prostatic hyperplasia, urinary incontinence, urinary tract infection, erectile dysfunction, and genitourinary case discussions, Certified Geriatric Pharmacist Preparation Course, Ontario Pharmacists Association. 2012, updated annually until 2015.
4. Genitourinary Therapeutics: Benign prostatic hyperplasia, urinary incontinence, Certified Geriatric Pharmacist Preparation Course, Ontario Pharmacists Association. 2007, updated annually until 2011.
5. Online: Clinical presentations of medication-related adverse effects in the elderly, Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program, offered through McMaster University (Department of Family Medicine), Dalhousie University, University of Toronto, and University of British Columbia, 2010.
6. A Case-Based Approach to Geriatric Care, Certified Geriatric Pharmacist Preparation Course, Ontario Pharmacists Association, 2009.
Educational program developed:
1. Understanding Potential Interactions with Prescription Drugs (Drug / Food, Drug / OTC, Drug / Herb, Drug / Alcohol, Drug / Smoking), Grey Bruce FOCUS Project, Public Health, Grey Bruce County ON, 2007-2009.
Educational program reviewed:
1. Online: 5 things to think about when using opioids for chronic pain, Pharmacy 5in5 (https://pharmacy5in5.ca), University of Waterloo, 2018.
2. Online: 5 things to think about when using opioids for acute and short-term pain, Pharmacy 5in5 (https://pharmacy5in5.ca), University of Waterloo, 2018.
Page 48 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Online: Edlund M, Pharmacological management of pain in the elderly, Certified Geriatric Pharmacist (CGP) Preparation Course – Medication Therapy Management for Older Adults, Ontario Pharmacists Association, 2018.
4. Krawchenko I, Opioids in pain management: The place and use of transdermal fentanyl, Meridian HealthComms Ltd, 2016.
5. Kwan D, Farrell B, CE Lesson: Polypharmacy: Optimizing medication use in elderly patients, Pharmacy Practice, 2015.
6. Buna DK, CE Lesson: Managing Pain in the Elderly, Pharmacy Practice, April 2014.
7. Self-Assessment Examination, Commission for Certification in Geriatric Pharmacy (CCGP), 2013.
8. Tam K, Thyroid module, Certified Geriatric Pharmacist preparation course, Ontario Pharmacists Association, 2009.
DATE: Apr 23, 2018.
Page 49 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
b) NAME:
COULSTON, Barb Adjunct Clinical Assistant Professor Member of the Graduate Faculty: no b) DEGREES:
ACPR, Women’s College Hospital, College of Pharmacy, 1990 BScPhm, University of Toronto, Leslie Dan Faculty of Pharmacy, 1989 c) EMPLOYMENT HISTORY:
2011- Clinical Pharmacist, The Centre for Family Medicine, Kitchener, ON 2011- Adjunct Clinical Assistant Professor, School of Pharmacy, University of Waterloo, ON 2010-2011 Structured Practical Experience Coordinator (SPEP), Faculty of Pharmacy, University of Toronto, ON 2000-2010 Clinical Pharmacist, Toronto Rehab Institute, Toronto, ON 1991-1992 Clinical Pharmacist, Mt. Sinai Hospital, Toronto, ON 1989-1990 Pharmacy Resident, Women’s College Hospital, Toronto, ON 1989 Pharmacy Intern, Clark Insitute of Psychiatry, Toronto, ON 1980-1987 Pharmacy Assistant, Lakeshore Pharmacy Ltd., Toronto, ON d) HONOURS: e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2017- Pharmacy Lead, The Centre for Family Medicine Family Health Team 2014-2016 Member, Collaborative Qualitiy Innovation Board, The Centre for Family Medicine Family Health Team 2015 Memory Clinic Training Program, The Centre for Family Medicine 2014 LEAP Palliative Care Continuing Education Course Certification 2011 Management of Oral Anticoagulation Therapy (MOAT) Primary Care Certificate f) GRADUATE SUPERVISIONS:
NONE
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion: Page 50 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
CLINICAL SUPERVISIONS:
PharmD: 16 completed; 0 in progress Residents: 1 completed; 0 in progress BSc Phm: 5 completed; 0 in progress
Name of Student Type (years of supervision) Dates Kavetha Selvathilagan Entry-to practice PharmD student, July-August, 2017 University of Waterloo Janny Xia Entry-to practice PharmD student, May – June, 2017 University of Waterloo Natasha Szabolics Entry-to practice PharmD student, March-April, 2017 Univeristy of Waterloo Ryan Vanderdrunk Entry-to practice PharmD student, January-February, 2017 University of Waterloo Luna Salameh Non-traditional , post baccalaureate November 2016 - PharmD student, University of February 2017 Toronto Jonathan Sun Entry-to practice PharmD student, September-October, 2016 University of Toronto Deanna Caldwell Entry-to practice PharmD student, August-September, 2016 University of Toronto Hala Al Loos Entry-to practice PharmD student, July-August, 2016 University of Waterloo Mackenzie Jonker Entry-to practice PharmD student, May-June, 2016 University of Uma Paranthaman Entry-to practice PharmD student, March-April, 2016 University of Michelle Holm Pharmacy Resident, McMaster February 2016 University Medical Centre Jeein Lee Entry-to practice PharmD student, September-December, University of Toronto 2015 Annie Cho Entry-to practice PharmD student, July-August, 2015 University of Waterloo Karthi Chandrakumaran Entry-to practice PharmD student, May-June, 2015 University of Waterloo Ben Harper Entry-to practice PharmD student, March-April, 2015 University of Waterloo Michelle Holm Entry-to practice PharmD student, January-February, 2015 University of Waterloo Holly Meginnis Entry-to practice PharmD student, January – Febraury, 2015 Page 51 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
University of Waterloo Monique Potvin BSc Phm student, University of September-December, Waterloo 2013 Jillian Bauer BSc Phm student, University of September-December, Waterloo 2012 Kaite Wakeford BSc Phm student, University of May-August, 2012 Waterloo Nicole Seymour BSc Phm student, University of January-April, 2012 Waterloo Joanna Oldenburger BSc Phm student, University of September-December, Waterloo 2011 Numerous SPEP and EPE students, University of 2010-2011 Toronto g) GRADUATE COURSES: past 7 years, by year
2012-2015 Lecturer, Pharm610 Topics in Drug Development h) 1. EXTERNAL RESEARCH FUNDING
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 0 - refereed journal articles ...... 0 - refereed conference proceedings...... 0 - presentations at conferences ...... 0 - technical reports ...... 0 - invited/keynote addresses ...... 0 - others (publications, workshops presented) ...... 5
Page 52 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Publications:
1. Coulston B, Whitehead C. Practice Spotlight: Collaborative Patient Care. CJHP. 2008: 61(2). DOI: http://dx.doi.org/10.4212/cjhp.v61i2.32
2. Coulston, B. Getting Back on Track, contributing to patient rehabilitation. Pharmacy Practice. 2007 Mar.
3. Coulston, B. Inter-professional education. Pharmacy Practice. 2006 Sept.
DATE: January 2018.
Page 53 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
DHAMI, Rita Adjunct Clinical Assistant Professor Member of the Graduate Faculty: no b) DEGREES: designation, institution, department, year
Doctorate of Pharmacy, University of Florida, USA, 2011 Bachelor of Science, Pharmacy, University of Toronto, Toronto ON, 2004 Bachelor of Science, Pre-Health Sciences, University of Waterloo, Waterloo ON, 2000 c) EMPLOYMENT HISTORY: dates, rank/position, department, institution/firm
2014 – Antimicrobial Stewardship Pharmacist, London Health Sciences Centre, Victoria Hospital, London, ON 2011 – Adjunct Clinical Assistant Professor, Wchool of Pharmacy, University of Waterloo, Waterloo, ON 2010 – Course Manager: PT 9543b Pharmacology; PT 9610b Pharmacology 2, School of Physical Therapy, Western University, Elborn College, London, ON 2007 –2013 Course Instructor, Pharmacy Technician Program, Fanshawe College, London, ON 2008 –2012 Clinical Pharmacist, Coronary Care Unit, London Health Sciences Centre, London, ON 2001 –2008 Clinical Pharmacist, Orthopaedic Surgery, London Health Sciences Centre, London, ON 2005 – Staff Pharmacist, Shoppers Drug Mart #1328, London, ON 2004 –2005 Clinical Pharmacist, General Medicine and General Surgery, Hamilton Health Sciences, Henderson Site, Hamilton, ON d) HONOURS: (F.R.S., F.R.S.C., Governor Generals Award, honorary degree, etc...)
May 2015 LHSC Department of Pharmacy: Dale Elviss Award for Outstanding Research Project design for the Candidemia in Critical Care Project Jan 2015 Accreditation Leading Practice Award for C.difficile Project Nov 2014 CSHP 2015 Success Story Award Recipient for Ontario Nov 2012 Nominee for CSHP Ontario Branch Clinical Pharmacist of the Year Award June 2012 LHSC Department of Pharmacy: Dale Elviss Award for Outstanding Research Project design for the DENISE-1 Project
Page 54 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Jan 2011 LHSC Foundation: Dianne Y Stewart Award for a commitment to life-long learning and education of others e) SCHOLARLY AND PROFESSIONAL ACTIVITIES: past 7 years only (eg. executive and editorial positions but not memberships in societies)
2017- Member, National Surgical Quality Improvement Project 2017- Member, Persons who Inject Drugs (PWID) Project Committee 2016 Vice President, Region of Waterloo Pharmacist Association yyyy – present Course Coordinator and Instructor, PHARM 130: Professional Practice II (core), School of Pharmacy, University of Waterloo yyyy – present Course Coordinator and Instructor, PHARM 377: Drug Induced Disease (elective), School of Pharmacy, University of Waterloo yyyy – present Guest Lecturer, PHARM 222: Integrated Patient Focused Care 3 (Female contraception), School of Pharmacy, University of Waterloo yyyy – present Guest Lecturer, PHARM 321: Integrated Patient Focused Care 6 (PUD and GERD) yyyy Developed and recorded online content for OPA online program: Assessing and Prescribing for Minor Ailments (Patient Triage & Assessment) yyyy- Content Developer & Assessor, OSCE final examinations, School of Pharmacy, University of Waterloo yyyy – Content developer, PHARM 229: Professional Practice 4, School of Pharmacy, University of Waterloo yyyy – Content developer, PHARM 329: Professional Practice 5 (Vaccines), School of Pharmacy, University of Waterloo yyyy – Coordinator, PHARM 401: Independent Study, School of Pharmacy, University of Waterloo yyyy – Teaching Assistant, PHARM 425: Symposium, School of Pharmacy, University of Waterloo 2014-2015 Member, Surviving Sepsis Campaign, London Health Scineces 2012-2015 Member, Curriculum and Program Evaluation Committee, Department of Physical Therapy, Facutly of Health Sciences, University of Western Ontario 2012-2014 Pharmacology Content Reviewer, Journal of the Canadian Dental Association 2012-2013 Member, Expanded Scope of Practice Task Force, Canadian Society for Hospital Pharmacists, Ontario Branch 2012-2013 Member, Look-alike Sound-alike Drugs Safety Project, London Health Sciences Centre 2012- Member, Canadian Pharmacists Association
Page 55 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2012 Member, Clinical Screening Manual Project, London Health Sciences Centre 2011-2012 Chair, Pharmacy Technician Task Force Committee, Canadian Society for Hospital Pharmacists 2011 Member, Dangerous Abbreviations, Medication Safety Committee, London Health Sciences Centre 2010 - Member, Ontario Pharmacist Association 2010 - Member, Ontario College of Pharmacists 2009-2012 Branch Delegate, National Councnil Ontario, Canadian Society of Hospital Pharmacists (CSHP) 2007-2010 Chair, Southwestern Ontario Chapter, Ontario Branch, Canadian Society of Hospital Pharmacists 2007-2010 Teaching Assistant, 4th year Pharmacy Students Structured Practical Experience Program (SPEP), Faculty of Pharmacy, Univeristy or Toronto 2008 - Technician Order Entry Project and “TechTalk” Lecture Series, LHSC Developed a pharmacy technician lecture series and streamlined operational process to improve quality of technician order entry 2006-2012 Journal Club Rounds Presenter, Department of Pharmacy, London Health Sciences Centre 2005-2012 Nursing In-Service Presentations 2006 Grand Rounds Speaker, Department of Medicine, London Health Sciences Centre 2004- Ontario Pharmacists Association 2004- Canadian Society of Hospital Pharmacists
f) GRADUATE SUPERVISIONS: master=s, doctoral, postdoctoral - completed/in progress
None
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion: g) GRADUATE COURSES: past 7 years, by year
None h) 1. EXTERNAL RESEARCH FUNDING: past 7 years only, by year, indicating source (granting councils, industry, government, foundations, other); amount; principal investigator; purpose (research, travel, publications, etc...)
Page 56 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Year Source Type* Amount per year Purpose**
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING: This includes university funds, SSHRC minor grants awarded through the University, etc.] Year Source Type* Amount per year Purpose**
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS: The Publications should be listed in the categories shown below and include the following information: books authored, books edited (a list of the chapters contributed by the editor must follow each title), chapters in books (other than those listed in the above category), papers in refereed journals, papers in refereed conference proceedings, technical reports, abstracts and/or papers read, and others. Each title must show the names of the authors in the order in which they appear in the original publication and inclusive page numbers. Publications submitted, but not yet accepted, must be listed separately within the various categories.
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 0 - refereed journal articles ...... 0 - refereed conference proceedings...... 0 - presentations at conferences ...... 11 - technical reports ...... 0 - invited/keynote addresses ...... 0 - others (workshops presented) ...... 18
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Journals:
Publications:
Page 57 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Abstracts and / or Papers Read:
1. Dhami R, Popovski Z, Elsayed S, Juba M. Improving Management of Clostridium difficile Infection by Direct Notification to Pharmacists. Association of Medical Microbiology and Infectious Diseases Canada Conference, Toronto ON. May 2017.
2. Dhami R, Popovski Z, Juba M, Elsayed S. Experience with Face-to-Face and Remote Provision of Antimicrobial Stewardship Recommendations for a General Medicine Inpatient Population. Association of Medical Microbiology and Infectious Diseases Canada Conference, Toronto ON. May 2017. 3. Oesch A, Dhami R, Lougheed C, Elsayed S. Thrombocytopenia during Treatment with Ceftolozane/Tazobactam. Canadian Society of Hospital Pharmacists Professional Practice Conference. Toronto ON, Feb 2017.
4. Dhami R, Popovski Z, Elsayed S, Jansen S, Vandersluis C. Speaking up on the use of Antimicrobials in Critical Care. Quality and Patient Safety Conference, London ON. October 2016.
5. Dhami R, Killeen R, Waite N, Jennings B. Advancing Professional Practice Skills for Recent Bachelor of Pharmacy Graduates. Lifelong Learning in Pharmacy Conference: Split: Croatia, July 2016.
6. Popovski Z, Dhami R, Elsayed S, Jansen S, Vandersluis C. We PIC’D our Battle: Canadian Society of Hospital Pharmacists Vision 2015 Success Story. October 2014.
7. Popovski Z, Dhami R, Elsayed S. Multidisciplinary Review Process indicates the Need for Pharmacist Intervention on Clostridium Difficile Infection. Canadian Society of Hospital Pharmacists Professional Practice Conference. Toronto ON, Feb 2014.
8. Dhami R, Kreutwiser D, Edwards-Lee K. The DaltEparin versus rivaroxabaN In total knee arthroplaSty patiEnts (DENISE-1) Study. Canadian Society of Hospital Pharmacists Ontario Branch Residency Poster Night. June 2012.
9. Adams C, Dhami R. Pharmacy Technician Analysis of Membership. Canadian Society of Hospital Pharmacists Mid-Term Council Meeting Feb 2012.
Workshops / Presentations Presented:
1. “Introduction to Antimicrobial Stewardship” Pharmacy Resident Lecture Series. London Health Sciences Centre. Jan 2018.
Page 58 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2. “Bugs & Drugs for RNs”. Critical Care Unit (CCTC & MS-ICU), London Health Sciences Centre, Nov 2017.
3. “Antimicrobials in Surgery”. Surgery Resident Orientation. C-STAR Training, London Health Sciences Centre. July 2017.
4. “Overview of Antimicrobial Stewardship”. Medical Resident Orientation. London Health Sciences Centre, July 2017.
5. “Antibiotics for UTI. Urology Academic Half-Day Teaching. University of Western Ontario, Schulich School of Medicine & Dentistry. June 2016.
6. “Psoriasis “. Canadian Health Network Education Series Webinar. 2014.
7. “Putting PPI Safety into Perspective”. London District Pharmacists Association Continuing Education London ON, March 26, 2014.
8. “Pharmacist Expanded Scope of Practice Program” London District Pharmacists Association Continuing Education. London ON. Feb 26, 2014
9. “Chronic Constipation: Advances in Management and Treatment Options”. Shoppers Drug Mart Associate Owners District Meeting London ON June 29, 2013.
10. “Morning Blood Pressure Surge and Cardiovascular Implications: A New Look at an Old Drug Class”. London District Pharmacists Association Continuing Education London ON, April 5, 2013.
11. “A Practical Approach to Stroke Prevent in Atrial Fibrillation.” London District Pharmacists Association Continuing Education London ON Dec 10, 2012.
12. “Seamless Transition from Hospital to Community”. Ontario Pharmacists Association Cardiovascular Certificate Program Toronto ON November 9, 2012
13. “Update on Psoriasis.” London District Pharmacists Association Continuing Education London ON October 18, 2012.
14. “Acute Coronary Syndrome: A review of recent oral antiplatelet management options”. London District Pharmacists Association Continuing Education London ON May 16, 2012.
15. “To the Heart of the Matter: NSAIDs in Cardiovascular Disease “. Shoppers Drug Mart Associate Owners District Meeting April 12 2012. Page 59 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
16. “Advances in Dual Anti-platelet Therapy for ACS”. Canadian Society of Hospital Pharmacists Ontario Branch, Southwestern Chapter Continuing Education, July 2011.
17. “New Strategies to aid Stroke Prevention in Atrial Fibrillation”. Canadian Society of Hospital Pharmacists Ontario Branch, Southwestern Chapter Continuing Education, June 28, 2011.
18. “Presented Managing Night-time Breakthrough Symptoms – the Role of a New PPIs”. London District Pharmacists Association Continuing Education London ON March 28, 2011.
DATE: April 2018
Page 60 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
EDGINTON, Andrea N. Associate Professor Member of the Graduate Faculty: Yes b) DEGREES:
Certificate, Academic Leadership Fellows Program, American Association of Colleges of Pharmacy, 2016
PhD, Environmental Toxicology, University of Guelph, Canada, 2004 BSc, Environmental Biology, University of Guelph, Canada, 1998 c) EMPLOYMENT HISTORY:
2015- Programmatic Assessment Officer, School of Pharmacy, University of Waterloo, Waterloo, ON 2014- Associate Professor, School of Pharmacy, University of Waterloo, Waterloo, ON 2013- Special Graduate Faculty, Department of Pharmaceutical Sciences, University of Tennessee College of Pharmacy, TN, USA 2012- Special Graduate Faculty, Bioinformatics, Department of Computer Science, University of Guelph, Guelph, ON 2010-2012 Graduate Officer, School of Pharmacy, University of Waterloo 2009- Cross-appointed Faculty, Biology, University of Waterloo 2008-2014 Assistant Professor, School of Pharmacy, University of Waterloo 2004-2008 Pharmacokinetics Consultant, Systems Biology, Bayer Technology Services, Leverkusen, Germany 2004-2006 Post-doctoral Fellow, Systems Biology, Bayer Technology Services, Leverkusen, Germany 2004 Study Director, Syngenta, Greensborough, NC, USA 2002-2004 Teaching Assistant, Department of Environmental Biology, University of Guelph 2001–2003 Lecturer, Department of Biomedical Sciences, University of Guelph 2000–2002 Technical Writer/Workshop Chair, Environment Canada, Methods Development Section, Ottawa, ON d) HONOURS:
2016 Outstanding Performance Award, University of Waterloo
Page 61 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015 Excellence in Science Teaching Award, one of two Science Faculty members for 2015 2013 Outstanding Performance Award, University of Waterloo - Given to 80 professors in 2013. The award recognizes the top 10 per cent of UW faculty. 3.5% increase in salary. e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2018 Invited Working Group Member, Bill & Melinda Gates Medical Research Institute event. PD Challenge Workshop: Collaborating to Improve Translational Medicine in Global Health 2017 External MSc thesis reviewer, Davide Matino. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON. 2016- Member, Editorial Advisory Board, Journal of Pharmacokinetics and Pharmacodynamics 2016- Member of the Scientific Advisory Board, Pharmaceutical Education and Research with Regulatory Links (PEARRL, a Marie Sklodowska-Curie European Training Network) 2015- Member, School Advisory Committee on Appointments (SACA), School of Pharmacy, University of Waterloo 2015- Chair, Assessment Committee, School of Pharmacy, University of Waterloo 2014-2015 Member, Editorial Board, Obstetrics and Pediatric Pharmacology Journal 2010- Member, Graduate Studies and Research Committee, School of Pharmacy, University of Waterloo 2015- Member of the Editorial Board, Journal of Pharmacokinetics and Pharmacodynamics 2009- Member of the Editorial Board, Therapeutic Drug Monitoring Journal 2008-2014 Member, Science Undergraduate Appeals Committee 2013-2016 Chair Elect, Clinical Research Ethics Committee, University of Waterloo 2012-2015 Member, Assessment Committee, School of Pharmacy, University of Waterloo 2009-2013 Member, Clinical Research Ethics Committee, University of Waterloo 2014 Grant Reviewer, Canadian Foundation for Innovation John R. Evans Leaders Fund 2013 NSERC Industrial Chair in Pharmacometrics Award. Role: Committee member (n=5) for review and site visit. 2013 Grant reviewer, Biotechnology and Biological Sciences Research Council (BBSRC), UK. "Mechanistic modeling of biologics" July 2013. 2013 Session Chair and speaker of Pediatric PBPK modeling session, American
Page 62 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Conference on Pharmacometrics, Fort Lauderdale, Florida, May 2013. 2012 Member, Academic Excellence Committee, School of Pharmacy, University of Waterloo 2011 External Ph.D. Reviewer, Mathieu Valcke, University of Montreal, Montreal, Quebec, November 2011. 2011 Grant reviewer, National Institute of Academic Anaesthesia, UK, "Plasticiser concentrations in children undergoing mechanical ventilation with sedation" April 2011 f) GRADUATE SUPERVISION:
Completed: 3 MSc, 2 PhD, 2 Post-doc, 2 PharmD resident, 4 co-supervision In Progress: 1 MSc, 3 PhD, 1 Post-doc
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Type (years of Title of Thesis or Project Status Student supervision) Binbing Development of a drug-drug interaction (Post-doc) 2014 Completed Ling laboratory focused on food animals Ishita Literature review of vancomycin (co-op) 2014 Completed Patel pharmacokinetics Literature review of drug-drug interaction Kevin Lee (co-op) 2014 Completed studies in food animals Alanna Physiologically-based pharmacokinetic model (MSc) 2013-2015 Completed McEneny of novel tacrine derivatives The consequences of a lack of adult IV Rabiya (MSc) 2012-2014 pharmacokinetic data in pediatric equivalent Completed Chandani dosing simulations Caroline Missed doses in a hospital setting – an (co-op) 2012-2013 Completed Wojick assessment of causes Laura Missed doses in a hospital setting – an (co-op) 2010-2011 Completed Dunn assessment of causes Decision tree development for accurate prediction of tissue: plasma partition Yejin Yun (MSc) 2010-2013 Completed coefficients within physiologically based pharmacokinetic models Venita (PhrmD rotation) 2009- Development of a multi-media tool for Completed Harris 2012 teaching Clinical Biochemistry to Pharmacy
Page 63 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
students
PBPK model development for prediction of Pardeep (RA) 2008-2010 the effects of exercise and heat stress on Completed Sidhu military personnel Anil (MSc/PhD) 2012-2016 Development of an oral mechanistic Completed Maharaj full time absorption model for pediatrics Alanna (PhD) 2015- full time Population PK modeling in Hemophilia In Progress McEneny Elliot (PhD) 2011-2016 part Design of preclinical toxicokinetic studies for Completed Offman time assessment of macromolecule biosimilarity Colin (Post doc) 2014-2016 Population PBPK modelling In Progress Phipps Pierre Population pharmacokinetic modelling in (Post doc) 2017- In Progress Chelle hemophilia Yejin Yun (PhD) 2018- full time PBPK for risk assessment in children In Progress Population pharmacokinetics – brand Jacky Yu (MSc) 2018- full time In Progress switching PK prediction
g) GRADUATE COURSES: past 7 years, by year 2012, 2016, 2018 - PHARM 609 – Advanced Pharmacokinetics 2011-2012 PHARM 608A – Special Topics in Pharmaceutical Sciences – Pharmacokinetics h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Role
Page 64 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2018- Canadian C $335,000 Research Principle Investigators: 2021 Institutes of Andrea Edginton and Health Research Alfonso Iorio Project Grant 2017- Hemophilia O $110,000 Research Supports post-doctoral 2019 Fellowship fellow position in Program, Pfizer Edginton Lab Inc. 2017- Natural C $140,000 Research Principal Investigator: 2022 Sciences and Andrea Edginton Engineering Research Council of Canada Discovery Grant 2015- Ontario Centres G $25,000 Research Principal Investigator: 2016 of Excellence – Andrea Edginton VIP I Program
2015- National G $45,000 Research Principal Investigator: K. 2020 Institute of Watt, Duke University Health, USA Consultant: A. Edginton 2015- Department of O $20,000 Research Principal Investigator: P. 2016 Psychiatry, Reddy, Queen’s Queen’s University University Co-Investigators: E. Ling and A. Edginton 2014- National G $40,000 Research Principal Investigator: M. 2018 Institute of Cohen-Wolkowiez, Duke Health, USA University Co-Investigators: E. Capparelli and A. Edginton 2014- Astellas O $102,000 Research Principal Investigator: 2018 Pharma Inc Andrea Edginton 2014- Astellas O $27,000 Research Principal Investigator: 2018 Pharma Inc Andrea Edginton 2009- Natural C $125,000 Research Principal investigator: A. 2016 Sciences and Edginton Engineering Research Council Discovery Page 65 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Grant 2008 Defense G $92,000/5 Research Principal investigator: A. Research & months Edginton Development Canada
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose Investigator 2010 CIHR Incentive O $8,000 Research Principal Investigator: A. Funding – one time Edginton University of Waterloo 2009-2011 Learning Fund O $13,475 Research Initiative Grant - University of Waterloo 2009 University of O $250,000 Research Waterloo Start- up Funds
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories: Chapters in books ...... 2 Papers in refereed journals ...... 52 Technical reports ...... 4 Others (workshops presented) ...... 115 Patents ...... 2
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Page 66 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Chapters in Books
1. Phipps C, Edginton AN. Population Generation for PBPK Models In Pharmacometrics: The Science of Quantitative Pharmacology, Second Edition. Ette E, Bies R, Williams P eds. Wiley. In press
Papers in Refereed Journals
1. Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. 2018. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. Clinical Pharmacokinetics. In press.
2. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. 2017. Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis. Pharmaceutics. 9(4): E 47. INVITED
3. Edginton AN. 2018. Using physiologically based pharmacokinetic modeling for mechanistic insight: cases of reverse translation. Clinical and Translational Science. 11(2):109-111. INVITED
4. Malik P, Phipps C, Edginton AN, Blay J. 2017. Pharmacokinetic considerations for antibody-drug conjugates against cancer. Pharmaceutical Research. 34(12):2579-2595. INVITED
5. Salerno S, Edginton A, Cohen-Wolkowiez M, Hornik C, Watt K, Jamieson B, Gonzalez D. 2017. Development of an adult physiologically based pharmacokinetic (PBPK) model of solithromycin in plasma and epithelial lining fluid. CPT: PSP. 6(12):814-822.
6. Maharaj AR, Gonzalez D, Cohen-Wolkowiez M, Hornik CP, Edginton AN. 2017. Improving pediatric protein binding estimates: an evaluation of α1-acid glycoprotein maturation in healthy and infected subjects. Clinical Pharmacokinetics. In press.
7. McEneny-King A, Osman W, Edginton AN, Rao PPN. 2017. Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity. Bioorg Med Chem Lett. 27(11):2443-2449.
8. Boerma M, Coyle, EA, Dietrich MA, Dintzner MR, Drayton SJ, Early J, Edginton AN, Horlen CK, Kirkwood CK, Lin A, Rager ML, Shah-Manek B, Welch AC, Toedter Williams N. 2017. Point/Counterpoint: Are Outstanding Leaders Born or Made? American Journal of Pharmaceutical Education. 81(3):58.
Page 67 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
9. Malik P, Hamadeh A, Phipps C, Edginton AN. 2017. Population PBPK modelling of trastuzumab: A framework for quantifying and predicting inter-individual variability. Journal of Pharmacokinetics and Pharmacodynamics. 44(3):277-290.
10. Hornik C, Cohen-Wolkowiez M, Gonzalez D, Edginton AN, Wu H, Watt, K. 2017. Development of a pediatric physiologically based pharmacokinetic model of clindamycin using opportunistic pharmacokinetic data. Clinical Pharmacokinetics. 56(11):1343-1353.
11. Delaney S, Malik P, Takeuchi M, Wong E, Stefan C, Edginton AN, et al. Drug monitoring and physiologically-based pharmacokinetic modeling of escitalopram in breast milk: Predicting plasma exposure in breast-feeding infants. Birth Defects Res. 2017;109 (Special Issue: Si):704. Abstract.
12. Iorio A, McEneny-King A, Keepanasseril A, Foster G, Edginton AN. 2017. What is the role of population pharmacokinetics in hemophilia? International Journal of Pharmacokinetics. 2(2): 125-136.
13. Iorio A, Edginton AN. 2017. Exploring some intersections between pharmacokinetics, factor VIII measurement, and human morphometrics – impact of recent advances in hemophilia study design on our understanding of optimal hemophilia treatment. Hemophilia. 23(4):488-490.
14. Offman E, Edginton AN. 2017. Pharmacokinetic time course scaling of a subcutaneously administered pegylated peptide conjugate for a first-in-human investigation. European Journal of Drug Metabolism and Pharmacokinetics. 42(1):69-78.
15. Maharaj AR, Edginton AN. 2016. Examining small intestinal transit time as a function of age – Is there evidence to support age- dependent differences among children? Drug Metabolism and Disposition. 44(7):1080-9. INVITED
16. Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L., WAPPS-Hemo co-investigator network. 2016. Development of a Web- Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc. 5(4):e239.
17. McEneny-King A, Foster G, Iorio A, Edginton AN. 2016. Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS- Hemo). JMIR Res Protoc. 5(4):e232.
Page 68 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
18. Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC. 2016. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically basedmodeling and simulation in mice. Cancer Chemother Pharmacol. 77(5): 1039-52.
19. McEneny-King A, Iorio A, Foster G and Edginton AN. 2016. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opinion on Drug Metabolism and Toxicology. 12(11): 1313-1321
20. Offman E, Phipps C, Edginton AN. 2016. Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide. In Silico Pharmacol. 4(1):3.
21. Keating S, Kerr C, McDonell W, Valverde A, Johnson R, Knych H, Edginton AN. 2016. Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. Veterinary Anaesthesia and Analgesia.
22. Maharaj AR, Edginton AN, Fotaki N. 2015. Assessment of age-Related changes in pediatric gastrointestinal solubility. Pharmaceutical Research. 1-20.
23. Wang J, Edginton AN, Avant D, Burkhart G. 2015. Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling. Journal of Clinical Pharmacology. 55(10):1175-83.
24. Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R, Wang XM, Gronda M, Boyaci E, Bojko B, Minden M, Sriskanthadevan S, Datti A, Wrana JL, Edginton AN, Pawliszyn J, Joseph JW, Quadrilatero J, Schimmer AD, Spagnuolo PA. 2015. Targeting mitochondria with avocatin B induces selective leukemia cell death. Cancer Research. 15;75(12):2478- 88
25. Keating S, Edginton AN, Pharmacokinetics of a constant rate infusion of fentanyl in dogs during isoflurane anesthesia and following administration of acepromazine or dexmedetomidine during anesthetic recovery. Veterinary Anaesthesia and Analgesia. In press.
26. Offman E, Edginton AN. 2015. A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide. Journal of Pharmacokinetics and Pharmacodynamics. 42(2):135-50.
27. Maharaj A, Fotaki N, Edginton AN. 2015. Parameterization of small intestinal water volume using PBPK modeling. European Journal of Pharmaceutical Science. 67:55-64.
Page 69 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
28. McEneny-King A, Edginton AN, Rao PP. 2015. Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. Bioorganic & Medicinal Chemistry Letters. 25(2):297-301.
29. Hu Z, Edginton AN, Laizure SC, Parker RB. 2014. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity - Effects on oseltamivir disposition. Clinical Pharmacokinetics. 53(9): 825-836.
30. Yun YE, Cotton C, Edginton AN. 2014. Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound. Journal of Pharmacokinetics and Pharmacodynamics. 41(1): 1-14.
31. Peng H, Edginton AN, Cheung B. Investigation of an alternative generic model for predicting pharmacokinetic changes during physiological stress. 2013. Journal of Clinical Pharmacology; 53(10): 1048-57.
32. Willmann S, Becker C, Burghaus R, Coboeken K, Edginton AN, Lippert J, Siegmund H, Thelen K, Mück W. 2014. Developxment of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clinical Pharmacokinetics; 53(1): 89-102.
33. Maharaj AR, Edginton AN. 2014. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. Clinical Pharmacology and Therapeutics: Pharmacometrics Systems Pharmacology. 3:e150.
34. Maharaj AR, Barrett JS, Edginton AN. 2013. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS. 15(2):455-464.
35. Edginton AN, Shah B, Sevestre M, Momper JD. 2013. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of six years. Clinical Pharmacokinetics; 52(8): 693-703.
36. Yun YE, Edginton AN. 2013. Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters. Xenobiotica. 43(10): 839-52.
37. Offman E, Edginton AN. 2013. Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development. Xenobiotica. 43(6):561-9.
38. Edginton AN, Power M, Stark A, Holbrook J. 2013. Using student feedback to design a more effective clinical biochemistry course component. Currents in Pharmacy Teaching and Learning. 5(1): 23-32. Page 70 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
39. Boscarino C, Edginton AN, Peng H, Riggs KW, Szeitz A, Cheung B. 2013. The effect of operational stressors on ibuprofen pharmacokinetics. European Journal of Clinical Pharmacology. 69(1): 31-41
40. Edginton AN, Joshi G. 2011. Have physiologically-based pharmacokinetic models delivered? Expert Opinion on Drug Metabolism and Toxicology. 7(8):929-34.
41. Edginton AN. 2011. Knowledge-driven approaches for the guidance of first-in-children dosing. Pediatric Anaesthesia. 21(3): 206-213.
42. Sidhu P, Peng H, Cheung B, Edginton AN. 2011. Simulation of differential drug pharmacokinetics under heat and exercise stress using a physiologically-based pharmacokinetic modeling approach. Canadian Journal of Physiology and Pharmacology. 89(5):365-82.
Technical Reports
Conferences Presented (oral)
1. Edginton AN. Pharmacokinetics in Hemophilia Workshop (Workshop moderator and presenter). 9th Annual Bayer Hemophilia Conference, Nov 2-4, 2017, Amsterdam, The Netherlands. *150 hemophilia treaters, 2 hour workshop.
2. Edginton AN. An introduction to PK-Sim®: the open source platform for PBPK modeling. Webinar for the Society of Toxicology Biological Modeling Specialty Section (BMSS). October 20, 2017.
3. Edginton AN. Physiologically based pharmacokinetic (PBPK) modeling and simulation in clinical trial planning. Translational-Oriented Quantitative Therapeutic Approaches: A Concerted Effort. Montreal, QC. June 13-15, 2017.
4. Edginton AN. The Midpoint Assessment: Development considerations, remediation options and lessons learned. Lunch and Learn - Student Progression and Remediation, School of Pharmacy, University of Alberta. March 9, 2017. (webinar)
5. McEneny-King A, Iorio A, Edginton AN. Individual pharmacokinetic assessment: the WAPPS-Hemo project. 61st Annual Meeting of the Society of Thrombosis and Hemostasis Research. Basel, Switzerland. Feb 15-18, 2017.
Page 71 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
6. Edginton AN. Physiologically based pharmacokinetic (PBPK) modeling and simulation in pediatric drug development. 6th FIP Pharmaceutical Sciences World Congress. Stockholm, Sweden. May 21-24, 2017.
7. Edginton AN. Modeling Pediatric Pharmacokinetics: Physiologically based pharmacokinetic (PBPK) modeling and simulation. IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network) Network’s Pediatric Pharmacology Scientific Retreat. Washington, DC. January 23-25, 2017.
8. Edginton AN. PBPK Model Extrapolation to the Pediatric Population: Querying Uncertainty, Defining a Role for Experimentation and Current Practices. International Society for the Study of Xenobiotics (ISSX) Workshop: Translating Preclinical Data to Human Clearance and Pharmacokinetics, Boston, MA. October 27-28, 2016.
9. McEneny-King A, Edginton AN, Foster G, and Iorio A. Web Accessible Population Pharmacokinetics Service? Hemophilia (WAPPS-Hemo): an innovative approach to tailored prophylaxis. SIAM Conference on the Life Sciences, July 11-16, 2016, Boston, MA, USA.
10. Richard C, Rigby A, Edginton AN. 2016. 2nd Year Midpoint Assessment to identify PharmD students for remediation. Opportunities and New Directions Conference, University of Waterloo, Waterloo, ON. April 28, 2016.
11. Edginton AN. 2nd Year Midpoint Assessment: Identifying At Risk Students. 73rd Annual General Meeting of the AFPC, 7th Annual Canadian Pharmacy Education & Research Conference. May 31-June 2, 2016.
12. Edginton AN. Physiologically-based pharmacokinetic (PBPK) Modelling and Simulation in Pediatric Drug Development. Canadian Society of Pharmaceutical Sciences Annual Meeting. Vancouver, BC, May 31 – June 2, 2016.
13. Edginton AN. Modeling and Simulation to Support Pediatric Drug Development. American Society for Pharmacology and Experimental Therapeutics/Experimental Biology Annual Meeting. San Diego, CA. April 2 - 6, 2016.
14. Edginton AN. PBPK modeling and simulation in drug development: a focus on pediatrics. Society of Toxicology Annual Meeting. New Orleans, LO. March 15-17, 2016.
15. Panetta C, Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD. Sorafenib Physiologically Based Pharmacokinetic modeling: a case study in model evaluation approaches. Workshop on Mathematical Oncology VI April 11-13, 2016 at the Fields Institute, Toronto, Canada. Page 72 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
16. Edginton AN. Physiologically based pharmacokinetic (PBPK) model development and application: a focus on children. School of Pharmacy and Pharmaceutical Sciences, University of Buffalo. December 10, 2015.
17. Maharaj AR, Edginton AN. Importance of experimental determination of factors that reduce uncertainty and allow for identifiability of other parameters. AcoP (American Association of Pharmacometrics) meeting in October 4-7, 2015
18. Edginton AN. Pediatric physiologically-based pharmacokinetic (PBPK) modeling: Current & potential approaches. IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network) Network’s Pediatric Pharmacology Workshop. 19 June 2015, Arlington, VA
19. Lee EA, Angka L, S Rota, Hanlon T, Hurren R, Wang XM, Gronda M, Bernard D, Minden MD, Mitchell A, Edginton AN, Sriskanthadevan S, Datti A, Wrana J, Joseph JW, Quadrilatero J, Schimmer AD, Spagnuolo PA. Inhibition of fatty acid oxidation with Avocatin B selectively targets AML cells and leukemia stem cells. 56th ASH Annual Meeting and Exposition, San Francisco, CA. December 6-9, 2014. (Abstract in Blood. 124(21): 268)
20. McEneny A, Osman W, Edginton AN, Nekkar P. Chemical structure modification of tacrine and its effect on CYP1A2 binding: in vitro and in silico investigations. CANAD 2014 - Canadian Alzheimer’s Disease Research Symposium, Quebec City, Quebec, Canada. October 2-4, 2014.
21. Edginton AN. Physiologically based pharamcokinetic modeling in children: Data in, knowledge out. 2014 Pediatric Pharmacogenomics and Personalized Medicine Conference. Children’s Mercy Hospital, Kansas City, MO, USA. April 10-11, 2014. (invited)
22. Edginton AN. Rational pediatric dose prediction: A role of physiologically-based pharmacokinetic (PBPK) models. International Society of Pharmacometrics (IsoP) local chapter meeting. Northbrook, IL, USA. Jan 29, 2014. (invited)
23. Edginton AN. Review of current practices in pediatric PBPK modelling. American Conference on Pharmacometrics (ACoP) 4th annual meeting, Fort Lauderdale, FL, USA. May 12-15, 2013. (Session chair and speaker)
24. Edginton AN, Holbrook J, Power M. Using student feedback to design a more effective Clinical Biochemistry course component. Opportunities and New Directions Conference, University of Waterloo, Waterloo, ON, Canada. April 26, 2012.
Page 73 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
25. Edginton AN, Holbrook J, Power M, Stark A. Assessing student engagement in a multi- media teaching tool in Pharmacy. Western Conference on Science Education,University of Western Ontario, London, July 6-8, 2011
26. Edginton AN. Physiologically based pharmacokinetic (PBPK) models for prediction of the age-dependence of drug disposition. Applied Pharmaceutical Analysis 2011: a meeting of The Boston Society, Cambridge, MA. Sept 11-14, 2011. (invited)
27. Edginton AN. Physiologically based pharmacokinetic (PBPK) models for prediction of the age-dependence of drug disposition. Food & Drug Administration (FDA), Silver Spring, Maryland. August 24, 2011. (invited)
28. Edginton AN. Developing and applying PBPK models in paediatrics: a day long workshop. Children’s Hospital of Philadelphia, Philadelphia, USA. August 22-23, 2011.
29. Edginton AN. Pediatric medications: Application of mechanistic models of absorption, distribution and elimination for dosing guidance. International Council for Industrial and Applied Mathematics 2011 conference. Vancouver, BC. July 18 – 22, 2011.
Conferences Presented (poster)
1. Balbas-Martinez V.*, Edginton AN, Michelet R, Meesters K, Trocóniz IF, Vermeulen A. Physiologically-based pharmacokinetic model for ciprofloxacin in healthy children and approximation to children with complicated urinary tract infection. Population Approach Group in Europe (PAGE) Annual Conference, Montreux, Switzerland. May 29 – June 1, 2018.
2. Yeung CHT, Bonanad S, Muñoz JCM, Ozelo MC, Edginton AN, Hobson N, IorioA. Developing and testing a population pharmacokinetic model for Fanhdi/Alphanate from clinical pharmacokinetic reporting of hemophilia A patients. World Federation of Hemophilia World Congress, Glasgow, Scotland. May 20-24, 2018.
3. Silvertown J, Sohms A, Iorio A, Foster G, Edginton AN, Shah A. Use of the WAPPS model for BAY 81-8973: external validation of the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) platform to determine individual BAY 81-8973 pharmacokinetics. World Federation of Hemophilia World Congress, Glasgow, Scotland. May 20-24, 2018.
4. Staibano P, McEneny-King A, Morfini M, Foster G, Hobson N, Navarro-Ruan T, Edginton AN, Iorio A. Comparative assessment of the performance of pharmacokinetic tools for prophylactic dosing of factorVIII concentrate in patients with heophilia A. Annual Page 74 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Congress of the European Association for Haemophilia and Allied Disorders, Madrid, Spain. Feb 7-9, 2018.
5. Gerhart JG, Watt KM, Edginton AN, Wade KC, Benjamin Jr. DK, Smith PB, Hornik CP, Cohen-Wolkowiez M, Duara S, Ross A, Shattuck K, Gonzalez D. Physiologically-based pharmacokinetic (PBPK) modeling of fluconazole using plasma and cerebrospinal fluid samples collected from preterm and term infants. 2018 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Orlando, FL. March 21-24, 2018.
6. McEneny-King A, Chelle P, Foster G, Keepanasseril A, Iorio A, Edginton AN. Development and evaluation of generic population pharmacokinetic models for factor VIII for use in dose individualization. 2018 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Orlando, FL. March 21-24, 2018.
7. Malik PRV, Edginton AN. Pediatric physiology in relation to the disposition of monoclonal antibodies. 2018 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Orlando, FL. March 21-24, 2018.
8. Stemberger M, Kasselbach F, Schmit E, McEneny-King A, Edginton AN, Iorio I, Kurnik K. Population pharmacokinetics profiling to tailor prophylaxis in hemophilia a patients: a pilot feasibility study. American Society of Hematology 59th Annual Meeting. Atlanta, Georgia, US. Dec 9-12, 2017. Conference Proceedings in Blood 2017. 130: 2404.
9. Staibano P, McEneny-King A, Morfini M, Foster G, Hobson N, Navarro-Ruan T, Edginton AN, Iorio A on behalf of the WAPPS network investigators. Comparative assessment of the performance of pharmacokinetic tools for prophylactic dosing of antihemophilic factor recombinant plasma/albumin-free method (rAHF-PFM) concentrate in patients with Hemophilia A. American Society of Hematology 59th Annual Meeting. Atlanta, Georgia, US. Dec 9-12, 2017. Conference Proceedings in Blood 2017. 130: 4934.
10. Malik P, Delaney S, Takeuchi M, Wong E, Stefan C, Colantonio D, Ito S, Edginton AN. Physiologically-based pharmacokinetic modelling of escitalopram in breastfeeding infants. Pharmacy Research Day, School of Pharmacy, University of Waterloo, Waterloo, ON. April 26, 2017.
11. Delaney S, Malik P,Takeuchi M, Stefan C, Ito S, Edginton AN, Colantonio D. Predicting drug exposure in breast-feeding infants: using physiologically-based pharmacokinetic modeling of escitalopram in breast milk to simulate infant plasma concentrations. 69th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo. July 30 – August 3, 2017. San Diego, CA, USA
Page 75 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
12. Malik P, Delaney S, Takeuch M, Wong E, Stefan C, Colantonio D, Ito S, Edginton AN. Physiologically-based pharmacokinetic modelling of escitalopram in breastfeeding infants. Pharmacy Research Day, University of Waterloo, Waterloo, ON. April 26, 2017.
13. Salerno S, Edginton AN, Cohen-Wokowiez M, Hornik C, Jamieson B, Fernandes P, Gonzalez D. Development of an Adult Physiologically Based Pharmacokinetic (PBPK) Model of Solithromycin in Plasma and Epithelial Lining Fluid. ASCPT Annual Meeting, March 15-18, 2017, Washington DC.
14. McEneny A, Iorio A, Edginton AN. 2016. Web Accessible Population PharmacokineticsService -Hemophilia (WAPPS-Hemo): An innovative approach to tailored prophylaxis. SIAM Conference on the Life Sciences, Boston, MA, United States. July 2014.
15. Malik P, Phipps C, Edginton AN. Using population PBPK modelling to explore variability in trastuzumab pharmacokinetics . Canadian Society of Pharmaceutical Science (CSPC), Vancouver, BC, Canada. May 31 – June 2, 2016.
16. McEneny-King, A, Edginton AN, Foster G, Iorio, A. (2015). Web Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo): a service for Bayesian post hoc estimation. American Conference on Pharmacometrics, Crystal City, October 4-7, 2015.
17. Offman E, Edginton AN. Incorporating allometric scaling factors and non-linear mixed- effect modeling to predict interindividual variability in the concentration vs. time course of a pegylated peptide following subcutaneous administration. American Association of Pharmaceutical Science (AAPS) Annual Meeting, Orlando, FL, October 25-29, 2015.
18. McEneny A, Edginton AN, Foster G, Iorio A, on behalf of WAPPS program investigators. Web Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo): a service for Bayesian post hoc estimation. American Conference on Pharmacometrics Conference , Crystal City, Virginia, October 4-7, 2015
19. Phipps C, Edginton AN. A PBPK model platform for nanoparticles including lymphatic and size-dependent transport. American Conference on Pharmacometrics Conference , Crystal City, Virginia, October 4-7, 2015
20. Offman E, Phipps C, Edginton AN. Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide. American Conference on Pharmacometrics Conference , Crystal City, Virginia, October 4-7, 2015
Page 76 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
21. McEneny A, Osman W, Edginton AN and Rao, PPN. CYP1A2 binding studies of novel tacrine derivatives. Laurier Protein Science Symposium. Waterloo, Ontario May 29, 2015
22. McEneny A, Osman W, Edginton AN and Rao, PPN. CYP1A2 binding studies of novel tacrine derivatives. Canadian Society for Pharmaceutical Sciences Conference . Toronto, May 26-28, 2015.
23. Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC. Physiologically based pharmacokinetic modeling of Sorafenib metabolism, transport, and enterohepatic recycling in mice. The American Conference on Pharmacometrics (ACoP), Las Vegas, NV, USA. October 12-15, 2014.
24. Denomme J, Harris V, Edginton AN, Hajducek D, Salvadori M. Vancomycin assessment of nonlinear kinetics in pediatrics (VANKo-P). Canadian Hospital Pharmacy Residency Board Southwestern Ontario Poster Night. July 17, 2014, Windsor, Ontario. (Julia Denomme won first prize for her poster, competition was the other hospital pharmacy residents in Southwestern Ontario)
25. Maharaj A, Edginton AN. Deconvolution of gastrointestinal permeability-surface area using PBPK modelling. American Association of Pharmaceutical Sciences (AAPS), San Antonio, TX, USA. November 10-14, 2013.
26. Rathi C, Madhura D, Trivedi A, Liu J, Lee RE, Edginton AN, Meibohm B. Physiological model-based prediction of the human pharmacokinetics of Lee1661, a novel anti- tuberculosis agent. PharmForum 2013, AAPS Student Chapter, Little Rock, AR, USA. May 19-21, 2013.
27. Chandani R, Maharaj A, Edginton AN. Comparative assessment of individualized pharmacokinetic predictions using a Pop-PK and PBPK lorazepam model. American Association of Pharmaceutical Sciences (AAPS), San Antonio, TX, USA. November 10-14, 2013.
28. Ryman JT, Edginton AN, Tang L, Meibohm B. PBPK Simulation of ABCC2 and ABCB1 ontological effect on ceftriaxone kinetics. American Association of Pharmaceutical Sciences (AAPS), San Antonio, TX, USA. November 10-14, 2013.
29. Rathi C, Madhura D, Trivedi A, Liu J, Lee RE, Edginton AN, Meibohm B. Physiologically based pharmacokinetic modeling of Lee1599, a novel anti-tuberculosis agent, for human pharmacokinetic prediction. 53rd meeting of ICAAC, Interscience Conference on Antimicrobial Agents and Chemotherapy September 10 - 13, 2013. Denver, CO, USA
Page 77 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
30. Keating SCJ, Kerr CL, Valverde A, McDonell WN, Johnson RJ, Edginton AN. Pharmacokinetics of a constant rate infusion of fentanyl in dogs during isoflurane anesthesia and following sedative administration during anesthetic recovery. American College of Veterinary Anesthesia and Analgesia conference, September 8-10, 2013. San Diego, CA, USA.
31. Maharaj A, Barrett J, Edginton AN. Scaling adult physiologically-based pharmacokinetic (PBPK) models to pediatrics: a logical workflow. American Association of Pharmaceutical Sciences (AAPS), Chicago, USA. October 14-18, 2012.
32. Yun EY, Edginton AN. Prediction of a tissue to plasma partition coefficient in rats using volume of distribution. World Conference on Pharmacometrics, Seoul, Korea. September 5-7, 2012.
33. Offman E, Edginton AN. Prediction accuracy of allometric approaches for macromolecules: application for biosimilar development. American Association of Pharmaceutical Sciences (AAPS), Chicago, USA. October 14-18, 2012
34. Edginton AN, Schaffler K. Pain perception and processing in a medicated state: a pilot study in an elderly cohort. American Society for Clinical Pharmacology and Therapeutics, Washington DC, Maryland. March 12-17, 2012.
35. Yun EY, Edginton AN. A decision tree for tissue: plasma partition coefficient algorithm selection based on physico-chemical space. American Society for Clinical Pharmacology and Therapeutics, Washington DC, Maryland. March 12-17, 2012.
36. Edginton AN, Sevestre M, Stingl J. A probabilistic risk assessment of breast cancer treatment failure during co-administration of tamoxifen and paroxetine as it relates to CYP2D6 genotype. American Society for Clinical Pharmacology and Therapeutics, Washington DC, Maryland. March 12-17, 2012.
Workshops Presented
1. Edginton AN. Pediatric physiologically-based pharmacokinetic (PBPK) modeling: Current & potential approaches. IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network) Network’s Pediatric Pharmacology Workshop. 19 June 2015, Arlington, VA (invited)
2. Edginton AN. Pharmacokinetics in kids: predict it, calculate it, understand it. Children’s Mercy Hospital, Kansas City, MO, USA. June 13, 2014. (invited)
Page 78 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Edginton AN. Physiologically based pharmacokinetic modeling and its use in pediatrics. St. Jude’s Hospital, Memphis, Tennessee, USA. May 10, 2012. (invited)
4. Edginton AN. Hands-on workshop on the development and application of PBPK models (full-day workshop). University of Tennesse –Health Sciences Centre, Memphis, Tennessee, USA. May 11, 2012. (invited)
5. Edginton AN. Physiologically based pharmacokinetic (PBPK) models: pediatric considerations (lecture). Phase 1 trial game (half-day workshop). Facilitating Pediatric Research with Modeling and Simulation, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. April 23-25, 2012. (invited)
6. Edginton AN. Pediatric PBPK Models – Development and Application for Dose Guidance. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology, Food and Drug Administration (FDA), National Harbor, Maryland. March 14, 2012. (invited)
7. Edginton AN. Developing and applying PBPK models in pediatrics: a day long workshop. Children’s Hospital of Philadelphia, Philadelphia, USA. August 22-23, 2011.
DATE: 16 APR 2018.
Page 79 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
EDWARDS, David Jardine Professor, Tenured Member of the Graduate Faculty: yes b) DEGREES:
MPH, Public Health, Wayne State University, 2011 PharmD, Pharmacy, SUNY/Buffalo, 1981 BScPhm, Pharmacy, University of Toronto, 1978 c) EMPLOYMENT HISTORY:
2011- Professor and Hallman Director, School of Pharmacy, University of Waterloo; Associate Dean, Faculty of Science, University of Waterloo 2003-2011 Chair, Dept. of Pharmacy Practice, Wayne State University 2000-2011 Professor, Dept. of Pharmacy Practice, College of Pharmacy and Health Sciences and Adjunct Professor, School of Medicine, Wayne State University 1988-2000 Associate Professor, Dept. of Pharmacy Practice, Wayne State University 1983-1988 Assistant Professor, Dept. of Pharmacy Practice, Wayne State University d) HONOURS:
Fellow, American College of Clinical Pharmacy (FCCP), 1992 e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
1991-2006 Member, Editorial Board, Clinical Pharmacology and Therapeutics f) GRADUATE SUPERVISIONS:
Completed: 18 (13 PharmD, 5 Post-Pharm D Fellowships).
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
g) GRADUATE COURSES: past 7 years, by year
Page 80 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2000-2011 Advanced Principles of Drug Action II (PSC 7020) h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator per year 2008-2013 National Institute of G $1,299,999 Research Co- Neurological Disorders investigator and Stroke (NIH/NINDS (PI: Diane U01 NS061264A Chugani, PhD).
2004-2009 National Institute of G $1,460,501 Research Co- Child Health and investigator, Development/NIH. G. PI: Jacob Children's Center for Aranda, Clinical Pharmacology (MD,PhD), Studies. Pediatric Pharmacology Research Unit (PPRU) *Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING: N/A i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
Books authored: ...... 1 Books edited: ...... 0 Chapters in books: ...... 5 Papers in refereed journal: ...... 93 Papers in refereed conference proceedings: ...... 0 Technical reports: ...... 0 Abstracts and/or papers read: ...... 48 Others (workshops presented): ...... 0
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Chapters in Books: Page 81 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1. Edwards DJ: Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology. In: Pharmacotherapy for Child and Adolescent Disorders, 3rd ed., Rosenberg DR, Davanzo PA, Gershon S, Editors, Wiley-Blackwell, Hoboken, NJ, 2012.
Papers in Refereed Journals:
1. Foong EA-L, Edwards DJ, Houle S, Grindrod KA. Ready or not: Pharmacist perceptions of a changing scope of practice before it happens. Can Pharm J. 2017;150:387-396.
2. Fouda AY, Newsome AS, Spellicy S, Waller JL, Zhi W, Hess DC, Ergul A, Edwards DJ, Fagan SC, Switzer JA. Minocycline in acute cerebral hemorrhage: An early phase randomized trial. Stroke. 2017;48:2885-2887.
3. Chugani DC, Chugani HT, Wiznitzer M, Parkih S, Evans PA, Hansen RL, Nass R, Janisse JJ, Dixon-Thomas P, Behen M, Rothermel R, Parker JS, Kumar A, Muzik O, Edwards DJ, Hirtz D and the Autism Center of Excellence Network. Efficacy of Low Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder. J Peds. 2016;170:45-53.
4. Edwards DJ. Dissemination of reseach results: On the Path to Practice Change. Can J Hosp Pharm. 2015;68:465-69.
5. Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Ensom M, Foster DR, Hardy B, Kiser T, laPorte C, Roberts J, Shulman R, Walker S, Zelenitsky S, Moher D. Reporting guidelines for clinical pharmacokinetic studies: The ClinPK statement. Clin Pharmacokin. 2015;54:783-95.
6. Lulic-Botica M, Sheer T, Edwards DJ, Thomas RL, Natarajan G. Impact of small-for- gestational age (SGA) status on gentamicin pharmacokinetics in neonates. J Clin Pharmacol. 2014;54:39-45.
7. Edwards DJ. Beneficial pharmacokinetic drug interactions. Adv Pharmacoepidem Drug Safety. 2012;S1:002. doi: 10.4172/2167-1052.
8. Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, Lonoardo F, Bepler G, Schwartz AG, Ethier SP. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thoracic Oncol. 2011;6:627-30.
Page 82 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
9. Gabra BH, Abidi MH, Al-Khadimi Z, Edwards DJ, Ibrahim RB. Systemic absorption of topical lidocaine in a bone marrow transplant recipient with hepatic sinusoidal obstruction syndrome. Am J Health Syst Pharm. 2011;68:135-137.
10. Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Single-dose daptomycin pharmacokinetics in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother. 2011;55:3505-3509.
11. Guglielmo BJ, Edwards DJ, Franks AS, Naughton CA,Schonder KS, Stamm PL, Thornton P, Popovich NG. Faculty Development: A Critical Appraisal and Recommended Next Steps. Am J Pharm Educ. 2011;75:122.
DATE: April 2, 2018
Page 83 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
FOLDVARI, Marianna Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
PhD, Pharmaceutical Sciences College of Pharmacy, Dalhousie University, Halifax, NS, 1988 DPharmSci, Doctorate in Pharmaceutical Science (Pharmacognosy-Microbiology- Philosophy; summa cum laude), Faculty of Pharmacy, Semmelweis Medical University, Budapest, Hungary, 1985 BSc, Pharmacy, Faculty of Pharmacy, Semmelweis Medical University, Budapest, Hungary, 1984. c) EMPLOYMENT HISTORY:
ACADEMIC APPOINTMENTS AND PROMOTIONS
2007–2014 Canada Research Chair in Bionanotechnology and Nanomedicine (CIHR, Tier 1), School of Pharmacy, University of Waterloo, 2012-2013 Visiting Professor, Nanomedicine Center, Dr Janos Szebeni Laboratory, Semmelweis University, Budapest, Hungary 2007–2010 Associate Director, Research and Graduate Studies, School of Pharmacy, University of Waterloo 2007- Professor - Chemistry- cross appointment, University of Waterloo, 2007- Professor - Chemical Engineering - cross appointment, University of Waterloo 2006- Professor (tenured), School of Pharmacy, University of Waterloo, 2006- Adjunct Professor, College of Pharmacy and Nutrition, University of Saskatchewan 2006 Visiting Professor, Department of Chemical Engineering, Dr Robert Langer’s Laboratory, Massachusetts Institute of Technology, 2004–2006 Associate Dean Research and Graduate Affairs, University of Saskatchewan 1998–2000 Head, Division of Pharmaceutical Sciences, University of Saskatchewan 1996–1999 Helix Chair in Industrial Pharmacy, University of Saskatchewan 1999–2006 Professor (tenured), College of Pharmacy and Nutrition, University of Saskatchewan 1999 Visiting Professor, Biomedical Engineering, Dr. Antonios Mikos Laboratory, Rice University 1991–1998 Associate Professor, College of Pharmacy and Nutrition, University of Saskatchewan
Page 84 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1988–1991 Assistant Professor, College of Pharmacy and Nutrition, University of Saskatchewan
INDUSTRIAL APPOINTMENTS
2017- President and Chief Scientific Officer, Transparent Pharma Laboratories 1995- President and Chief Scientific Officer, DDS Research Inc. 2003–11 President and Chief Scientific Officer, Forte Pharmaceutical Laboratories Inc. 1999–2002 Vice President R&D, Helix BioPharma Inc. 1991–2002 Board Member, PharmaDerm Laboratories Ltd. 1991–2002 President and Director R&D and Founder PharmaDerm Laboratories Ltd.
d) HONOURS:
2017 Honorary Award for Outstanding Lifetime Achievements in Nanoscience and Nanotechnology in Ontario 2017 AAPS Fellow 2017 The AFPC Pfizer Research Career Award 2006 Nominated for Distinguished Graduate Supervisor 2006 Nominated for NSERC 2005 Synergy Award 2005 Nominated for CIHR Knowledge Translation Award 2005 Saskatchewan 25 Science Achievements, Government of Saskatchewan, Saskatchewan Centennial 2005 Sabex Award of Innovation, University of Saskatchewan and Innovation Place 2002 Listing in Annie Wood’s book, Canadian Women Invent! 1997 YWCA Women of Distinction Award Recipient (Entrepreneur/Innovator Category) 1991 Scanning Microscopy International Presidential Scholarship for Conference Presentation 1990 Robert A. Chesebrough Gold Medal for Original Research on Vaseline® Petroleum Jelly, $5,000 (Third Place) 1987-1989 Izaak Walton Killam Memorial Scholarship e) SCHOLARLY AND PROFESSIONAL ACTIVITIES: past 7 years only
PROFESSIONAL ASSOCIATIONS AND COMMITTEES YEARS REQUIRED 1986- American Association of Pharmaceutical Scientists (AAPS) 1995- American Association for the Advancement of Science (AAAS) 1993 Controlled Release Society 2008- American Society for Nanomedicine (ASNM), Board Member and Founding Director 2008- ASNM Communications Officer (web-site designer and web-master) Page 85 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2010-2015 Annual Conference Organizer and Chair, Member, Pachyonychia Congenita (PC) Consortium and Scientific Advisory Committee Member for PC Project 2005 - present 2010 Organizing Committee and Conference Chair: NT10 -11th International Conference on the Science and Application of Nanotubes. CNBMT – 3rd Carbon Nanotube Biology, Medicine and Toxicology Satellite. Montreal QC
SCIENTIFIC JOURNAL EDITORIAL BOARDS 2014- Editorial Board Member, Journal of Controlled Release 2012- Editorial Board Member, International Journal of Theoretical and Applied Nanotechnology 2015- Advisory Board Member, International Society for Phytocosmetic Science (ISPS) and the International Journal of Phytocosmetics and Natural Ingredients(Dermatology Specialty) 2015- Editorial Board Member, OA Drug Design and Delivery 2013- Editorial Board Member, Nanomedicine Journal 2012- Honorary Editorial Board Member, Research and Reports in Transdermal Drug Delivery 2012- Editorial Board Member, International Journal of Theoretical and Applied Nanotechnology 2014- Editorial Board Member, Scientifica (Pharmaceutics Division)- 'The Open Access Journal of Science' 2011 Editor, Hot Topic Issues on “Nanomedicine - the application of nanotechnology to develop better treatments for patients" for Current Drug Delivery 2010- Editorial Board Member, Journal of Nanomedicine & Biotherapeutic Discovery 2010- Editorial Board member: Current Patents in Nanomedicine 2006- Associate Editor, Nanomedicine: Nanotechnology, Biology and Medicine
SCIENTIFIC JOURNAL REVIEWER (recurring reviews past 5 years)
Science Translational Medicine Future Medicine – Nanomedicine Current Topics in Medicinal Chemistry Nature Methods Nature Nanotechnology Nanomedicine: Nanotechnology, Biology and Medicine European Journal of Pharmaceutics and Biopharmaceutics Biotechnology Advances Journal of Rheumatology Biomaterials Molecular Pharmaceutics Journal of Controlled Release Page 86 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Drug Discovery Today IOVS Current Topics in Medicinal Chemistry Nature Protocols Gene Therapy Journal of Controlled Release European Journal of Pharmaceutics and Biopharmaceutics Experimental Parasitology Journal of Medicinal Chemistry Current Drug Delivery Journal of Pharmaceutical Sciences Journal of Pharmacy and Pharmaceutical Sciences European Journal of Pharmaceutical Sciences Pharmaceutical Research
GRANTING AGENCY REVIEWER (past 5 years)
Israel Science Foundation CIHR Foundation Scheme Peer Review Stage 3 Committee 2015 Wellcome Trust, UK Medical Research Council, UK Swiss National Science Foundation – NCCR Selection Committee NanoBioMed, Bern, Switzerland Expert Committee Member - EuroNanomed 2013 “EUROPEAN INNOVATIVE RESEARCH & TECHNOLOGICAL DEVELOPMENT PROJECTS IN NANOMEDICINE” Canada Foundation for Innovation (CFI) CIHR-NSERC joint program grants CIHR, Emerging Team Grant Program Panel NSERC EWR Steacie Memorial Fellowship NSERC, I2I Program NIH, SBIR, Review Panel Topic 300, Therapeutics and Theranostics Based on Nanotechnology Bill & Melinda Gates Foundation Natural Sciences and Engineering Research Council NIH General Medical Sciences Canada Foundation for Innovation, New Opportunities Fund Canadian Institutes of Health Research Manitoba Institute of Child Health Alberta Heritage Foundation Canada Foundation for Innovation
DEPARTMENTAL AND COLLEGE COMMITTEES
Page 87 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2014- Member, Petitions Committee School of Pharmacy, University of Waterloo 2013- Member, Tenure and Promotion Committee School of Pharmacy, University of Waterloo 2006 – 2010 Executive Committee, Member School of Pharmacy, University of Waterloo 2006 – 2010 Research and Graduate Studies Committee, Chair School of Pharmacy, University of Waterloo 2006 - Director, Pharmacy Core Research Facility School of Pharmacy, University of Waterloo f) GRADUATE SUPERVISIONS:
Completed: 5 MSc, 9 PhD In Progress: 0 MSc, 5 PhD
Name of Student Type (years of Title of Thesis or Project Status supervision) Daniella Calderon- (MSc) 2015-2018 Improving the delivery and Completed Nieva immunogenicity of an inhalable CpG-ODN DNA vaccine by bio-adhesive gemini nanoparticles in neonatal chickens Samih Alqawlaq (MSc) 2010-2013 Targeted gene therapy for Completed optic nerve regeneration in glaucoma Chilbert Dong (MSc) 2010-2013 Characterization of gemini Completed nanoparticle assembly by fluorescence correlation spectroscopy Mukasa Bagonluri (MSc) 2004–2010 Evaluation of some Completed pharmaceutical properties of carbon nanotubes for use in drug delivery systems Vanessa Roberta (PhD) 2011 – 2012 Layered double hydroxides as Completed Rodriges da Cunha (sandwich program drug delivery systems for with Brazil) anticancer drugs Osama Alaidi (PhD) 2012-2014 Structural characterization of Completed (Co-supervision) gemini nanoparticles for delivery of DNA Hanan Abdelkarim (PhD) 2007–2008 Targeting nerve regenerative Completed Salman function in glaucoma
Page 88 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Lokesh Narsineni (PhD) 2014- Synthesis of a new generation In progress peptide-modified dicationic amphiphiles as nanoparticle building-blocks for the non- invasive gene therapy for optic nerve regeneration in glaucoma Amirreza Rafiee (PhD) 2014-2017 Development of In progress multifunctional gemini nanoparticles for non- Invasive, nonviral topical shRNA-based therapy of localized scleroderma Ding Wen (Roger) (PhD) 2012- 3D cell co-culture to study In progress Chen retinal ganglion cell survival Roger Chen: “2014-Young Scholar Award” sponsored by Dove Medical Press. The Award was presented at the 12th Annual Current Issues in Medicine, Biotech and Pharma Conference held at Rensselaer Polytechnic Institute in Troy, New York on September 17-18, 2014 Thusari (PhD) 2012- In ovo delivery of In progress Gunawardana (Co-supervision) oligodeoxynucleotides containing CpG motifs (CpG- ODN) for immunization of chickens Kalhari Bandana (PhD) 2012- Oral delivery In progress (co-supervision) oligodeoxynucleotides containing CpG motifs (CpG- ODN) in chickens
POSTDOCTORAL FELLOWS SUPERVISED • Dr Nafiseh Nafissi - Genetic engineering of retinal cells using non-viral neurotrophic factor gene therapy to support optic nerve regeneration. 2013-2015 • Dr Marjan Gharagozloo - Cellular mechanisms of non-viral gene delivery. 2013-2015 • Dr Constanze Lamprecht - Carbon nanotubes as pharmaceutical excipients. 2011-2012 • Dr Sattar Taheri-Araghi - Mathematical modeling of gene delivery. 2010-2011 • Dr Torin Huzil - Designing the Next Generation of Transdermal Page 89 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
• Drug Delivery Systems Through Systematic Multiscale Simulations of the Stratum Corneum. 2009-2014 • Dr Mahmoud El Sabahy - Development of gemini nanoparticles as gene delivery systems. 2009-2011 • Dr. Shaoping Li - Non-viral gene delivery vector design. 2008-2011 g) GRADUATE COURSES:
2010 PHARM 604 – Gene Therapy 2014 PHARM 604 – Gene Therapy 2014 Pharm 898 (Sask) – Nanotechnology in vaccine development 2016 PHARM 604 – Gene Therapy h) 1. EXTERNAL RESEARCH FUNDING: past 7 years
Year Source Type* Amount per Purpose** Investigator year 2016- Ontario Centres of C and $70,000 Research Foldvari, M. (PI) 2018 Excellence, NSERC and O Mirexus Biotechnologies Inc. Non-invasive drug delivery by Phytospherix nanoparticles. VIP Project. 2004- NSERC-CRDPJ with C and $273,000 Research Gomis S, Tikoo S 2009 Chicken Farmers of O and Foldvari M. Saskatchewan, (co-PIs) Canadian Poultry Research Council, Sunrise Poultry Processors Ltd., Prairie Pride Natural Foods Ltd. Oligodeoxynucleotides containing CpG motifs (CpG-ODN) as an alternative to antibiotics in the broiler chicken industry Page 90 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2014– NSERC Discovery C $25,000 Research Foldvari, M. 2019 Rational design of soft nanoparticles for non- invasive drug delivery. 2012- NIH Conference grant C $43,000 Conference Gendelman H, 2013 ASNM conference organization Chang E, Balogh L, organization Bawa R, Foldvari M, Wang K. 2013 CFI Tracking F $995,220 Research Yucel, Y., Gupta, N., Nanoparticles in infrastructure (and others)- Whole-Animal Imaging Foldvari, and Hyperspectral M.(collaborator) Microscopy: A Novel University of Strategy for Toronto, Keenan Identifying Biomarkers Research Centre at and Treatments for The Li Ka Shing Diabetes. Knowledge Institute of St. Michael's Hospital, 2013- CIHR Operating Grant C $134,000 Research Foldvari M. 2018 Targeted nanomedicines for gene therapy applications. 2011- Agriculture Funding O $275,000 Research Gomis, S., Tikoo, S. 2015 Consortium and Foldvari, M. Formulation and (co-PIs) delivery of immunostimulatory oligodeoxynucleotides containing CpG motifs (CpG-ODN) as alternatives to antimicrobials.
2011- NSERC-CRD C $136,860 Research Gomis, S., Tikoo, S. 2015 Formulation and and Foldvari, M. delivery of (co-PIs) immunostimulatory oligodeoxynucleotides containing CpG motifs Page 91 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
(CpG-ODN) with carbon nanotubes (CNTs) against poultry diseases. 2009- NIH Grand C $2.7M Research Kaspar, R., 2010 Opportunities (GO) Milstones, L. Grant Contag, C. (PIs), Transdermal delivery Foldvari, M. et al of nucleic acids.
2009- NSERC CRD. C $120,000 Research Chen, P. (PI), 2011 Self-assembling Foldvari, M. peptides for anticancer drug delivery. 2009- Ontario Research Fund G $2,599,960 Research Khandani (PI), 2014 for Research total Foldvari, M. (and Excellence Funding project others) Mobile Health: A new cost frontier in wireless technology.
2008– NSERC Discovery C $97,500 Research M. Foldvari. 2013 grant. over five Micro- and nanoscale years. systems for macromolecules: gene delivery.
2007– Tier I, Canada G $200,000 Research M. Foldvari., 2014 Research Chair per year Canada Research for seven Chair in years. Bionanotechnology and Nanomedicine. 2007– Canada Foundation for F $329,221 Research M. Foldvari 2014 Innovation in total Zeiss Confocor3 confocal and fluorescence correlation spectroscopy. Bioimaging system for studying the live Page 92 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
transport and targeting of nanomedicines, Canada Research Chair Infrastructure. 2006– CIHR Regenerative C $1.5 Research M. Foldvari (PI), T. 2011 Medicine and million Haas, P. Grochulski, Nanomedicine: over five A. Nazarali Innovative Approaches years in Health Research, Team Grant Program Design and development of targeted gene delivery systems.
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING: This includes university funds, SSHRC minor grants awarded through the University, etc.
Year Source Type Amount per year Purpose 2014-16 UW-CIHR Incentive $8,000 Research Fund Gene therapy for rheumatoid arthritis 2014-16 UW-CIHR Incentive $8,000 Research Fund Transdermal protein and peptide delivery systems for skin and autoimmune diseases and regenerative medicine. 2011-12 UW-CIHR Incentive $8,000 Research Fund Gene therapy of glaucoma
Page 93 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
i) PUBLICATIONS: 1) Life-time summary (count) according to the following categories: Books authored …………………………………………………………………….…………1 Books edited …………………………………………………………………………...………0 Chapters in books ……………………………………………………………...……………9 Papers in refereed journal ………………………………….…………….…………132 Papers/Abstracts in refereed conference proceedings ……….…………88 Technical reports …………………………………………………………………….…….13 Others (workshops presented) …………………………………….…….……….…81 Patents ……………………………………………………………………………….…………25
2) Details for past seven (7) years same categories as above:
Book chapters and review articles:
1. Calderon-Nieva D, Bandara-Goonewardene K, Gomis S, Foldvari M. (2017) Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals. Drug Deliv Transl Res DOI 10.1007/s13346-017-0400-9
2. Foldvari M. and Kumar P. (2017) Perspectives on dermal delivery of macromolecular drugs. In: Percutaneous penetration enhancers. Drug penetration into/through the skin. Dragicevic-Curic, N. and Maibach, H. (eds.), Springer-Verlag Berlin Heidelberg DOI 10.1007/978-3-662-53270-6_21
3. Foldvari M and Chen, DW. (2016) The intricacies of neurotrophic factor therapy for retinal ganglion cell rescue in glaucoma: a case for gene therapy. Invited Review, Neural Regen. Res.11:875-877.
4. Nafissi N. and Foldvari M. (2016) Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8:240- 254. DOI: 10.1002/wnan.1361
5. Bottini M and Foldvari M (2016) Targeted nanosystems as therapeutic and diagnostic tools: The beautiful voyage of nanomedicine. Nanomedicine: NMB, DOI: http://dx.doi.org/10.1016/j.nano.2015.12.358
6. Foldvari M, Chen DW, Nafissi N, Calderon D, Narsineni L, Rafiee, A. (2015) Non-viral gene therapy: gains and challenges of non-invasive administration methods. J. Control. Rel. 240, 165-190. doi:10.1016/j.jconrel.2015.12.012
Page 94 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
7. Gharagozloo, M., Majewski, S. and Foldvari, M. (2015) Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction. Nanomedicine: NBM 11:1003-18.
8. Nafissi N. and Foldvari M. (2015) Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. DOI: 10.1002/wnan.1361
9. Nafissi N. and Foldvari M. (2015) Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools. Front. Neurosci. 9:355.
10. Foldvari M. and Kumar P. (2015) Permeation enhancement by molecular organization switching (MOS): Biphasic vesicles for the cutaneous delivery of proteins. In: Percutaneous penetration enhancers. Dragicevic-Curic, N. and Maibach, H. (eds.), Springer (in press)
11. Elsabahy M, Loureiro MJ, Foldvari M. (2015) Application of nanotechnology in non- invasive topical gene therapy. In: Clinical Nanomedicine. Ed.: R. Bawa, Pan Stanford Press, (in press)
12. Foldvari, M. and Rafiee, A. (2015) Perspectives on using nanoscale delivery systems in dermatological treatment. Curr. Derm. Rep. 4:1-7.
13. Foldvari, M. (2014) Non-invasive ocular drug delivery: Potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma. J. Glaucoma 23:8, Suppl 1, S80-82.
14. Foldvari M (2014) Nanopharmaceutics Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods. J Nanomedicine Biotherapeutic Discov 4: e135. doi: 10.4172/2155-983X.1000e135
15. Gendelman, H. E., Balogh, L. P., Bawa, R., Bradbury, M., Chang, E. H., Chiu, W., Farokhzad, O., Foldvari, M., Lanza, G., Wang, K. (2014) The 4th Annual Meeting of the American Society for Nanomedicine. J. Neuroimmune Pharmacol. 9 (Suppl1) S1-3.
16. Foldvari, M., Gharagozloo, M. and Li, C. (2014) Nanoparticles for dermal and transdermal delivery: Permeation pathways and applications. In: Torchilin, V. (ed.) Frontiers in nanobiomedical research. World Scientific Publishing, Volume 2, Chapter 7, pp 231-260. doi: 10.1142/9789814520652_0024
17. Elsabahy, M, Foldvari M. (2013) Needle-free gene delivery through the skin: an overview of recent strategies. Curr. Pharm. Des. 19:7301-15. Page 95 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
18. Elsabahy M, Badea I, Verrall R, Donkuru M and Foldvari M. (2014) Dicationic gemini nanoparticle design for gene therapy. In: Organic nanomaterials. Torres, T. and Bottari, G. (eds) Wiley, pp 509-528.
19. Foldvari M. (2014) Nanopharmaceutics: Structural Design of Cationic Gemini Surfactant- Phospholipid-DNA Nanoparticles for Gene Delivery. In: Horizons in Clinical Nanomedicine. Eds.: Karagkiozaki V. and Logothetidis S., Pan Stanford Publishing, pp. 129-146
20. Alqawlaq S, Huzil, JT, Ivanova MV, Foldvari M. (2012) Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. Nanomedicine (Lond), 7:1067-83.
21. Foldvari M and Kumar P. (2012) Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection. Ther. Deliv. 3:1005- 1017.
22. Foldvari M. (2012) HPV infections: can it be eradicated using nanotechnology? (Editorial Perspective in Clinical Nanomedicine) Nanomedicine: NBM. 8:131-135.
23. Lamprecht C, Huzil JT, Ivanova MV and Foldvari M. (2011) Non-covalent functionalization of carbon nanotubes with surfactants for pharmaceutical applications – A critical mini-review. Drug Deliv Lett 1: 45-57.
24. Foldvari M and Elsabahy M. (2011) Nanotechnology enables superior medical therapies. (Editorial) Curr. Drug Deliv. 8:225.
25. Elsabahy, M. and Foldvari, M. (2013) Needle-free Gene Delivery Through the Skin: An Overview of Recent Strategies. Current Pharmaceutical Design, 19: 7301-7315
26. Huzil JT, Sivaloganathan S, Kohandel M, and Foldvari M. (2011) Drug Delivery Through the Skin: Molecular Simulations to Design More Effective Dermal and Transdermal Systems for Small Molecules, Biologics and Cosmetics. Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology (Wiley). 3:449-462.
27. Elsabahy M, Nazarali A and Foldvari M. (2011) Non-viral nucleic acid delivery: Key challenges and future directions. Curr. Drug Del. 8:235-244.
Papers in Refereed Journals
Page 96 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1. Chen D.W., Pauloff K. and Foldvari M. (2018) Three-dimensional co-culture bioassay for screening of retinal gene delivery systems. Methods Mol. Biol. 1715:79-88. doi: 10.1007/978-1-4939-7522-8_6.
2. Bandara Goonewardene K, Popowich S, Gunawardana, T, Gupta A, Kurukulasuriya S, Karunarathna R, Chow-Lockerbie B, Ahmed KA, Tikoo S, Foldvari M, Willson P and Gomis S.. (2017) Intrapulmonary Delivery of CpG-ODN Microdroplets Provides Protection Against Escherichia coli Septicemia in Neonatal Broiler Chickens Avian Diseases 61 (4), 503-511.
3. Chen DW and Foldvari M. (2016) In vitro bioassay model for screening non-viral neurotrophic factor gene delivery systems for glaucoma treatment. Drug Deliv. Transl. Res. 6:676-685. doi:10.1007/s13346-016-0324-9
4. Gharagozloo M, Rafiee A, Chen DW, Foldvari M. (2015) A flow cytometric approach to study the mechanism of gene delivery to cells by gemini-lipid nanoparticles: an implication for cell membrane nanoporation. J. Nanobiotechnol. 13:62.
5. Cunha VR, Guilherme VA, de Paula E, de Araujo DR, Silva RO, Medeiros J VR, Leite JR, Petersen PA, Foldvari M, Petrilli HM, Constantino VR. (2015) Delivery system for mefenamic acid based on the nanocarrier Layered Double Hydroxide: physicochemical characterization and evaluation of anti-inflammatory and antinociceptive potential. Mater. Sci. Eng. C Mater. Biol. Appl. 58:629-38.
6. Huzil JT, Saliaj E, Ivanova M, Gharagozloo M, Loureiro JM, Lamprecht C, Korinek A, Chen DW, Foldvari M. (2015) Selective nuclear localization of siRNA by metallic versus semiconducting single wall carbon nanotubes in keratinocytes. Future Sci. OA FSO17
7. Dong C, Badea I, Poorghorban M, Verrall R, Foldvari M. (2015) Impact of phospholipids on plasmid packaging and toxicity of gemini nanoparticles. J. Materials Chem. B, 3: 8806-8822.
8. Foldvari M. (2015) Membrane fusion intermediates captured in liposomal dispersion by freeze-fracturing. F1000 Research 2015, 4:4 (doi: 10.12688/ f1000research.6003.1)
9. Gunawardana T, Foldvari, M, Zachar T, Popowich S, Chow-Lockerbie B, Ivanova M, Tikoo S, Kurukulasuriya S, Willson P and Gomis S.. (2015) Protection of neonatal broiler chickens following in ovo injection of oligodeoxynucleotides containing CpG motifs (CpG-ODN) formulated with carbon nanotubes or liposomes. Avian Dis. 59:31-37.
10. Alqawlaq S, Sivak J, Huzil JT, Ivanova MV, Flanagan, J, Beazely, M, Foldvari M. (2014) Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after Page 97 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
intravitreal and topical administration for glaucoma gene therapy. Nanomedicine: NBM 10:1637-1647.
11. Nafissi N, Alqawlaq S, Foldvari M, Lee E, Spagnuolo P, Slavcev R. (2014) Ministring DNA: Superior gene delivery vector. Mol. Ther. Nucleic Acids 3, e165 doi:10.1038/mtna.2014.16
12. Moghadam SH, Saliaj E, Wettig SD, Dong C, Ivanova MV, Huzil JT and Foldvari M. (2013) Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm 10:2248-2260.
13. King M, Kumar, P, Michel, D, Batta, R, Foldvari, M. (2013) Sustained dermal delivery of interferon alpha using topically applied biphasic vesicles in guinea pigs. Eur J Pharm Biopharm 84: 532-539.
14. Ivanova MV, Loureiro MJ, Lamprecht C, Foldvari M. (2012) Characterization of commercial solid and dispersed carbon nanotubes towards applications as pharmaceutical excipients. Int J Nanomed 2012:7-403-415.
15. Donkuru, M, Wettig, SD, Verrall, RE, Badea, I and Foldvari, M. (2011) Non-viral gene delivery into keratinocytes using pH-sensitive gemini nanoparticles. J. Materials Chem. 22:6232-6244.
16. Badea I, Virtanen C, Verrall R, Foldvari M. (2012) Topical interferon-γ gene therapy using gemini (dicationic) nanoparticles improves pathophysiological markers of scleroderma in Tsk1/+ mice. Gene Ther. 19:978-87.
17. Huzil JT, Sivaloganathan S, Kohandel M, and Foldvari M. (2011) Modeling the effects of lipid composition on stratum corneum bilayers using molecular dynamics simulations. AIP Conf. Proc. 1368:175-178.
18. Badea I, Shaterian N, Foldvari M. (2011) Topical lipid nanoparticles and tape- electroporation mediated cutaneous gene delivery in mice. Drug Deliv Lett 1:62-66.
19. Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, He Z, Yeboah E, Gaspar K, Hull P, Shear NH. (2011) Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr Drug Deliv 8:307-319.
20. Singh J, Yang P, Michel D, Verrall RE, Foldvari M, Badea I. (2011) Amino Acid-Substituted Gemini Surfactant-Based Nanoparticles as Safe and Versatile Gene Delivery Agents. Curr Drug Deliv 8: 299-306. Page 98 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
21. Foldvari, M. (2010) Biphasic Vesicles: A Novel Topical Drug Delivery System J Biomed Nanotechnol 6, 543-557.
22. Foldvari M, Badea, I, Wettig S, Baboolal D, Kumar P, Creagh AL, Haynes CA (2010) Topical delivery of interferon alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum. Mol Pharm 7:751-762.
23. Yang P, Singh J, Wettig S, Foldvari M, Verrall RE, Badea, I. (2010) Enhanced gene expression in epithelial cells transfected with amino-acid substituted gemini nanoparticles. Eur J Pharm Biopharm 75:311-320.
24. Badea I, Babiuk S, Babiuk L, Foldvari M. (2010) Gemini nanoparticles as a co-delivery system for antigen – CpG oligodeoxynucleotide adjuvant combination. Int J Biomed Nanosci Nanotechnol 1:290-307.
25. Kumar, P., Batta, R., LaBine, G., Shen, J., Gaspar, K., Docherty, J., Foldvari, M. (2009) Stabilization of interferon alpha-2b in a topical cream. Pharm Technol 33:80-86.
26. Taghavi A, Allan B, Mutwiri G, Foldvari M, Van Kessel A, Willson P, Babiuk L, Potter A, Gomis S. (2009) Enhancement of immunoprotective effect of CpG–ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr Drug Deliv 6:76–82.
Patents and Trademarks
1. Foldvari M. (2017) Topical nucleic acid delivery system. US Provisional Patent Appl. No 62463041 (Feb 11, 2017)
2. Foldvari M. (2017) Multicompartmental lipid vesicle compositions. US Provisional Patent Appl. No 62463023 (Feb 24, 2016)
3. Foldvari M. (2017) Lipid vesicle compositions. US Provisional Patent Appl. No 62463015 (Feb 24, 2017)
4. Foldvari M. and Narsineni L. (2017) Compositions for gene delivery to the retina. US Provisional Patent Appl. No 62463087 (Feb 24, 2017)
5. Foldvari M. and Alqawlaq S. (2014) Nanoparticles for ocular administration. US Provisional Patent Appl. No. 61909193 (Nov 26, 2014).
Page 99 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
6. Gomis S, Tikoo S, Ivanova MV, Foldvari M. (2013) CpG oligonucleotide formulations and methods and uses thereof. PCT/CA2013/000190 Filing date: March 6, 2013.
7. Foldvari M. Kumar P, Docherty J. Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery. US 2013/0224283 granted (Pub. Date: Aug 29, 2013)
8. I. Badea, R.E. Verrall, P. Yang, J. M. Chitanda, M. Foldvari, D. Michel (2012) Drug delivery agents and pharmaceutical compositions comprising the same. PCT 13764-140.
Papers in Conference Proceedings and Abstracts
1. Calderon-Nieva D, Goonewardene Bandera K, Gomis S, Foldvari M (2017) Pulmonary nanoparticle vaccines as antimicrobial alternatives for poultry. Controlled Release Society Meeting, Boston, MA.
2. Chen D.W. and Foldvari M., 2017. Three-dimensional co-culture bioassay for screening of neurotrophic factor gene therapy systems for glaucoma therapy. 20th Annual American Society of Gene and Cell Therapy Conference in Washington D.C., USA.
3. Foldvari, M. Taheri-Araghi, S., Kohandel, M., Sivaloganathan, S. (2016) Tuning effects of cationic to anionic charge ratio and helper lipids on non-viral gene delivery systems: a theoretical study on gemini nanoparticles. AAPS 2016 Annual Meeting and Exposition, Nov 2016, Denver, CO.
4. Nafissi N., Chen D.W., and Foldvari M., 2015. Neurotrophic factor gene therapy in glaucoma by minicircle DNA biopharmaceutical. Canadian Association of Pharmaceutical Sciences in Toronto, Ontario, Canada.
5. Chen DW, Nafissi N, Foldvari M. (2015) Characterization of minicircle gemini-surfactant phospholipid nanoparticle for the delivery of brain-derived neurotrophic factor in retinal co-culture models. Canadian Society for Pharmaceutical Sciences – Controlled Release Society (CSPS/CC-CRS) Symposium, Toronto, ON., Canada, May 2015.
6. Gharagozloo M, Rafiee, A, Chen DW, Foldvari M. (2015) A flow cytometric approach to study the mechanism of gene delivery to cells by gemini-lipid nanoparticles: An implication of cell membrane nanoporation. Canadian Society for Pharmaceutical Sciences – Controlled Release Society (CSPS/CC-CRS) Symposium, Toronto, ON., Canada, May 2015.
Page 100 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
7. Rafiee A, Chen DW, Gharagozloo M, Foldvari M. (2015) Gemini nanoparticle formulation design for non-invasive cutaneous gene delivery: Effect of neutral helper-lipids on transfection efficiency in vitro. Canadian Society for Pharmaceutical Sciences – Controlled Release Society (CSPS/CC-CRS) Symposium, Toronto, ON., Canada, May 2015.
8. Nafissi N, Chen DW, Foldvari M. (2015) Neurotrophic Factor Gene Therapy in Glaucoma by Minicircle DNA Biopharmaceuticals. Canadian Society for Pharmaceutical Sciences – Controlled Release Society (CSPS/CC-CRS) Symposium, Toronto, ON., Canada, May 2015.
9. Gunawardana T, Foldvari M, Zachar T, Popowich T, Chow-Lockerbie B, IvanovaS M, Tikoo S, Kurukulasuriya S, Willson P, GomisP G. Metabolomic profile of broiler chickens following administration of oligodeoxynucleotides containing CpG motifs (CpG-ODN)) XVII INTERNATIONAL SYMPOSIUM OF THE WORLD ASSOCIATION OF VETERINARY LABORATORY DIAGNOSTICIANS (WAVLD 2015), June 2015 in Saskatoon, Canada
10. Gunawardana T, Foldvari M, Zachar T, Popowich T, Chow-Lockerbie B, IvanovaS M, Tikoo S, Kurukulasuriya S, Willson P, GomisP G. Protection of neonatal broiler chickens following in ovo injection of oligodeoxynucleotides containing CpG motifs (CpG-ODN) formulated with carbon nanotubes or liposomes. American Association of Avian Pathologists Western Poultry Disease Conference (WPDC) 63rd Western Poultry Disease Conference & XXXIX Convención Anual ANECA 2 – 5 April 2014 Puerto Vallarta, Jalisco, México
11. Chen DW and Foldvari M. (2014) Development and characterization of a co-culture of healthy and oxidatively stressed retinal cells as a model for evaluating gene delivery systems for the treatment of glaucoma. Abstract accepted and poster presentation to be delivered at American Association of Pharmaceutical Scientists, San Diego, CA, November 2014
12. Alqawlaq S, Sivak JM, Huzil T, Ivanova M, Flanagan J, Beazely M, Foldvari M. (2014) Gemini surfactant-phospholipid nanoparticles as gene carriers for glaucoma gene therapy. Abstract accepted and poster presentation to be delivered at American Association of Pharmaceutical Scientists, San Diego, CA, November 2014
13. Gunawardana T, Popowich S, Chow-Lockerbie B, Foldvari M, Ivanova MV, Tikoo S, Kurukulasuriya S, Willson P and Gomis S.. (2013) Analysis of immunostimulatory cytokine gene expression in chicken embryos following administration of oligodeoxynucleotides containing CpG motifs (CpG-ODN) using a multiplex assay. American Association of Avian Pathologists Meeting, July 2013, Chicago, IL
Page 101 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
14. Dong C, Huzil JT, Foldvari M. (2012) Investigation of gemini nanoparticle assembly by fluorescence correlation spectroscopy. Chemical Biophysics Symposium. University of Toronto, Canada
15. Dong C, Alqawlaq S, Huzil JT, Ivanova M, Elsabahy M, Pio SantosA, Foldvari M. (2012) Physical and transfection properties of non-viral gemini surfactant-phospholipid nanoparticles. American Society for Cell and Gene Therapy Meeting, Philadelphia, PA.
16. King M, Michel D, Batta R, Foldvari M, Docherty J and Kumar P. (2011) Dermal delivery of Interferon alpha-2b using BiphasixTM Technology. 27th International Papillomavirus Conference and Clinical Workshop. Sept 2011, Berlin, Germany
17. Huzil JT, Sivaloganathan S, Kohandel M, and Foldvari M. (2011) Non-invasive Dermal and Transdermal Delivery Systems for Macromolecules International Conference on Applied Mathematics, Modeling and Computational Science – AMMCS-2011, Waterloo. ON.
18. Elsabahy M, Donkuru M, Badea I, Verrall R and Foldvari M. (2011) pH-Sensitive Gemini Surfactant-Lipid Composite Nanoparticles as Novel Constructs for Topical Gene Therapy. Controlled Release Society Meeting, Baltimore MD.
19. Elsabahy M, Badea I, Verrall R, and Foldvari M. (2011) Cutaneous Gene Delivery Using Pyrene-Substituted Gemini-Lipid Nanoparticles. American Society for Cell and Gene Therapy Meeting, Seattle, WA.
Invited Presentations
1. Foldvari, M. Invited Speaker, Non-viral Gene Therapy for the Retina and Optic Nerve with Neurotrophic Factors: Implications for Glaucoma 2017 Annual Canadian Society of Pharmacology and Therapeutics (CSPT) Meeting — Pharmacology in the 21st Century: Marijuana, Precision Medicine and the Brain. Dalhousie University, Halifax, Nova Scotia.
2. Foldvari M. Keynote Lecture, Nanotechnology tools in gene therapy: approaches to regenerating the retina and the optic nerve. 1st International Society for Nanomedicine (ISNM) Congress, Korea University, Seoul, South Korea, 2016
3. Foldvari M. Lecturer, Innate immunity to nanoparticles. First Summer School in Asia at the 1st International Society for Nanomedicine (ISNM) Congress, Korea University, Seoul, South Korea, 2016
Page 102 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
4. Foldvari, M. Invited Speaker, Neurotrophic factor delivery nanotools for neuroprotection and regeneration of retina and optic nerve in glaucoma. 3rd Annual Personalized Nanomedicine Symposium, Miami, FL. 2016
5. Foldvari M. Invited Speaker American Association of Ophthalmic Oncologists and Pathologists (AAOOP)/American Association of Ophthalmology (AAO) Symposium, AAO Annual Meeting, November 2015, Las Vegas, USA
6. Foldvari M. Invited Speaker, Aerosol School, 2015, ISAM McMaster University and St Joseph’s Healthcare, Hamilton, ON.
7. Foldvari M. Invited Speaker, Mirexus Inc. Guelph, ON., 2015
8. Foldvari M. Invited presentation to Blueline Bioscience Venture Capital Forum, Waterloo, ON. http://www.bluelinebio.com/
9. Foldvari M. Invited Keynote Speaker, Nano 2014, Current Issues in Medicine, Biotech and Pharma. 12th Annual International Conference 2014, Rensselaer Polytechnic Institute, Troy, N.Y.
10. Foldvari M. Invited Speaker, Aerosol School, 2014 ISAM McMaster University and St Joseph’s Healthcare, Hamilton, ON.
11. Foldvari M. Invited Speaker , Nano Medical Sciences Symposium of the 2013 TechConnect World, Biotech 2013 Conference
12. Foldvari M. Invited Speaker, Nano 2013, Rensselaer Polytechnic Institute, Troy, N.Y.
13. Royal Canadian Institute (RCI) for the Advancement of Science - Round Table Invitation - Chair, 2012; Needle-free nanomedicines -- developing drug delivery systems for protein and DNA drugs. http://www.royalcanadianinstitute.org/
14. Foldvari M. Invited Speaker, Needle-free Nanomedicines: Focus on the Skin and the Eye. Nano 2012, May 2012, Rensselaer Polytechnic Institute, Troy, N.Y.
15. Foldvari M. Invited Speaker, 5th European Conference for Clinical Nanomedicine, Basel; May 2012
16. Foldvari M. Invited Speaker, Needle-free Nanomedicines: Applications in Gene Therapy. 9th International Conference on Nanosciences & Nanotechnologies – NN12, Thessaloniki, Greece; July 2012 Page 103 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
17. Foldvari M. Invited Speaker, American Society of Nanomedicine. 9th International Conference on Nanosciences & Nanotechnologies – NN12, Thessaloniki, Greece; July 2012
18. Foldvari M. Invited Speaker, Applications of nanotechnology in Dermatology and Ophthalmology ISSON12 Thessaloniki, Greece; July 2012 19. Foldvari M. Invited Speaker, Gene therapy and delivery system design for optic nerve regeneration. 9th Annual World Congress on Brain, Spinal Cord Mapping and Image Guided Therapy, Society for Brain Mapping and Therapeutics, June 2012.
20. Foldvari M. Invited Speaker, Characterization of nanoproducts. FIP Centennial Congress, Amsterdam, The Netherlands, October 2012. Characterization of nanomedicines drug products. BREAKTHROUGH TECHNOLOGIES AND THE PARADIGM SHIFT IN NANOMEDICINES
21. Foldvari M. Invited Speaker, Potential transcorneal delivery of therapeutic molecules. Nineteenth Annual Glaucoma Foundation. Optic Nerve Rescue and Restoration Think Tank. EXFOLIATION SYNDROME: GEARING UP FOR A CURE. New York, NY., September 2012.
22. Foldvari M. Needle-free Nanomedicines: Applications in Gene Therapy. Northeastern University, IGERT Nanomedicine Seminar Series, NNMD 7270 Graduate course, Nov ember 2012.
23. Foldvari, M. Keynote Speaker, Toxicology Perspectives of Nanomedicines. 5TH SZEGED INTERNATIONAL WORKSHOP ON ADVANCES IN NANOSCIENCE -SIWAN 2012, October 2012
24. Foldvari, M. Keynote Speaker, 2nd International Conference on Nanotechnology: Fundamentals and Applications (ICNFA), July 2011, Ottawa, On. Building Better Drug Delivery Systems using Nanoscale Biomaterials
25. Foldvari, M. Invited Speaker, Canada-Japan Nanotechnology Workshop, November 2011. Non-invasive Nanomedicines: Delivering an Army of Small and Large Molecules to do the Job. University of Waterloo
26. Foldvari, M. Invited Speaker, Phospholipid Conference, Heidelberg, Germany Designing the next generation of dermal and transdermal delivery systems for macromolecules using phospholipids. September 2011, Heidelberg, Germany
Page 104 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
27. Foldvari, M. Invited Speaker, Waterloo Institute of Nanotechnology (WIN) – Bordeaux/Aquitaine Workshop and Innovation Roundtable. May 2011
28. Foldvari, M. Invited Speaker, Taiwan-WIN Strategic Workshop on Nanotechnology. April 2011
29. Foldvari, M. Invited Speaker, Waterloo Institute of Nanotechnology - Soochow University Nanotechnology Workshop. July 2011 30. Foldvari, M. Invited Speaker, Building better drug delivery systems using nanoscale materials. October 2011. UW Physics seminar
31. Foldvari, M. Keynote Speaker, Nano 2011, Rensselaer Polytechnic Institute, Toy, N.Y.
DATE: 23 APRIL 2018.
Page 105 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice) a) NAME:
GAMBLE, John-Michael Associate Clinical Professor, tenure-track Member of the Graduate Faculty: yes b) DEGREES:
PhD, School of Public Health, University of Alberta, 2012 MSc, School of Public Health, University of Alberta, 2008 BScPharm, University of Alberta, 2005 BSc, Faculty of Science, Lakehead University, 2001 c) EMPLOYMENT HISTORY:
2017- Associate Clinical Professor, Faculty of Science, University of Waterloo 2012-2017 Assistant Professor, School of Pharmacy, Memorial University of Newfoundland 2012-2017 Cross-Appointment, Faculty of Medicine, Memorial University of Newfoundland 2012-2017 Family Medicine Pharmacist, Family Practice Unit, Discipline of Family Medicine, Health Sciences Centre, St. John’s, NL. 2009 Ambulatory Care Clinical Pharmacist, Grey Nuns Community Hospital Stroke Prevention Clinic, Edmonton, AB. 2008-2009 Pharmacist (Part-time), Grey Nuns Community Hospital, Edmonton, AB. 2005-2006 Staff Pharmacist, Shoppers Drug Mart, Campbell River, BC. d) HONOURS:
2017 Primary Healthcare Researcher of the Year, Memorial University 2013 New Investigator Award, Canadian Institutes of Health Research, 2013-2018 2013 Clinician Scientist Award, Canadian Diabetes Association, 2013-2018 2011 Pharmaceutical Policy Research Collaboration Fellowship e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2018- Coordinator and instructor, PHARM 222-Integrated Patient Focused Care 3, University of Waterloo, School of Pharmacy 2018 Lecturer, PHARM 371, 377, 609, University of Waterloo, School of Pharmacy 2017- Member, Ontario College of Pharmacists Page 106 of 337 Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2017- Member, Admissions Committee, University of Waterloo School of Pharmacy 2017- Member, Pharmacy Council, University of Waterloo School of Pharmacy 2016, 2017 Member, Application Review Committee, Drug Safety and Effectiveness Cross- Disciplinary Training (DSECT) Program 2014-2016 Clinical Preceptor, Pharmacy, Memorial University 2016 Chair, Search Committee for Canada Research Chair Tier 2 Position in Healthcare Sustainability and Policy Evaluation 2015- Member, Panel of Examiners, Pharmacy Examining Boar of Canada (PBEC) 2015- Board Member, Canadian Association of Population Therapeutics (CAPT) 2015- Member, Membership and Marketing Committee, Canadian Association of Population Therapeutics 2015- Member, Student Committee, Canadian Association of Population Therapeutics 2014- Member, Research Exchange Group on Primary Care, Newfoundland Centre for Applied Health Research (NLCAHR) 2014- Member, Doctoral Research Awards B Review Committee, Canadian Institutes of Health Research (CIHR) 2013- Newfoundland and Labrador representative: Methods team; Training team; Knowledge translation team, Canadian Network for Observational Drug Effect Studies (CNODES) 2013-2017 Member, Clinic Management Committee-Discipline of Family Medicine, Memorial University of Newfoundland, Faculty of Medicine 2013-2017 Member, Medical Ethics Planning Committee-Discipline of Family Medicine, Memorial University of Newfoundland, Faculty of Medicine 2013-2017 Member, Graduate Studies and Research Committee, Memorial University of Newfoundland, Faculty of Medicine 2013-2017 Course lecturer, Phar 4504, Research and Evaluation I, Memorial University of Newfoundland, School of Pharmacy 2015-2017 Member, Newfoundland Support Education Committee, Translational Personalized Medicine Initiative (TMPI) 2015-2017 Member, Personnel Awards Committee, Canadian Diabetes Association 2015-2016 Member, Teaching Equivalencies Evaluation Committee, Memorial University of Newfoundland, School of Pharmacy 2014-2016 Member, Admissions Committee, Memorial University of Newfoundland, School of Pharmacy 2007-2016 Member, Canadian Society of Hospital Pharmacists 2015 Member, local chapter of the International Diabetes Epidemiology Group (IDEG) organizing committee for the IDEG World Diabetes Congress (held in Vancouver, BC, Dec 2015) 2015 Member, Assistant Professor in Pharmacy Education Search Committee, Memorial University of Newfoundland, School of Pharmacy Page 107 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015 Guest instructor, MED 6730, Professional Practice, Memorial University of Newfoundland, Faculty of Medicine 2015 Peer reviewer, Stigma and Diabetes Grant Competition, Canadian Diabetes Association (CDA) 2014 Coordinator and instructor, Phar 4505-Research and Evaluation II, Memorial University of Newfoundland, School of Pharmacy 2013-2014 Associate Member, College of Family Physicians of Canada 2013 Member, Dean of Pharmacy Search Committee, Memorial University of Newfoundland, School of Pharmacy 2013 Guest lecturer, MED 6400-Clinical epidemiology seminar, Memorial University of Newfoundland, Faculty of Medicine 2013 Coordinator and instructor, Phar 4502-Research and Evaluation III, Memorial University of Newfoundland, School of Pharmacy 2005-2013 Member, Alberta College of Pharmacy 2012- Member, Research Exchange Group on Chronic Disease, Newfoundland Centre for Applied Health Research (NLCAHR) 2012- Clinical teaching, Family Medicine Clinic, teaching rounds, Memorial University of Newfoundland, Faculty of Medicine 2012- Pharmacist License, Newfoundland & Labrador Pharmacy Board (#12-1264) 2012-2017 Member, academic Council, Memorial University of Newfoundland, School of Pharmacy 2012-2017 Member, Newfoundland and Labrador Pharmacy Board 2012-2017 Member, Pharmacists Association of Newfoundland and Labrador 2010-2012 Teaching Assistant and course lecturer, PHS 693-Critical Appraisal of the Health Sciences Literature, University of Alberta, School of Public Health 2011 Evaluator, Alberta Pharmacy Residents Research Projects, University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences 2010-2011 Small group Facilitator, Practice Skills: Monitoring drug therapy using laboratory values, University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences 2009- Member, Canadian Diabetes Association, Clinical & Scientific Section 2008- Member, International Society for Pharmacoepidemiology 2007- Member, Canadian Association of Population Therapeutics
Editorial and Peer-Review Tasks
Journals – Ad Hoc Reviews Annals of Pharmacotherapy (n=2) BioDrugs (n=1) BMC Health Services Research (n=1) British Medical Journal (n=6) British Journal of Clinical Pharmacology (n=1) Page 108 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
BMJ Open (n=1) Canadian Journal of Diabetes (n=7) Canadian Journal of Hospital Pharmacy (n=3) Canadian Medical Association Journal (n=7) Canadian Medical Association Journal Open (n=1) Canadian Pharmacists Journal (n=2) Clinical and Investigative Medicine (n=1) Circulation (n=1) Chronic Illness (n=1) Clinical Therapeutics (n=2) Diabetes Management (n=1) Diabetic Medicine (n=3) Diabetes, Obesity, and Metabolism (n=4) Diabetes Research and Clinical Practice (n=3) Drug Safety (n=3) Healthcare Policy (n=4) Health Policy (n=1) Journal of Population Therapeutics and Clinical Pharmacology (n=1) Journal of General Internal Medicine (n=1) Lancet Diabetes and Endocrinology (n=1) Medical Care (n=1)
Abstracts - Scientific Meetings International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 23-26, 2012, Barcelona, Spain (n=30). Canadian Society for Pharmaceutical Sciences, June 10-13, 2014, Montreal, QC (n=5). Canadian Society for Pharmaceutical Sciences, May 26-28, 2015, Toronto, ON (n=6).
f) GRADUATE SUPERVISIONS: past 7 years only, by year
Completed: 2 MSc, 0 PhD In Progress: 1 MSc, 1 PhD
Name of Student Type (years of Title of Thesis or Project Status supervisio n) Jennifer Donnan PhD (May 2015- Comparative Safety and Effectiveness In progress of SGLT2 inhibitors Zachary MSc (Jan2015- Utilization of Benzodiazepines and Completed Giovannini- May 2018 Antipsychotics Amongst Senior Citizens Green in Newfoundland and Labrador Page 109 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Patricia Howse MSc (2014- Comparative Safety and Effectiveness In Progress of Anti-diabetic medications in patients with chronic kidney disease Waseem Abu MSc (Jan 2013- Association Between Diabetes And Completed Ashour May 2016) Infection
OTHER SUPERVISIONS: past 7 years only, by year
Completed: 6 BSc, 7 PharmD, 1 other research In Progress: 2 BSc; 0 PharmD, 4 other research
Name of Trainee Program Type (years of supervision) Status
Jenna Hache BSc Pharmacy Memorial University, Undergraduate In progress Career Experience Program (MUCEP) (2017- ) Catherine Grandy BSc Pharmacy Memorial University, Undergraduate In progress Career Experience Program (MUCEP) (2016- ) Daniel Curnew BSc Pharmacy Memorial University, Completed Undergraduate Career Experience Program (MUCEP) (2016) Tomisin Jenrola BSc Computer Memorial University, Completed Science Undergraduate Career Experience Program (MUCEP) (2016) Lyudmila BSc Pharmacy Memorial University, Summer Completed Chibrikova Undergraduate research student (2014, 2015) Megan Snow BSc Pharmacy Memorial University, summer Completed undergraduate research student (2013) Kristina Myers BSc Pharmacy Memorial University, summer Completed undergraduate research student (2013) Daniala Weir BScEpidemiology University of Alberta, completed Completed summer research studentship (2012) Nicole Chiasson PharmD Memorial University, Completed Clinical Preceptor (Feb-Apr 2016) Iqshuvaka Mishra PharmD Memorial University, Completed Clinical Preceptor (Feb-Apr 2015)
Page 110 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Michael Bernard PharmD Memorial University, Completed Clinical Preceptor (Feb-Apr 2014) Amy Conway PharmD Idaho State University, Advanced Completed Pharmacy Practice Research Elective (Nov-Dec 2013) Terri Genge PharmD Idaho State University, Advanced Completed Pharmacy Practice Research Elective (Sept-Oct 2013) Logan McNeil PharmD University of British Columbia, Clincal Completed Preceptor (May-Jun 2006) Lindsey Doepker PharmD University of Saskatchewan, Clinical Completed Preceptor (May-Jun 2006) Eugeny Chibrikov Data Analyst School of Pharmacy, Memorial In progress University (June 2015- ) Jamie Marra Research Analyst School of Pharmacy, Memorial Completed University (Oct 2014-Nov 2015) Hilary Price Research School of Pharmacy, Memorial Completed Assistant University (Sept 2013-Jun 2014) Meghan Agnew Research School of Pharmacy, Memorial Completed Assistant University (Sept 2013-Jun2014) Cindy Sun Data Analyst School of Pharmacy, Memorial Completed University (May 2013-Nov2014) g) GRADUATE COURSES:
2013, 2015 Phar 6105-Pharmacoepidemiology, Memorial University of Newfoundland
h) 1. EXTERNAL RESEARCH FUNDING
Year Source Type* Amount Purpose** Investigator 2018- Canadian Institutes for C $359,550 Research Principal 2020 Health Research-Project Investigator: Scheme Fall 2017 Gamble JM, Competition Co-PI: Eurich Sodium Safety of the D Sodium Glucose Co- transporter-2 (SGLT-2) Inhibitors in Patients with Type 2 Diabetes 2017- Canada Foundation for O $258,685 Research Principal
Page 111 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2022 Innovation- John R. Evans Investigator: Leaders Fund Gamble JM Drug Information Science Research and Training Laboratory
2017- Canadian Respiratory F $105,450 Research PI: Midodzi 2018 Research Network (CRRN) - W CRRN Project Funding Co- Investigators Pharmaco-Epidemiological : Gamble JM, Study of Cardio-Respiratory Farrell J, Gao Safety of B2-agonists for the Z. Treatment and Management of Asthma-COPD Overlap Syndrome 2016- Canadian Institutes for C $17,500,000 Research Principal 2021 Health Research- DSEN Applicants: Collaborating Centre for Suissa S, Dormuth C, Observational Studies (2016) Henry D, Platt Canadian Network for R, Sketris I Observational Drug Effect Studies (CNODES) 2015- Canadian Institutes of Health C $1,373,522 Research Principal 2019 Research- Drug Safety and Applicants: Effectiveness Network Dolovich L, (DSEN) Training Grant 2015- Bernatsky S, 08-04 Beyene J, et The Drug Safety and al. Effectiveness Cross- Disciplinary Training (DSECT) Program 2015- Canadian Institutes of Health C $1,000,000 Research Aubrey- 2020 Research Bassler K (PI) 2015- Health Research Foundation- F $150,000 Research Davis E (Co- 2018 Academic Interdisciplinary PI), Hawboldt Health Research Team J (Co-PI) Co- Grants investigators: Increasing Quality of Life and Gamble JM, Page 112 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Reducing Pulmonary Fitzgerald M, Exacerbations In Chronic Farrell J Obstructive Pulmonary Disease (COPD) by providing pharmacist-driven improvement in medication adherence: A Pragmatic Cluster Randomized Controlled Trial 2014- Canadian Institutes of Health C, O $9,780,856 Research Rahman P 2019 Research- Strategy for (PI), Barrett Patient Oriented Research B (Co-PI)
(SPOR) SUPPORT Units A Business Plan from Memorial University and Government of Newfoundland and Labrador for the Canadian Institutes of Health Research SUPPORT Unit Proposal 2014- NL Government, RDC, CIHR, C, G, $41,000,000 Research Rahman P 2019 IBM O (PI), Barrett Translational Personalized B (Co-PI) Medicine Initiative 2013- Canadian Institutes of Health C $300,000 Research Gamble JM 2018 Research- New Investigator (PI) Award 2012 Competition Comparative safety and effectiveness of antidiabetic medications 2013- Canadian Diabetes F $50,000 Research Gamble JM 2018 Association- Clinician (incentive (PI) Scientist Salary Award funding) Comparative safety and effectiveness of antidiabetic medications 2016- NL Centre for Applied Health G $15,000 Research Gamble JM
Page 113 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2017 Research- NL Development (PI) Grant Advancing Capacity for Conducting Quantitative Benefit-Risk Analysis in Newfoundland and Labrador 2013- Canadian Institutes of Health C $175,524 Research Gamble JM 2017 Research- Open Operating (PI), Grant Fall 2012 Competition Majumdar SR (co-PI) Comparative safety and effectiveness of the Incretins 2014- Canadian Institutes of Health C $150,003 Research Suissa S (PI), 2016 Research- Rapid Funding for Gamble JM DSEN Targeted Research (co-PI), Newfoundland and Labrador Dormuth C CNODES Demonstration (co-PI), Henry Project D (co-PI)
2012- Research and Development O $100,000 Research Gamble JM 2016 Corporation- IgniteR&D (PI) Impact of Insulin Therapy on Cardiovascular Outcomes in Patients with Type 2 Diabetes 2013- Heart and Stroke Foundation F $124,540 Research Gamble JM 2015 of Canada- Grant-in–Aids (PI), 2012 Competition Majumdar SR (co-PI) Comparative Cardiovascular Effects of Incretins 2014 Canadian Institutes of Health C, F $75,000 7 Research Godwin M Research- Strategy for (PI) Patient Oriented Research (SPOR) Network in Primary and Integrated Health Care Innovations Strategy for Patient Oriented Research (SPOR) Network in Primary and Integrated Page 114 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Health Care Innovations 2013 Memorial University of O $5000 Research Gamble JM Newfoundland- Summer (PI), Davis EM Undergraduate Research (co-PI) Project Systematic Review of Drug- Induced Dysglycemia 2009- Canadian Institutes of Health C $15,000 Research Gamble JM 2012 Research- Frederick Banting (PI) and Charles Best Canada Co-applicants: Johnson JA, Graduate Scholarship Eurich DT. (research stipend portion of Doctoral award) The Impact of Restrictive Drug Coverage Policies on Pharmacoepidemiologic Methods and Health Outcomes 2007- Alberta Innovates – Health G $4,500 Research Gamble JM 2012 Solutions- Health Research (PI) Full-time Studentship Co-applicants: (research stipend portion of Johnson JA, award) Eurich DT. The Impact of Restrictive Drug Coverage Policies on Pharmacoepidemiologic Methods and Health Outcomes
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
1. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2017 UW Pharmacy S $200,000 research, Dr. Gamble travel, publication Page 115 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
fees, student stipends, etc.
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs……………………………………………………………2 - refereed journal articles ...... 35 - refereed conference proceedings...... 40 - presentations at conferences ...... 11 - technical reports ...... 1 - invited/keynote addresses ...... 24 - others (workshops presented) ...... 8
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Books Authored:
N/A
Books Edited:
N/A
Chapters in Books:
1. Groves KE, MacKinnon N, Sketris I, Gamble JM (2016). Prescribing Behavior. In: Rickles N, Wertherimer A, Schommer J (eds). Social and Behavioral Aspects of Pharmacy Practice. Kendall Hunt, Dubuque IA.
2. Gamble JM, Butalia S (2015). Medical Practice Variations in Diabetes Mellitus. In: Sobolev B (Series ed), Johnson A, Stukel T (eds). Health Services Research Series. Medical Practice Variations. Springer, New York, pp 1-40. Page 116 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Papers in Refereed Journals:
1. Gamble JM, Chibrikov E, Midodzi WK, Twells LK, Majumdar SR. A Cohort Study Examing the Risk of Depression or Self-Harm Associated with Incretin-based Therapies Used to Manage Hyperglycemia in Patients with Type 2 Diabetes. BMJ (submitted February 2018) 2. Gamble JM, Donnan JR, Chibrikov E, Twells LK, Midodzi WK, Majumdar SR. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose- lowering Therapies for Three Acute Outcomes. Scientific Reports (submitted March 2018) 3. Gamble JM, Donnan JR, Chibrikov E, Midodzi WK, Twells LK. Initiation with a Glucagon- like Peptide-1 Receptor Agonist and the Risk of Respiratory Tract Infections. JAMA (submitted March 2018) 4. Donnan JR, Grandy C, Chibrikov E, Marra C, Aubrey-Bassler K, Johnston K, Najafzadeh M, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. Comparative Safety of the Sodium Glucose Co-transporter (SGLT2) Inhibitors: A systematic review and meta-analysis. BMJ Open (submitted March 2018) 5. Grandy CA, Donnan JR, Peddle J, Romme K, Kim S, Gamble JM. A Systematic Review of Machine-Readable Clinical Drug Data Sources for Building Knowledge Translation Products. JAMIA (submitted March 2018). 6. Gamble JM, Traynor Robyn L., Gruzd Anatoliy, Mai Philip, Dormuth Colin R., Sketris Ingrid S. Measuring the impact of pharmacoepidemiologic research using altmetrics: A case study of a CNODES drug‐safety article. Pharmacoepidemiology and Drug Safety; online early March 24, 2018. doi:10.1002/pds.4401.
7. Gamble JM, Donnan JR, Chibrikov E, Twells LK, Midodzi WK, Majumdar SR. The Risk of Fragility Fracture in New Users of Dipeptidyl Peptidase-4 Inhibitors Compared to Sulfonylureas and Other Anti-Diabetic Drugs: A Cohort Study. Diabetic Research and Clinical Practice 2018;136:159-167. DOI: 10.1016/j.diabres.2017.12.008 [Impact factor 3.6] PMID: 29258886 8. Abu-Ashour W, Twells LK, Valcour J, Gamble JM. Diabetes and the Occurrence of Infection in Primary Care: A Matched Cohort Study. BMC Infec Dis 2018;18:67. DOI 10.1186/s12879-018- 2975-2 [Impact factor 2.8] PMID: 29402218 9. Anand K, Sketris I, Zhang Y, Levy A, Gamble JM. The impact of FDA and Health Canada warnings related to the safety of high dose simvastatin. Drugs – Real World Outcomes 2017; 4:215-233 DOI: 10.1007/s40801-017-0116-7 10. Abu-Ashour W, Twells LK, Valcour J, Randell A, Donnan J, Howse P, Gamble JM. The Association Between Diabetes Mellitus and Incident Infections: A Systematic Review and Meta-Analysis Of Observational Studies. BMJ Open Diabetes Res Care 2017;5:e000336. DOI: 10.1136-bmjdrc-2016-000336 PMID: 28761647. Page 117 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
11. Gamble JM, Chibrikov E, Twells LK, Midodzi WK, Young SW, MacDonald D, Majumdar SR. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol 2017;5:43-52. DOI: 10.1016/S2213- 8587(16)30316-3 [Impact factor 16.3] PMID: 27865756.
12. Davis EM, Marra C, Gamble JM, Farrell J, Lockyer J, FitzGerald JM, Abu-Ashour W, Gillis C, Hawboldt J. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): A pragmatic cluster randomized controlled trial. Trials 2016; 17:502. DOI: 10.1186/s13063-016-1623-7 [Impact factor 1.9] PMID: 27737686. 13. Alwashmi M, Hawboldt J, Davis E, Marra C, Gamble JM, Abu Ashour W. The effect of smartphone interventions on patients with Chronic Obstructive Pulmonary Disease exacerbations: A systematic review and meta-analysis. J Med Internet Res 2016; 4:e105. DOI: 10.2196/mhealth.5921 [Impact factor 4.5] PMID: 27589898. 14. Howse PM, Chibrikova LN, Barrett BJ, Twells LK, Gamble JM. Safety and Efficacy of Incretin- based Therapies in Patients with Type 2 Diabetes and Chronic Kidney Disease: Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68:733-742. DOI: 10.1053/j.ajkd.2016.06.014 [Impact factor 5.9] PMID: 27528374 15. Gamble JM, Thomas JM, Twells LK, Midodzi WK, Majumdar SR. Comparative Effectiveness of Incretins and the Risk of Death and Cardiovascular Events In 38233 New Metformin Users. Medicine 2016;95:26. DOI: 10.1097/MD.0000000000003995 [Impact factor 5.7] PMID: 27368005. 16. Abu-Ashour W, Midodzi WK, Twells L, Gamble JM. Factors Associated With Early Insulin Initiation in Type 2 Diabetes: A Canadian Cross-Sectional Study. Diabetic Medicine 2017;43:229-234. DOI: 10.1111/dme.13082 [Impact factor 3.2] PMID: 26802577. 17. Gamble JM, Clarke A, Myers KJ, Agnew MD, Hatch K, Snow MM, Davis EM. Incretin-based medications for type 2 diabetes: an overview of reviews. Diabetes Obes Metab 2015;17:649- 658. DOI: 10.1111/dom.12465 [Impact factor 5.5] PMID: 25772666 18. Price HI, Agnew MD, Gamble JM. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: A systematic review. BMJ Open 2015;5:e006341. DOI:10.1136/bmjopen-2014-006341 [Impact factor 2.1] PMID: 25762229 19. Gamble JM, Johnson JA, McAlister FA, Majumdar SR, Simpson SH, Eurich DT. Limited Impact of Exposure Misclassification Due to Incomplete Drug Data in Observational Studies of Drug Safety and Effectiveness: a cohort study. Clinical Therapeutics 2015;37:629-642. DOI: 10.1016/j.clinthera.2014.12.014 [Impact factor 2.6] PMID: 25596665 20. Gamble JM. An Introduction to the Fundamentals of Cohort and Case-Control Studies. Can J Hosp Pharm 2014;67:366-372. Available: http://www.cjhp- online.ca/index.php/cjhp/article/view/1391/2014 [Impact factor n/a] PMID: 25364019
Page 118 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
21. Gamble JM, Hall JJ, Marrie TJ, Sadowski CA, Majumdar SR, Eurich DT. Medication Transitions and Polypharmacy in Older Adults Following Acute Care. Therapeutics and Clinical Risk Management 2014;10:189-196. DOI: 10.2147/TCRM.S58707 [Impact factor 1.4] PMID: 2467223 22. Gamble JM, Majumdar SR, Johnson JA, McAlister FA, Simpson SH, Eurich DT. Changes in Thiazolidinedione Use and Outcomes Following Removal of a Prior Authorization Policy: Controlled Time-Series Analysis. Med Care 2014;52:47-55. DOI: 10.1097/MLR.0000000000000006 [Impact factor 3.3] PMID: 24309670 23. Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert JM, Qiu W, Simpson SH. Risk of Acute Coronary Events Associated with Glyburide Use Compared to Gliclazide in Patients with Type 2 Diabetes: A Nested Case-Control Study. Diabetes Obes Metab 2014;16:22-9. DOI: 10.1111/dom.12173 [Impact factor 5.2] PMID: 23802997 24. Boussageon R, Gamble JM, Gueyffier F, Cornu C. Clinically pertinent efficacy of insulin therapy in patients with type 2 diabetes. Therapie 2013;68:415-17. DOI: 10.2515/therapie/2013063 [Impact factor 0.4] PMID: 24246125 25. Abdelmoneim AS, Eurich DT, Gamble JM, Simpson SH. Utilization Patterns of Antidiabetic Regimens by Type 2 Diabetes Patients in Alberta, Canada, 2000-20008. Can J Diabetes 2013;37:394-400 DOI: 10.1016/j.jcjd.2013.04.008 [Impact factor 0.5] PMID: 243121720 26. Gamble JM, Johnson JA, Majumdar SR, McAlister FA, Simpson SH, Eurich DT. Evaluating the Introduction of a Computerized Prior Authorization System on the Completeness of Drug Exposure Data. Pharmacoepidemiol Drug Saf 2013;22:551-555. DOI: 10.1002/pds.3427 [Impact factor 2.9] PMID: 23475736 27. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Impact of Guideline-Concordant Antibiotics and Macrolide/B-lactam combinations in 3203 Patients Hospitalized with Pneumonia: Prospective Cohort Study. Clinical Microbiol Infect 2013;19:257-264. DOI: 10.1111/j.1469-0691.2012.03783.x [Impact factor 4.5] PMID: 22404691 28. Gamble JM, McAlister FA, Johnson JA, Eurich DT. Restrictive Drug Coverage Policies Can Induce Substantial Drug Exposure Misclassification In Pharmacoepidemiologic Studies. Clin Ther 2012;34:1379-1386. DOI: 10.1016/j.clinthera.2012.04.009 [Impact factor 3.1] PMID: 22554975 29. MacIntyre EJ, Majumdar SR, Gamble JM, Minhas-Sandhu JK, Marri TJ, Eurich DT. Stress hyperglycemia and newly diagnosed diabetes in 2130 patients hospitalized with pneumonia: population-based cohort study. Am J Med 2012;125:e17-23. DOI: 10.1016/j.amjmed.2012.01.026 [Impact Factor 5.4] PMID: 22863217 30. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Guideline Adherence and Macrolides Reduced Mortality in 2973 Outpatients with Pneumonia. Respir
Page 119 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Med 2012;106:451-458. DOI:10.1016/j.rmed.2011.11.017 [Impact factor 2.5] PMID: 22182341 31. Gamble JM, Hoang H, Eurich DT, Jindal KK, Senior PA. Patient Level Evaluation of Community-Based, Multifactorial Intervention to Prevent Diabetic Nephropathy. J Prim Care Community Health 2012;3:111-119. DOI: 10.1177/2150131911417718 [Impact factor n/a] PMID: 23803454 32. Gamble JM, McAlister FA, Johnson JA, Eurich DT. Quantifying the Impact of Drug Exposure Misclassification Due to Restrictive Drug Coverage in Administrative Databases: A Simulation Cohort Study. Value Health 2012;15:191-197. DOI: 10.1016/j.va.2011.08.005 [Impact factor 2.9] PMID: 22264988 33. Gamble JM, Weir DL, Johnson JA, Eurich DT. Analysis of Drug Coverage Before and After the Introduction of Canada’s Common Drug Review. CMAJ 2011;183:E1259-E1266. DOI: 10.1503/cmaj.110670 [Impact factor 9.0] PMID: 22025648 34. Simpson SH, Gamble JM, Mereu L, Chambers T. Dose-Response Relationships between Aspirin, All-Cause Mortality, and Cardiovascular Events in People with Diabetes: Systematic Review and Meta-Analysis. J Gen Intern Med 2011;26:1336-1340. DOI: 10.1007/s11606-011- 1757-y [Impact factor 2.7] PMID: 21647746 35. Gamble JM, Eurich DT, Ezekowitz JA, Kaul P, Quan H, McAlister FA. Patterns of Care and Outcomes Differ for Urban Versus Rural Patients With Newly Diagnosed Heart Failure, Even in a Universal Healthcare System. Circulation: Heart Failure 2011;4:317-323. DOI: 10.1161/CIRCHEARTFAILURE.110.959262 [Impact factor 3.4] PMID: 21430285 36. Majumdar SR, Eurich DT, Gamble JM, Senthilselvan A, Marrie TJ. Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: population-based cohort study. Clin Infect Dis 2011;52:325-331. DOI: 10.1093/cid/ciq076 [Impact Factor 8.2] PMID: 21217179
Refereed Conference Proceedings
1. Gamble JM, Daley PK, Chibrikov E, Aubrey-Bassler K, Bishop LD, Davis EM, Dicks E, Farrell G, Fleet L, Barrett B, Parfrey P. Variation in Prescribing Rates of Oral Antibiotics Among General Practitioner and Emergency Department Physicians in Newfoundland and Labrador, Canada. Canadian Association for Population Therapeutics. Oct 23-24, 2017, Toronto, ON. J Popul Ther Clin Pharmacol 2017; 24(3):e67-e68. 2. Donnan JR, Grandy C, Chibrikov E, Marra C, Aubrey-BaslerK, Johnston K, Najafzadeh M, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. Comparative Safety of the Sodium Glucose Co-transporter (SGLT2) Inhibitors: A Systematic Review and Meta-analysis. Canadian Association for Population Therapeutics. Oct 23-24, 2017, Toronto, ON. J Popul Ther Clin Pharmacol 2017; 24(3):e61-e62.
Page 120 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Gamble JM, Donnan JR, Chibrikov E, Twells LK, Midodzi WK, Majumdar SR. The Risk of Fragility Fracture in New Users of Dipeptidyl Peptidase-4 Inhibitors Compared to Sulfonylureas and Other Anti-Diabetic Drugs: A Cohort Study. Canadian Association for Population Therapeutics. Oct 23-24, 2017, Toronto, ON. J Popul Ther Clin Pharmacol 2017; 24(3):e65. 4. Chibrikov E, Gamble JM. An Algorithm for Identifying and Representing Treatment Exposure Patterns. Abstracts of the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 26-30 August 2017, Montreal, QC. Pharmacoepidemiol Drug Saf 2017;26(S2):98. 5. Alwashmi M, Hawboldt J, Davis E, Marra C, Gamble JM, AbuAshour W. The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis. iproc 2017;3(1):e6.
6. Giovannini-Green Z, Parfrey P, Barrett B, Dicks E, Gamble JM. Utilization of Benzodiazepine and Antipsychotic Medications in Urban versus Rural Dwelling Seniors in Newfoundland and Labrador. Canadian Association for Population Therapeutics. Oct 16- 17, 2016, Toronto, ON. J Popul Ther Clin Pharmacol 2016; 23(3):e213.
7. Howse Westcott PM, Barrett B, Chibrikov E, Twells LK, Midodzi WK, Majumdar SR, Gamble JM. Risk of mortality associated with starting DPP-4 inhibitors in a cohort of new- users of metformin with chronic kidney disease. Canadian Association for Population Therapeutics. Oct 16-17, 2016, Toronto, ON. J Popul Ther Clin Pharmacol 2016; 23(3):e209-210.
8. Genge T, Chibrikova LN, Davis EM, Asghari S, Flynn H, Godwin M, Gamble JM. Assessment of laboratory testing for monitoring of the safety and effectiveness of antihyperglycemic medications in NL primary care practices. Canadian Association for Population Therapeutics. Nov 1-3, 2015, Toronto, ON. J Popul Ther Clin Pharmacol 2015: 22(3):e262.
9. Gamble JM, Clarke A, Myers JJ, Agnew MD, Snow MM, Hatch K, Davis EM. Incretin-based Medications for Type 2 Diabetes: An Overview of Reviews. 17th Annual CDA/CSEM Professional Conference and Annual Meeting. Oct 22-25, 2014, Winnipeg, MB. Can J Diabet 2014;38:S59. 10. Davis EM, Snow MM Price HI, Genge T, Hatch L, Myers KJ, Gamble JM. The Incidence of Drug-Induced Diabetes in Patients Taking Antihypertensive and Lipid-lowering Agents: An Overview of Systematic Reviews. 17th Annual CDA/CSEM Professional Conference and Annual Meeting. Oct 22-25, 2014, Winnipeg, MB. Can J Diabet 2014;38:S71. 11. Abu-Ashour W, Midodzi WK, Twells L, Gamble JM. Predictors of Early Insulin Use in Patients with Type 2 Diabetes: A Cross-Sectional Study. 17th Annual CDA/CSEM
Page 121 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Professional Conference and Annual Meeting. Oct 22-25, 2014, Winnipeg, MB. Can J Diabet 2014;38:S70-S71. 12. Sketris IS, Gruzd A, Mai P, Gamble JM, Dormuth C. Analyzing the Short-term Social Media Impact of a Drug Safety Publication – A Case Study Approach. 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 24-27 October 2014, Taipei. Pharmacoepidemiol Drug Saf 2014;23:120. 13. Lester K, Twells L, Gregory DM, Kovacs CS, Gamble JM. Improvement of glycemic control in prediabetic and type 2 diabetic patients undergoing laparoscopic sleeve gastrectomy (LSG). Canadian Obesity Summit. May 1-4, 2013, Vancouver, BC. Can J Diabetes 2013;37:S238.
14. Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert J, Qiu W, Simpson SH. Risk of Acute Coronary Syndrome Differs Between Glyburide And Gliclazide Treatment in Patients With Type 2 Diabetes and Ischemic Heart Disease: A Population-Based Cohort Study. 48th Annual Meeting of the European Association for the Study of Diabetes. October 1-5th, 2012, Berlin, Germany. Diabetologia 2012;55(Suppl 1):28. 15. Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert J, Qiu W, Simpson SH. Glyburide is Associated with a Higher Risk of Acute Coronary Events Compared to Gliclazide: A Nested Case-control Study. 15th Annual CDA/CSEM Professional Conference and Annual Meeting. Oct 10-13, 2012, Vancouver, BC. Can J Diabet 2012;36(Suppl 1):S21- 22. 16. Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert J, Qiu W, Simpson SH. Glyburide Is Associated With An Increased Risk Of Acute Coronary Events Compared To Gliclazide In Patients With A History Of Ischemic Heart Disease. Abstracts of the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23-26 August 2012, Barcelona, Spain. Pharmacoepidemiol Drug Saf 2012;21(Suppl. 3):271. 17. Gamble JM, Johnson JA, McAlister FA, Majumdar SR, Simpson SH, Eurich DT. Impact of Exposure Misclassification Due to Incomplete Drug Data in Observational Studies of Safety and Effectiveness. Abstracts of the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23-26 August 2012, Barcelona, Spain. Pharmacoepidemiol Drug Saf 2012;21(Suppl. 3):176. 18. Gamble JM, Johnson JA, Majumdar SR, McAlister FA, Simpson SH, Eurich DT. Drug Exposure Misclassification Because of Prior-Authorization Policies: A Cautionary Tale for Researchers Using Databases Limited to Formulary-Approved Prescriptions. Abstracts of the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23-26 August 2012, Barcelona, Spain. Pharmacoepidemiol Drug Saf 2012;21(Suppl. 3):176-177.
Page 122 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
19. Gamble JM, Majumdar SR, Johnson JA, McAlister FA, Simpson SH, Eurich DT. Changes in Thiazolidinedione Use and Outcomes Following Removal of a Prior Authorization Policy: Controlled Time-Series Analysis. 72nd Annual American Diabetes Association scientific sessions. June 8-12, 2012, Philadelphia, PA. Diabetes 2012;61(Suppl 1):A374 (abstract 1436-P).
20. Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert J, Qiu W, Simpson SH. Risk Difference Between Glyburide and Gliclazide for Acute Coronary Events Depends on a History of Ischemic Heart Disease: A Nested Case-control Study. 72nd Annual American Diabetes Association scientific sessions. June 8-12, 2012, Philadelphia, PA. Diabetes 2012;61(Suppl 1):A346(abstract 1334-P).
21. Gamble JM, Johnson JA, McAlister FA, Majumdar SR, Simpson SH, Eurich DT. Impact of Exposure Misclassification Due to Incomplete Drug Data in Observational Studies of Drug Safety and Effectiveness: a cohort study. Canadian Association for Population Therapeutics (CAPT) Annual Meeting, May 6-8, 2012, Montreal, QC. J Popul Ther Clin Pharmacol 2012;19:e119.
22. MacIntyre EJ, Majumdar SR, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Eurich DT. Stress hyperglycemia and newly diagnosed diabetes in 2135 patients hospitalized with pneumonia: population-based cohort study. Canadian Diabetes Association Annual Meeting, October 26-29, 2011,Toronto, ON. Can J Diabetes 2011;35(Suppl 1):375.
23. Abdelmoneim AS, Eurich DT, Gamble JM, Simpson SH. Trend of use of combination antidiabetic regimens for type 2 diabetes patients in Alberta, 1998-2008. CDA/CSEM Canadian Diabetes Association Professional Conference & Annual Meeting, October 26- 29, 2011, Toronto, ON. Canadian Journal of Diabetes 2011:35(Suppl 1:). 24. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Impact of using guideline-concordant antibiotics in 3203 patients hospitalized with pneumonia: prospective cohort study. Oral Presentation, Canadian Society of Internal Medicine Annual Scientific Meeting, October 12-15 2011, Halifax, NS. Can J Gen Intern Med 2011;6(in press). 25. Gamble JM, McAlister FA, Johnson JA, Eurich DT. Misclassifying Drug Exposure Data within Administrative Databases: An Ecologic Approach. Abstracts of the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 14-17 August 2011, Chicago, IL. Pharmacoepidemiol Drug Saf 2011;20(Suppl 1): S255. 26. Gamble JM, McAlister FA, Johnson JA, Eurich DT. Quantifying the Impact of Drug Exposure Misclassification Due to Restrictive Drug Coverage in Administrative Databases: A Simulation Cohort Study. Abstracts of the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 14-17 August 2011, Chicago, IL. Pharmacoepidemiol Drug Saf 2011;20(Suppl 1): S255-S256.
Page 123 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
27. Gamble JM, Weir DL, Johnson JA, Eurich DT. Streamlining drug coverage in Canada: an analysis of new drug products before and after the introduction of the Common Drug Review Process. Canadian Association for Population Therapeutics (CAPT) Annual Meeting, Apr 17-19, 2011, Ottawa, ON. J Popul Ther Clin Pharmacol 2011;18:e187. 28. Gamble JM, Eurich DT, Ezekowitz JA, Kaul P, Quan H, McAlister FA. Sex differences in one-year mortality in people with heart failure among urban and rural residences in Alberta, Canada. Canadian Association for Population Therapeutics (CAPT) Annual Meeting, Mar 28-30, 2010, Toronto, ON. Can J Clin Pharmacol Vol 2010;17(1):e90-e127.
29. Simpson SH, Gamble JM, Mereu L, Chambers T. Association between Aspirin Dose and Cardiovascular Outcomes: A Meta-analysis. 70th Annual American Diabetes Association scientific sessions. June 25-29, 2010, Orlando, FL. Diabetes 2010;59(Suppl 1): abstract 788-P. Technical reports
1. Gamble JM, MacDonald D, Dowden J, Young S, West R, Dormuth C, Henry D, Suissa S. Drug Safety and Effectiveness Network (DSEN) Report: Newfoundland and Labrador CNODES Demonstration Project. Submitted to the DSEN coordinating office in March 2016.
Registered Study Protocols (n=5):
1. Catherine Anne Grandy, Jennifer Donnan, Justin Peddle, Kristen Romme, Satpyul Kim, John-Michael Gamble. A systematic review of clinical drug data for building drug information knowledge translation products. PROSPERO 2017:CRD42017067456 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017067456 2. Donnan J, Marra C, Aubrey-Bassler K, Johnston K, Najafzadeh M, Swab M, Gamble JM. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and network meta-analysis. PROSPERO 2016:CRD42016038715 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016038715 3. Price H, Agnew M, Gamble JM. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. PROSPERO 2014:CRD42014007631 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014007631 4. Snow M, Davis E, Myers K, Hatch K, Gamble JM. The incidence of drug-induced diabetes in patients taking anti-hypertensive and lipid-lowering medications: an overview of systematic reviews. PROSPERO 2013:CRD42013005150 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013005150 Page 124 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
5. Myers K, Gamble JM, Davis E, Snow M, Hatch K. Incretin based drugs for type 2 diabetes: an overview of systematic reviews. PROSPERO 2013:CRD42013005149 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013005149
Invited Presentations (n=24):
1. Digital Footprints: altmetrics as a tool to demonstrate scholarly output. CNODES Semi-annual meeting, Montreal, ON. October 25, 2017.
2. Using Altmetrics to Illustrate Research Impact. DSECT Symposium, Toronto, ON. May 3rd, 2017.
3. Is High Insulin Exposure Associated with Mortality in Type 2 Diabetes? Pharmacy Research Seminar Series. University of Waterloo, Waterloo, ON. January 20, 2017.
4. Is Insulin Intensity Associated with Death? Primary Healthcare Research Unit Research in Progress Seminar Series. Memorial University, St. John’s, NL. December 14, 2016.
5. Informatics and Drug Safety and Effectiveness Research. Drug Safety and Effectiveness Cross- disciplinary Training Program Trainee Seminar. Online Webinar. August 26, 2016.
6. Panel participant, Atlantic Pharmacy Advancement Conference (APAC), St. John’s, NL, Saturday, November 7th, 2015.
7. Discussing the risks of medications with patients. The good, the bad, and the ugly. Canadian Society of Hospital Pharmacists NL Branch Professional Development Day, St. John’s, NL, October 17th, 2015.
8. Exposure ascertainment of drugs with restrictive drug coverage policies: A blind spot in administrative databases. Online Webinar hosted by the International Society of Pharmacoepidemiology Society. January 21, 2015.
9. Exposure ascertainment of drugs with restrictive drug coverage policies: A blind spot in administrative databases. University of Toronto, Department of Pharmaceutical Sciences Seminar Series. Hosted by the International Society of Pharmacoepidemiology UotT Student Chapter. Toronto, ON, November 4, 2014.
10. Prescribing Tips. NL Chapter of the Canadian College of Family Physicians Annual Scientific Assembly. Capitol Hotel, St. John’s, NL, October 3rd, 2014.
Page 125 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
11. Communicating Health Statistics to Patients and the Healthcare Team. Canadian Society of Hospital Pharmacists Summer Education Sessions, St. John’s, NL, August 10th, 2014.
12. Academic Detailing. Medical Ethics Workshop 2013: Physicians’ Interactions with Industry. The Landing, University Centre, Memorial University of Newfoundland, June 5, 2013.
13. Unveiling the real world effects of medications and their policies. Heart and Stroke Foundation Research Tour, Memorial University of Newfoundland, November 16th, 2012.
14. New Drugs for Diabetes: Unveiling the risk-benefit ratio through postmarketing drug safety and effectiveness research. Graduate Studies and Research Seminar Series, School of Pharmacy, Memorial University of Newfoundland, November 1, 2012.
15. Contemporary Issues in Pharmacoepidemiology. Med 6400, Clinical Epidemiology Seminar, Faculty of Medicine, Memorial University of Newfoundland, September 26, 2012.
16. The Confluence of Drug Coverage Policies and Study Validity. ACHORD Research Retreat, Banff, AB, March 9, 2012.
17. The Confluence of Drug Coverage Policies and Study Validity. School of Public Health Research Seminar, Edmonton, AB, January 27, 2012.
Workshops (n=8):
1. Appraising Randomized Clinical Trials Workshop: Advanced Concepts. Canadian Agency for Drugs and Technologies in Health (CADTH) Offices, Ottawa, ON. March 25-26th, 2018. I co- designed and co-delivered the workshop in collaboration with Dr. Dean Eurich.
2. Appraising Observational Studies Workshop: Advanced Concepts. Canadian Agency for Drugs and Technologies in Health (CADTH) Offices, Toronto, ON. December 1st, 2017. I designed and delivered the workshop.
3. Appraising Observational Studies Workshop: Advanced Concepts. Canadian Agency for Drugs and Technologies in Health (CADTH) Offices, Ottawa, ON. November 30th, 2017. I designed and delivered the workshop.
4. Appraising Observational Studies Workshop: Core Concepts. Canadian Agency for Drugs and Technologies in Health (CADTH) Offices, Ottawa, ON. November 20-21st, 2017. I designed and delivered the workshop.
Page 126 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
5. Appraising Observational Studies Workshop: Core Concepts. Canadian Agency for Drugs and Technologies in Health (CADTH) Offices, Toronto, ON. November 2-3rd, 2017. I designed and delivered the workshop.
6. Incorporating patient preferences into benefit-risk analysis. School of Pharmacy Practice Lab, Memorial University, St. John’s, NL. July 27-28th, 2016. I designed, planned, and chaired this workshop.
7. Does that drug really do that? Critical Appraisal of Observational Pharmacoepidemiology. Canadian Society of Epidemiology and Biostatistics Biennial Conference, St. John’s, NL. June 24th, 2013. I co-delivered this workshop with my colleague Dr. Erin Davis.
8. Critical Appraisal 102: Evidence Appraisal for the Non-Researcher. Canadian Agency for Drugs and Technologies Symposium 2013, St. John’s, NL. May 5, 2013. I co-delivered this workshop with my colleague Dr. Erin Davis. DATE: May 1 2018
Page 127 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
GRINDROD, Kelly b) Assistant Professor Member of the Graduate Faculty: yes
c) DEGREES:
MSc, Pharmaceutical Sciences, University of British Columbia, 2009 PharmD, Pharmaceutical Sciences, University of British Columbia, 2009 BSc, Pharmacy & Pharmaceutical Sciences, University of Alberta, 2003 d) EMPLOYMENT HISTORY: 2018- Associate Professor, School of Pharmacy, University of Waterloo 2009- 2018 Assistant Professor, School of Pharmacy, University of Waterloo 2015- Clinical Pharmacist, Kitchener Downtown Community Health Center, Kitchener 2011-2014 Clinical Pharmacist, Schill’s Remedy Rx, Waterloo 2011-2010 Director, Evaluation, British Columbia Ministry of Heath, Westminister BC 2005-2009 Pharmacist, Shopper’s Drug Mart, Vancouver 2005 Pharmacist, St Paul’s Hospital, Vancouver
d) HONOURS:
2014 Canadian Foundation for Pharmacy Wellspring Leadership Award 2014 Canadian Pharmacists Journal Best Paper of the Year “Houle S, Grindrod K, Chatterly T, Tsuyuki RT. Paying pharmacists for patient care: A systematic review of remunerated pharmacy clinical care services. Can Pharm J 2014; 147:209-232.” 2013 Canadian Pharmacists Journal Best Paper of the Year “Marra CA, Lynd LD, Grindrod KA, Joshi P, Isakovic A. Evaluating the labour costs associated with pharmacy adaptation services in British Columbia. Can Pharm J 2012; 145:2:78-82.” 2011 CIHR Institute of Health Services and Policy Research Travel Award 2010 CIHR Institute of Health Services and Policy Research: Summer Institute on Primary Care
e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
Peer Review Preventing Chronic Disease (Dec 2014 to present) Page 128 of 337 Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
J Med Internet Research (June 2014 to current) Systematic Review (Dec 2013) Research in Social and Administrative Pharmacy (Oct 2013) Journal of the American Pharmacy Association (Oct 2013) Health Policy and Technology (Oct 2013) Implementation Science (July 2013) Currents in Pharmacy Teaching and Learning (August 2013 to current) International Journal of Pharmacy Practice (August 2013 to current) Health Policy (Nov 2010 to present) Annals of Pharmacotherapy (Jul 2007 to present) Canadian Pharmacists Letter (Jul 2007 to present) Canadian Pharmacy Journal (Jul 2007 to present)
Community Work
Public and pharmacist naloxone education (19 sessions) Youth-seniors workshop for online health information (8 sessions) Engineering Science Quest Camp, July-Aug 2011 (8 sessions) o Project: Hand cream compounding with ages 6-7 years Loran/Canada Merit Scholarship Committee o Interviewer 2008 (Vancouver) o Reviewer 2010 (Vancouver) o Reviewer 2011 (Kitchener-Waterloo) o Reviewer 2013 (Kitchener-Waterloo)
Consulting & Contract Work
2014- Expert legal witness for medical malpractice cases 2014 Evaluation of Adoption, eHealth Centre of Excellent Role: Evaluation of Adoption 2013 Expert Witness, Ontario College of Pharmacists 2013 Evaluating an eHealth implementation plan for ClinicalConnect in the Waterloo- Wellington LHIN Role: Consultant 2010 Evaluation of over-the-counter nonsteroidal anti-inflammatory medications for the National Association of Pharmacy Regulatory Authorities. Role: Consultant Report: Grindrod KA. Scheduling review of OTC NSAID products in Canada. 2011. f) GRADUATE SUPERVISIONS:
Page 129 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Completed: 2 M.Sc.; • Huda Wali, Developing a strategy to help low health literacy populations understand complex medication information, 2015 • Zain Hudani, Exploring adherence measures for older adults with cognitive impairment, 2015 In progress: 1 PhD; 0 M.Sc. • Kathryn Mercer, Playing telephone: exploring how patients, pharmacists and physicians communicate about medication decision making, 2012- g) GRADUATE COURSES:
2015-, Pharm 610: Topics in Drug Develop (1 annual lecture) h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount per year Purpose**
2017- Ontario College of O $130,000 Research 2020 Pharmacists Principle Investigators: Grindrod K
2017- NSERC C $79,000 Research 2020 Principle Investigators: Burns C, Grindrod K
2015- CIHR Operating C $121,237 Research 2016 Grant Principle Investigators: Grindrod K, Burns C, Abidi S, Dogba MJ.
2015- Kitchener Waterloo 2016 Community Foundations C $30,000 Research Principle Investigators: Mercer K, Grindrod K
2015- Ontario Ministry of Health C $55,000 Research 2017 and Long Term Care Principle Investigators: Grindrod K
2014- CIHR Research, Planning C $10,000 Research 2015 & Dissemination Grant Principle Investigators: Grindrod KA, Alarakhia M, Burns CM, McMurray DJ
2015- Telus Health C $450,000 Research 2018 Principle Investigators: Grindrod KA, Burns C Page 130 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2014- Officer of the Privacy C $50,000 Research 2016 Commissioner Contributions Fund Principle Investigators: Grindrod K, Ong S, Gebotys C
2013- CIHR Planning Grant C $23,923 Research 2014 Principle Investigators: Stolee, P
2009- BC Pharmacists Association C $228,660 Research 2011 Principle Investigators: Marra C, Lynd L
2009- Canadian Initiative for C $57,342 Research 2010 Outcomes in Rheumatology Principle Investigators: Marra C, Lacaille D
2009- Canadian Arthritis C %119,963 Research 2010 Network Principle Investigators: Marra C, Lacaille D
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount per year Purpose**
2016- University of Waterloo C $10,000 Research 2017 Chronic Disease Prevention See Grant Principle Investigator: Grindrod K
2014- University of Waterloo C $8000 Research 2015 CIHR Research Incentive Fund Principle Investigators: Grindrod K, Burns C
2013- University of Waterloo C $10,000 Research 2014 Chronic Disease Prevention Seed Grant
Page 131 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Principle Investigators: Baskerville NB, Burns C, Chang F, Giangregorio L, Maxwell CJ, Middleton L, Penny Light T, Tomasson Goodwin T
i) PUBLICATIONS: 1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 4 - refereed journal articles ...... 38 - refereed conference proceedings...... 3 - presentations at conferences ...... 47 - technical reports ...... 0 - invited/keynote addresses ...... 25 - others (workshops presented) ...... 19
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Journals:
1. Grindrod KA, Khan H, Hengartner U, Ong S, Logan AG, Vogel D, Gebotys R, Yang J. Evaluating authentication options for mobile health applications in younger and older adults. PLOS One 2018; 13(1): e0189048. Citations: 0.
2. Foong A, Edwards D, Houle S, Grindrod K. Ready or not? Pharmacist perceptions of a changing scope of practice before it happens. Accepted to the Can Pharm J on Feb 27, 2017. Citations: 0.
3. Grindrod K, Alsabbagh W. Managing medications during Ramadan fasting. Can Pharm J 2017; 150(3): 146-49. Citations: 0
4. McMurray J, Grindrod K. Burns C. How appropriate is all this data sharing? Building consensus around what we need to know about shared electronic health records in extended circles of care. Healthcare Quarterly 2017; 19(4):28-36. Citations: 0
5. Lieffers JRL, Arocha JF, Grindrod K, Hanning RM. Experiences and Perceptions of Adults Accessing Publicly Available Nutrition Behavior-Change Mobile Apps for Weight Management. J Acad Nutr Diet 2017 (June): S2212-2672(17): 30419-7. Citations: 0. Citations: 0.
Page 132 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
6. Grindrod K, Boersema J, Waked K, Gebotys C, Yang J. Locking it down: The privacy and security of mobile medication apps. Can Pharm J 2016; 150(1): 60-66. Citations: 0
7. Mercer K, Li M, Giangregorio L, Burns C, Grindrod K. Behavior change techniques present in wearable activity trackers: A critical analysis. JMIR mHealth uHealth 2016;4(2):615- 623. Citations: 21.
8. Grindrod K, Nagge J. QT Prolongation. Can Pharm J 2016; 149(3): 138. Citations: 1.
9. Grindrod K, Beazely M. Fitting naloxone into community practice. Can Pharm J 2016; 149(6): 329-331. Citations: 1. Altmetric: 26.
10. Wali H, Grindrod K. Don't assume the patient understands: Qualitative analysis of the challenges low health literate patients face in the pharmacy. Res Soc Admin Pharm 2016; 12(6): 885-92. Citations: 4.
11. Wali H, Hudani Z, Grindrod K. A systematic review of interventions to improve medication information for low health literate populations. Res Soc Admin Pharm 2016; 12(6): 830- 64. Citations: 2.
12. Mercer K, Giangregorio L, Schneider E, Chilana P, Li M, Grindrod K. Acceptance of commercially available wearable activity trackers with adults over age 50 and with chronic illness: a mixed methods evaluation. JMIR mHealth uHealth 2016; 4(1):168-84. Citations: 27.
13. Mercer K, Li M, Grindrod K. Do wearable activity trackers have a place in pharmacies? Can Pharm J 2015; 148(3): 134-7. Citations: 3.
14. Mercer K, Baskerville N, Burns CM, Chang F, Giangregorio L, Tomasson Goodwin J, Sadat Rezai L, Grindrod K. Using a Collaborative Research Approach to Develop an Interdisciplinary Research Agenda for the Study of Mobile Health Interventions for Older Adults. JMIR mHealth uHealth 2015; 3(1):e11. Citations 4.
15. Baskerville NB, Struik LL, Hammond D, Guindon GE, Norman CD, Whittaker R, Burns C, Grindrod K, Brown KS. Effect of a mobile phone intervention on quitting smoking in a young adult population of smokers: randomized controlled trial study protocol. JMIR Research Protocols 2015; 4(1): e10. Citations: 16.
16. Grindrod K, Gates A, Dolovich L, Slavcev R, Drimmie R, Adhaei B, Poon C, Khan S, Leat SJ. ClereMed: Lessons learned from a pilot study of a mobile screening tool to identify and
Page 133 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
support adults who have difficulty with medication labels. JMIR mHealth uHealth 2014; 2(3):e35. Citations: 3.
17. Houle S, Grindrod K, Chatterly T, Tsuyuki RT. Paying pharmacists for patient care: A systematic review of remunerated pharmacy clinical care services. Can Pharm J 2014; 147: 209-232. Citations: 39.
18. Houle S, Grindrod K. Self-denigrating terms. Can Pharm J 2014; 147(6): 328. Citations: 0.
19. Grindrod K, Li M, Gates A. Evaluating the perceptions of mobile medication management applications with adults 50 and older. JMIR mHealth uHealth 2014; 2(1): e11. Citations: 48.
20. Marra CA, Grubisic M, Cibere J, Grindrod K, Woolcott JC, Gastonguay L, Esdaile JM. Cost- utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of the PhiT-OA study. Arthritis Care and Research 2014; 66(6):810-6. Citations: 5.
21. Houle S, Grindrod K, Chatterly T, Tsuyuki RT. Publicly funded remuneration for the administration of injections by pharmacists: An international review. Can Pharm J 2013; 146(6):353-64. Citations: 7.
22. Grindrod K. How the threat of antibiotic apocalypse helped a pharmacist find her voice. Can Pharm J 2013; 146:151-154. Citations: 1.
23. Grindrod K, Forgione A, Tsuyuki R, Gavura S, Giustini D. Pharmacy 2.0: A scoping review of social media use in the profession. Res Soc Admin Pharm 2013; 10(1): 256-70. Citations: 23.
24. Grindrod K, Rahman I, Roy M, Sanghera N, Tritt M. Living MedsCheck. Can Pharm J 2013; 146(1): 33-38. Citations: 5.
25. Marra C, Cibere J, Grubisic M, Grindrod K, Gastonguay L, Thomas J, Emberly P, Colley L, Tsuyuki R, Kkan K, Esdaile J. Pharmacist initiated intervention trial in osteoarthritis (PhIT- OA): a multidisciplinary intervention for knee osteoarthritis. Arthritis Care and Research 2012; 64(12):1847. Citations: 27.
26. Marra CA, Lynd LD, Grindrod K, Joshi P, Isakovic A. Evaluating the labour costs associated with pharmacy adaptation services in British Columbia. Can Pharm J 2012; 145:2:78-82. Citations: 5.
Page 134 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
27. Menear M, Grindrod K, Clouston, K, Legare F, Norton P. Advancing knowledge translation in primary care. Can Fam Physician 2012; 58:623-7. Citations: 12.
28. Grindrod K, Lynd L, Joshi P, Rosenthal M, Isakovic A, Marra C. Pharmacy owner and manager perceptions of pharmacy adaptation services in British Columbia. Can Pharm J 2011; 144:231-5. Citation: 3.
29. Heinrich N, Joshi P, Grindrod K, Lynd L, Marra C. Family physicians' perceptions of pharmacy adaptation services in British Columbia. Can Pharm J 2011; 144(4): 172-8. Citations: 6.
30. Grindrod K, Marra CA, Colley L, Tsuyuki RT, Lynd LD. Pharmacists' preferences for providing patient-centered services: a discrete choice experiment to guide health policy. Ann Pharmacother 2010;44(10):1554-64. Epub 2010 Sep 14. Citations: 19.
31. Grindrod K, Marra C, Colley L, Cibere J, Tsuyuki R, Esdaile J, Gastonguay L, Kopec J. After people are diagnosed with knee OA, what do they do? Arthritis Care and Research 2010; 62(4): 510-5. Citations: 30.
32. Rosenthal M, Grindrod K, Lynd L, Marra C, Bougher D, Wilgosh C, Tsuyuki R. Pharmacists' perspectives on providing chronic disease management services in the community - Part II: Development and implementation of services. Can Pharm J 2009; 142(6): 284-9. Citations: 8.
33. Grindrod K, Rosenthal M, Lynd L, Marra C, Bougher D, Wilgosh C, Tsuyuki R. Pharmacists' perspectives on providing chronic disease management services in the community - Part I: Current practice environment. Can Pharm J 2009; 142(5): 234-9. Citations: 15.
34. Grindrod K, Yoshida EM, Partovi N. Questioning the role of routine liver enzyme monitoring in statin therapy. Can Pharm J 2008, 141(suppl 2): S21-2.. Citations: 0.
35. Chan P*, Grindrod K*, Bougher D, Pasutto FM, Wilgosh C, Eberhart G, Tsuyuki R. A systematic review of remuneration systems for pharmacy clinical care services. Can Pharm J 2008; 141(2):102-12. (*co-first author with an undergraduate student). Citations: 45.
36. Grindrod K, Taddei A. The role of the pharmacists in procedural sedation and analgesia in the emergency department. Can J Hospital Pharm 2008; 61(1):46-51. Citations: 2.
37. Grindrod K, Patel P, Martin JM. What Interventions should pharmacists employ to impact health practitioners' prescribing practices? Ann Pharmacother 2006; 40(9):1546-57. Citations: 56. Page 135 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
38. Grindrod K, Chambers CR, Hicks J. Updating a survey for medication error prevention. J Oncol Pharm Pract 2002; 8(4):105-117. Citations: 3.
39. Chambers CR, Dimaculangan DM, Grindrod K, Hanson J, Pataky F, Vu TT. Clinical effectiveness of trastuzumab: Early experience. J Oncol Pharm Pract 2002; 8(1):19-25. Citations: not available.
Book Chapters
1. Grindrod KA. Social media marketing. Pharmacy Management in Canada. Mississauga, ON: Canadian Foundation for Pharmacy; 2015.
2. Grindrod KA. Module 5: Consumer Health Informatics. Association of Faculties of Pharmacy of Canada Informatics for Pharmacy Students e-Resource. Updated August 2014.
3. Grindrod KA, Marra CA. Osteoarthritis. In: Repchinsky C, ed. Patient Self Care (2nd Ed.). Toronto: Canadian Pharmacists Association; Updated Mar 2018.
4. Grindrod KA, Marra CA. Low Back Pain. In: Repchinsky C, ed. Patient Self Care (2nd Ed.). Toronto: Canadian Pharmacists Association; Updated Mar 2018.
Invited Presentations
International Meetings
1. Grindrod K. Mobile health technology: Are we on the cusp of more seamless care? American College of Clinical Pharmacy Annual Meeting. Phoenix, ON. October 9, 2017.
2. Grindrod K, Aungst T. Welcome to the E-Patient Movement: Patients Becoming More Involved in Their Health Through Technology. Association of Health System Pharmacy Midyear 2016. Las Vegas, Nevada. December 9, 2016.
3. Grindrod K. The Pharmacist is Online: Social media for pharmacists. 76th International Pharmacy Federation World Congress of Pharmacy and Pharmaceutical Sciences. Buenos Aires, Argentina. Aug 29, 2016.
National Meetings
1. Grindrod K. Building pharmacy 5in5. Edmonton, AB, Canadian Society of Hospital
Page 136 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Pharmacists Alberta Branch Symposium 2017. Oct 14, 2017.
2. Visiting professor, University of Alberta. Presentation: Teaching social media to pharmacy students. Edmonton, AB. Oct 13, 2017.
3. Grindrod K. Implementing a naloxone lab in the PharmD program. Association of Faculties of Pharmacy of Canada Annual Meeting. Quebec City, Quebec. June 6, 2017.
4. Grindrod K, Chang F. Rethinking our approach to opioid prescribing. Canadian Pharmacists Conference. Quebec City, QC. June 3, 2017.
5. Grindrod K. Opioid harm reduction strategies and the pharmacist. Canadian Pharmacists Conference. Quebec City, QC. June 3, 2017.
6. Grindrod K. The great debate: Opioids. Canadian Pharmacists Conference. Quebec City, QC. June 5, 2017.
7. Grindrod K. Burning Questions: Using Surveys, Interviews and Focus Groups to Boost Your Care. Canadian Association of Pharmacy in Oncology. Niagara Falls, Ontario. April 16, 2016.
8. Grindrod K. Send in the robots: technology and pharmacy. Pharmacy Development Week. Niagara Falls, ON. Jan 9, 2016.
9. Grindrod K. How technology is revolutionizing the pharmacist/patient relationship. Commitment to Care Awards. Toronto, ON. Nov 23, 2015.
10. Grindrod K. Social media primer for pharmacists. Canadian Pharmacists Association Annual Meeting. Ottawa, ON. May 28, 2015.
11. Grindrod K. Bridging the “internet of things” to the patient. Primary Care Today. Toronto, ON, May 8, 2015.
12. Grindrod K (Moderator): Embracing personal technology for better health. Panelists: Choudri S, Couture S, Reeves J. Rx&D Stakeholder Engagement Conference. Toronto, ON. Nov 19, 2014.
13. Grindrod K. Pharmacy 2.0. Canadian Association of Chain Drug Stores 2012 Canadian Drugstore Conference. Toronto, ON. October, 2012.
14. Grindrod K. Pharmacy 2.0. Canadian Foundation for Pharmacy Annual Meeting. Toronto, ON. November, 2011. Page 137 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
15. Grindrod K. Pharmacists’ preferences for providing new services. Association of Faculties of Pharmacy Annual General Meeting. Vancouver, BC. June 1, 2010.
Provincial/Local
1. Grindrod K. Possibilities Cafe - A practical approach to take-home naloxone training for pharmacists. Ontario Pharmacists Association Annual Conference. London, ON. June 16, 2017.
2. Grindrod K. Social media and technology in pharmacy. Ontario Pharmacists Association Annual Conference. Niagara Falls, ON. June 19-21. 2014.
3. Grindrod K. Usability of mHealth application for adults over age 50. University Health Network eHealth seminars. Dec 11, 2013.
4. Grindrod K. Navigating osteoarthritis: a roadmap for pharmacists. British Columbia Pharmacy Association Annual Conference. Victoria, BC. May, 2009.
5. Grindrod K. Osteoarthritis & The Pharmacist. The Banff Seminar, Canadian Society of Hospital Pharmacists. Banff, Canada. March, 2009.
6. Grindrod K. The role of the pharmacist in managing arthritis. BC Pharmacists Association Conference. Vancouver, BC. May, 2008.
7. Grindrod K. Monitoring statins: measuring at your leisure, more for pleasure than treasure. Therapeutics Initiative Drug Therapy Decision Making Course. Vancouver, BC. April, 2008.
Research Posters
1. Foong A-L, Grindrod K, Houle S. Will I lose my license for that? A closer look at disciplinary cases and what it means for pharmacists’ expanded scope. OPEN Summit, Toronto ON, Oct 3, 2017.
2. Waked K, Mercer K, Burns C, Abidi S, Boersema J, Chabot C, Chin J, Dogba MJ, Guénette L, Guirguis L, Kerestecioglu D, Légaré F, McKinnon A, Grindrod K. Playing telephone: Understanding the state of medication decision making in growing healthcare teams in the time of electronic health records. OPEN Summit, Toronto ON, Oct 3, 2017.
Page 138 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Foong A-L, Grindrod K, Houle S. Will I lose my license for that? A closer look at disciplinary cases and what it means for pharmacists’ expanded scope. Ontario Pharmacists Association Annual Conference. London, ON, June 16-18, 2017.
4. Waked K, Mercer K, Burns C, Abidi S, Boersema J, Chabot C, Chin J, Dogba MJ, Guénette L, Guirguis L, Kerestecioglu D, Légaré F, McKinnon A, Grindrod K. Playing telephone: Understanding the state of medication decision making in growing healthcare teams in the time of electronic health records. Ontario Pharmacists Association Annual Conference. London, ON, June 16-18, 2017.
5. Foong A, Edwards D, Houle S, Grindrod K. Ready or not? Pharmacist perceptions of a changing scope of practice before it happens. Canadian Pharmacists Association Annual Meeting. Quebec City, QC. Friday, June 2-6, 2017.
6. Waked K, Mercer K, Burns C, Abidi S, Boersema J, Chabot C, Chin J, Dogba MJ, Guénette L, Guirguis L, Kerestecioglu D, Légaré F, McKinnon A, Grindrod K. Playing telephone: Understanding the state of medication decision making in growing healthcare teams in the time of electronic health records. McMaster Waterloo Wellington Clinical Research & Quality Improvement Symposium. Kitchener, ON. May 31, 2017.
7. Foong A, Edwards D, Houle S, Grindrod K. Ready or not? Pharmacist perceptions of a changing scope of practice before it happens. McMaster Waterloo Wellington Clinical Research & Quality Improvement Symposium. Kitchener, ON. May 31, 2017.
8. Grindrod K, Mercer K, Burns C, Abidi S, Boersema J, Chabot C, Chin J, Dogba MJ, Guénette L, Guirguis L, Kerestecioglu D, Légaré F, McKinnon A, Waked K. What patients want: Understanding how patients view shared decisions about treatment. Canadian Association of Health Services and Policy Research. Toronto ON. May 23-26, 2017.
9. Grindrod K, Mercer K, Burns C, Abidi S, Boersema J, Chabot C, Chin J, Dogba MJ, Guénette L, Guirguis L, Kerestecioglu D, Légaré F, McKinnon A, Waked K. Playing telephone: Understanding the state of medication decision making in growing healthcare teams in the time of electronic health records. Canadian Association of Health Services and Policy Research. Toronto ON. May 23-26, 2017.
10. Grindrod K, Mercer K, Burns C, Abidi S, Boersema J, Chabot C, Chin J, Dogba MJ, Guénette L, Guirguis L, Kerestecioglu D, Légaré F, McKinnon A, Waked K. What patients want: Playing telephone: Understanding the state of medication decision making in growing healthcare teams in the time of electronic health records. Canadian Association of Health Services and Policy Research (CIHR SPOR SUMMIT). Toronto ON. May 23-26, 2017.
11. Grindrod K, Burns C, Chin J, Mercer K, Kerestecioglu D, Boersema J, Waked K. Playing Page 139 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
telephone: Medication management and integrated electronic health records. CIHR Strategies for Patient Oriented Research Summit. Ottawa, ON. Oct 25-27, 2016.
12. Grindrod K, Wali H, Leuck S. The future of pharmacy counseling: Feasibility of providing low health literacy medication counseling through AudibleRx. 76th International Pharmacy Federation World Congress of Pharmacy and Pharmaceutical Sciences. Buenos Aires, Argentina. Aug 30, 2016.
13. Grindrod K, Khan H, Hengartner U, Ong S, Logan A, Vogel D, Yang J. Locking it down: The privacy and security of mobile medication apps. 76th International Pharmacy Federation World Congress of Pharmacy and Pharmaceutical Sciences. Buenos Aires, Argentina. Aug 30, 2016.
14. Grindrod K, Boersema J, Waked K, Smith V, Gebotys C, Yang J. User testing of authentication techniques for mobile medication applications in diverse populations. 76th International Pharmacy Federation World Congress of Pharmacy and Pharmaceutical Sciences. Buenos Aires, Argentina. Aug 30, 2016.
15. Grindrod K, Boersema J, Waked K, Smith V, Gebotys C, Yang J. Locking it down: The privacy and security of mobile medication apps. Ontario Pharmacy Association Annual Conference. Toronto, ON. June 9-11, 2016.
16. Grindrod K, Burns C, Chin J, Mercer K, Kerestecioglu D, Boersema J, Waked K. Playing telephone: Medication management and integrated electronic health records. Ontario Pharmacy Association Annual Conference. Toronto, ON. June 9-11, 2016.
17. Grindrod K, Boersema J, Waked K, Smith V, Gebotys C, Yang J. Locking it down: The privacy and security of mobile medication apps. McMaster Waterloo-Wellington Clinical Research and Quality Improvement Symposium. Kitchener, On. May 25, 2016.
18. Grindrod K, Burns C, Chin J, Mercer K, Kerestecioglu D, Boersema J, Waked K. Playing telephone: Medication management and integrated electronic health records. McMaster Waterloo-Wellington Clinical Research and Quality Improvement Symposium. Kitchener, On. May 25, 2016.
19. Mercer K, Waked K, Boersema J, Guirguis L, Grindrod K. Embrace complexity: Realities of shared decision making and information sharing. McMaster Waterloo-Wellington Clinical Research and Quality Improvement Symposium. Kitchener, On. May 25, 2016.
20. Grindrod K. Evaluating security features for mobile health applications in older adults. McMaster Waterloo-Wellington Clinical Research and Quality Improvement Symposium. Kitchener, On. May 25, 2016. Page 140 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
21. McMurray J, Grindrod K, Alarakhia M, Burns C, Chilana P, St-Maurice J. How appropriate is all this data sharing? Building consensus on electronic health information exchange in extended circles of care. Canadian Association for Health Services and Policy Research. Montreal, QC. May 25-28, 2015.
22. Wali H, Hudani Z, Grindrod K. Don’t assume health literacy: Medication information for the low health literate population systematic review. Canadian Pharmacists Association Annual Meeting. Ottawa, ON. May 28-31, 2015.
23. Wali H, Hudani Z, Grindrod K. Don’t assume health literacy: Medication information for the low health literate population systematic review. Institute for Healthcare Advancement Annual Health Literacy Conference. Irvine, CA, USA. May 6-8, 2015.
24. Grindrod KA, Mercer K, Giangregorio L, Chilana P, Schneider E. “Back it up and simplify”: Wearable activity trackers for adults 50+ living with chronic illness. Medicine 2.0. Maui, Hawaii, USA. Nov 12-13, 2014.
25. Grindrod KA, Li M, Gates A. Exploring the usability of medication management applications with older adults. Stanford Medicine X, Palo Alto CA. Sept 2013.
26. Forgione A, Grindrod K. An environmental scan of pharmacy social media use in Canada. Association of Faculties of Pharmacy of Canada Pharmacy Education and Research Conference. Niagara-on-the-Lake, ON. June 2013.
27. Grindrod, Tsuyuki R, Giustini D, Gavura S. Pharmacy 2.0: Exploring novel ways to network and support pharmacists for practice change in Canada. Presented at: Canadian Pharmacists Association Annual Meeting, Montreal BC (May 2010).
28. Grindrod K, Colley L, Marra A, Lynd L, Koehoorn M. Factors associated with taking antihypertensives: A population-based cross-sectional study of hypertensive individuals in the Canadian Community Health Survey. Presented at: Vancouver Coastal Health Research Institute, Celebrate Research Week, Vancouver, BC. (March, 2009).
29. Grindrod K, Marra C, Tsuyuki R, Lynd L. Expanded scope of practice: What do pharmacists want? Presented at: Vancouver Coastal Health Research Institute, Celebrate Research Week, Vancouver, BC. (March, 2009).
Conference Proceedings
1. Grindrod K, Tran P, Burns C. Medication Reconciliation: More than just a check. Human Factors and Ergonomics in Healthcare. Baltimore, MD. Presented April 29, 2015. Page 141 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Conference Abstracts
2. Grindrod KA, Colley L, Marra C, Lynd L, Koehoorn M. Factors associated with taking antihypertensives – a population-based cross-sectional study of hypertensive patients in the Canadian Community Health Survey. Can J Clin Pharmacol 2009; 16(1):e202-233.
3. Grindrod KA, Marra CA, Colley B, Oteng L, Gastonguay L, Tsuyuki RT. What patients do following a new diagnosis of knee osteoarthritis? Canadian Pharmacists Journal 2009; 142 (1):43.
DATE: May 2018
Page 142 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
HO, Emmanuel Associate professor, tenured Member of the Graduate Faculty: yes b) DEGREES: designation, institution, department, year
Ph.D. Pharmaceutical Sciences, University of Toronto, 2007 HonsB.Sc., Toxicology, University of Toronto, 2001 c) EMPLOYMENT HISTORY: dates, rank/position, department, institution/firm
2017- Associate Professor, School of Pharmacy, University of Waterloo 2017- Member, Waterloo Institute of Nanotechnology 2017- Member, Centre for Bioengineering and Biotechnology 2010-2017 Associate Professor, College of Pharmacy, University of Manitoba 2009-2010 Research Assistant Professor, Department of Bioengineering, University of Utah 2007-2009 CIHR/MSFHR Post-Doctoral Fellow, Department of Experimental Therapeutics, British Columbia Cancer Agency d) HONOURS: (F.R.S., F.R.S.C., Governor Generals Award, honorary degree, etc...)
2016-2021 Leslie F. Buggey Professorship 2015 Association of Faculties of Pharmacy of Canada (AFPC) New Investigator Research Award 2014 GSK/CSPS Early Career Award 2013 Rh Award for Excellence in Research (Interdisciplinary Category) 2008-2009 Michael Smith Foundation for Health Research (MSFHR) Post-Doctoral Fellowship 2007-2009 Canadian Institutes of Health Research (CIHR) Post-Doctoral Fellowship, 2007- 2008 Gordon Cressy Student Leadership Award 2005-2007 Natural Sciences and Engineering Research Council of Canada (NSERC) Industrial Postgraduate (Ph.D.) Scholarship 2006-2007 University of Toronto Top-Up Award 2006-2007 National Cancer Institute of Canada (NCIC) Student Travel Award 2005-2006 University of Toronto Top-Up Award 2005-2006 Biocontact / CIHR Student Award 2005-2006 Ontario Graduate (Ph.D.) Scholarship (OGS) 2004-2005 University of Toronto Provost Award 2004-2005 University of Toronto Open Fellowship 2004-2005 AFPC Canadian Pharmacy National Student Poster Award Page 143 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2003-2004 CSCP Travel Award 2003-2004 University of Toronto Top-Up Award 2003-2004 University of Toronto Open Fellowship 2002-2003 University of Toronto Open Fellowship 1999-2000 5 Year Ontario Volunteer Service Award
e) SCHOLARLY AND PROFESSIONAL ACTIVITIES: past 7 years only (eg. executive and editorial positions but not memberships in societies)
University of Waterloo
2018 Chair, Canadian Society for Pharmaceutical Sciences / Canadian Chapter Controlled Release Society, Session: “Crossing Biological Membranes” 2018 – Member, Faculty of Science Scholarship Committee, University of Waterloo 2018 – Director, Canadian Society for Pharmaceutical Sciences 2017 – Member, School of Pharmacy PharmD Curriculum Committee 2016 – Associate Editor, Journal of Pharmacy & Pharmaceutical Sciences 2014 – Committee Member, CC-CRS / CSPS Annual Conference Organizing Committee 2013 – Editorial Board Member, Journal of Pharmaceutics and Drug Development 2012 – Editorial Board Member, Journal of Molecular Pharmaceutics and Organic Process Research 2012 – Member, Controlled Release Society Mentor-Protégé Program
University of Manitoba
2016 – Member, Faculty of Graduate Studies Programs and Guidelines Committee 2017 Member, College of Pharmacy, University of Manitoba Faculty Search Committee 2016 – 2017 Member, Instructor II or Senior Instructor Search Committee 2016 – 2017 Invited Guest Editor, Drug Delivery and Translational Research 2016 Moderator, Controlled Release Society, Session: “Parenteral Systemic Delivery of Biopharmaceuticals: Overcoming Product Development and Regulatory Challenges” 2015 – 2017 President, Canadian Chapter Controlled Release Society 2015 – 2017 Member, Assessment Work Group Committee (PharmD Program) 2015 – 2017 Member, Prerequisites and Admissions Committee (PharmD Program) 2015 – 2017 Member, Endowment Fund Committee 2015 Chair, Canadian Society for Pharmaceutical Sciences / Canadian Chapter Controlled Release Society, Session: “Mucosal Drug Delivery” 2014 – 2015 Secretary, Canadian Chapter Controlled Release Society 2013 Workshop Organizer and Speaker, China Pharmaceutical University, Page 144 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Nanjing, China 2013 – 2014 Member-at-Large, Canadian Chapter Controlled Release Society 2013 – 2015 Member, Controlled Release Society Young Scientist Committee 2013 Chair, Canadian Society for Pharmaceutical Sciences / Canadian Chapter Controlled Release Society, Session: “Nanomedicine and Gene Delivery” 2012 – 2014 Associate Editor, Versita Publishing 2012 July Chair, Controlled Release Society Young Scientist Session 2011 – 2012 Member, Canadian Society for Pharmaceutical Sciences (CSPS) Webinar Organizing Committee 2011 – 2012 Judge, Canadian Centre for Agri-Food Research in Health and Medicine (CCARM) Graduate Student Poster Competition 2011 – 2017 Member, CAPSI Compounding Competition 2011 – 2012 Member, Faculty of Pharmacy, University of Manitoba Faculty Search Committee 2011 – 2012 Member, Pharmacy Accreditation Committee 2011 – 2012 Member, 5-Year Strategic Planning Committee 2011 Member, Faculty of Pharmacy, University of Manitoba Pharmacy Practice Instructor Search Committee 2011 Chair, University of Manitoba, Ph.D. Thesis Defense
f) GRADUATE SUPERVISIONS: master=s, doctoral, postdoctoral - completed/in progress
Completed: 1 M.A., 2 Ph.D., 2 Postdoctoral In progress: 2 Ph.D.
Postdoctoral Fellows:
Emeka Okeke, College of Pharmacy, University of Manitoba: April 2016-January 2017. “Development of a Topical Nano-Medicine for the Combination Delivery of Immunomodulatory Peptides for Accelerated Chronic Wound Healing”
Jijin Gu, College of Pharmacy, University of Manitoba: Aug 2012-July 2016. “To Design, Develop, and Characterize a Stable Intravaginal Film Formulation for the Targeted Delivery of siRNA-encapsulated Nanoparticles to Immune Cells”.
Awards/Scholarships 2015 CSPS/CC-CRS Travel Award (Toronto) 2013 – 2015 Manitoba Health Research Council (MHRC) Post-Doctoral Fellowship
Graduate Students:
Page 145 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Name of Student Type (years of Title of Thesis or Project Status supervision) Yannick Traore (PhD) 2014- Development of Stimuli-Responsive In Progress Intravaginal Ring Drug Delivery Devices Seung II Kim (MSc) 2014 – Synthesis and Characterization of Novel In Progress Co-supervisor pH-Responsive Polyurethane Films for Biomedical Applications Yufei Chen (PhD) 2011- Intravaginal Ring – An Innovative Drug In Progress Delivery Strategy for the Prevention of HIV-1 Infection Sidi Yang (PhD) 2011-2017 Development and Characterization of a Completed Novel Intravaginal Microbicide for the Regulation of Autophagy as a Strategy for Preventing HIV Infection Miral Fumakia (MSc) 2014-2016 Development of a Dual-Combination Completed Nanomedicine for the Delivery of Peptides for Wound Healing Applications
g) GRADUATE COURSES: past 7 years, by year
University of Manitoba
Novel Drug Delivery Systems (PHRM7130) – Course Coordinator, 3 credit hour course, 5 students (2013 to 2017) Course Objective – Introduce graduate students to the field of drug delivery and pharmaceutics; discussing its applications in healthcare and the advancements and challenges of the field.
Scientific and Medical Writing in Pharmaceutical Biotechnology (PHRM7120) – Course Coordinator, 3 credit hour course, 5 students (2014 to 2017) Course Objective – Assist graduate students to develop and strengthen their critical thinking skills and scientific writing and oral communication skills.
h) 1. EXTERNAL RESEARCH FUNDING: past 7 years only, by year, indicating source (granting councils, industry, government, foundations, other); amount; principal investigator; purpose (research, travel, publications, etc...) Page 146 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Year Source Type* Amount Purpose** Investigator 2018 – CIHR G $154,530 Operating PI: K. Fowke 2023 2015 – NSERC G $25,000 Research PI: E. Ho 2020 2014 – CIHR G $124,478 Operating PI: N. 2019 Tanphaichitr 2016 – Leslie F. Buggey F $40,000 Operating PI: E. Ho 2021 Professorship 2015 – Diagnostic Services G $15,000 Operating PI: E. Ho 2017 Manitoba 2016 CIHR G $7,800 EOI PI: E. Ho 2015 – Population Council, O $24,619 USD Operating PI: E. Ho 2016 Inc. (New York) 2015 – University Research O $7,500 Operating PI: E. Ho 2016 Grant Program 2014 – Manitoba Health G $84,993 Operating PI: E. Ho 2016 Research Council 2013 – CIHR Canadian HIV G $124,146 Operating PI: K. Fowke 2016 Vaccine Initiative 2012 – Manitoba Health G $33,333 Program PI: E. Ho 2015 Research Council 2011 – CIHR G $ 131,323 Operating PI: E. Ho 2014 2012 – Canada Foundation G $324,352 Infrastructure PI: E.Ho 2013 for Innovation 2011 – Dr. Paul Thorlakson F $28,000 Operating PI: E. Ho 2012 Fund 2011 – CIHR Canadian HIV G $25,000 LOI PI: K. Fowke 2012 Vaccine Initiative 2011 – University Research F $7,500 Operating PI: E. Ho 2012 Grants Program 2011 – Manitoba Medical F $19,000 Operating PI: E. Ho 2012 Service Foundation 2010 – Bill and Melinda F $100,000USD Operating PI: N. 2011 Gates Foundation Tanphaichitr *Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
Page 147 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2. INTERNAL RESEARCH FUNDING: This includes university funds, SSHRC minor grants awarded through the University, etc.]
Year Source Type* Amount Purpose** Investigator
j) PUBLICATIONS: The Publications should be listed in the categories shown below and include the following information: books authored, books edited (a list of the chapters contributed by the editor must follow each title), chapters in books (other than those listed in the above category), papers in refereed journals, papers in refereed conference proceedings, technical reports, abstracts and/or papers read, and others. Each title must show the names of the authors in the order in which they appear in the original publication and inclusive page numbers. Publications submitted, but not yet accepted, must be listed separately within the various categories.
1) Life-time summary (count) according to the following categories: - books and monographs...... 0 - edited book and monographs...... 0 - chapters in books and monographs...... 1 - refereed journal articles...... 30 - refereed conference proceedings...... 33 - technical reports ...... 0 - Abstracts and/or papers read...... 33
- invited/keynote addresses ...... 11 - others (workshops presented) ...... 1
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Chapters in Books:
1) Gu, J. and Ho, E.A.* (2015) “Drug Delivery: Intravaginal, Advantages and Challenges. In Encyclopedia of Biomedical Polymers and Polymeric Biomaterials, 1st Ed.; Mishra, M., Ed.; Taylor and Francis: New York, 2015; Vol. 4, 2712-2725
Papers in refereed Journals:
1) Yang, S., Jimenez, C., Ho, E.A.* (2018) Autophagy induction and PDGFR- knockdown by siRNA-encapsulated nanoparticles reduce chlamydia trachomatis infection. (Scientific Reports – Under Revisions) (IF = 4.847)
Page 148 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2) Chen, Y., Traore, Y., Yang, S., Lajoie, J., Fowke, K., Rickey, D., Ho, E.A.* (2018) Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. Journal of Controlled Release 277(10): 102-113 (IF = 8.450)
3) Lajoie, J., Birse, K., Mwangi, L., Chen, Y., Cheruiyot, J., Akolo, M., Mungai, J., Romas, L., Mutch, S., Kimani, M., Oyugi, J., Ho, E.A., Burgener, A., Kimani, J., Fowke, K. (2018) Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract. Journal of the International AIDS Society (In Press) (IF = 6.296)
4) Ghanbar, S. Fumakia, M., Ho, E.A., Liu, S.* (2017) A new strategy for battling bacterial resistance: turning potent, non-selectively and potentially non-resistance-inducing biocides into selective ones. Nanomedicine: Nanotechnology, Biology, Medicine 14(2):471-481 (IF = 6.379)
5) Traore, Y., Fumakia, M., Gu, J., Ho, E.A.* (2018) Dynamic mechanical behavior of nanoparticle-loaded biodegradable PVA films used for microbicide applications. Journal of Biomaterials Applications 32(8):1119-1126 (IF = 2.346)
6) Novaes, J., Lillico, R., Sayre, C., Nagabushnam, K., Majeed, M., Chen, Y., Ho, E.A., Oliveira, A., Martinez, S., Alrushaid, S., Davies, N., Lakowski, T. (2017) Disposition, metabolism and histone deacetylase and acetyltransferase inhibition activity of tetrahydrocurcumin and other curcuminoids. Pharmaceutics 9(4): 45
7) Kim, S., Traore, Y., Lee, J., Kim, J., Ho, E.A., Liu, S.* (2017) Self-assembled nanoparticles made from a new PEGylated poly(aspartic acid) graft copolymer for intravaginal delivery of poorly water-soluble anti-HIV drugs. Journal of Biomaterials Science: Polymer Edition 28(17): 2082-2099 (IF = 1.900)
8) Doschak, M.R., Allen, C., Ho, E.A.* (2017) Editorial. Drug Delivery and Translational Research 7(4):465 (IF = 3.094)
9) Gu, J., Al-Bayati, K., Ho, E.A.* (2017) Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Delivery and Translational Research 7(4):497-506 (IF = 3.094)
10) Kim, S., Chen, Y., Ho, E.A.*, Liu, S.* (2016) Reversibly pH-responsive polyurethane membranes for on-demand intravaginal drug delivery. Acta Biomaterialia 47:100-112 (IF=6.383)
Page 149 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
11) Fumakia, M., Ho, E.A.* (2016) Nanoparticles encapsulated with LL37 and serpin A1 promotes wound healing and synergistically enhances antibacterial activity. Molecular Pharmaceutics 13(7):2318-31 (IF = 4.167)
12) Fumakia, M., Yang, S., Gu, J., Ho, E.A.* (2016) Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction. Reviews in Medical Virology 26(1): 4-20 (IF = 4.879)
13) Traore, Y., Chen, Y., Bernier, A., Ho, E.A.* (2015) Impact of hydroxychloroquine-loaded polyurethane intravaginal rings on lactobacilli. Antimicrobial Agents and Chemotherapy 59(12): 7680-7686 (IF = 4.516)
14) Gu, J., Yang, S., Ho, E.A.* (2015) Biodegradable film for the targeted delivery of siRNA- loaded nanoparticles to vaginal immune cells. Molecular Pharmaceutics 12(8):2889-903. (IF = 4.167)
15) Martinez, S., Chen Y., Ho, E.A., Martinez, S.A., Davies, N.M. (2015) Pharmacological effects of a C-phycocyanin-based multicomponent nutraceutical in an in-vitro canine chondrocyte model of osteoarthritis. Canadian Journal of Veterinary Research 79(3): 241- 249. (IF = 1.125)
16) Wang, X., Wang, Q., Kong, W., Minuk, G., Burczynski, F., Ho, E.A., Gong, Y. (2015) Expression and regulation of bone morphogenetic protein 4 in hepatocellular carcinoma. Integrative Cancer Science and Therapeutics 2(1):70-74
17) Chen, Y., Yang, S., Ho, E.A.* (2014) Development of an Analytical Method for the Rapid Quantitation of Peptides used in Microbicide Formulations. Chromatographia 77 (23- 24):1713-1720. (IF = 1.142)
18) Chen, Y., Traore, Y., Li, A., Fowke, K., Ho, E.A.* (2014) Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine. Drug Design, Development and Therapy 8: 1801-1815. (IF = 2.962)
19) Yang, S., Chen, Y., Gu, K., Dash, A., Sayre, C., Davies, N, and Ho, E.A.* (2013) Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells. International Journal of Nanomedicine 8:2847-2858. (IF = 5.008)
20) Ho, E.A. (2013) Intravaginal Rings as a Novel Platform for Mucosal Vaccination. Molecular Pharmaceutics & Organic Process Research 1(2):e103 doi:10.4172/jmpopr.1000e103
21) Ho, E.A. and Davies, N.M. (2013) Targeting the metabolism of leukemia stem cells as a novel therapeutic strategy. Drugs in Context 212252; doi:10.7573/dic.212252 Page 150 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
22) Yang, S., Chen, Y., Ahmadie, R., and Ho, E.A.* (2013) Advancements in the field of intravaginal siRNA delivery. Journal of Controlled Release 167(1):29-39. (IF = 8.450)
23) Ho, E.A.*, Osooly-Talesh, M., Strutt, D., Masin, D., Yang, Y., Yan, H., and Bally, M. (2013) Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. Journal of Pharmaceutical Sciences 102(1):227-236. (IF = 3.051) (This article was ranked as one of the TOP 10 Most Downloaded Articles between January-March 2013).
24) Ho, E.A.*, Ramsay, E., Ginj, M., Anantha, M., Bregman, S., Sy, J., Woo, J., Osooly-Talesh, M., Yapp, D., and Bally, M. (2010) An optimized PEGylated cationic liposome formulation that demonstrates extended plasma residence times and tumor vasculature targeting properties. Journal of Pharmaceutical Sciences 99(6):2839-53. (IF = 3.051)
25) Lim Soo, P., Cho, J., Grant, J., Ho, E.A., Piquette-Miller, M., and Allen, C. (2008) Drug release mechanism of paclitaxel from a chitosan-lipid implant system: Effect of swelling, degradation and morphology. European Journal of Pharmaceutics and Biopharmaceutics 69(1): 149-57. (IF = 4.389)
26) Ho, E.A., Allen, C. and Piquette-Miller, M. (2007) Novel drug delivery strategies for the treatment of ovarian cancer. Expert Review of Obstetrics and Gynecology 2(5):587-593.
27) Ho, E.A. and Piquette-Miller, M. (2007) KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. Biochemical and Biophysical Research Communications 353(3):679-85. (IF = 2.392)
28) Ho, E.A., Lim Soo, P., Allen, C. and Piquette-Miller, M. (2007) Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of p-glycoprotein in ovarian tumors. Journal of Controlled Release 117(1):20-7. (IF = 8.450)
29) Yanze, M., Ho, E.A., MacGregor Jr., R. and Piquette-Miller, M. (2006) In vivo disposition and stability of DNA frayed wires in mice. International Journal of Biological Macromolecules 39(4-5):310-6. (IF = 3.220)
30) Ho, E.A. and Piquette-Miller, M. (2006) Regulation of multidrug resistance by pro- inflammatory cytokines. Current Cancer Drug Targets 6(4):295-311. (IF = 3.412)
31) Ho, E.A., Vassileva, V., Allen, C. and Piquette-Miller, M. (2005) In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system containing paclitaxel. Journal of Controlled Release 104(1):181-191. (IF = 8.450) Page 151 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
(This article was listed as one of the TOP 25 Hottest Articles on ScienceDirect - Nov 10, 2005).
Papers/Abstracts in Refereed Conference Proceedings
1) Walker, L., Chen, Y., Traore, Y. and Ho, E.A. (2017) Mathematical prediction of hydrophilic chemotherapeutic elution kinetics from a reservoir polyurethane intravaginal ring fabricated by fused deposition modeling 3D printing. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Montreal, Quebec, CANADA.
2) Yang, S., Gu, J., Chen, Y., Fumakia, M. and Ho, E.A. (2016) pH-sensitive RNAi-based combination nanomicrobicide for the induction of autophagy as a strategy for preventing vaginal transmission of HIV. Controlled Release Society Annual Meeting, Seattle, Washington.
3) Chen, Y., Traore, Y., Yang, S., Stalker, A., Lajoie, J., Fowke, K.R., Rickey, D., and Ho, E.A. (2016) Vaginal Delivery of Hydroxychloroquine via a Trackable Polyurethane Implant Protects against Nonoxynol-9 Induced Inflammation. Controlled Release Society Annual Meeting, Seattle, Washington.
4) Al-Bayati, K., Gu, J. and Ho, E.A. (2016) Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
5) Jimenez, C., Yang, S., and Ho, E.A. (2016) Novel application of siRNA-PEI encapsulated nanoparticles in preventing vaginal infection of chlamydia trachomatis via PDGFR-b knockdown and autophagy induction. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
6) Traore, Y., Jimenez, V., Padilla, F., Ho, E.A. (2016) Development of a segmented intravaginal ring for the combination delivery of hydroxychloroquine and siRNA- encapsulated nanoparticles as a novel strategy for preventing HIV infection. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
7) Fumakia, M. and Ho, E.A. (2016) Topical nanoformulation for the combination delivery of peptides for accelerated wound healing and synergistic antibacterial activity. Canadian
Page 152 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
8) Chen, Y. Traore, Y., Yang, S., Fowke, K.R., and Ho, E.A. (2016) Hydroxychloroquine attenuated vaginal tissue inflammation and T-cell activation in vivo. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
9) Yang, S., Chen, Y., Fumakia, M., and Ho, E.A.* (2016) pH-sensitive nanomicrobicide for the targeted delivery of siRNA to vaginal mucosal CD4+ immune cells in a mouse model. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
10) Traore, Y., Chen, Y., Bernier, A., and Ho, E.A. (2015) Reservoir-type intravaginal ring for controlled long-term release of hydroxychloroquine as a novel strategy for the treatment of bacterial vaginosis. American Society for Microbiology General Meeting, New Orleans, Louisiana, USA.
11) Gu, J., Yang, S., and Ho, E.A. (2015) Biodegradable film for the targeted delivery of siRNA- loaded nanoparticls to vaginal immune cells. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Toronto, Ontario, CANADA. 12) Yang, S. and Ho, E.A. (2015) RNAi-based nanomicrobicide for the efficient intravaginal gene knockdown of CCR5 and Nef in CD4+ Immune Cells. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Toronto, Ontario, CANADA.
13) Chen, Y., Traore, Y., and Ho, E.A. (2015) Evaluating the drug release and in vivo biocompatibility of an intravaginal implantable device in a rabbit model. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Toronto, Ontario, CANADA.
14) Fumakia, M., Traore, Y., and Ho, E.A. (2015) Nanoparticles encapsulated with serpin A1 and LL37 promote wound healing in vitro and possess antibacterial properties. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Toronto, Ontario, CANADA.
15) Traore, Y., Chen, Y., and Ho, E.A. (2015) Evaluating the impact of hydroxychloroquine- loaded polyurethane intravaginal rings on lactobacilli. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Toronto, Ontario, CANADA.
Page 153 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
16) Adria, J., Gu, J., Prashar, T., and Ho, E.A. (2015) Targeted brain delivery of siRNA using dual-antibody modified chitosan nanoparticles. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Toronto, Ontario, CANADA.
17) Chen, Y., Traore, Y.L., Li, A. and Ho, E.A. (2014) Development of surface modified matrix and segmented reservoir intravaginal ring devices for the sustained delivery of hydroxychloroquine. Globalization of Pharmaceutical Education Network, Helsinki, Finland.
18) Yang, S., Gu, J., and Ho, E.A. (2014) Intravaginal Gel for the Targeted Delivery of siRNA to T-cells as a Potential Strategy for HIV-1 Prevention. Controlled Release Society Annual Meeting, Chicago, Illinois.
19) Gu, J., Yang, S., and Ho, E.A. (2014) Biodegradable Intravaginal Film for the Targeted Delivery of siRNA-loaded Nanoparticles to Immune Cells. Controlled Release Society Annual Meeting, Chicago, Illinois.
20) Chen, Y., Fowke, K., and Ho, E.A. (2014) Sustained Delivery of Hydroxychloroquine from a Polyether Urethane Intravaginal Ring. Controlled Release Society Annual Meeting, Chicago, Illinois.
21) Yang, S., Gu, J., and Ho, E.A. (2014) RNAi-based Nanomicrobicide for the Prevention of Male-to-Female Transmission of HIV. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Montreal, Quebec, CANADA. (Invited Oral Presentation); (1st Place Poster Award)
22) Chen, Y., Fowke, K., and Ho, E.A. (2014) Fabrication and Characterization of a Matrix Intravaginal Ring Device for the Sustained Release of Hydroxychloroquine. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Montreal, Quebec, CANADA.
23) Li, A., Chen, Y., Traore, Y., and Ho, E.A. (2014) Fabrication and characterization of a segmented reservoir intravaginal ring device for controlled release of hydroxychloroquine. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Montreal, Quebec, CANADA. Poster presentation
24) Yang, S., Gu, J., and Ho, E.A. (2013) Nanoparticle-based Gel for the Intravaginal Targeted Delivery of siRNA to Immune Cells of the Mucosa. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA. Page 154 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
25) Chen, Y., Ahmadie, R., Baart, N., and Ho, E.A. (2013) An Innovative Two-Component Intravaginal Ring for Sustained Protein Delivery. Canadian Society for Pharmaceutical Sciences / Canadian-Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
26) Dash, A., Yang, S., Chen, Y., Gu, K., Sayre, C., Davies, N, and Ho, E.A. (2013) Development and Characterization of a Novel Intravaginal Nanomedicine for the Targeted Delivery of Saquinavir to CD4+ T-Cells. Canadian Society for Pharmaceutical Sciences / Canadian- Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA.
27) Yang, S., Gu, K., and Ho, E.A. (2013) Design and Characterization of a Nanomedicine for the Targeted Delivery of Saquinavir. Manitoba Pharmacy Conference, Winnipeg, Manitoba, CANADA
28) Chen, Y. and Ho, E.A. (2013) In Vitro Characterization of a Hydrophilic Matrix Intravaginal Ring for the Sustained Delivery of Hydroxychloroquine. Manitoba Pharmacy Conference, Winnipeg, Manitoba, CANADA
29) Yang, S., Panos, G., Chan, D., Chen, Y., and Ho, E.A. (2012) Design and Characterization of a Nanomedicine for the Targeted Delivery of Saquinavir. 39th Annual Meeting of the Controlled Release Society, Quebec City, Quebec, CANADA
30) Ho, E.A. (2011) Development and characterization of novel medical devices and drug delivery strategies for the treatment and prevention of HIV/AIDS and other infectious diseases. CIHR 10th Annual New Principal Investigators Meeting, Mont Gabriel, Quebec.
31) Ho, E.A. (2011) Development and characterization of novel medical devices and drug delivery strategies for the treatment and prevention of HIV/AIDS and other infectious diseases. CIHR Institute of Infection and Immunity New Investigator Forum, Lac Delage, Quebec, CANADA.
32) Ho, E.A., Damian, F., Tuitupou, A., Shelke, N., Clark, M., Friend, D. and Kiser, P. (2010) A Combination Intravaginal Ring for the Protection Against HIV and Unwanted Pregnancy. 37th Annual Meeting of the Controlled Release Society, Portland, Oregon.
33) Clark, M., Loxley, A., Ho, E.A., Tuitupou, A., McConnell, J., Okoh, O., Goldman, L., Morgan, C., Mitchnick, M., Kiser, P., and Friend, D. (2010) In Vitro and In Vivo Release of Antiretroviral UC781 from Polyurethane and Ethylene-Vinylacetate Copolymer Intravaginal Ring Segments. 37th Annual Meeting of the Controlled Release Society, Portland, Oregon, U.S.A. Page 155 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
INVITED ORAL PRESENTATIONS AND KEYNOTE LECTURES
1) Ho, E.A. (2018) “Fundamentals of Vaccine Formulation and Delivery” CC-CRS workshop on Formulation and Delivery of Biologics: Vaccines, Peptide/Protein and Gene Therapeutics.
2) Ho, E.A. (2017) “Emerging Nanotherapeutics for HIV Prevention and Wound Healing” Nanotechnology and Society: Interdisciplinary Research Meeting
3) Ho, E.A. (2015) “Application of Nanotechnology and Medical Device Design in Microbicide Development” HIV-TB Symposium, Winnipeg, Manitoba
4) Ho, E.A. (2015) “Application of Nanotechnology and Medical Device Design in Microbicide Development” University of Manitoba, Department of Pharmacology and Therapeutics. 5) Ho, E.A. (2014) “Nano-medicines: The Way of the Future?” TEDx UManitoba, Winnipeg, Manitoba
6) Ho, E.A. (2014) “Intravaginal Microbicides for the Prevention of HIV Infection” Canadian Society of Pharmaceutical Sciences / Canadian Chapter Controlled Release Society Annual Meeting, Montreal, Quebec, CANADA (GSK/CSPS Early Career Award Lecture)
7) Ho, E.A. (2014) “Intravaginal Rings for the Modulation of Mucosal Immunity”. 6th Prairie Infectious Immunology Network Meeting, Hecla Island, Manitoba.
8) Ho, E.A. (2013) “Intravaginal Microbicides for the Prevention of HIV Transmission” University of Waterloo, School of Pharmacy.
9) Ho, E.A. (2013) “Intravaginal Delivery of siRNA as Potential Microbicides”. Canadian Society of Pharmaceutical Sciences / Canadian Chapter Controlled Release Society Annual Meeting, Vancouver, British Columbia, CANADA
10) Ho, E.A. (2011) “Intravaginal Rings as a Microbicide”. University of Manitoba, Department of Immunology.
11) Ho, E.A. (2011) “Intravaginal Delivery of siRNA”. Controlled Release Society, National Harbor, Maryland, USA
12) Ho, E.A. (2011) “How Close Are We to an HIV Vaccine?” Mid-Canada Association of Analytical Communities, Winnipeg, Manitoba, CANADA (KEYNOTE Speaker)
DATE: April 10, 2018 Page 156 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Page 157 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
HOULE, Sherilyn Assistant Professor, tenure-track Member of the Graduate Faculty: yes b) DEGREES:
PhD, Experimental Medicine, University of Alberta, 2014 Bachelor of Science in Pharmacy (BSP), University of Saskatchewan, 2006 c) EMPLOYMENT HISTORY:
2014- Assistant Professor, School of Pharmacy, University of Waterloo 2014- Assistant Professor (cross-appointment), Faculty of Applied Health Sciences, University of Waterloo 2008-2014 Community Pharmacist, Overwaitea Food Group, St. Albert, Alberta 2007-2009 Home care pharmacist, Alberta Health Services, Edmonton, Alberta 2006 Hospital pharmacist, Red Deer Regional Hospital, Red Deer, Alberta d) HONOURS:
2017 Education Sabbatical Grant, Canadian Society of Hospital Pharmacists 2015 Wellspring Pharmacy Leadership Award, Canadian Foundation for Pharmacy 2015 Best Paper Award (2014), Canadian Pharmacists Journal 2014 Travel Award, Institute of Health Services and Policy Research – Canadian Institutes of Health Research 2014 Student Travel Bursary, Canadian Association for Health Services and Policy Research (CAHSPR) 2013 Canadian Hypertension Congress Student Travel Award, Hypertension Canada 2013 Magnum Opus Award, Canadian Healthcare Network 2012 Canadian Hypertension Congress Student Travel Award. Hypertension Canada 2012 Outstanding Poster Presentation Award, Young Investigators Forum, Institute of Circulatory and Respiratory Health – Canadian Institutes of Health Research 2012 Travel Award, Young Investigators Forum, Institute of Circulatory and Respiratory Health – Canadian Institutes of Health Research 2012 Doctoral Research Award (Hypertension Priority Area), Canadian Institutes of Health Research 2011 Best Research Poster by a Doctoral Student, Canadian Hypertension Congress, Hypertension Canada 2011 Canadian Hypertension Congress Student Travel Award, Hypertension Canada Page 158 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011 Queen Elizabeth II Scholarship – Master’s Level, University of Alberta 2011 Graduate Student Scholarship, Alberta Advanced Education and Technology - Government of Alberta 2011 Student Travel Award, Canadian Agency for Drugs and Technologies in Health 2010 Walter H. Johns Graduate Fellowship, University of Alberta Faculty of Graduate Studies and Research 2010 Frederick Banting and Charles Best Canada Graduate Scholarship – Master’s Level, Canadian Institutes of Health Research 2009 Queen Elizabeth II Scholarship – Master’s Level, University of Alberta e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2018- Member, National Pharmacy Practice Research Working Group for Canadian Pharmacists Association 2017- Member, Pharmacist Prescribing Working Group, Canadian Society of Hospital Pharmacists Ontario Branch 2017- Chair, Canadian Pharmacy Practice Research Group 2017- Columnist (Travel Health), Pharmacy Practice + Business magazine 2017 Expert Assistance for Ontario College of Pharmacists Discipline Committee 2017 Phase 1 reviewer for CIHR Project Grant, Fall 2016 competition 2016- Executive Committee Member, Ontario Pharmacy Evidence Network (OPEN) 2016-2017 Chair-Elect, Canadian Pharmacy Practice Research Group 2016 Expert reviewer of Dalhousie University Immunization and Injection Continuing Education Program, and University of Toronto Immunization and Injection Program 2016 Expert reviewer for Association of Faculties of Pharmacy of Canada, Informatics for Pharmacy Students e-Resource (Chapter 6: Evidence Based Medicine and Clinical Guidelines) 2015- Editorial Board Member, Research in Social and Administrative Pharmacy 2015- Member, Ontario Ministry of Health and Long-Term Care Pharmacy Travel Vaccines Working Group 2015-2016 Member, Pharmacists’ Practice Committee, Ontario Pharmacists Association 2014-2016 Member-at-Large, Canadian Pharmacy Practice Research Group Executive Committee 2012 Assessor for the Pharmacy Examining Board of Canada’s Objective Structured Performance Evaluation (OSPE) for Pharmacy Technicians 2012-2014 Alberta Branch Delegate, national council of the Canadian Society of Hospital Pharmacists 2012- Moderator, ADAPT Patient Care Skills Development Program, Canadian Pharmacists Association 2012-2014 Member, Alberta College of Pharmacists Hearing Tribunal Committee 2010- Awards committee appraiser, Canadian Society of Hospital Pharmacists Page 159 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2010-2012 Member, Practice Standards Steering Committee, Canadian Society of Hospital Pharmacists 2009 Member, Working Group to review the Competency Profile for Alberta Pharmacists, Alberta College of Pharmacists 2009-2014 Assessor, Pharmacy Examining Board of Canada’s Objective Structured Clinical Examination 2009-2011 Member, pharmacist consultation group for public awareness campaigns by the Alberta College of Pharmacists 2007-2010 Presidential Officer (Internal Portfolio), Canadian Society of Hospital Pharmacists Alberta Branch f) GRADUATE SUPERVISIONS: past 7 years only, by year Completed: 0 MSc, 0 PhD In Progress: 1 MSc, 0 PhD
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Heidi Fernandez MSc (2018-present) TBD In Progress g) GRADUATE COURSES:
N/A h) 1. EXTERNAL RESEARCH FUNDING
Year Source Type* Amount Purpose** Investigator 2017 International Society of Travel F $7,500 Research Principal Medicine Investigator: Title: The Association Between S Houle the Proportion of Pharmacists Authorized to Administer Injections and the Proportion of Patients Adherent to Multiple-Dose Travel Vaccine Regimens: A Retrospective Cohort Analysis of Administrative Data in Alberta, Canada 2017 Canadian Institutes of Health G $48,575 Research Principal Page 160 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Research Investigators: Title: Selling Health: How do J Shelley, L Pharmacists Consider their Minaker Ethical Conduct in Relation to Front-of-Store Sales? 2017 Merck O $35,250 Education Principal Title: Using Micro-Learning to Investigator: Help Pharmacists and N Waite Pharmacy Technicians Conduct Productive Vaccine Conversations 2017 Canadian Society of Hospital F $6,700 Research Principal Pharmacists Investigator: Title: Estimating the W Alsabbagh proportion of emergency department visits that may be managed appropriately by pharmacists within expanded scope of practice 2017 Institute Community Support G $1,500 Travel Principal Canadian Institutes for Health Investigator: Research S Houle 2015 Canadian Foundation for F $17,220 Research Principal Pharmacy Investigator: Title: Determining the clinical S Houle effectiveness and patient satisfaction of a pharmacist- managed travel medicine clinic under an expanded scope of practice. 2015 Neighbourhood Pharmacy F $75,992 Research Principal Association of Canada Investigator: Title: Economic analysis of S Houle community pharmacists providing influenza vaccination in Ontario.
2014 Institute of Health Services G $2,500 Travel Principal and Policy Research, Canadian Investigator: Institutes of Health Research S Houle 2014 Alberta Innovates – Health G $4,952 Research Principal Solutions Investigator: Page 161 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Title: A Knowledge Translation R Tsuyuki Pilot Intervention in Community Pharmacies using the PARiHS Framework
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2018 Ontario Pharmacy Research O $21,770 Research Principal Collaboration Investigator: Title: Community Pharmacy-based S Houle Travel Medicine Services: Current Landscape and Perceptions of Implementation Following Expansion of Scope in Ontario 2017 Learning Innovation and Teaching O $5,000 Research Principal Enhancement (LITE) Grant Investigator: J Title: Measuring the value of Nagge including experiential opportunities as part of a blended learning continuing professional development program for prospective providers of anticoagulation 2017 International Research O $39,109 Research Principal Partnership Grant Investigators: Title: Giving a ‘Shot in the Arm’ to N Waite and S Global Pharmacists as Immunizers Houle 2016 Ontario Pharmacy Research O $19,884 Research Principal Collaboration Investigator: Title: Influenza vaccine distribution N Waite models 2015 Ontario Pharmacy Research O $23,029 Research Principal Collaboration Title: Determining investigator: the perspectives of stakeholders on S Houle priorities for economic analyses of billable pharmacy services in Ontario Page 162 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015 Network for Aging Research O $10,000 Research Principal University of Waterloo Title: The Investigator: provision of home care by S Houle. pharmacists: Current practice in Canada
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs…………………………………………………………..3 - refereed journal articles ...... 38 - refereed conference proceedings...... 0 - presentations at conferences ...... 37 - technical reports ...... 0 - invited/keynote addresses ...... 10 - others (workshops presented) ...... 1
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Books Authored:
N/A
Books Edited:
N/A
Chapters in Books:
1. Houle S. Chapter 706: Expanding and evolving roles for pharmacists. Encyclopedia of Pharmacy Practice and Clinical Pharmacy. Elsevier, Inc. (in press).
2. Carter CA, Houle SKD. Chapter 714: Evidence-based medicine: An overview for pharmacists. Encyclopedia of Pharmacy Practice and Clinical Pharmacy. Elsevier, Inc. (in press).
Page 163 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Houle SKD. Chapter 9: Vaccination Schedules, Registries, and Resources. Informatics for Pharmacy Students e-resource, version 3, 2017. Association of Faculties of Pharmacy of Canada.
Papers in Refereed Journals:
1. Tsuyuki RT, Houle SKD, Charrois TL, Kolber MR, Rosenthal MM, Lewanczuk R, Cooney D, McAlister FA. A randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: The Alberta clinical trial in optimizing hypertension (RxACTION). Circulation. 2015;132:93-100.
2. Rosenthal MA, Houle SKD, Eberhart G, Tsuyuki RT. Prescribing by pharmacists in Alberta and its relation to culture and personality traits. Res Soc Admin Pharm. 2015;11(3):401-11.
3. Houle SKD, Padwal R, Poirier L, Tsuyuki RT. The 2015 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update. Can Pharm J. 2015;148(4):180-6.
4. Bascom CS, Rosenthal MA, Houle SKD. Are pharmacists ready for a greater role in travel health? An evaluation of the knowledge and confidence in providing travel health advice of pharmacists practicing in a community pharmacy chain in Alberta, Canada. J Trav Med. 2015;22(2):99-104.
5. Houle SKD. An introduction to the fundamentals of randomized controlled trials in pharmacy research. Can J Hosp Pharm. 2015;68(1) 28-32.
6. Rosenthal MA, Tsuyuki RT, Houle SKD. A cluster-randomized controlled knowledge translation feasibility study in Alberta community pharmacies using the PARiHS framework: Study Protocol. Pilot and Feasibility Studies. 2015;1:2. doi: 10.1186/2055- 5784-1-2.
7. Houle SKD, Grindrod KA, Chatterley T, Tsuyuki RT. Paying Pharmacists for Patient Care: A Systematic Review of Remunerated Pharmacy Clinical Care Services. Can Pharm J. 2014;147(4):209-232.
8. Houle SKD, Chatterley T, Tsuyuki RT. Multidisciplinary approaches to the management of high blood pressure. Curr Opin Cardiol 2014;29(4):344-353.
9. Houle SKD, Padwal R, Poirier L, Tsuyuki RT. The 2014 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update. Can Pharm J. 2014;147(4):203- 208.
Page 164 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
10. Houle SKD, Kolber MR, Chuck AW. Should vitamin B12 tablets be included in more Canadian drug formularies? An economic model of the cost-saving potential from increased utilization of oral versus intramuscular vitamin B12 maintenance therapy for Alberta seniors. BMJ Open. 2014;4:e004501. doi:10.1136/bmjopen-2013-004501.
11. Kolber MR, Houle SKD. Oral vitamin B12: a cost-effective alternative. Can Fam Phys. 2014;60(2):111-112.
12. Houle SKD, Rosenthal MM, Tsuyuki RT. A case study in mobilizing all pharmacy team members in the community setting: A clinical facilitation role for pharmacy technicians. Can Pharm . 2014;147(2):85-88.
13. Lyster RL, Houle SKD. Abnormal vaginal bleeding following pharmacist prescribing of metformin leads to the detection of complex endometrial hyperplasia. Ann Pharmacother. 2013;47(11):1581-3.
14. Houle SKD, Grindrod KA, Chatterley T, Tsuyuki RT. Publicly Funded Remuneration for the Administration of Injections by Pharmacists: An International Review. Can Pharm J. 2013;146(6):353-64.
15. Houle SKD, Tsuyuki RT, Padwal R. The 2012-2013 Canadian Hypertension Education Program (CHEP) Guidelines for Pharmacists: An Update. Can Pharm J. 2013;146(3):146- 150.
16. Al Hamarneh YN, Houle SKD, Chatterley P, Tsuyuki RT. The validity of blood pressure kiosk validation studies: A systematic review. Blood Press Monit. 2013;18(3):167-72.
17. Houle SKD, McAlister FA, Jackevicius CA, Chuck AW, Tsuyuki RT. Does Performance-Based Remuneration for Individual Health Care Practitioners Impact Patient Care? A Systematic Review. Ann Intern Med. 2012;157:889-99.
18. Houle SKD, Chuck AW, McAlister FA, Tsuyuki RT. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). Pharmacotherapy. 2012;32(6):527-37.
19. Houle SKD, Chuck AW, Tsuyuki RT. Blood pressure kiosks for medication therapy management programs: Business opportunity for pharmacists. J Am Pharm Assoc. 2012;52(2):188-94.
20. Houle SKD, Tsuyuki RT, Campbell NRC. The Canadian Hypertension Education Program (CHEP) 2011 guidelines for pharmacists. Can Pharm J. 2011;144(6):295-304. Page 165 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
21. Charrois TL, McAlister FA, Cooney D, Lewanczuk R, Kolber MR, Campbell NRC, Rosenthal M, Houle SK, Tsuyuki RT. Improving hypertension management through pharmacist prescribing; the rural Alberta clinical trial in optimizing hypertension (Rural RxACTION): trial design and methods. Implementation Science. 2011;6(94). doi:10.1186/1748-5908-6- 94.
22. Kassamali A, Houle S, Rosenthal M, Tsuyuki RT. Case finding: The missing link in chronic disease management. Can Pharm J. 2011;144(4):170-2.
23. Houle S, Campbell N, Tsuyuki RT. Home Blood Pressure Monitoring Plays a Key Role in Hypertension Management – Review of Applications, Effectiveness, and Technique for Pharmacists. Can Pharm J. 2011;144(1):18-20.
Invited / Keynote Addresses
1. Canadian Evidence on Pay-for-Performance in Pharmacy – The RxACTION Trial. Canadian Pharmacists Association Pay-for-Performance Working Group meeting. Ottawa ON. March 2018.
2. Pharmacist-managed travel health clinics under an expanded scope: Evidence of clinical effectiveness and patient satisfaction from Alberta. Canadian Pharmacy Practice Research Group Webinar Series. October 2017.
3. ‘HOT’ Topics in Travel Medicine. University of Waterloo School of Pharmacy reunion 2017. Kitchener ON. September 2017.
4. The Expansion of Pharmacare in Ontario (OHIP+). Health Policy (SWK601R), School of Social Work, Renison University College. Waterloo ON. August 2017.
5. Students Helping Students: Intra-Professional Collaboration Across Pharmacy Schools Through Video-Conferencing. Canadian Conference on Pharmaceutical Education and Research. Quebec City QC. June 2017.
6. The clinical effectiveness and patient satisfaction of a pharmacist-managed travel medicine clinic under an expanded scope of practice. Canadian Foundation for Pharmacy Innovation Gala. Toronto ON. April 2017.
7. From ‘Eh’ to Zika: Protecting Canadian Travellers from the Zika virus. University of Waterloo School of Pharmacy reunion 2016. Kitchener ON. September 2016.
Page 166 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
8. Travel Medicine for Pharmacists: An Introduction to Conducting Pre-Travel Consultations in Community Practice. Canadian Pharmacists Association conference. Calgary AB. June 2016.
9. Hypertension Guidelines: What’s New and What’s Still Important for Pharmacists. Canadian Pharmacists Association conference. Calgary AB. June 2016.
10. The Alberta Clinical Trial in Optimizing Hypertension (RxACTION) and the Role of the Pharmacist in Hypertension Care. Renal Pharmacy Rounds, Grand River Hospital. Waterloo ON. September 2015.
Workshops Presented
1. From Guidelines to Pharmacy Practice: A Review and Case-Based Approach for the Care of Patients with Hypertension. Canadian Pharmacists Conference 2017. Quebec City QC. June 2017.
Papers in Refereed Conference Proceedings
N/A
DATE: April 2, 2018
Page 167 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
JOSEPH, Jamie William Associate Professor Member of the Graduate Faculty: yes b) DEGREES:
PhD, Physiology, University of Toronto, Toronto, ON, 2004 MSc, Physiology, University of Toronto, Toronto, ON, 1999 HBSc, Physiology, University of Western Ontario, London, ON, 1997 c) EMPLOYMENT HISTORY: (*current and linked to program under review) 2013- Associate Professor, School of Pharmacy, University of Waterloo 2007-2013 Assistant Professor,* CIHR New Investigator, School of Pharmacy, University of Waterloo 2004- CIHR Postdoctoral Fellow, Department of Pharmacology, Duke 2007 University, Durham, NC 2003 Invited researcher, BioCurrents Research Centre, Woods Hole, MA 1999-2004 Teaching Assistant, Faculty of Medicine, University of Toronto, 1998-2004 Teaching Assistant, Department of Physiology, University of Toronto, d) HONOURS:
2018 School of Pharmacy Outstanding Faculty Mentor in the Graduate Program (honourary award) 2014 University of Waterloo Outstanding Performance Award, recognizes “the top 10 per cent of the faculty”. 4% increase in salary. 2014 University of Waterloo NSERC Research Incentive Fund (UW-RIF) - competitive research funding to help obtain NSERC funding, $15,000 2012 University of Waterloo CIHR Research Incentive Fund (UW-RIF) - competitive research funding to help obtain CIHR funding, $8,000 2010 University of Waterloo Outstanding Performance Award, recognizes “the top 10 per cent of the faculty”. 4% increase in salary. 2010-2014 Early Researcher Award (Ministry of Research and Innovation), $190,000 2009 UWaterloo Course Internationalization Award, $1500 2008-2013 Canadian Institutes of Health Research New Investigator Award, $300,000
Page 168 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
Committees
Provincial, National, International Committees
2015- Diabetes. Role: reviewed 1 paper for publication.
2015- Nature. Role: reviewed 1 paper for publication.
2015- Diabetologia. Role: reviewed 2 papers for publication.
2013- Journal Editorial Board member: Endocrinology. Role: Member. I am involved in reviewing journal articles for publication. The expectation is to review a maximum of two new manuscripts per month.
2013- UK Diabetes Research peer review committee member. Role: Member. I was involved in reviewing and ranking grants (online review process).
2012- Journal of Molecular and Cellular Endocrinology. Role: reviewed 1 paper for publication.
2012 American Diabetes Association meeting. Role: Chair: Stimulus-Secretion Coupling in Islet Cells for the Guided Audio Poster Tour.
2012- Journal of Molecular Endocrinology. Role: reviewed 1 paper for publication.
2012- Journal of Visualized Experiments. Role: reviewed 1 paper for publication.
2011- FASAB Journal. Role: reviewed 1 paper for publication.
2011- American Diabetes Association Meeting Abstract Reviewer. Role: Reviewed abstracts and helped plan meeting sessions.
2010- Canadian Institutes of Health Research (CIHR)-Diabetes, Obesity, Lipid & Lipoprotein Disorders (DOL) peer review committee member. Role: Member. I was involved in reviewing and ranking grants submitted to the CIHR-DOL peer review committee (meeting held in Ottawa).
2010- NSERC external grant reviewer. Role: reviewed 8 grants.
Page 169 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2010- Islet Journal. Role: reviewed 3 papers for publication.
2009- Endocrinology (Journal). Role: reviewed 29 papers for publication
2010 McGraw-Hill - Textbook reviewer. Role: Reviewed one textbook for publication).
2009- Journal of Biological Chemistry. Role: reviewed 23 papers for publication.
2009- Journal of Cellular and Molecular Medicine. Role: reviewed 5 papers for publication.
2009 NSERC/CIHR-Collaborative Health Research Projects Grant Reviewer. Role: reviewed one grant,
2008- Biochemistry and Cell Biology Journal. Role: reviewed 6 papers for publication.
2008- Canadian Diabetes Association external grant reviewer. Role: reviewed 7 grants.
2008- PLOS Journal. Role: reviewed 6 papers for publication.
2007- American Journal of Physiology. Role: reviewed 21 papers for publication.
2007- Canadian Journal of Diabetes. Role: reviewed 3 papers for publication.
University Committees
2013 University of Waterloo CIHR research incentive fund (RIF). Role: Member. Committee is in charge of reviewing UW incentive fund grants from UW faculty. Responsibilities: reviewed 10 applications for funding.
2011- University of Waterloo Central Animal Facility Advisory Committee (CAFAC). Role: Member. Committee is in charge of managing the new central animal facility. Responsibilities included providing guidance in the management of the new central animal facility.
2008-2014 University of Waterloo Animal Care Committee (ACC). Role: Member. Responsibilities included reviewing University of Waterloo applications for animal research and teaching. Other responsibilities included reviewing animal research policies at the University of Waterloo.
2010- University of Waterloo Laboratory Safety Committee. Role: Member. To review the University of Waterloo laboratory safety policies. Page 170 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2010- University of Waterloo Radioactive Isotope monitoring/inspection committee. Role: Member. To monitor and assure proper use of radioactive isotopes at the University of Waterloo.
2009-2011 University of Waterloo Animal Care Forms Committee – Sub-committee for review of UW ACC. Role: Member. To review the process of how applications for animal research and teaching are done.
2011 University of Waterloo Facility Design Committee. Role: To review the University of Waterloo design plans and oversee the building of the new central animal facility on main campus.
Faculty Committees
2010- University of Waterloo Science Faculty Council (SFC) (Pharmacy Representative). Role: Member. Act as Pharmacy’s voting representative on the council.
2008- University of Waterloo Faculty Committee on Student Appeals. Role: Member. Assess undergraduate and graduate student discipline appeals.
Department Committees
2015- Graduate student committee, Pharmacy, Jonathan Blay (PhD student, Bogdan Diaconu). Role: Member. Assess student progress.
2015-2017 Graduate student committee, Pharmacy, Tejal Patel (MSc student Haya Fernandez). Role: Member. Assess student progress.
2014 Graduate Student committee, Pharmacy, Mike Beazely (MSc student Azita Kouchmeshky). Role: Member. Assess student progress.
2013-2014 Departmental Promotion and Tenure Committee. Members: Jamie Joseph, Eric Schneider, Jonathan Blay, David J. Edwards (chair). Role: Evaluate application for tenure and promotion.
2013-2014 Faculty Performance Review Committee. Members: Jamie Joseph, Eric Schneider, Nancy Waite, David J. Edwards (chair). Role: Evaluate yearly performance of faculty. 2013-2014 Faculty Performance Review Committee. Members: Jamie Joseph, Eric Schneider, Nancy Waite, David J. Edwards (chair). Role: Evaluate yearly performance of faculty. Page 171 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011- Pharmaceutical Science Undergraduate Program Development Committee. Members: Jamie Joseph (co-chair), Shawn Wettig (co-chair), Jamie Forrest, David J. Edwards. Role: To develop and implement a new undergraduate Pharmaceutical Science program.
2010- Pharmacy Graduate Studies Committee. Role: Member. The committee is involved in all aspects of graduate studies in the School of Pharmacy. As the graduate program in Pharmacy is new we were also responsible for the development and implementation of both the MSc and PhD programs.
2008-2014 Graduate student committee, Chemistry, Guy Guillemette (PhD student, Valentina Taiakina). Role: Member. Assess student progress.
2008-2014 Graduate student committee, Biology, David Spafford (PhD student, Patrick McCamphill). Role: Member. Assess student progress.
2011 Graduate student final defence, Kinesiology, Jim Rush (PhD student Rebecca Ford). Role: External examiner of final thesis defense.
2010-2011 University of Waterloo School of Pharmacy Canadian Council for Accreditation of Pharmacy Programs (CCAPP) Committee and Program Review Committee. Role: Member. Involved in the development of the standards for faculty and staff for the upcoming CCAPP review (committee's role included developing information for 1. Faculty and Staff: Quantitative Factors; 2. Faculty and Staff: Qualitative Factors; 3. Individual Faculty Evaluation.
2010-2010 Pharmacy Executive committee. Role: Member. I was part of this committee when I filled in as interim Associate Director of Research and Graduate Studies.
2009-2011 University of Waterloo School of Pharmacy Director Selection Committee. Role: Member. Assess potential candidates to be hired as the new Director of the School of Pharmacy (selected David Edwards).
2010 Hiring Committee - Lecturer/Lab coordinator for Pharm 110/ Pharm 111. Role: Chair. Hired Lisa Allen. 2010 Hiring Committee - Laboratory Technician for Pharm 110 and Pharm 111. Role: Chair. Hired Yogajothi Arumugam to help with both the Anatomy and Physiology labs.
2010 Graduate student final defence, Kinesiology, Russ Tupling (PhD student Eric Bombardier). Role: External examiner on final thesis defense. Page 172 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
f) GRADUATE SUPERVISIONS:
Completed: 2 MSc; 2 PhD In Progress: 1 PhD
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Status supervision) Project Stefanie Schaeffer (MSc) 2008-2010 Improving islet Completed transplantation success Mei Huang (PhD) 2008-2015 The study of insulin Completed secretion through metabolomics Renjitha Pillai (PhD) 2009-2015 The role of Completed metabolite transport in insulin secretion Sarah Janssen (MSc) 2015-2017 The role of PHD in In Progress insulin secretion Monica Hoang (PhD) 2015- The role of ARNT in In Progress insulin secretion g) GRADUATE COURSES: past 7 years, by year None. h) 1. EXTERNAL RESEARCH FUNDING
Page 173 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Year Source Type* Amount Purpose** Investigator 2014-2020 NSERC (Discovery C $25,000 Research Principal investigator: Grant) J. Joseph 2009-2014 NSERC (Discovery C $25,000 Research Principal investigator: Grant) J. Joseph 2010-2015 ERA (Discovery C $30,000 Research Principal investigator: Grant) J. Joseph 2008-2013 CIHR (New C $60,000 Research Principal investigator: Investigator Award) J. Joseph 2008-2011 CIHR (Operating C $85,512 Research Principal investigator: Grant) J. Joseph 2011-2016 CIHR (Operating C $120,100 Research Principal investigator: Grant) J. Joseph 2010-2015 CIHR (Operating C $112,000 Research Principal investigator: Grant) Russ Tupling Co- investigator: J. Joseph 2008-2009 CFI (Leaders C $251,487 Infrastruct Principal investigator: Opportunity Fund) ure J. Joseph Principal investigator: 2008-2009 CFI (Leaders C $251,487 Infrastruct J. Joseph Opportunity Fund) ure 2008-2009 Juvenile Diabetes F $101,452 Research Principal investigator: Research P. MacDonald / J. Foundation Joseph (Innovative Grant)
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2009 University of O $1,500 Teaching Principal Waterloo (Course investigator: Internationalization J. Joseph Award) i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories
Chapters in books ...... 2 Page 174 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Papers in refereed journals ...... 40 Papers in refereed conference proceedings...... 55 Invited presentations ...... 20 Patents ...... 1
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Chapters in Books
1. MacDonald PM, Joseph JW, (2011). Islets: Biology, Immunology, and Clinical Transplantation. Chapter: Secretory pathways and exocytosis in insulin secretion (Springer). Under revision.
2. R. Pillai, JW. Joseph (2011). Distinct role for ARNT/HIF1β in pancreatic beta-cell function, insulin secretion and type 2 diabetes. In. Biochemistry/Book 1. Ed. In Tech. d.o.o. (Chapter - in press ISBN 979-953-307-484-8).
Papers in Refereed Journals
1. Paglialunga S., G. Simnett, H. Robson, M. Hoang, R. Pillai, A.M. Arkell, J.A. Simpson, A. Bonen, M. Huising, J.W. Joseph and G.P. Holloway (2017). The Rab-GTPase activating protein, TBC1D1, is critical for maintaining normal glucose homeostasis and β-cell mass. Applied Physiology, Nutrition, and Metabolism. 42(6):647-655 Percent Contribution: 30% of the work.
2. Huang M., S. Paglialunga, J.M.K. Wong, M. Hoang, R. Pillai, and J.W. Joseph (2016). Role of prolyl hydroxylase domain proteins in the regulation of insulin secretion. Physiological Reports, 4 (5), 2016, e12722. Joseph Lab Percent Contribution: 100% of the work.
3. Pillai R., S. Paglialunga, M. Hoang, K. Cousteils, K.J. Prentice, E. Bombadier, M. Huang, F.J. Gonzalez, A.R. Tupling, M.B. Wheeler, and J.W. Joseph (2015). Deletion of ARNT/HIF-1β in pancreatic beta cells does not impair glucose homeostasis in mice, but is associated with defective glucose sensing ex vivo. Diabetologia 58(12):2832-42. Joseph Lab Percent Contribution: 90% of the work.
4. Lee E.A., Angka L., Rota S.G., Hanlon T., Mitchell A., Hurren R., Wang X.M., Gronda M., Boyaci E., Bojko B., Minden M., Sriskanthadevan S., Datti A., Wrana J.L., Edginton A., Pawliszyn J., Joseph J.W., Quadrilatero J., Schimmer A.D., Spagnuolo P.A. (2015). Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. Cancer Research 75(12):2478-88. Joseph Lab Percent Contribution: 20% of the work.
Page 175 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
5. Pereira S., A. Shah, G.I. Fantus, J.W. Joseph, A. Giacca (2015). Effect of N-acetyl-L-cysteine on insulin resistance caused by prolonged FFA elevation. Journal of Endocrinology Apr 225(1):1-7. Joseph Lab Percent Contribution: 20% of the work.
6. Neuman J.C., Truchan N.A., Joseph J.W., Kimple M.E. (2014). A method for mouse pancreatic islet isolation and intracellular cAMP determination. J Vis Exp. 2014 Jun 25;(88). doi: 10.3791/50374. Joseph Lab Percent Contribution: 20% of the work.
7. Patterson J.N., K. Cousteils, J.E. Manning Fox, P.E. MacDonald, J.W. Joseph (2014). Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated insulin secretion. J. Biol. Chem. VOL. 289, NO. 19, pp. 13335–13346. Joseph Lab Percent Contribution: 90% of the work.
8. Huang M. and J.W. Joseph (2014). Metabolomic analysis of biphasic insulin secretion reveals key metabolic pathways involved in regulating time-course based insulin secretion. Endocrinology 155(5):1653-66. Joseph Lab Percent Contribution: 100% of the work.
9. Wang H., T. Kaur, N. Tavakoli, J.W. Joseph, S. Wettig (2013). Transfection and structural properties of phytanyl substituted gemini surfactant‐based vectors for gene delivery. Phys Chem Chem Phys 15, 20510‐20516. Joseph Lab Percent Contribution: 10% of the work.
10. Luu L, F.F. Dai, K.J. Prentice, X. Huang, A.B. Hardy, J.B. Hansen, Y. Liu, J.W. Joseph, M.B. Wheeler (2013). The loss of Sirt1 in mouse pancreatic beta cells impairs insulin secretion by disrupting glucose sensing. Diabetologia 56(9):2010-20. Joseph Lab Percent Contribution: 10% of the work.
11. Fox J.M., Seeburger K., Dai X.D., Lyon J., Spigelman A.F., Kolic J., Hajmrle C., Joseph J.W., Kin T., Shaprio A.M.J., Korbutt G., MacDonald P.E. (2013). Functional plasticity of the human infant β-cell exocytotic phenotype. Endocrinology 154(4):1392-9. Percent Contribution: 10% of the work.
12. Wilkins H.M., D. Kirchhof, E. Manning, J.W. Joseph, and D.A. Linseman (2013). Mitochondrial glutathione transport is a key determinant of neuronal susceptibility to oxidative and nitrosative stress. Journal of Biological Chemistry 288(7):5091-101. Percent Contribution: 10% of the work.
13. K. Koulajian, T. Desai, G.C. Liu, A. Ivovic J.N. Patterson, C. Tang, J. El-Benna, J. W. Joseph, J. W. Scholey, A. Giacca (2013). NADPH Oxidase Inhibition Prevents Beta Cell Dysfunction Induced by Prolonged Elevation of Oleate In vivo. Diabetologia 56(5):1078-87. Joseph Lab Percent Contribution: 10% of the work.
Page 176 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
14. Huang M. and J.W. Joseph (2012). Metabolomic analysis of pancreatic β-cell insulin release in response to glucose. Islets 4(3):210-22. Joseph Lab Percent Contribution: 100% of the work.
15. Huypens P., M. Huang and J.W. Joseph (2012). Overcoming the spatial barriers of the stimulus secretion cascade in pancreatic beta cells. Islets 4(1):1-9. Joseph Lab Percent Contribution: 100% of the work.
16. Pillai R.*, P. Huypens*, M. Huang, S. Schaefer, T. Sheinin, S.D. Wettig and J.W. Joseph (2011). ARNT/HIF-1β plays a critical role in maintaining glucose competence of insulin secreting pancreatic β-cells. Journal Biological Chemistry 286(2):1014-24. Joseph Lab Percent Contribution: 100% of the work. * Co-first author
17. Huypens P., R. Pillai, T. Sheinin, S. Schaefer, M. Huang, M.L. Odegaard, S.M. Ronnebaum, S.D. Wettig, J.W. Joseph (2011). The dicarboxylate carrier plays a role in mitochondrial malate transport and in the regulation of glucose-stimulated insulin secretion from pancreatic β-cells. Diabetologia 54(1):135-145. Joseph Lab Percent Contribution: 90% of the work.
18. Rahul R., A. Stinchcombe, J.W. Joseph, B. Ingalls (2011). Model of a Metabolic Coupling Factor for the Amplification Pathways in Pancreatic β-Cells. Chemical Biophysics. Percent Contribution: 10% of the work.
19. Wettig S.D., R. Deubry, J. Akbar, T. Kaur, H. Wang, T. Sheinin, J.W. Joseph, R.A. Slavcev (2010) "Thermodynamic Investigation of the Binding of Dissymmetric Pyrenyl-Gemini Surfactants to DNA", Physical Chemistry Chemical Physics 12(18):4821-6. Percent Contribution: 20% of the work.
Papers in Refereed Conference Proceedings
1. Paglialunga S., G. Simnett, H. Robson, J. Houad, S.S. Jain, E.A.F. Herbst, L.A. Snook, A.M. Arkell, R. Pillai, D.J. Dyck, J.A. Simpson, A. Bonen, J.W. Joseph and G.P. Holloway (2015). TBC1D1, a Rab-GTPase Activating Protein, is Critical for Maintaining β-cell Mass and Glucose Homeostasis. Experimental Biology, Boston, MA, USA, abstract.
2. Patterson J.N., K. Cousteils, J.E. Manning Fox, P.E. MacDonald, J.W. Joseph (2014). Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated insulin secretion. Keystone: Islet and -cell Biology/Diabetes. Keystone, Colorado, USA, Abstract 2008.
Page 177 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Paglialunga S., G. Simnett, S.S. Jain, E.A.F. Herbst, L.A. Snook, A.M. Arkell, R. Pillai, D.J. Dyck, J.A. Simpson, A. Bonen, J.W. Joseph and G.P. Holloway (2014). The Rab-GTPase activating protein, TBC1D1, is critical for maintaining normal glucose homeostasis and β-cell mass. 5th Muscle Health Awareness Day, York University, abstract.
4. Simnett G.M., S.S. Jain, D.C. Wright, J.W. Joseph, A. Bonen, G.P. Holloway (2013). TBC1D1 ablation causes impaired carbohydrate metabolism independent of the GLUT4 signalling pathway in rats. CSEP conference, abstract.
5. Pillai R., J.W. Joseph (2012). Replenishment of TCA Intermediates in Pancreatic β-cells Deficient in ARNT/HIF1β Expression Rescues the Defective Insulin Secretion. Graduate Student Research Conference, Waterloo, Ontario, Abstract.
6. Pillai R., J.W. Joseph (2012). Replenishment of TCA Intermediates in Pancreatic β-cells Deficient in ARNT/HIF1β Expression Rescues the Defective Insulin Secretion. Rx and D Pharmacy Student Research Poster Competition, Waterloo, Ontario, Abstract.
7. Sharma R., A. Stinchcombe, J.W. Joseph and B. Ingalls (2011). Dynamic Modeling of Metabolism in Pancreatic β-Cells AMMCS. Paper 138.
8. Pillai R., P. Huypens, M. Huang, S. Schaefer, T. Sheinin, S.D. Wettig, J.W. Joseph (2011). Aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor-1β (ARNT/HIF1β) plays a critical role in maintaining glucose-stimulated anaplerosis and insulin release from pancreatic β-cells. Current Research in Engineering, Science, & Technology (CREST) Meeting, McMaster University, Hamilton, Abstract.
9. Pillai R., J.W. Joseph (2011). Replenishment of TCA Intermediates in Pancreatic β-cells Deficient in ARNT/HIF1β Expression Rescues the Defective Insulin Secretion. American Diabetes Association, San Diego, Abstract P-1990. Selected to be showcased in a Guided Audio Poster Tour
10. Huang M., J.W. Joseph (2011). Metabolomic analysis of pancreatic β-cell insulin release in response to glucose. American Diabetes Association, San Diego, Abstract 127−LB.
Invited Presentations
1. Joseph J.W. (December 2014). Metabolic signalling molecules and insulin release from pancreatic β-cells. McGill University, Montreal.
2. Joseph J.W. (November 2014). Novel metabolic signalling molecules involved in the regulation of insulin release from pancreatic β-cells. University of Toronto, Toronto.
Page 178 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Joseph J.W. (October 2012) The Role of Mitochondrial Metabolite Carriers in Insulin Secretion. University of Toronto, Toronto.
4. Joseph J.W. (June 2011) Session Number: IB-SY06, Symposium - Mitochondrial Metabolism and Insulin Secretion. Title: Novel Insights into Anaplerosis and Insulin Secretion. American Diabetes Association, San Diego.
DATE: 2 April 2018.
Page 179 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
MAXWELL, Colleen J. Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
PhD, University of Waterloo, Health Studies, 1995 MA, University of Waterloo, Gerontology, 1991 BSc (Hon), University of Waterloo, Health Studies, 1988 c) EMPLOYMENT HISTORY:
2011- Professor, School of Pharmacy, University of Waterloo 2011- Professor with Cross-Appointment to School of Public Health & Health Systems, University of Waterloo 2011- Adjunct Professor, Department of Community Health Sciences, University of Calgary 2011- Adjunct Scientist, Institute for Clinical Evaluative Sciences (ICES), Toronto 2010-2011 Professor, Departments of Community Health Sciences & Medicine, University of Calgary 2003-2010 Associate Professor, Departments of Community Health Sciences & Medicine, University of Calgary 1997-2003 Assistant Professor, Departments of Community Health Sciences & Medicine, University of Calgary d) HONOURS:
2017-2024 University Research Chair, University of Waterloo 2016 Outstanding Performance Award – Faculty of Science, University of Waterloo 2007 Watanabe Award for Overall Excellence – Faculty of Medicine, University of Calgary 2006-2013 Health Scholar Award, Alberta Heritage Foundation for Medical Research (AHFMR) 2003-2006 Population Health Investigator Award, Alberta Heritage Foundation for Medical Research (AHFMR) 2002-2007 CIHR New Investigator Award, Institute of Aging Partnership Program 2000-2003 Population Health Investigator Award and Establishment Grant, Alberta Heritage Foundation for Medical Research (AHFMR)
Page 180 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1995 Nominated for Gold Medal Award (PhD Dissertation), Faculty of Applied Health Sciences, University of Waterloo 1994-1995 Ontario Graduate Scholarship, University of Waterloo 1994 University of Waterloo – Graduate Scholarship 1993-1994 Ontario Graduate Scholarship, University of Waterloo 1993 University of Waterloo – Graduate Scholarship 1992 University of Waterloo – Graduate Scholarship 1992-1993 Ontario Graduate Scholarship, University of Waterloo 1987 Department of Health Studies – Upper Year Scholarship 1986-1987 Department of Health Studies – Lois Matthews Scholarship 1984 University of Waterloo – Entrance Scholarship e) SCHOLARLY AND PROFESSIONAL ACTIVITIES: 2017- Member, Expert Advisory Group, CIHI Dementia Project 2017- Member, Expert Advisory Group, CIHI Frailty Project 2017- Guest Editor, Canadian Journal of Public Health 2015- Member, Population Health Workshop on Dementia Prevalence and Monetary Costs, Alzheimer Society of Canada 2014- Associate Editor, Canadian Geriatrics Journal 2013- Member, Health System Performance Research Network (HSPRN), MOHLTC 2013- Board Member, Propel Centre for Population Health Impact, University of Waterloo 2013- Board Member, Canadian Society for Epidemiology and Biostatistics (CSEB) 2012- Member, Survey Research Centre, University of Waterloo 2010-2012 Member, Canadian Institute for Health Information (CIHI) Home & Continuing Care Advisory Committee. 2010- Member, Canadian Chronic Disease Surveillance System for Neurological Conditions (CCDSS-NC) Working Group, Public Health Agency of Canada 2010 Mentor, CIHR-IA / Alberta Centre on Aging: Summer Program in Aging 2011- Member, Institute for Public Health (IPH), University of Calgary 2010-2011 Executive committee member, Calgary Institute for Population & Public Health (CIPPH), University of Calgary 2010-2011, Member, University Research Grants Committee, University of Calgary 2009–2012 Board Member & Academic North America Representative, International Society for Pharmacoepidemiology (ISPE) http://www.pharmacoepi.org/
Grant Review CIHR-Health Services Evaluation & Interventions Research 1 & 2 (HS1 & HS2) Committee Chair, 2018, 2017, 2016, 2015 CIHR College of Reviewers [Member] June 2017 - present Retired Teachers of Ontario (RTO) Grant Review, April 2017-March 2018 Page 181 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
CIHR Cluster Chair, Project Grant, Oct 2016 – May 2017 Reviewer, CIHR Gold Leaf Awards, Sept – Dec, 2016 External Reviewer, Tenure & Promotion Application, Memorial University, Nov 2016 External Reviewer, P.S.I. Foundation, May 2016 External Reviewer, United States – Israel Binational Science Foundation, March 2016 Panel Member, Michael Smith Foundation for Health Research (MSFHR) Scholar Program, Health Services Research, 2015-2016. External Reviewer, Canada Research Chair Tier 2, Dec 2015. External Reviewer, TVN Transformative Grant Competition, Dec 2015. CIHR-Health Services Evaluation & Interventions Research 1 (HS1) Committee Chair, 2015. CIHR-Health Services Evaluation & Interventions Research 2 (HS2) Peer Review Committee (operational grants), 2014, 2013, 2012, 2011. CIHR Foundation Grant Stage 1 – Virtual Chair, 2014 Propel Centre for Population Health Impact, University of Waterloo, Chronic Disease Prevention Initiative – Seed Grants, 2014-2015. M.S.I. Foundation, Operational Grants, Alberta, 2012. External Reviewer, Canada Research Chair Tier 1, Aug 2010. CIHR Operating Grant: Prevention of Cardiovascular & Respiratory Diseases Committee Member, Sept 2009. External Reviewer, Ontario Ministry of Health and Long-Term Care, Career Scientist Award, May 2009. External Reviewer, Tenure & Promotion Application, University of Toronto, Department of Health Policy Management & Evaluation, June 2012. f) GRADUATE SUPERVISIONS: Primary Supervisor Completed: 5 MSc, 4 PhD In Progress: 1 MSc, 1 PhD
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Razan Amoud (PhD in Pharmacy) Thesis topic TBD. School of In progress 2018- Pharmacy, University of
Page 182 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Waterloo. Sarah Leslie (MSc in Health Role of social support as an In progress Studies & effect modifier of frailty – Gerentology) health outcome associations in older adults. School of Pubilc Health & Health Systems, University of Waterloo Dr. Monica Cepoiu- (PhD in Health Decision analysis of care Completed Martin Research) 2011- transitions for older adults 2016 in long term care.” Dept. of Community Health Sciences, University of Calgary (received AXA Doctoral Fellowship 2011- 2014). Elizabeth Freiheit (PhD in Frailty, Cognition, and Completed Epidemiology) Depression in Older 2010-2015 Subjects with Coronary Artery Disease Dept. of Community Health Sciences, University of Calgary. (received AHFMR Summer Studentship and CIHR Strategic Training Fellowship in TORCH [Tomorrow’s Research Cardiovascular Health Professionals]. Alison Supina (PhD in Prevalence and associated Completed Epidemiology) risks of concurrent use of 2004-2008 cholinesterase inhibitors, antipsychotic and/or anticholinergic medications in patients with Alzheimer’s disease Dept. of Community Health Sciences, University of Calgary. (received AHFMR Studentship, 2005- 08). Page 183 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Jennifer D. Walker (PhD in Potentially avoidable Completed Epidemiology) hospitalizations from long 2001-2006 term care Kathryn Stock (MSc in Health High-risk medication use, Completed Studies & frailty and hospitalization Gerontology) 2013- among older assisted living 2015 residents Morgan Aho (MSc in Prevalence and correlates Completed Epidemiology) of neurocognitive function 2005-2009 in older adults presenting for coronary care Shelly A. Vik (MSc in Prevalence and correlates Completed Epidemiology) of medication non- 1998-2001 adherence among older home care clients Megan Piket (MSc in Health The prevalence and Completed Research) 2004- pharmacological w/d management of pain in older home care clients Eleanor Pineau (MSc in Health The effect of social Completed Studies & vulnerability on Gerontology) 2014- hospitalization and 2016 cognitive decline among assisted living residents with and without dementia
Supervisory Committee Member Completed: 17 MSc, 9 PhD In Progress: 3 MSc, 2 PhD g) GRADUATE COURSES: past 7 years, by year
2016 HLTH 750 - Fundamentals of Aging, Health and Well-being, Faculty of Applied Health Sciences, University of Waterloo (lecturer). 2015 Graduate Workshop on Systematic Review & Meta-Analysis, University of Waterloo (Course Coordinator and Lecturer). 2012-15 PHARM 610 - Topics in Drug Development, School of Pharmacy, University of Waterloo (lecturer).
Page 184 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2014 HSG 620 - Selected Topics (Introduction to Pharmacoepidemiology) School of Public Health & Health Systems, University of Waterloo 2008-11 MDSC 709 - Advanced Epidemiology, Community Health Sciences, University of Calgary (coordinator and lecturer) h) 1. EXTERNAL RESEARCH FUNDING (from 2009 to present):
Year Source Type* Amount Purpose** Investigator Per Year 2018- Canadian Frailty Network-- C $79,977 Research Maxwell CJ (PI), Nakhla 2019 Assessing and N, Tadrous M (Co-PIs), understanding frailty and Hogan DB, Bronskill SE, high-risk non-prescription Heckman G, Guirguis L, drug use in community Blackburn D, Joseph J. pharmacy practice. 2018- CIHR--Family-administered C $142,800 Research Fiest, KM (PI), Stelfox, 2021 delirium detection in the HT (Co-PI), Bagshaw, S; critically ill. Davidson, J; Dodek, P; Doig, C; Ely, EW; Fowler, R; Grant, C; Ismail, Z; Maxwell, C; Parsons Leigh; Turgeon, A. 2017- P.S.I Foundation-- F $100,000 Research Seitz DP (PI), Rej S, 2019 Comparative Safety and Kurdyak P, Vigod SN, Efficacy of Antipsychotic Rajji T, Davies S, Medications in Late-life Hermann N, Gill SS, Psychotic Disorders: A Maxwell C, Austin P. Population-Based Study from Ontario. 2017- MOHLTC HSRF Program-- G $521,425 Research Sveistrup H, McGilton K 2018 Informing Health System (Co-PIs); Boscart V, Reform for Long-Term and Bronskill S, Heckman G, Community Care: Quality Walker P, Tanuseputro for Individuals who P, Wodchis W; Co- require Long-Term investigators include support (QUILT) Program. Maxwell CJ among others. 2017- RBC/UW Applied Health O $14,820 Research Tyas SL, Iraniparast M, 2018 Sciences Partnership Maxwell CJ, (Co-PIs). Page 185 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Fund- Healthy aging trajectories: longitudinal analysis of heathy aging and its predictors after retirement. 2017- Network on Aging O $19,979.70 Research Tyas SL, Maxwell CJ, 2018 Research-- Predictors of Iraniparast M, (Co-PIs). cognitive state trajectories in longitudinal studies of aging. 2017- CIHR-- The association C $69,972 Research Oremus M, Maxwell 2018 between social support, CJ, Tyas S, Konnert C, depression and cognition Law J, Tuokko H in mid-to late-life: A cross- sectional analysis of the Canadian Longitudinal Study on Aging. 2017- MS Society of Canada F $51,387 Research Rotstein D, Marrie RA, 2019 Operating Research Grant- Tu K, Tu J, Maxwell C. - Immigration and the risk of Multiple Sclerosis. 2016- Consortium of MS F $39,8880.5 Research Rotstein D, Marrie RA, 2017 Centers-- Immigration and 0 (US) Tu K, Tu J, Maxwell C. the risk of Multiple Sclerosis. 2016- CIHR -- Broad and Deep C $189,000 Research Rotstein D, Marrie RA, 2021 Analyses in Tu K, Tu J, Maxwell C. Neurodegeneration (BRAIN): Projects 4 & 6. 2015- CIHR - Optimizing C $24,945 Phase I LOI Bell CM, Bronskill SE, 16 prescribing in late life for Support Gruneir A, Rochon PA women and men. Team (Co-PIs); Austin PC, Grant in Late Life Issues. Farrell B, Gill SS, Herrmann N, Jeffs L, de Lemos J, Lix L, Maxwell CJ, McCarthy L, Metge C, Seitz DP, Wodchis WP (Co-Is).
Page 186 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015- CIHR - A systematic review $100,000 Knowledge Seitz DP, and co- 16 and meta-analysis of the Synthesis investigators (including accuracy of depression Grant Maxwell CJ). rating scales to diagnose depression in older adults with Alzheimer’s disease and other dementias.
2014- TVN Strategic Impact C $596,906 Research Morris A, Bell C, 17 Grant - FRAMING-LTC: Bronskill S, Jeffs L, Frailty and Recognizing Maxwell CJ (co-PIs) Appropriate Medications IN Geriatrics and Long- Term Care.
2014- CIHR - Early-life factors C $180,000 Research Tyas SL, Maxwell CJ, 17 and later-life cognitive Riley K, Santacruz K, St. resilience: linking evidence John P, Zeng L. across a lifetime.
2014- CCNA-CIHR - Prevention C $1,011,616 Research Herrmann N, Lanctot 19 and treatment of KL, Seitz DP (Co-PIs), neuropsychiatric and co-investigators symptoms (CCNA Team (including Maxwell CJ). 11).
2014- Alzheimer Society C $119,998 Research Guthrie DM, Reid C, 16 Research Program - The Maxwell CJ, Mitchell L. development of a screening tool for caregiver burden in home care 2014- CIHR-DSEN Bridge Funding C $100,000 Research Maxwell CJ, Bronskill 15 - Exploring frailty and its SE, Austin P, Gill S, role in the assessment of Gruneir A, Hogan D, high risk medications and Patten S, Seitz D, Teare risk for poor health G, Wodchis W. outcomes in vulnerable populations 2013- CIHR - Emerging research C $24,150 Planning Maxwell CJ, Bagshaw Page 187 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
14 and clinical priorities in Grant S, Bronskill S, the detection and Hemmelgarn B, Hogan management of frailty in D. older patients across acute care settings 2013- Clinical Teachers’ F $20,000 Research Seitz DP, Maxwell CJ, 15 Association at Queen’s Gill S, Vigod S, Endowment Fund - Effects Blumberger D, Brander of a volunteer ‘friendly R. visitor’ program on depressive symptoms among home bound older adults who live alone 2011- Public Health Agency of G $209,496 Research Korngut L, Jetté N, 13 Canada - Neurological Pringsheim T (Co-PIs), Registry Best Practice Maxwell CJ, et al. Guidelines and Implementation Toolkit. ~ National Population Health Study of Neurological Conditions). Research 2010- Public Health Agency of G $1,477,342 Research Hirdes JP, Maxwell CJ, 13 Canada - Innovations in Jetté N (Co-PIs), Berg K, Data, Evidence and Bronskill SE, Clarke B, Applications (IDEAs) for Colantonio A, Doran D, Persons with Neurological Heckman G, Hogan D, Conditions. National Kergoat M-J, Marrie R- Population Health Study of A, Martin L, Mitchell L, Neurological Conditions Postuma R, Pringsheim T, Zygun D. 2010- Public Health Agency of G $402,000 Research Jetté N & Pringsheim T 13 Canada - Understanding (Co-PIs), Maxwell CJ et the epidemiology of al. neurological conditions and building the methodological foundation for surveillance. ~ National Population Health Study of Neurological Conditions)
Page 188 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2010- CIHR/Arthritis Society C $240,000 Research Marshall DA (PI), Co- 12 Award - A Decision Investigators: C. Frank, Support (SD) Tool for T. Noseworthy, P. Planning Integrated Rogers, T. Rohleder, M. Sustainable Health Carter, C. Maxwell, D. Services for Patient with Mosher, S. Vanderby Osteoarthritis of the Hip and Knee 2009- Alberta Mental Health G $210,000 Research Maxwell CJ (PI), 13 Research Partnership Academic Team: Strain Program - Enhancing LA, Hogan DB, Patten system capacity to SB, Hagen B, Sales AE, improve the quality and Gruneir A; continuity of mental Decision/Policy Maker health care for seniors in Team: Le Clair K, assisted living and long- Wilson K, term care. – Collaborative Stelmachovich D, Research Grant Initiative: Grabusic C, West B, Mental Wellness in Schalm C, Andison EA, Seniors and Persons with Dharma-Wardene M, Disabilities Berry B, Zieber C 2009- CIHR Catalyst Grant - C $49,778 Research Dalby DM, Hirdes JP, 10 Enhancing the use of Stolee P, Fletcher PC, standardized assessment Papaioannou A, data for quality Maxwell CJ, Poss J, improvement in home Berg KO care 2009- CIHR Meetings, C $14,900 Meeting/Pl Dalby DM, Reid C, 10 Partnerships and anning Broemeling A, Maxwell Dissemination Grants - Grant. CJ, Archibald K. Effective use of RAI data for informed decision- making and improved home health services quality
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator Page 189 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Per Year 2015- Chronic Disease Prevention C $10,000 Research Middleton L, 16 Initiative Seed Grant – Giangregorio L, PROPEL Centre for Heckman G, Maxwell Population Health Impact - CJ, Hobson N, Tyas S, Getting older adults with Regan K. MCI and dementia active: what do we need? 2013- Chronic Disease Prevention C $10,000 Research Grindrod K, Burns C, 14 Initiative Seed Grant – Baskerville B, Chang F, PROPEL Centre for Giangregorio L, Population Health Impact - Maxwell CJ, Middleton Building an interdisciplinary L, Penny Light T, team to research mobile Tomasson Goodwin J. health applications for older adults 2010 University of Waterloo, S $150,000 Research Start-up Fund
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories: Chapters in books………………………………………………………………………………………………....1 Papers in refereed journal……………………………………………………………………………...…127 Papers in refereed conference proceedings………………………………………………..…….101 Technical reports ...... 26 Others (workshops presented)………………………………………………………………………….213
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Chapters in Books:
1. Hogan DB, Maxwell CJ. Book Chapter: Frailty, hospitalization, and the ability to tolerate intensive forms of medical therapy. In: La fragilité des personnes âgées: approche globale, pluridisciplinaire et international. Éditeur: Presses de l'École des Hautes Études en Santé Publique (EHESP), pp. 105-121, 2013. Page 190 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Papers in Refereed Journals:
1. Maxwell CJ, Campitelli MA, Hogan DB, Diong C, Austin PC, Amuah JE, Lapane K, Seitz DP, Gill SS, Gruneir A, Wodchis WP, Bronskill SE. Relevance of frailty to mortality associated with the use of antipsychotics among community-residing older adults with impaired cognition. Pharmacoepidemiol Drug Saf 2018; 27(3):289-98.
2. Macri JC, Iaboni A, Kirkham JG, Maxwell CJ, Gill SS, Vasudev A, Whitehead M, Seitz DP. Association between antidepressants and fall-related injuries among long-term care residents. Am J Geriatr Psychiatry 2017;25(12):1326-1336.
3. Thavorn K, Maxwell CJ, Gruneir A, Bronskill SE, Bai Y, Koné Pefoyo AJ, Petrosyan Y, Wodchis WP. Effect of socio-demographic factors on the association between multimorbidity and healthcare costs: a population-based, retrospective cohort study. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264.
4. Sheikh F, Ismail Z, Mortby ME, Barber P, Cieslak A, Fischer K, Granger R, Hogan DB, Mackie A, Maxwell CJ, Menon B, Mueller P, Patry D, Pearson D, Quickfall J, Sajobi T, Tse E, Wang M, Smith EE. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. Int Psychogeriatr 2018; 30(2):233-244. doi: 10.1017/S104161021700151X.
5. Maclagan LC, Maxwell CJ, Gandhi S, Guan J, Bell C, Hogan D, Daneman N, Gill S, Morris A, Jeffs L, Campitelli M, Seitz D, Bronskill SE. Frailty and potentially inappropriate medication use at nursing home transition. J Am Geriatr Soc 2017;65(10):2205-2212.
6. Campitelli MA, Maxwell CJ, Giannakeas V, Bell CM, Daneman N, Jeffs L, Morris AM, Austin PC, Hogan DB, Ko DT, Lapane KL, Maclagan LC, Seitz DP, Bronskill SE. The variation of statin use among nursing home residents and physicians: A cross-sectional analysis. J Am Geriatr Soc 2017;65(9):2044-2051.
7. Stock KJ, Hogan DB, Lapane K, Amuah JE, Tyas SL, Bronskill SE, Morris AM, Bell CM, Jeffs L, Maxwell CJ. Antipsychotic use and hospitalization among older assisted living residents: Does risk vary by frailty status? Am J Ger Psych 2017;25(7):779-90.
8. Daneman N, Campitelli MA, Giannakeas V, Morris AM, Bell CM, Maxwell CJ, Jeffs L, Austin PC, Bronskill SE. Influences on the start, selection and duration of treatment with antibiotics in long-term care. CMAJ 2017 June 26;189:E851-60. doi: 10.1503/cmaj.161437. Visual abstract available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.161437/-/DC2.
Page 191 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
9. Mondor L, Maxwell CJ, Hogan DB, Bronskill SE, Gruneir A, Lane NE, Wodchis WP. Multimorbidity and healthcare utilization among home care clients with dementia in Ontario, Canada: A retrospective analysis of a population-based cohort. PLoS Med [Special Issue on Dementia] 2017;14(3):e1002249. doi:10.1371/journal.pmed.1002249.
10. Hogan DB, Maxwell CJ, Afilalo J, Arora RC, Bagshaw S, Basran J, Bergman H, Bronskill SE, Carter C, Dixon E, Hemmelgarn B, Madden K, Mitnitski A, Rolfson D, Stelfox HT, Tam- Tham H, Wunsch H. A scoping review of frailty and acute care in middle-aged and older individuals with recommendations for further research. Can Ger J Dec 2017;20(1):22-37.
11. Stock KJ, Amuah JE, Lapane KL, Hogan DB, Maxwell CJ. Prevalence of, and resident and facility characteristics associated with antipsychotic use in assisted living vs. long-term care facilities: A cross-sectional analysis from Alberta, Canada. Drugs Aging 2017;34(1):39-53.
12. Kirkham J, Sherman C, Velkers C, Maxwell C, Gill SS, Rochon PA, Seitz D. Antipsychotic use in dementia. Can J Psychiatry 2017;62(3):170-181.
13. Wilcox ME, Freiheit EA, Faris P, Hogan DB, Patten SB, Anderson T, Ghali WA, Knudtson M, Demchuk A, Maxwell CJ. Depressive symptoms and functional decline following coronary interventions in older patients with coronary artery disease: A prospective cohort study. BMC Psychiatry 2016;16:277.
14. Petrosyan Y, Bai YQ, Koné Pefoyo AJ, Gruneir A, Thavorn K, Maxwell CJ, Bronskill SE, Wodchis WP. The relationship between diabetes care quality and diabetes-related hospitalizations, and the modifying role of comorbidity. Can J Diabetes 2017;41(1):17-25.
15. Campitelli MA, Bronskill SE, Hogan DB, Diong C, Amuah JE, Gill S, Seitz D, Thavorn K, Wodchis WP, Maxwell CJ. The prevalence and health consequences of frailty in a population-based older home care cohort: A comparison of different measures. BMC Geriatrics 2016;16:133.
16. Muscedere J, Andrew MK, Bagshaw SM, Estabrooks C, Hogan D, Holroyd-Leduc J, Howlett S, Lahey W, Maxwell C, McNally M, Moorhouse P, Rockwood K, Rolfson D, Sinha S, Tholl B. Screening for frailty in Canada’s health care system: A time for action. Can J Aging 2016;35(3):281-297.
17. Mondor L, Maxwell CJ, Bronskill SE, Gruneir A, Wodchis WP. The relative impact of chronic conditions and multimorbidity on health-related quality of life in Ontario long- stay home care clients. Qual Life Res 2016;25(10):2619-2632.
Page 192 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
18. Gruneir A, Bronskill SE, Maxwell CJ, Bai Y, Kone A, Thavorn K, Petrosyan Y, Calzavara A, Wodchis WP. The association between multimorbidity and hospitalization is modified by individual demographics and physician continuity of care: a retrospective cohort study. BMC Health Services Research 2016;16:154. DOI: 10.1186/s12913-016-1415-5.
19. Freiheit EA, Hogan DB, Patten SB, Wunsch H, Anderson T, Ghali WA, Knudtson M, Maxwell CJ. Frailty trajectories after treatment for coronary artery disease in older patients. Circ Cardiovasc Qual Outcomes 2016;9:230-238. doi: 10.1161/CIRCOUTCOMES.115.002204. [with editorial by Afilalo J. Circ Cardiovasc Qual Outcomes 2016;9:194-96. doi: 10.1161/CIRCOUTCOMES.116.002852.]
20. Fiest KM, Roberts JI, Maxwell CJ, Hogan DB, Smith EE, Frolkis A, Cohen A, Kirk A, Pearson D, Pringsheim T, Venegas-Torres A, Jetté N. The prevalence and incidence of dementia due to Alzheimer disease: a systematic review and meta-analysis. Can J Neurol Sci 2016;43(Suppl 1):S51-82.
21. Hogan DB, Jetté N, Fiest KM, Roberts JI, Pearson D, Smith EE, Roach P, Kirk A, Pringsheim T, Maxwell CJ. The prevalence and incidence of frontotemporal dementia: a systematic review. Can J Neurol Sci 2016;43(Suppl 1):S96-109.
22. Cepoiu-Martin M, Tam-Tham H, Patten S, Maxwell C, Hogan DB. Predictors of long-term care placement in persons with dementia: a systematic review and meta-analysis. Int J Geriatr Psychiatry 2016;31(11):1151-1171.
23. Jetté N, Maxwell CJ, Fiest KM, Hogan DB. Systematic reviews and meta-analyses of the incidence and prevalence of dementia and its commoner neurodegenerative causes. Can J Neurol Sci 2016;43(Suppl 1):S1-2.
24. Fiest KM, Jetté N, Roberts JI, Maxwell CJ, Smith EE, Black S, Blaikie L, Cohen A, Day L, Holroyd-Leduc J, Kirk A, Pearson D, Pringsheim T, Venegas-Torres A, Hogan DB. The prevalence and incidence of dementia: a systematic review and meta-analysis. Can J Neurol Sci 2016;43(Suppl 1):S3-50.
25. Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, Steeves T, Smith EE, Pearson D, Jette N. The prevalence and incidence of dementia with Lewy Bodies: a systematic review. Can J Neurol Sci 2016;43(Suppl 1):S83-95.
26. Bansal S, Hirdes JP, Maxwell CJ, Papaioannou A, Giangregorio LM. Identifying Fallers Among Home Care Clients with Dementia and Parkinson’s Disease. Can J Aging 2016;35(3):319-331.
Page 193 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
27. Lane NE, Maxwell CJ, Gruneir A, Bronskill SE, Wodchis WP. Absence of a socioeconomic gradient in older adults’ survival with multiple chronic conditions. EBioMedicine 2015;2: 2094-2100.
28. Marshall DA, Vanderby S, Barnabe C, MacDonald KV, Maxwell C, Mosher D, Wasylak T, Lix L, Enns E, Frank C, Noseworthy T. Estimating the burden of osteoarthritis to plan for the future. Arthritis Care & Research 2015;67(10):1379-1386.
29. Koné Pefoyo A, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, Maxwell CJ, Bai Y, Wodchis W. The increasing burden and complexity of multimorbidity. BMC Public Health 2015;15:415.
30. Maxwell CJ, Amuah JE, Hogan DB, Cepoiu-Martin M, Gruneir A, Patten SB, Soo A, Le Clair K, Wilson K, Hagen B, Strain LA. Elevated hospitalization risk of assisted living residents with dementia in Alberta, Canada. Journal of the American Medical Directors Association 2015 16(7):568-77.
31. Patten SB, Burton J, Fiest KM, Wiebe S, Bulloch AGM, Koch M, Dobson KS, Metz LM, Maxwell CJ, Jetté N. Validity of four screening scales for major depression in MS. Multiple Sclerosis Journal 2015;21(8):1064-71.
32. Maxwell CJ, Stock K, Seitz D, Herrmann N. Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider and system factors. Can J Psychiatry 2014; 59(12):624-631.
33. Fiest KM, Patten SB, Altura KC, Bulloch AGM, Maxwell CJ, Wiebe S, Macrodimitris S, Jetté N. Patterns and frequency of the treatment of depression in persons with epilepsy. Epilepsy & Behavior 2014;39:59-64.
34. Fiest KM, Patten SB, Wiebe S, Bulloch AGM, Maxwell CJ, Jetté N. Validating screening tools for depression in epilepsy. Epilepsia 2014;55(10):1642-50.
35. Danila O, Hirdes JP, Maxwell CJ, Marrie RA, Patten SB, Pringsheim T, Jetté N. Prevalence of neurological conditions across the continuum of care based on interRAI assessments. BMC Health Services Research 2014;14:29.
36. Hogan DB, Amuah JE, Strain LA, Wodchis WP, Soo A, Eliasziw M, Gruneir A, Hagen B, Teare G, Maxwell CJ. High hospitalization rates among older residents in assisted living facilities: opportunities for intervention and impact on acute care. Open Medicine 2014;8(1):33-45.
Page 194 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
37. Vu M, Hogan DB, Patten SB, Jetté N, Bronskill SE, Heckman G, Kergoat M-J, Hirdes JP, Chen X, Zehr M, Maxwell CJ. A comprehensive profile of the sociodemographic, psychosocial and health characteristic of Ontario home care clients with dementia. Chronic Diseases & Injuries in Canada 2014;34(2-3): 132-144.
38. Pringsheim T, Lam D, Day L, Genge A, Hogan DB, Shevell M, Fortin CM, Maxwell C, Fiebelkorn G, Barlow K, Kapral MK, Casha S, Mobach T, Johnston M, Korngut L, Jetté N. Validation and interpretation of neurological registry data. Can J Neurol Sci 2013;40:Suppl. 2:S54-56.
39. Johnston M, Campbell C, Hayward R, Lowerison M, Noonan VK, Pfister T, Maxwell C, Fortin CM, Smith E, Mah JK, Kapral MK, Jetté N, Pringsheim T, Korngut L. Registry data storage and curation. Can J Neurol Sci 2013;40: Suppl. 2:S38-43.
40. Jetté N, Atwood K, Hamilton M, Hayward R, Day L, Mobach T, Maxwell C, Fortin CM, Fiebelkorn G, Barlow K, Shevell M, Kapral MK, Casha S, Johnston M, Wiebe S, Korngut L, Pringsheim T. Linkage between neurological registry data and administrative data. Can J Neurol Sci 2013;40: Suppl. 2:S35-37.
41. Smith E, Warner J, Johnston M, Atwood K, Hall R, Mah JK, Maxwell C, Fortin CM, Lowerison M, Kapral MK, Noonan VK, Pfister T, MacKean G, Casselman L, Pringsheim T, Jetté N, Korngut L. Neurological registry data collection methods and configuration. Can J Neurol Sci 2013;40:Suppl. 2:S29-34.
42. Maxwell CJ, Vu M, Hogan DB, Patten SB, Jantzi M, Kergoat M-J, Jetté N, Bronskill SE, Heckman G, Hirdes JP. Patterns of dementia pharmacotherapy in a population-based cohort of home care clients. Drugs Aging 2013;30(7):569-85.
43. Maxwell CJ, Soo A, Hogan DB, Wodchis WP, Amuah JE, Gilbart E, Eliasziw M, Hagen B, Strain LA. Predictors of nursing home placement from assisted living settings in Canada. Canadian Journal on Aging / La Revue canadienne du vieillissement 2013;32(4):333-48, Available on CJO 2013 doi:10.1017/S0714980813000469.
44. Tam-Tham H, Cepoiu-Martin M, Ronksley PE, Maxwell CJ, Hemmelgarn BR. Dementia case management and risk of long-term care placement: a systematic review and meta- analysis. Int J Geriatr Psychiatry 2013; 28:889-902.
45. Hogan DB, Freiheit EA, Strain LA, Patten SB, Schmaltz HN, Rolfson D, Maxwell CJ. Comparing frailty measures in their ability to predict adverse outcomes among older residents of assisted living. BMC Geriatrics 2012;12:56.
Page 195 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
46. Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, Bulloch AGM, Jette N. Depression in Epilepsy: A Systematic Review and Meta-Analysis. Neurology 2013;80:1-10. (with accompanying editorial and podcast).
47. Freiheit EA, Hogan DB, Eliasziw M, Patten SB, Demchuk AM, Faris P, Anderson T, Galbraith D, Parboosingh JS, Ghali WA, Knudtson M, Maxwell CJ. A dynamic view of depressive symptoms and neurocognitive change among patients with coronary artery disease. Arch Gen Psychiatry 2012;69:244-255.
48. Hirdes JP, Mitchell L, Maxwell CJ, White N. Beyond the “Iron Lungs of Gerontology”: Using evidence to shape the future of nursing homes in Canada. Can J Aging 2011;30(3):371-390.
49. Freiheit EA, Hogan DB, Strain LA, Schmaltz HN, Patten SB, Eliasziw M, Maxwell CJ. Operationalizing frailty among older residents of assisted living facilities. BMC Geriatrics 2011;11:23.
50. Foebel AD, Heckman GA, Hirdes JP, Tyas SL, Tjam EY, McKelvie RS, Maxwell CJ. Clinical, demographic and functional characteristics associated with pharmacotherapy for heart failure in older home care clients. Drugs Aging 2011;28(7):561-73.
51. Rawson NSB, Downey W, Maxwell CJ, West R. 25 years of pharmacoepidemiologic innovation: The Saskatchewan Health Administrative Databases. Journal of Population Therapeutics & Clinical Pharmacology 2011;18(2):e245-9.
52. Sales A, O’Rourke H, Draper K, Teare GF, Maxwell CJ. Prioritizing information for quality improvement using resident assessment instrument data: experiences in one Canadian province. Healthcare Policy 2011;6(3):55-67.
Papers in Refereed Conference Proceedings:
1. Maxwell CJ, Campitelli MA, Hogan DB, Diong C, Austin PC, Amuah JE, Lapane K, Seitz DP, Gill SS, Gruneir A, Wodchis WP, Bronskill SE. Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Oral presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Montreal, Canada, August 27-30, 2017. Abstract published in Pharmacoepidemiology & Drug Safety 2017;26(Suppl. 2): 456-457.
2. Maclagan LC, Maxwell CJ, Campitelli MA, Rochon P, Hogan DB, Lapane KL, Bronskill SE. Sex differences in potentially inappropriate medication use and frailty at nursing home transition: a retrospective cohort study. Poster presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Montreal, Page 196 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Canada, August 27-30, 2017. Abstract published in Pharmacoepidemiology & Drug Safety 2017;26(Suppl. 2): 193-194.
3. Maxwell CJ, Hogan DB, Amuah JE, Strain LA. Clinical and Healthcare Outcomes of Assisted Living Residents: A Canadian Perspective. Oral presented at the 21st IAGG World Congress of Gerontology and Geriatrics, San Francisco, California, July 23-27, 2017. Abstract published in Innovation in Aging 2017;1(S1):pp. 719-720.
4. Wodchis WP, Mondor L, Maxwell CJ, Bronskill S, Gruneir A, Lane N, Pefoyo AK, Bai YQ, Thavorn K. Health Care Outcomes for People with Multiple Chronic Conditions in Ontario, Canada. Oral presented at the 21st IAGG World Congress of Gerontology and Geriatrics, San Francisco, California, July 23-27, 2017. Abstract published in Innovation in Aging 2017;1(S1):pp.1043-1044.
5. Daneman N, Campitelli MA, Giannakeas V, Morris AM, Bell CM, Maxwell CJ, Jeffs L, Austin PC, Bronskill SE. Prescriber tendencies influence antibiotic initiation, selection and duration in long term care facilities. Poster presented at the Annual Conference of the Canadian Association for Clinical Microbiology and Infectious Disease, Toronto, ON, May 3-6, 2017. Abstract published in Journal of the Association of Medical Microbiology and Infectious Disease Canada 2017;Supplement:105.
6. Bronskill SE, Guan J, Vermeulen M, Yates E, Ng R, Wang X, Walker J, Maxwell CJ. Trends in prevalence, incidence, health system use and cost by persons with dementia in Ontario from 2004-2013: a population-based study. Abstract published in International Journal for Population Data Science 2017;1(1): apr. 2017. ISSN 2399-4908. Available at: https://ijpds.org/article/view/321
7. Campitelli MA, Maxwell CJ, Giannakeas V, Morris A, Bell CM, Bronskill SE. Statin therapy and mortality among new long-term care residents in Ontario, Canada: the contribution of clinical assessment data to a population-based cohort study. Abstract published in International Journal for Population Data Science 2017;1(1): apr. 2017. ISSN 2399-4908. Available at: https://ijpds.org/article/view/337
8. Seitz D, Woosley R, Baranchuk A, Hussain M, Maxwell CJ, Gill SS. Prevalence and correlates of use of medications associated with prolongation of the corrected QT interval in older adults. Poster presented at the 2017 Annual Meeting of the American Association for Geriatric Psychiatry, Dallas, TX, March 24-27, 2017. Abstract published in Am J Geriatr Psychiatry 2017;25(3)(Suppl 1):S145-6.
9. Maxwell CJ, Stock K, Amuah JE, Lapane KL, Hogan DB. Resident and facility level predictors of antipsychotic use in assisted living. Poster presentation, 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, Page 197 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Aug 25-28, 2016. Abstract published in Pharmacoepidemiology and Drug Safety 2016;25(Suppl. 3):363-4.
10. Stock K, Maxwell CJ, Amuah JE, Lapane K, Tyas SL, Bronskill SE, Morris AM, Bell CM, Jeffs L, Hogan DB. Antipsychotic use, frailty and health outcomes among residents of assisted living. Oral presentation, 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, Aug 25-28, 2016. Abstract published in Pharmacoepidemiology and Drug Safety 2016;25(Suppl. 3):263.
11. Maxwell CJ, Mondor L, Hogan DB, Bronskill SE, Gruneir A, Lane N, Wodchis WP. Relative impact of multimorbidity on health-related quality of life: A comparison of persons with and without dementia. Poster presentation, Alzheimer’s Association International Conference, Toronto ON, July 22-28, 2016. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2016;[need issue, pg].
12. Bronskill SE, Gandhi S, Maxwell CJ, Li Q, Campitelli M, Gill SS, Daneman N, Seitz D, Bell C, Hogan DB. Exposure to potentially inappropriate medication among long-term care residents with cognitive impairment in Ontario. Is there an association with frailty? Poster presentation, Alzheimer’s Association International Conference, Toronto ON, July 22-28, 2016. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2016;[need issue, pg].
13. Bronskill SE, Ng R, Yates E, Nylen K, Antflick J, Jaakkimainen L, Tu K, Hogan DB, Maxwell CJ. Trends in dementia prevalence, incidence and health system costs: A population- based analysis from Ontario, Canada. Poster presentation, Alzheimer’s Association International Conference, Toronto ON, July 22-28, 2016. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2016;[need issue, pg].
14. Ismail Z, Barber P, Cieslak A, Fischer K, Granger R, Hogan DB, Jones H, Mackie A, Maxwell CJ, Menon B, Mueller P, Palmer A, Patry D, Pearson D, Pomerance B, Quickfall J, Tse E, Smith EE. Prevalence of mild behavioral impairment (MBI) in a memory clinic population and the impact on caregiver burden. Poster presentation, Alzheimer’s Association International Conference, Toronto ON, July 22-28, 2016. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2016;[need issue, pg].
15. Iraniparast M, Wu Y, Zeng L, Maxwell CJ, Kryscio RJ, St. John PD, SantaCruz KS, Tyas SL. Cognitive resilience predicts reverse transitions from mild cognitive impairment to normal cognition: Findings from the Nun Study. Poster presentation [winner of best student poster in Public & Psychosocial Theme], Alzheimer’s Association International Conference, Toronto ON, July 22-28, 2016. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2016;[need issue, pg].
Page 198 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
16. Stock K, Hogan DB, Tyas S, Bronskill SE, Morris AM, Bell CM, Jeffs L, Maxwell CJ. The identification of frailty and its role as an effect modifier of adverse drug-related outcomes among assisted living residents. Oral presentation, 44th Annual Scientific & Educational Meeting, Canadian Association on Gerontology, Calgary, AB, Oct 23-25, 2015. Abstract published in C J Aging (TBA).
17. Pineau E, Hogan DB, Strain L, Amuah JE, Maxwell CJ. Correlates and outcomes of social vulnerability among Assisted Living residents with and without dementia. Poster presentation, 44th Annual Scientific & Educational Meeting, Canadian Association on Gerontology, Calgary, AB, Oct 23-25, 2015. Abstract published in C J Aging (TBA).
18. Maxwell CJ, Bronskill SE, Walker JD, Yates E, Gunraj N. Health system use, transitions to long-term care and survival among community-dwelling older adults with dementia in Ontario, Canada. Oral presentation, Alzheimer’s Association International Conference, Washington, DC, July 19-23, 2015. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2015;11(7):p180.
19. Maxwell CJ, Bronskill SE, Diong C, Hogan DB, Patten SB, Jetté N, Marrie RA. Depressive symptom trajectories in older adults with dementia and associated risk of functional decline. Poster presentation, Alzheimer’s Association International Conference, Washington, DC, July 19-23, 2015. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2015;11(7):p873.
20. Cepoiu-Martin M, Patten SB, Maxwell CJ, Tam-Tham H, Hogan DB. Predictors of institutionalization in dementia – A systematic review and meta-analysis. Poster presentation, Alzheimer’s Association International Conference, Washington, DC, July 19- 23, 2015. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2015;11(7):p342.
21. Maxwell CJ, Amuah JE, Hogan DB, Cepoiu-Martin M, Gruneir A, Patten SB, Le Clair K, Wilson K, Strain L. Acute care transitions and outcomes among assisted living residents with and without dementia. Poster presentation, Alzheimer’s Association International Conference, Copenhagen, Denmark, July 12-17, 2014. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2014 Vol. 10, Issue 4, Supplement, Pages P735-6.
22. Maxwell CJ, Leah J, Bronskill SE, Hogan DB, Jetté N, Patten SB, Jantzi M, Heckman G, Hirdes JP. The burden and correlates of persistent depressive symptoms among older home care clients with dementia. Poster presentation, Alzheimer’s Association International Conference, Copenhagen, Denmark, July 12-17, 2014. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2014 Vol. 10, Issue 4, Supplement, Page P602. Page 199 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
23. Petrosyan Y, Wodchis W, Maxwell CJ, Bronskill SE, Kone A, Gruneir A, Thavorn K, Bai Y. Impact of dementia on diabetes care quality in Ontario. Poster presentation, Alzheimer’s Association International Conference, Copenhagen, Denmark, July 12-17, 2014. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association 2014 Vol. 10, Issue 4, Supplement, Page P313.
24. Marshall DA, Vanderby S, Frank C, Wasylak T, Mosher D, Noseworthy T, Maxwell C, MacDonald KV, Carter M. What could the future hold? Simulating the demand for osteoarthritis (OA) care in Alberta to plan a sustainable OA care system. Published abstract in Osteoarthritis and Cartilage. 2014; 22 (supplement): S214-S215.
25. Maxwell CJ, Zehr M, Vu M, Hogan DB, Patten SB, Jettė N, Bronskill SE, Kergoat MJ, Heckman G, Danilla OM, Hirdes JP. Neuropsychiatric symptoms in dementia: Variation by care setting and gender. Poster presentation, Alzheimer’s Association International Conference, Boston MA, July 15-18, 2013. Abstract published in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association Vol. 9, Issue 4, Supplement, Page P758.
26. Bansal S, Giangregorio LM, Maxwell CJ, Papaioannou A, Jette N, and Hirdes JP. Risk Factors for Falls in Ambulatory Home Care Clients with Parkinson’s Disease. Presented as a poster at the 2013 Annual Scientific Meeting of the American Geriatrics Society May 4, 2013. Grapevine, TX. Abstract published in Journal of the American Geriatrics Society 2013;61 Suppl 1:s211.
27. Marshall DA, Vanderby S, Frank C, Enns E, Kulin N, Wasylak T, Mosher D, Noseworthy T, Rogers P, Maxwell C, Rohleder T, Pykerman K, Carter M. Simulation modeling with system dynamics (SD) to plan osteoarthritis care delivery in Alberta. Published abstract in Osteoarthritis and Cartilage. 2013; 21(supplement): S167-S168.
28. Marshall D, Vanderby S, Enns E, Frank C, Wasylak T, Mosher DP, Noseworthy T, Rogers P, Maxwell C, Sundaram A, Carter M. Simulation modeling with system dynamics (SD) using real-world observational data to plan osteoarthritis care delivery in Alberta [published abstract PMS89]. Value in Health. 2012; 15(4): A34.
29. Maxwell CJ, Amuah J, Cepoiu-Martin M, Soo A, Gruneir A, Hogan D, Patten S, LeClair K, Wilson K, Strain L. Resident and facility predictors of hospitalization among older adults with dementia residing in assisted living facilities. Oral presentation, Alzheimer’s Association International Conference, Vancouver, BC, July 14-19, 2012. Abstract published in Alzheimer’s & Dementia 2012;8(4) Suppl. P429.
30. Cepoiu-Martin M, Strain L, Soo A, Hogan D, Patten S, Gruneir A, LeClair K, Wilson K, Amuah J, Maxwell CJ. Resident and facility determinants of long-term care placement Page 200 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
among older adults with dementia residing in assisted living facilities. Oral presentation, Alzheimer’s Association International Conference, Vancouver, BC, July 14-19, 2012. Abstract published in Alzheimer’s & Dementia 2012;8(4) Suppl. P251.
31. Cepoiu-Martin M, Tam H, Maxwell CJ, Drummond N, Ronksley P, Hemmelgarn B. The effect of dementia case-management in community-dwelling individuals with dementia on resource utilization: A systematic review and meta-analysis. Poster presentation, Alzheimer’s Association International Conference, Vancouver, BC, July 14-19, 2012. Abstract published in Alzheimer’s & Dementia 2012;8(4) Suppl. P567.
32. Roberts JI, Maxwell C, Roach P, Fiest K, Hogan D, Dykeman J, Day L, Pearson D, Cohen A, Smith E, Venges-Torres A, Steeves T, Pringsheim T and Jetté N. The incidence and prevalence of dementia – a systematic review and meta-analysis. Canadian Journal of Neurological Sciences Conference: 47th Annual Congress of the Canadian Neurological Sciences Federation Ottawa, ON Canada. Conference Start: 20120605 Conference End: 20120608. Abstract published in Can J Neurol Sci, 39 (3 SUPPL. 3): S42-S43.
Technical Reports:
1. Alzheimer Society of Canada and Public Health Agency of Canada - Population Health Expert Panel (Co-authors including Maxwell CJ). Chambers LW, Bancej C, McDowell I (Editors). Prevalence and Monetary Costs of Dementia in Canada. Toronto, ON, Canada. 2016.
2. Hogan DB, Maxwell CJ, Afilalo J, Arora RC, Bagshaw S, Basran J, Bergman H, Bronskill SE, Dixon E, Hemmelgarn B, Madden K, Mitnitski A, Rolfson D, Stelfox HT, Tam-Tham H, Wunsch H. A critical review of frailty and acute care: recommendations for further research. Discussion paper based on a CIHR-funded invitational expert consultation meeting on Frailty in Acute Care, February 2016.
3. Ng R, Maxwell CJ, Yates EA, Nylen K, Antflick J, Jetté N, Bronskill SE. Brain Disorders in Ontario: Prevalence, Incidence and Costs from Health Administrative Data. Toronto, ON: Institute for Clinical Evaluative Sciences, 2015.
4. Maxwell CJ. Enhancing System Capacity to Improve the Quality and Continuity of Mental Health Care. Alberta Health Services, Alberta Addiction & Mental Health Research Partnership Program, Collaborative Research Grant Initiative Final Research Report, April 2014. http://www.albertahealthservices.ca/research/Page11190.aspx
5. Jetté N & Pringsheim T (Eds), on behalf of research team, including Maxwell CJ. Systematic reviews on the incidence and prevalence of neurological conditions. Technical
Page 201 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
report for the Public Health Agency of Canada and the Neurological Health Charities of Canada, June 2013.
6. Pringsheim T & Jetté N (Eds), on behalf of research team, including Maxwell CJ. Inventory of existing neurological registries in Canada and selected developed countries: A synthesis. Technical report for the Public Health Agency of Canada and the Neurological Health Charities of Canada, June 2013.
7. Jetté N & Pringsheim T (Eds), on behalf of research team, including Maxwell CJ. Recommendations: Best sources of ascertainment for neurological conditions for surveillance purposes. Technical report for the Public Health Agency of Canada and the Neurological Health Charities of Canada, June 2013.
8. Fraser K, Schalm C, et al., including Maxwell CJ. Data for improvement and clinical excellence: Final Research Report. Canadian Foundation for Healthcare Improvement. June 2013 (www.cfhi-fcass.ca)
9. Strain LA, Maxwell CJ, Wanless D, Gilbart E. Designated Assisted Living (DAL) and Long- Term Care (LTC) in Alberta: Selected Highlights from the Alberta Continuing Care Epidemiological Studies (ACCES). Edmonton, AB: ACCES Research Group, University of Alberta, 2011. http://hdl.handle.net/10402/era.23779
10. Wanless D, Strain LA, Maxwell CJ. Designated Assisted Living (DAL) and Long-Term Care (LTC) in Alberta: Alberta Continuing Care Epidemiological Studies (ACCES) Methodology. Edmonton, AB: ACCES Research Group, University of Alberta, 2011. http://hdl.handle.net/10402/era.23788
Others: (Conference presentations, workshops)
1. Iraniparast M, Dubin JA, Maxwell CJ, St John PD, Tyas SL. Patterns of cognitive change in older adults include improvement from cognitive impairment to normal cognition. Symposium on Aging Research (SoAR) - University of Waterloo, Canada, April 25, 2018
2. Franklin DP, Maxwell CJ, Neiterman E, Tyas SL. So positive emotions predict healthy aging? Symposium on Aging Research (SoAR) – University of Waterloo, Canada, April 25, 2018.
3. Rutter EC, Oremus M, Maxwell CJ, Tyas SL. Is perceived availability of social support associated with better memory in older adults? Symposium on Aging Research, Waterloo, ON: April 25, 2018.
Page 202 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
4. Maclagan LC, Maxwell CJ, Guan J, Campitelli MA, Herrmann N, Lapane K, Hogan DB, Amuah JE, Seitz DP, Gill SS, Bronskill SE, on behalf of FRAMING-LTC Research Team. Cholinesterase inhibitor use among older adults with dementia prior to and after admission to long-term care: What is the influence of frailty? Poster presented at the 9th Canadian Conference on Dementia in Toronto, ON, November 4, 2017.
5. Oremus M, Maxwell CJ, Tyas S, Konnert C, Law J, Tuokko H. Social support availability and depressive symptoms among middle- and older-aged Adults: A preliminary analysis of baseline data from the Canadian Longitudinal Study on Aging. Oral presented at the Canadian Society for Epidemiology & Biostatistics: 2017 Biennial Conference: Epidemiology and Biostatistics: From Molecules to Population, Banff, AB, May 30-June 2, 2017.
6. Oremus M, Tyas S, Maxwell CJ, Tuokko H, Law J, Konnert C. Social support availability and cognitive function among middle- and older-aged Adults: A cross-sectional analysis of the Canadian Longitudinal Study on Aging. Oral presented at the Canadian Society for Epidemiology & Biostatistics: 2017 Biennial Conference: Epidemiology and Biostatistics: From Molecules to Population, Banff, AB, May 30-June 2, 2017.
7. Zahradnik M, Jeffs L, Steinberg M, Kruger S, Maxwell C, Bell C, Morris A, Bronskill S. Conditions and factors associated with potentially inappropriate medication use in frail older adults: a mixed methods analysis in long-term care. Poster presented at the Canadian Association for Health Services & Policy Research (CAHSPR) Annual Conference, Toronto, ON, May 24-26, 2017.
8. Quinn KL, Bell CM, Daneman N, Morris A, Jeffs L, Maxwell CJ, Bronskill SE. Going beyond antimicrobial stewardship to identify outliers in drug prescribing: a protocol for a cohort study of frail older adults. Poster presented at the Canadian Frailty Network Annual Conference, Toronto, ON, April 23-24, 2017.
9. Wodchis WP Bai YC, Song K, Thavorn K, Lane N, Bronskill SE, Maxwell CJ, Gruneir A, Kone A. Population healthcare costs for 17 non-communicable diseases in Ontario, Canada. Poster presentation, 4th Global Symposium on Health Systems Research, Vancouver BC, Nov 14-18, 2016.
10. MacKinley ML, Iraniparast M, Costa SM, Maxwell CJ, Tyas SL. Is bigger better? How brain weight and cortical atrophy contribute to cognitive resilience. Poster presented at the Canadian Association on Gerontology, 45th Annual Scientific and Educational Meeting, Montreal, Quebec, Oct 20-22, 2016.
11. Campitelli MA, Maxwell CJ, Giannakeas V, Morris A, Bell CM, Bronskill SE. Statin therapy and mortality among new long-term care residents in Ontario, Canada: the contribution Page 203 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
of clinical assessment data to a population-based cohort study. Oral presentation, International Population Data Linkage Conference (IPDLN), Wales, UK, Aug 24-26, 2016.
12. Bronskill SE, Guan J, Vermeulen M, Yates E, Ng R, Wang X, Walker J, Maxwell CJ. Trends in the prevalence, incidence, health system use and cost by persons with dementia in Ontario from 2004 to 2013: A population-based study. Poster presentation, International Population Data Linkage Conference (IPDLN), Wales, UK, Aug 24-26, 2016.
13. Campitelli M, Maxwell CJ, Austin P, Giannakeas V, Bronskill SE, on behalf of the FRAMING-LTC Research Team. The variation of statin therapy among long-term care residents, physicians and facilities in Ontario. Poster presentation, AcademyHealth Annual Research Meeting, Boston, MA, June 26-28, 2016.
14. Bronskill SE, Walker JD, Vermeulen M, Yates E, Wang X, Maxwell CJ, Guan J. Trajectories of health system use and survival for community-dwelling persons with dementia: a population-based analysis from Ontario, Canada. Poster presentation, AcademyHealth Annual Research Meeting, Boston, MA, June 26-28, 2016.
15. Mondor L, Maxwell CJ, Hogan DB, Bronskill SE, Gruneir A, Lane N, Wodchis WP. Impact of multimorbidity on health-related quality of life in a population-based study of home care clients with dementia in Ontario. Poster presentation, Campus Alberta Neuroscience 2016 International Conference: Promoting Healthy Brain Aging and Preventing Dementia, Research and Translation. Banff, Alberta, May 24-27, 2016.
16. Campitelli M, Maxwell CJ, Austin P, Giannakeas V, Bronskill SE, on behalf of the FRAMING-LTC Research Team. The variation of statin therapy among long-term care residents, physicians and facilities in Ontario. Oral presentation, Canadian Association for Health Services & Policy Research (CAHSPR) Conference, Toronto, Ontario, May 9-12, 2016.
17. Walker JD, Guan J, Vermeulen M, Yates E, Wang X, Maxwell CJ, Bronskill SE. Trajectories of health system use and survival for community-dwelling persons with dementia: a population-based analysis from Ontario, Canada. Oral presentation, Canadian Association for Health Services & Policy Research (CAHSPR) Conference, Toronto, Ontario, May 9-12, 2016.
18. Maclagan L, Guan J, Gandhi S, Maxwell CJ, Campitelli M, Gill SS, Daneman N, Seitz D, Hogan D, Morris A, Bell CM, Bronskill SE. Exposure to potentially inappropriate medication among long-term care residents with cognitive impairment in Ontario: Is there an association with frailty? Oral presentation, Canadian Association for Health Services & Policy Research (CAHSPR) Conference, Toronto, Ontario, May 9-12, 2016.
Page 204 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
19. Thavorn K, Bai Y, Maxwell CJ, Gruneir A, Bronskill S, Kone Pefoyo A, Petrosyan Y, Wodchis W. Multimorbidity and health system costs among older adults in Ontario, Canada. Oral Presentation, 2nd Biennial Asia-Pacific Conference - Society for Medical Decision Making, Hong Kong, Jan 8-10, 2016.
20. Strain LA, Maxwell C. Family Caregivers of Nursing Home Residents: Changes in Visiting and Caregiver Well-being. Poster presentation, 68th Annual Scientific meeting of the Gerontological Society of America, Orlando, Florida, Nov 21, 2015.
21. Iraniparast M, Dubin JA, Maxwell CJ, Tyas SL. The effect of apolipoprotein E-ԑ4 on the trajectory of cognitive decline to dementia: A comprehensive review of the literature. Poster presentation, Network for Aging Research (NAR) symposium, University of Waterloo, Waterloo, Ontario, October 27, 2015.
22. Maxwell CJ, Bronskill SE, Diong C, Hogan DB, Patten SB, Jetté N, Marrie RA. Depressive symptom trajectories in older adults with dementia and associated risk of functional decline. Poster presentation, 8th Canadian Conference on Dementia, Ottawa, ON, Oct 1- 3, 2015.
23. Maxwell CJ, Morris A, Bell CM, Bronskill SE, Jeffs L. Frailty and Recognizing Appropriate Medications in Geriatrics and Long-Term Care [FRAMING-LTC]. Oral presentation, 3rd Annual TVN Conference on improving care for frail elderly Canadians, Toronto, ON, Sept 27-29, 2015.
24. Stock K, Hogan DB, Patten SB, Bronskill SE, Gandhi S, Maxwell CJ, on behalf of the FRAMING-LTC team. The coexistence of frailty, dementia and depression in older adults. Poster presentation, 3rd Annual TVN Conference on improving care for frail elderly Canadians, Toronto, ON, Sept 27-29, 2015.
25. Stock K, Hogan DB, Tyas SL, Bronskill SE, Morris AM, Bell CM, Jeffs L, Gandhi S, Maxwell CJ. Frailty, drug use and hospitalization among older assisted living residents. Poster presentation, 3rd Annual TVN Conference on improving care for frail elderly Canadians, Toronto, ON, Sept 27-29, 2015.
26. Mainville C, Jeffs LP, Maione M, Zahradnik M, Morris A, Bell C, Bronskill S, Maxwell CJ, Tscheng D, Sever L, Hyland S. Frailty and recognizing appropriate medications in geriatrics and long term care [FRAMING-LTC]: Protocol. Poster presentation, 3rd Annual TVN Conference on improving care for frail elderly Canadians, Toronto, ON, Sept 27-29, 2015.
27. Strain LA, Maxwell CJ. Well-being of family caregivers of assisted living: Changes over time. Oral presentation, 5th International Conference on Health Wellness, and Society, Madrid, Spain, Sept 3, 2015. Page 205 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
28. Gruneir A, Bronskill SE, Maxwell C, Bai Y, Kone A, Thavorn K, Petrosyan Y, Calvazara A, Wodchis W. Individual demographics and continuity of care modified the association between multimorbidity and hospitalization. Oral presentation, Academy Health 2015 Annual Research Meeting, Minneapolis, MN, June 14-16, 2015.
29. Wodchis, W.P., Bai, Y., Thavorn, K., Petrosyan, Y., Lane, N.E., Bronskill, S., Maxwell, C., Gruneir, A. & Kone, A. Comparative healthcare costs of 17 chronic conditions in Ontario. Oral presentation, Canadian Association for Health Services and Policy Research Annual Conference, 2015 May; Montreal, Canada.
30. Mondor L, Maxwell CJ, Bronskill SE, Grunier A, Wodchis WP. How Does Multimorbidity Affect Health-Related Quality of Life in Ontario Home Care Clients? Oral presentation at the 2014 Canadian InterRAI Conference, Winnipeg, MB Canada. October 7, 2014. 31. Marshall DA, Vanderby S, Frank C, Wasylak T, Mosher D, Noseworthy T, Maxwell C, MacDonald K, Carter M. What Could the Future Hold? Simulating the Demand for Osteoarthritis (OA) Care in Alberta to Plan a Sustainable OA Care System. Oral Presentation at the Health Technology assessment International (HTAi) Annual Scientific Conference; Washington DC, USA: June 14-18, 2014.
32. Lane NE, Maxwell CJ, Bronskill SE, Wodchis WP. Does socioeconomic status moderate the effect of increasing chronic disease burden on three-year survival in a population- based cohort? Oral presentation, 2014 Geriatric Medicine Combined Research Day, 2014 June 20 Toronto, Canada.
33. Lane NE, Maxwell CJ, Gruneir A, Bronskill SE, Wodchis WP. Does socioeconomic status moderate the effect of increasing chronic disease burden on three-year survival in a population-based cohort? Oral presentation, AcademyHealth Annual General Meeting, 2014 June 6, San Diego, United States of America.
34. Lane NE, Maxwell CJ, Gruneir A, Bronskill SE, Wodchis WP. Does socioeconomic status moderate the effect of increasing chronic disease burden on three-year survival in a population-based cohort? Poster presentation, AcademyHealth Annual General Meeting, 2014 June 9, San Diego, United States of America.
35. Lane N, Maxwell CJ, Gruneir A, Bronskill SE, Wodchis W. Does socioeconomic status moderate the effect of increasing chronic disease burden on three-year survival in a population-based cohort? Poster presentation at the Canadian Association for Health Services and Policy Research (CAHSPR), Toronto, ON, May 12-15, 2014. [Winner of 1st Prize, Poster Competition].
Page 206 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
36. Petrosyan Y, Wodchis W, Bronskill S, Kone A, Gruneir A, Thavorn K, Maxwell CJ, Bai Y. The comorbidity pattern and the quality of diabetes care in Ontario. Poster panel presentation at the Canadian Association for Health Services and Policy Research (CAHSPR), Toronto, ON, May 12-15, 2014.
37. Reynolds S, Wodchis W, Bronskill S, Maxwell CJ. A comparative analysis of long-term care policies and placements. Poster presentation at the Canadian Association for Health Services and Policy Research (CAHSPR), Toronto, ON, May 12-15, 2014.
38. Marshall DA, Vanderby S, Frank C, Wasylak T, Mosher D, Noseworthy T, Maxwell C, MacDonald K, Carter M. What could the future hold? Simulating the demand for Osteoarthritis (OA) care in Alberta to plan a sustainable OA care system. Poster presentation at the Canadian Association for Health Services and Policy Research (CAHSPR), Toronto, ON, May 12-15, 2014.
39. Marshall DA, Vanderby S, Frank C, Wasylak T, Mosher D, Noseworthy T, Maxwell C, MacDonald K, Carter M. What Could the Future Hold? Simulating the Demand for Osteoarthritis (OA) Care in Alberta to Plan a Sustainable OA Care System. Poster presentation at the Osteoarthritis Research Society International (OARSI) World Congress; Paris, France: April 24-27, 2014.
40. Strain L, Maxwell C. Far and farther: adult children caring long-distance for parents in care settings. Oral presentation, 42nd Annual Scientific & Educational Meeting, Canadian Association on Gerontology, Halifax, NS, Oct 17-19, 2013.
41. Maxwell CJ, Vu M, Hogan DB, Patten SB, Jettė N, Bronskill SE, Kergoat MJ, Heckman G, Hirdes JP. Correlates of neuropsychiatric symptoms among older women and men with dementia across continuing care settings. Poster presentation at the 7th Canadian Conference on Dementia, Vancouver, BC, October 3-5, 2013.
42. Gruneir A, Bronskill SE, Maxwell CJ, Konė A, Petrosyan Y, Bai Y, Wodchis W. Multimorbidity and hospitalization outcomes over one year. Poster panel presentation at the Canadian Association for Health Services and Policy Research, Vancouver, BC, May 28-31, 2013.
43. Konė A, Calzavara A, Bai Y, Bronskill SE, Gruneir A, Thavorn K, Maxwell CJ, Wodchis W. Prevalence and Characteristics of Multimorbidity in Ontario. Poster panel presentation at the Canadian Association for Health Services and Policy Research, Vancouver, BC, May 28-31, 2013.
44. Thavorn K, Wodchis W, Maxwell CJ, Konė A, Gruneir A, Bronskill SE, Petrosyan Y, Bai Y. Economic burden of Multimorbidity in Ontario’s Health Care System. Poster panel Page 207 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
presentation at the Canadian Association for Health Services and Policy Research, Vancouver, BC, May 28-31, 2013.
45. Petrosyan Y, Wodchis W, Bronskill SE, Konė A, Gruneir A, Thavorn K, Maxwell CJ, Bai Y. The impact of comorbid conditions on the quality of diabetes care in Ontario. Poster panel presentation at the Canadian Association for Health Services and Policy Research, Vancouver, BC, May 28-31, 2013.
46. Marshall DA, Vanderby S, Frank C, Enns E, Kulin N, Wasylak T, Mosher D, Noseworthy T, Rogers P, Maxwell C, Rohleder T, Pykerman K, Carter M. Simulation modeling with system dynamics (SD) to plan osteoarthritis care delivery in Alberta. Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis; Philadelphia, PA: April 18-21, 2013. (Poster presentation).
47. Jetté N, Pringsheim T, Day L, De Robles P, Fiest K, Hamilton M, Hogan DB, Korngut L, Kwon CS, Lam D, Mah J, Marrie RA, Maxwell C, Metcalfe A, Oskoui M, Patten SB, Pearson D, Reid A, Smith E, Steeves T, Svenson L, Wiebe and Dykeman J. The international incidence and prevalence of neurological diseases. Do we really know how common neurological conditions are? Challenges in interpreting international epidemiological studies. American Academy of Neurology (San Diego, CA) March 2013 (oral and poster presentations).
48. Marshall D, Enns E, Vanderby S, Frank C, Maxwell C, Wasylak T, Mosher DP, Barnabe C, Noseworthy T. Building a Decision Support Tool for Delivery of Health Services for Patients with Hip and Knee Osteoarthritis. Oral presentation at the International Society on Priorities in Health Care (ISPHC; Priorities 2012); Vancouver, British Columbia, Canada: September 16- 19, 2012.
49. Marshall D, Vanderby S, Enns E, Frank C, Wasylak T, Mosher DP, Noseworthy T, Rogers P, Maxwell C, Sundaram A, Carter M. Simulation modeling with system dynamics (SD) using real-world observational data to plan osteoarthritis care delivery in Alberta. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); Washington, D.C., USA: June 4-6, 2012.
50. Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, Bulloch AGM, Jetté N. Depression in Epilepsy: A Systematic Review and Meta-Analysis. Presented at the Canadian League Against Epilepsy Annual Meeting, Calgary, AB, October 2012.
51. Maxwell CJ, Amuah J, Cepoiu-Martin M, Soo A, Gruneir A, Hogan D, Patten S, LeClair K, Wilson K, Strain L, for the ACCES-Mental Health Research Group. Resident and facility predictors of hospitalization among older adults with dementia residing in assisted living facilities. Oral presentation, Canadian Coalition for Seniors’ Mental Health & Canadian Academy of Geriatric Psychiatry 2012 Joint Conference, Banff, AB, Sept 21-22, 2012. Page 208 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
52. Maxwell CJ, Bronskill S, Leah J, Jetté N, Hogan D, Patten S, Heckman G, Jantzi M, Hirdes J, on behalf of the ideasPNC research team. The course of depressive symptoms and associated factors among older home care clients. Oral presentation, Canadian Coalition for Seniors’ Mental Health & Canadian Academy of Geriatric Psychiatry 2012 Joint Conference, Banff, AB, Sept 21-22, 2012.
53. Vu M, Hogan DB, Jetté N, Bronskill S, Heckman G, Patten SB, Chen J, Hirdes JP, Maxwell CJ, on behalf of the ideasPNC research team. A population-based study of home care clients with dementia in Ontario. Poster presentation, Canadian Coalition for Seniors’ Mental Health & Canadian Academy of Geriatric Psychiatry 2012 Joint Conference, Banff, AB, Sept 21-22, 2012. 54. Strain LA, Maxwell CJ. Families caring for assisted living and nursing home residents with dementia: Does setting matter? Oral presentation, International Sociological Association’s Second Forum of Sociology, Buenos Aires, Argentina, August 1-4, 2012.
55. Maxwell CJ, Soo A, Strain LA, Hogan DB, Patten SB, Cepoiu-Martin M, Gruneir A, Le Clair K, Wilson K, Amuah JE, on behalf of the ACCES-Mental Health Research Group. Factors associated with long term care placement among older adults with dementia residing in Assisted Living facilities. Poster presented at the 6th Canadian Conference on Dementia, Montreal QC, Oct 27-29, 2011.
56. Hogan DB, Donaldson EE, Charlton AM, Pearson DM, Quickfall J, Cohen AF, Patry D, Maxwell CJ, Smith EE. The evolving profile of patients seen in a Canadian dementia clinic. Poster presented at the 6th Canadian Conference on Dementia, Montreal QC, Oct 27-29, 2011.
57. Donaldson E, Charlton A, Fischer K, Pearson DM, Quickfall J, Cohen AF, Patry D, Maxwell CJ, Hogan DB, Smith EE. A prospective clinic-based research registry for persons with cognitive symptoms. Poster presented at the 6th Canadian Conference on Dementia, Montreal QC, Oct 27-29, 2011.
58. Maxwell CJ, Strain LA, Hogan D, Patten S, Wanless D, Gilbart E, Cepoiu-Martin M, on behalf of the ACCES-Mental Health Group. Dementia and Depression in Continuing Care Settings in Alberta: Priority Issues for Care and Policy. Poster Presentation (and winner Best Poster by Operating Grant Participant) at the Found in Translation Conference: Sharing Alberta Research for Mental Wellness in Seniors and Persons with Disabilities. Part of the Collaborative Research Grant Initiative: Mental Wellness in Seniors and Persons with Disabilities, Edmonton, AB, April 18, 2011.
59. Maxwell CJ, Strain LA, Soo A, Gilbart E, Wanless D, Hogan DB, Wodchis W, Amuah JE, on behalf of the ACCES Research Group. Factors associated with long term care placement Page 209 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
among residents of assisted living facilities. Oral Presentation at the Canadian Geriatrics Society 31st Annual Scientific Meeting, Vancouver, BC, April 14-16. 2011.
60. Freiheit EA, Hogan DB, Strain LA, Schmaltz HN, Patten SB, Eliasziw M, Maxwell CJ. Operationalizing frailty among older residents of assisted living facilities. Oral Presentation at the Canadian Geriatrics Society 31st Annual Scientific Meeting, Vancouver, BC, April 14-16. 2011. (E. Freiheit was awarded the Edmund V. Cowdry Prize for best oral presentation by a graduate student).
DATE: 26 April 2018
Page 210 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
MCFARLANE, Thomas Clinical Lecturer, definite term Member of the Graduate Faculty: yes b) DEGREES:
PharmD, Idaho State University, 2011 BScPhm, University of Toronto, 1996 c) EMPLOYMENT HISTORY:
2015- Clinical Lecturer, School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, ON 2012-2015 Clinical Assistant Professor, School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, ON 2005-2015 Clinical Pharmacist, Oncology/Hematology/Palliative Care, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON 2010-2012 Adjunct Clinical Lecturer, School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, ON d) HONOURS:
2017 Canadian Association of Pharmacy in Oncology (CAPhO) Merit Award 2017 Best Research Poster Award (“Educational Impact and Registrant Perspectives for an Online Fundamental Oncology Pharmacy Conference in Canada”), CAPhO Conference 2017 AFPC / PEBC Award for Excellence in Research or Innovation in Assessment of Competence 2016 Student Support Recognition Award, University of Waterloo School of Pharmacy e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2016 - Member, Board of Directors, Canadian Association of Pharmacy in Oncology 2016 - Chair, Research Committee, Canadian Association of Pharmacy in Oncology 2016 - Petitions Committee, University of Waterloo School of Pharmacy
Page 211 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015-2016 Student Midpoint Assessment Subcommittee, University of Waterloo School of Pharmacy 2015-2016 Planning Committee, CAPhO Conference 2016, Canadian Association of Pharmacy in Oncology 2014- Genitourinary Cancers Disease Site Group Formulary Advisory Committee, Cancer Care Ontario 2012- Curriculum Assessment Committee, University of Waterloo School of Pharmacy 2014- Education Committee, Canadian Association of Pharmacy in Oncology 2014- Undergraduate Education Subcommittee, Canadian Association of Pharmacy in Oncology 2014-2016 CAPhO 2020 Standards Development Committee, Canadian Association of Pharmacy in Oncology 2012-2104 Accreditation Self-Assessment Committee, University of Waterloo School of Pharmacy 2005-2015 Oncology Quality and Operations Council, Cambridge Memorial Hospital 2005-2015 Affiliate Physician Group, Oncology, Cambridge Memorial Hospital 2005-2015 Oncology Clinical Trials Group, Cambridge Memorial Hospital 2011 Accreditation Standards Committee, Oncology, Cambridge Memorial Hospital f) GRADUATE SUPERVISIONS:
N/A g) GRADUATE COURSES: past 7 years, by year
N/A h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2016 Prostate F $50,000 Research Cancer Canada 2016 Astellas O $10,000 Research 2016 Janssen O $10,000 Research
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc. Page 212 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2016 LITE Seed O $5,000 Research Grant 2015 UW S $15,000
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- refereed conference proceedings...... 1 - presentations at conferences ...... 17 - others (workshops presented) ...... 46
Peer Reviewed Articles
1. Zargar M, McFarlane T, Chan KKW, Wong WWL. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. The Oncologist 2018 Feb;23(2):225-233. doi: 10.1634/theoncologist.2017-0277.
2. Richard CL, Lillie E, Mathias K, McFarlane T. Peer review of teaching in a Canadian pharmacy school: attitudes and impact on teaching practice. Am J Pharm Educ, 9 Feb 2018 [Epub Ahead of Print]
Refereed Conference Proceedings
1. Curran J, McFarlane T. Pharmacists’ Attitudes and Perceptions Regarding Natural Health Product (NHP) Use in Oncology: A Cross-Sectional National Survey. J Oncol Pharm Practice 2018; 24(4 supp):12.
2. Leslie T, Tina Crosbie T, McFarlane T, McFadyen R, Wiernikowski J. Educational Impact and Registrant Perspectives for an Online Fundamental Oncology Pharmacy Conference in Canada. J Oncol Pharm Practice 2017; 23(4 supp):38.
3. Leslie T, Crosbie T, McFarlane T, McFadyen R, Wiernikowski J. Educational Impact and Registrant Perspectives for an Online Fundamental Oncology Pharmacy Conference in
Page 213 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Canada. Presented at Canadian Association of Pharmacy In Oncology (CAPhO) Annual Conference, April 21-23, 2017.
4. Dick MB, McFarlane T. A Cross-sectional National Study of the Adherence of Cancer Centres to 5-HT3 Receptor Antagonist Dosing Guidelines in HEC Regimens. Presented at Canadian Association of Pharmacy In Oncology (CAPhO) Annual Conference, April 21-23, 2017.
5. McFarlane T. Building an Oncology Curriculum in a New Pharmacy Program: The University of Waterloo Experience. Poster Presentation, National Oncology Pharmacy Symposium, Vancouver BC, November 14-17, 2013.
Presentations at Conferences
1. Thomas McFarlane. Adverse Effects of Immunotherapy. CAPhO Oncology Fundamentals Day (OFD) 2017, Online Conference, September 30, 2017.
2. Thomas McFarlane (chair), Scot Dowden, Oliver Bathe. Advances in the Treatment of Metastatic Colorectal Cancer and the Role of Multidisciplinary Management in Optimizing Patient Outcomes. Satellite Symposium, CAPhO Conference, Banff, AB, April 21, 2017.
3. Thomas McFarlane. Fundamentals of Solid Tumours – Colorectal Cancer. CAPhO Oncology Fundamentals Day (OFD) 2016, Online Conference, October 1, 2016.
4. Thomas McFarlane. Checkpoint Inhibitors: The New Oncology Blockbusters. Plenary Session, CAPhO Conference, Niagara Falls, ON, April 17, 2016.
5. Thomas McFarlane, Mark Pasetka, Melanie Danilak, Lynne Nakashima. Oncology Pharmacy Residency Training and Preparing for the Real World, Oncology Undergraduate Education. Breakout Panel Discussion, CAPhO Conference, Niagara Falls, ON, April 16, 2016.
6. Thomas McFarlane, Tara Leslie, Diane Johnson, Christopher Ralph. Pushing the Limits: Sharing Ideas in Innovative Clinical Oncology Pharmacy. Plenary Panel Discussion, CAPhO Conference, Niagara Falls, ON, April 16, 2016.
7. Thomas McFarlane, Lori Sax, Colleen Olsen, Mike Lipkin, Scott Ernst. A Case in Checkpoint: Let’s Talk About Their Place in Pharmacy Practice. Satellite Symposium, CAPhO Conference, Niagara Falls, ON, April 15, 2016.
Page 214 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
8. Thomas McFarlane, Anna Granic. Improving the Patient Journey with Oral Cancer Therapies. Invited Event, CAPhO Conference, Niagara Falls, ON, April 14, 2016.
9. Thomas McFarlane, Scott Edwards, Biljana Spirovski. Cinq-a-sept: Improving Oral Chemotherapy Safety and Efficacy through Adherence. Satellite Symposium of the Canadian Association of Pharmacy in Oncology (CAPhO) Conference, St. John’s, NL, May 21-24, 2015.
10. Thomas McFarlane, Scott Edwards. SNAP program training: Strategies for Nurses and Pharmacists in Colorectal Cancer, Neutropenia, and Bone Health Management. Ancillary event, Canadian Association of Pharmacy in Oncology (CAPhO) Conference, St. John’s, NL, May 21-24, 2015.
11. Thomas McFarlane, Sandy Linseman. Oral Anti-Cancer Agents: Conveniences and Challenges. 9th Annual Multidisciplinary Oncology Regional Conference, Waterloo Wellington Regional Cancer Program, Cambridge, ON, April 17, 2015.
12. Thomas McFarlane, Steve Stricker, Tara Leslie. Experimental Therapies in GI Cancers. International Society of Oncology Pharmacy Practitioners XIV Symposium, Montreal, QC, April 2-5, 2014.
13. Thomas McFarlane. Facilitator, Group Breakout Sessions, Innovations in Palliative Care Session. International Society of Oncology Pharmacy Practitioners XIV Symposium, Montreal, QC, April 2-5, 2014.
14. Thomas McFarlane, Sebastian Hotte. New Treatment Options for Castrate-Resistant Prostate Cancer. Satellite Symposium of the International Society of Oncology Pharmacy Practitioners XIV Symposium, Montreal, QC, April 2-5, 2014.
15. Thomas McFarlane, Scott Edwards. Speaker Training Forum, ProACT Education Program for Pharmacists. Ancillary event, International Society of Oncology Pharmacy Practitioners XIV Symposium, Montreal, QC, April 2-5, 2014.
16. Thomas McFarlane. Biologics: What Pharmacists Need to Know About Monoclonal Antibodies. Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, ON, February 1-5, 2014.
17. Thomas McFarlane, Alan So. The ABCs of Castrate Resistant Prostate Cancer. Satellite Symposium of the National Oncology Pharmacy Symposium, Vancouver, BC, November 14-17, 2013.
Page 215 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
18. Thomas McFarlane, Linda Yamata. What We Know Now: Tackling the Evolution of Metastatic Prostate Cancer – A Case Based, Interactive Approach. Satellite Symposium of the National Oncology Pharmacy Symposium, Vancouver, BC, November 14-17, 2013.
19. Thomas McFarlane, Scott Edwards. Speaker Training Forum, ProACT Pharmacy Education Program. Ancillary event of the National Oncology Pharmacy Symposium, Vancouver, BC, November 14-17, 2013.
20. Thomas McFarlane. New Approaches to Castrate-Resistant Prostate Cancer. Satellite Symposium of the Northeastern Section Meeting of the American Urology Association, Niagara Falls, ON, September 14-17, 2012.
21. Thomas McFarlane, Sandeep Sehdev, Sunil Verma. Panel Discussion – Challenges Faced by Clinicians in Lung Cancer. Eli Lilly Canada National Meeting, Toronto, ON, January 9, 2012.
22. Thomas McFarlane. Lung Cancer: Pathophysiology, Features, and Management. Eli Lilly Canada National Meeting, Toronto, ON, January 9, 2012.
23. Thomas McFarlane, Sunil Verma, Vikas Aggarwal. Advances in the Management of NSCLC: Three Perspectives. Satellite Symposium of the National Oncology Pharmacy Symposium, Quebec City, QC, November 3-6, 2011.
24. Thomas McFarlane, Jean Dufresne, Annick Dufour. Skeletal Metastases in Solid Tumor – A Case Study. Satellite Symposium of the National Oncology Pharmacy Symposium, Quebec City, QC, November 3-6, 2011.
25. Thomas McFarlane. Perspectives in Lung and Prostate Cancer Treatment. AstraZeneca Canada National Meeting, Toronto, ON, August 16, 2011.
Others (workshops, webinars, invited presentations)
1. Thomas McFarlane. The Rapidly Changing Landscape of Chronic Lymphocytic Leukemia. CAPhO Educational Webinar Series. Archived at CAPhO.org. November 25, 2015.
2. Thomas McFarlane. Lenalidomide Maintenance After Autologous Stem-Cell Transplant in Multiple Myeloma. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, October 24, 2015.
3. Thomas McFarlane. An Overview and Update on Bevacizumab: Oncology Pharmacist and Nurse Train the Trainer. Hoffman-La Roche Dinner Presentation, Cambridge, ON, September 10, 2015. Page 216 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
4. Thomas McFarlane. American Society of Hematology 2014 Annual Meeting Update: Focus on B-Cell Malignancies. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 29, 2015.
5. Thomas McFarlane. ASCO Genitourinary Cancers Symposium 2015: An Overview. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 15, 2015.
6. Thomas McFarlane. HER-2 Positive Metastatic Breast Cancer: What’s New in the Treatment Landscape? Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 8, 2015.
7. Thomas McFarlane. American Society of Hematology 2014 Annual Meeting Update: CML – Where are we at in 2015? Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, January 28, 2015.
8. Thomas McFarlane. ProACT: Management of EGFR Related Rash for Pharmacists. Archived Webinar, Oncologyeducation.com, January 9, 2015.
9. Thomas McFarlane. ProACT: Management of Neutropenia for Pharmacists. Archived Webinar, Oncologyeducation.com, January 9, 2015.
10. Thomas McFarlane. ProACT: Management of Cancer Related Bone Disease for Pharmacists. Archived Webinar, Oncologyeducation.com, December 14, 2014.
11. Thomas McFarlane, John Papastergiou, Freda Leung. Panel Discussion – Traditional and Non-Traditional Practice Settings. OPA Dinner and Learn, University of Waterloo School of Pharmacy, Kitchener, ON, September 29, 2014.
12. Thomas McFarlane, Beverly Cleland, Peter Lin. Round Table Discussion, Castrate Resistant Prostate Cancer. Archived eCME program, Canadian Urology Association, July 2014.
13. Thomas McFarlane. Adapting to a New Standard of Care for Chronic Lymphocytic Leukemia (CLL) and indolent Non-Hodgkin Lymphoma (iNHL) in Daily Practice. Clinical Rounds, London Regional Cancer Centre, London, ON, June 26, 2014.
14. Thomas McFarlane. Adapting to a New Standard of Care for Chronic Lymphocytic Leukemia (CLL) and indolent Non-Hodgkin Lymphoma (iNHL) in Daily Practice. Clinical Rounds, Erie St. Clair Regional Cancer Program, Sarnia, ON, June 19, 2014.
Page 217 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
15. Thomas McFarlane. Monoclonal Antibodies in Cancer Therapy: A Primer for Pharmacists. Archived Webinar, Ontario Pharmacists’ Association, April 22, 2014.
16. Thomas McFarlane. Perjeta and Kadcyla – New HER-2 Targeted Agents in Metastatic Breast Cancer. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, December 18, 2013.
17. Thomas McFarlane. Chemotherapy Induced Nausea and Vomiting – Moving Toward Best Practice. Clinical Rounds, Hamilton Niagara Haldimand Brant Regional Cancer Program, Stoney Creek, ON, June 13, 2013.
18. Thomas McFarlane. ASCO Gastrointestinal Cancers 2013 Symposium Clinical Update. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 19, 2013.
19. Thomas McFarlane. New Treatment Approaches in Hormone-Refractory Prostate Cancer. Pharmacy Awareness Week 2013 Presentation, Cambridge Memorial Hospital, Cambridge, ON, March 6, 2013.
20. Thomas McFarlane. New Treatments, New Paradigms: An Update from the ASCO 2012 Annual Meeting. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, September 11, 2012.
21. Thomas McFarlane. ASCO Gastrointestinal Cancers Symposium 2012: An Update. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, June 13, 2012.
22. Thomas McFarlane. Denosumab – An Update of the Literature. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, May 28, 2012.
23. Thomas McFarlane. HER-2 and its Role in Gastroesophageal Cancer. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, December 14, 2011.
24. Thomas McFarlane, Scott Edwards, Rick Abbott. PROTTEX – An Education Program for Pharmacists on Prostate Cancer. Live and archived webinar presentation, November 24, 2011.
25. Thomas McFarlane. Treatment-Related Cardiotoxicity in Cancer Patients – Are We Doing Enough? St. Mary’s General Hospital Cardiology Journal Club, Kitchener, ON, November 17, 2011. Page 218 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
26. Thomas McFarlane. Management of Skeletal Related Events (SREs) in Cancer. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, June 26, 2011.
27. Thomas McFarlane. Bone Metastasis and Disease in Cancer Patients: Current and Emerging Treatments. Pharmacy Awareness Week 2011 Presentation, Cambridge Memorial Hospital, Cambridge, ON, March 8, 2011.
28. Thomas McFarlane. Multiple Myeloma: Pathogenesis, Features, and Treatment. Clinical Rounds, Outpatient Nephrology Unit, Grand River Hospital, Kitchener, ON, February 9, 2011.
Others (workshops, webinars, invited presentations)
1. Thomas McFarlane. The Rapidly Changing Landscape of Chronic Lymphocytic Leukemia. CAPhO Educational Webinar Series. Archived at CAPhO.org. November 25, 2015.
2. Thomas McFarlane. Lenalidomide Maintenance After Autologous Stem-Cell Transplant in Multiple Myeloma. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, October 24, 2015.
3. Thomas McFarlane. An Overview and Update on Bevacizumab: Oncology Pharmacist and Nurse Train the Trainer. Hoffman-La Roche Dinner Presentation, Cambridge, ON, September 10, 2015.
4. Thomas McFarlane. American Society of Hematology 2014 Annual Meeting Update: Focus on B-Cell Malignancies. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 29, 2015.
5. Thomas McFarlane. ASCO Genitourinary Cancers Symposium 2015: An Overview. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 15, 2015.
6. Thomas McFarlane. HER-2 Positive Metastatic Breast Cancer: What’s New in the Treatment Landscape? Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 8, 2015.
7. Thomas McFarlane. American Society of Hematology 2014 Annual Meeting Update: CML – Where are we at in 2015? Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, January 28, 2015.
Page 219 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
8. Thomas McFarlane. ProACT: Management of EGFR Related Rash for Pharmacists. Archived Webinar, Oncologyeducation.com, January 9, 2015.
9. Thomas McFarlane. ProACT: Management of Neutropenia for Pharmacists. Archived Webinar, Oncologyeducation.com, January 9, 2015.
10. Thomas McFarlane. ProACT: Management of Cancer Related Bone Disease for Pharmacists. Archived Webinar, Oncologyeducation.com, December 14, 2014.
11. Thomas McFarlane, John Papastergiou, Freda Leung. Panel Discussion – Traditional and Non-Traditional Practice Settings. OPA Dinner and Learn, University of Waterloo School of Pharmacy, Kitchener, ON, September 29, 2014.
12. Thomas McFarlane, Beverly Cleland, Peter Lin. Round Table Discussion, Castrate Resistant Prostate Cancer. Archived eCME program, Canadian Urology Association, July 2014.
13. Thomas McFarlane. Adapting to a New Standard of Care for Chronic Lymphocytic Leukemia (CLL) and indolent Non-Hodgkin Lymphoma (iNHL) in Daily Practice. Clinical Rounds, London Regional Cancer Centre, London, ON, June 26, 2014.
14. Thomas McFarlane. Adapting to a New Standard of Care for Chronic Lymphocytic Leukemia (CLL) and indolent Non-Hodgkin Lymphoma (iNHL) in Daily Practice. Clinical Rounds, Erie St. Clair Regional Cancer Program, Sarnia, ON, June 19, 2014.
15. Thomas McFarlane. Monoclonal Antibodies in Cancer Therapy: A Primer for Pharmacists. Archived Webinar, Ontario Pharmacists’ Association, April 22, 2014.
16. Thomas McFarlane. Perjeta and Kadcyla – New HER-2 Targeted Agents in Metastatic Breast Cancer. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, December 18, 2013.
17. Thomas McFarlane. Chemotherapy Induced Nausea and Vomiting – Moving Toward Best Practice. Clinical Rounds, Hamilton Niagara Haldimand Brant Regional Cancer Program, Stoney Creek, ON, June 13, 2013.
18. Thomas McFarlane. ASCO Gastrointestinal Cancers 2013 Symposium Clinical Update. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, April 19, 2013.
19. Thomas McFarlane. New Treatment Approaches in Hormone-Refractory Prostate Cancer. Pharmacy Awareness Week 2013 Presentation, Cambridge Memorial Hospital, Cambridge, ON, March 6, 2013. Page 220 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
20. Thomas McFarlane. New Treatments, New Paradigms: An Update from the ASCO 2012 Annual Meeting. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, September 11, 2012.
21. Thomas McFarlane. ASCO Gastrointestinal Cancers Symposium 2012: An Update. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, June 13, 2012.
22. Thomas McFarlane. Denosumab – An Update of the Literature. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, May 28, 2012.
23. Thomas McFarlane. HER-2 and its Role in Gastroesophageal Cancer. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, December 14, 2011.
24. Thomas McFarlane, Scott Edwards, Rick Abbott. PROTTEX – An Education Program for Pharmacists on Prostate Cancer. Live and archived webinar presentation, November 24, 2011.
25. Thomas McFarlane. Treatment-Related Cardiotoxicity in Cancer Patients – Are We Doing Enough? St. Mary’s General Hospital Cardiology Journal Club, Kitchener, ON, November 17, 2011.
26. Thomas McFarlane. Management of Skeletal Related Events (SREs) in Cancer. Clinical Rounds, Waterloo Wellington Regional Cancer Program, Cambridge Memorial Hospital, Cambridge, ON, June 26, 2011.
27. Thomas McFarlane. Bone Metastasis and Disease in Cancer Patients: Current and Emerging Treatments. Pharmacy Awareness Week 2011 Presentation, Cambridge Memorial Hospital, Cambridge, ON, March 8, 2011.
28. Thomas McFarlane. Multiple Myeloma: Pathogenesis, Features, and Treatment. Clinical Rounds, Outpatient Nephrology Unit, Grand River Hospital, Kitchener, ON, February 9, 2011.
DATE: April 6, 2018
Page 221 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME: NAGGE, Jeffrey Associate Clinical Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
PharmD, University of Toronto, Canada, 2004 BScPhm, University of Toronto, Canada, 2000 BSc (Honours Science, Minor in Chemistry), University of Waterloo, Canada, 1995 c) EMPLOYMENT HISTORY:
2016- Associate Clinical Professor, School of Pharmacy, University of Waterloo 2006-2015 Clinical Assistant Professor (Adjunct), School of Pharmacy, University of Waterloo 2006- Assistant Clinical Professor (Adjunct), Department of Family Medicine, Michael G. DeGroote School of Medicine, McMaster University 2014- Pharmacy Lead, Waterloo Regional Campus, Michael G. DeGroote School of Medicine, McMaster University, Kitchener, Ontario 2006-2015 Clinical Pharmacist, Centre for Family Medicine Academic Family Health Team, Kitchener, Ontario 2004-2006 Clinical Site Leader, Heart and Circulation Program, Department of Pharmacy, University Health Network, Toronto, Ontario 2001-2004 Clinical Pharmacist, Heart and Circulation Program, Department of Pharmacy, University Health Network, Toronto, Ontario d) HONOURS:
2014 Interprofessional Preceptor of the Year Award. Michael G. DeGroote School of Medicine, McMaster University, Kitchener-Waterloo and area Family Medicine Residency program 2012 Interprofessional Preceptor of the Year Award. Michael G. DeGroote School of Medicine, McMaster University, Kitchener-Waterloo and area Family Medicine Residency program 2011 Excellence in Teaching – Academic (undergraduate). Michael G. DeGroote School of Medicine, McMaster University, Waterloo Regional Campus 2010 Canadian Society of Hospital Pharmacists Western Branches Seminar Best Research Poster Award Page 222 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2007 Doctor of Pharmacy Preceptor of the Year. University of Toronto, Faculty of Pharmacy e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2015- Best practices committee, Centre for Family Medicine Family Health Team, member 2006- Curriculum committee, member 2006-2012 Admissions committee, member 2006-2009 E-health committee, Waterloo-Wellington Local Health Integration Network 2001-2010 Canadian Society of Hospital Pharmacists Educational Services Committee 2010- British Medical Journal, peer-reviewer 2010- Annals of Internal Medicine, peer-reviewer 2005- Canadian Journal of Hospital Pharmacy, peer-reviewer f) GRADUATE SUPERVISIONS:
Completed: 13 post-baccalaureate PharmD; 6 pharmacy residents; 2 medical residents
2017 Nicole Domanski, University of Waterloo 2016 Luna Salameh, University of Toronto 2015 Waisum Szeto, University of Waterloo 2014 Anthony Amadio, University of British Columbia 2013 Vanessa Raco, McMaster University Medical Centre 2012 Sarah Stabler, University of British Columbia 2012 Stephanie Carlin, McMaster University Medical Centre 2012 Sarah Stabler, University of British Columbia 2011-2012 Randy Bahadur, McMaster University 2011-2012 Ela Bednarska, McMaster University 2011 Melani Sung, University of Toronto g) GRADUATE COURSES:
Seminars:
2008- Evidence-based medicine for medical residents 2008- Academic half day for medical residents (anticoagulation, dyslipidemia, practice guidelines, shared-decision making, hypertension, atrial fibrillation)
Page 223 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2008- Ontario Medical O $5,000 Clinical program Co-Principal 2009 Association development investigator: Jeff Nagge 2008- MOHLTC/MTCU G $63,000 curriculum Co - Principal 2009 development investigator: Jeff Nagge
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2017 University of O $5,000 Curriuculum Principal Waterloo development investigator: Jeff Nagge 2013 McMaster O $5,000 Curriculum Principal University development investigator: Mike Lee-Poy *Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- refereed journal articles ...... 14 - refereed conference proceedings...... 14 - presentations at conferences ...... 27 - invited/keynote addresses ...... 40
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Journals:
1. Nagge J, Lee-Poy MF, Richard CL. Evaluation of a unique interprofessional education program involving medical and pharmacy students. American Journal of Pharmaceutical Education. 2017; 81(10): Article 6140. Page 224 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2. Nagge J, Killeen R, Jennings B. Using a course pilot in the development of an online problem-based learning (PBL) therapeutics course in a post-professional PharmD program. Currents in Pharmacy Teaching and Learning 2017; article available online October 18, 2017 ahead of print.
3. Grindrod K, Nagge J, Poon A. QT prolongation (Practice Tool). Can Pharmacists Journal 2016;149(3):138.
4. Nagge J, Bauer J. Different perspective on ASA use. Can Fam Physician 2016; 62:30-31.
5. Sridhar V*, Ho-Yan Leung P*, Seymour N*, Nagge J. Evaluation of a 4mg warfarin initiation protocol for atrial fibrillation in the outpatient setting. Can Fam Physician 2014;60:e535-40.
6. Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, Mamdani MM, Juurlink DN. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: A population-based cohort study. Ann Intern Med 2013;158(6):447-455.
DATE: April 6, 2018
Page 225 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
NAKHLA, Nardine Adjunct Clinical Assistant Professor Member of the Graduate Faculty: no b) DEGREES: designation, institution, department, year
Doctor of Pharmacy, Albany College of Pharmacy and Health Sciences, Albany, NY, 2007
ADDITIONAL CERTIFICATIONS AND TRAINING
2018 WHIMIS 2015 2017 Core Competency Module for Sex and Gender in the Analysis of Data from Human Participants, CIHR Institute of Gender and Health 2017 Medical Abortion Training Program, SOGC 2017 Certified CPR and AED Training for Healthcare Providers, APhA 2017 Systematic Review Training, Cochrane Canada Symposium 2016 Instructional Skills Workshop, University of Waterloo
2016 Cardiovascular Program, Green Shield Canada Health Coaching 2016 TCPS 2: Course on Research Ethics (CORE), Panel on Research Ethics, Government of Canada 2013 Minor Ailments 2-day Certificate Program, Ontario Pharmacists Association 2012 Authorization to Administer Injections, Ontario 2008 OTC Advisor Certificate Program, APhA Proctor and Gamble
c) EMPLOYMENT HISTORY: dates, rank/position, department, institution/firm
2017 – Clinical Lecturer, School of Pharmacy, University of Waterloo, Kitchener, ON 2017 – Adjunct Lecturer, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON 2009- Relief Pharmacist, United Drug Mart, Toronto, ON 2008- Part Owner/Relief Pharmacist, Ash Medical Pharmacy, Scarborough, ON 2017 Consultant for Nonprescription Product Seal, Canadian Pharmacists Association 2011 – 2017 Adjunct Clinical Assistant Professor, School of Pharmacy, University of Waterloo, Kitchener, ON 2013-2017 Lecturer, CPD Education Coordinator, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON 2012-2013 Sessional Instructor, International Pharmacy Graduate Program, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON Page 226 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011-2013 Staff Pharmacist, St. Mark’s Pharmacy, Oakville, ON 2010 –2011 Adjunct Clinical Lecturer, School of Pharmacy, University of Waterloo, Kitchener, ON 2009 –2010 Sessional Instructor, School of Pharmacy, University of Waterloo, Kitchener, ON 2008-2010 Per-Diem Pharmacist, Main Drug Mart, Kitchener, ON 2008 Pharmacy Intern (SPT Internship), Main Drug Mart, Kitchener, On 2007-2008 Per-Diem Pharmacist/Educator, Syracuse University, Syracuse, NY, USA 2007-2008 Staff Pharmacist, Rite Aid Pharmacy #10735, Cazenovia, NY, USA
d) HONOURS: (F.R.S., F.R.S.C., Governor Generals Award, honorary degree, etc...)
2017 AFPC/PEBC Award for Excellence in Research or Innovation in Assessment of Competence 2015 Student Support Recognition Award, University of Waterloo 2015 Nominated for OPA Mentorship Award, Ontario Pharmacists Association 2007 Cum Laude, Albany College of Pharmacy 2007 Elected to give Commencement Address, Albany College of Pharmacy 2007 Who’s Who Among Students in American Universities and Colleges 2007 Dean’s List, Albany College of Pharmacy 2001-2007 Trustee Scholarship for Academic Excellence, Albany College of Pharmacy 2005 Claudia Delgiacco Memorial Prize 2004 Lucy Manvel Membership Award 2000 National Honor Society, Fayetteville-Manlius High School 2000 Who’s Who Among America High School Students e) SCHOLARLY AND PROFESSIONAL ACTIVITIES: past 7 years only (eg. executive and editorial positions but not memberships in societies)
2017- Primary Investigator, Drug Products in Education Programs draft position statement, Ontario College of Pharmacists and University of Waterloo School of Pharmacy 2017- Consultant/Contributor, Modernization of Self-Care Product Regulation, Health Canada 2017- Member, Advisory Committee for Jurisprudence Evaluation, Ontario College of Pharmacists 2017- Member, CPERC 2018 Conference Planning Committee 2017- Member, AFPC Awards Committee 2017- Faculty Advisor, WhiteCoat Collaboration Club 2016- Sig Member, AFPC Skills Lab 2016- Developer, Assessor, Pharmacist Health Coaching, Green Shield Canada Cardiovascular program Page 227 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015- Academic Lead, Assessing and Treating Minor Ailments Program, University of Toronto Continuous Professional Development Department 2013- Member, Assessment Committee, School of Pharmacy, University of Waterloo 2012- Member, Jurisprudence Steering Committee, Ontario College of Pharmacists 2012- Creator/Author, Dr. Nakhla’s OTC Updates; Facebook blog 2011- Judge, Canadian Association of Pharmacy Students and Interns (CAPSI) Competition 2017 Developer/Author, Enhancing Eye Care through Interprofessional Collaboration, a continuing education program for Pharmacists, Optometrists and Students; University of Waterloo School of Pharmacy, University of Waterloo School of Optometry, and Centre for Contact Lens Research (Alcon) 2017 Member, Progression Through the Ranks (PTR) Teaching Review Committee, Leslie Dan Faculty of Pharmacy, University of Toronto 2017 Volunteer, Canadian Pillar of Pharmacy Awards Dinner 2017 Mock Objective Structured Clinical Examination Assessor (OSCE), UW Student Counseling Club 2017 Faculty member developer, Irritable Bowel Syndrome-Constiption (IBS-C) Project, Allergan 2016-2017 Content Developer, Practice Essentials for Today’s Pharmacist (online); Apotex and University of Toronto Continuous Professional Development Department 2016-2017 Member, PharmD Committee, Leslie Dan Faculty of Pharmacy, University of Toronto 2014-2017 Member, Continuing and Professional Education (CPE) Committee, Leslie Dan Faculty of Pharmacy, University of Toronto 2013-2017 Member, Pri-Med (previously Primary Care Today) Planning Committee, Leslie Dan Faculty of Pharmacy, University of Toronto 2016 Co-founder, Dermatology Contest Award, La Roche-Posay & University of Waterloo School of Pharmacy 2016 Co-developer, Management of Fever using OTC antipyretics and Febrile Seizures, a customized antipyretic tool for ccaregivers on proper OTC antipyretic dosing; Pfizer 2016 Contributor, Health Literacy and Self-Care Initiative Grant/Award, Consumer Health Products Canada 2016 Participant, Code of Ethics (COE) Stakeholder Focus Group, Ontario College of Pharmacists 2016 Volunteer, Canadian Pillar of Pharmacy Awards Dinner 2013-2016 Faculty Contributor, Optimizing Patient Care (OPC) Project, Ontario College of Pharmacists and University of Toronto 2013-2015 Co-developer/Facilitator, Clinical Skills Training Program, Shoppers Drug Mart and University of Toronto Continuous Professional Development 2014 Spokesperson, Acetaminophen Awareness Campaign; Johnson & Johnson, https://www.getreliefresponsibly.ca/ 2013 Contributor, Infant Care & Nutrition Program, Ontario Pharmacists Association Page 228 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2012-2013 Contributor, Minor Ailment 2-Day CE Certificate Program, Ontario Pharmacists Association 2011 OSCE Assessor, Pharmacy Examining Board of Canada 2002-2006 Member, Constitution Committee, Albany College of Pharmacy 2002-2003 Member, Curriculum Committee, Albany College of Pharmacy f) GRADUATE SUPERVISIONS: masters, doctoral, postdoctoral - completed/in progress
None
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
UNDERGRADUATE SUPERVISIONS:
Name of Student Type (years of Title of Thesis or Project Status supervision) Areen Duqoum PharmD (2017- Frail is not (always) old – a Completed Co-supervisor: 2018) community pharmacy perspective Colleen Maxwell (PHARM 401) Melanie PharmD (2017- The Knowledge, Skills & Behaviours Completed Sanderson 2018) Associated with Pharmacists’ Co-supervisor: Assessment & Management of Tejal Patel Headaches in the Community (PHARM 401)
g) GRADUATE COURSES: None
UNDERGRADUATE COURSES: past 7 years, by year
University of Waterloo, School of Pharmacy
2018 PHARM 129 Professional Practice 1 (course coordinator, 75% instruction) PHARM 362 Advanced Patient Self-Care, Winter (course coordinator, 75% instruction) *significant revamp PHARM 127 Professional Communication Skills (presentation assessor, 28% instruction) PHARM 366 Concepts in Nutritional Sciences, Winter (8% instruction) PHARM 120 Introduction to the Profession of Pharmacy (4% instruction) PHARM 329 OSCE, Winter (OTC Case Lead & Assessor)
Page 229 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2017 PHARM 129 Professional Practice 1 (course coordinator, 78% instruction) PHARM 362 Advanced Patient Self-Care, Winter (course coordinator, 75% instruction) PHARM 127 Professional Communication Skills (presentation assessor, 28% instruction) PHARM 366 Concepts in Nutritional Sciences, Winter (8% instruction) PHARM 120 Introduction to the Profession of Pharmacy (4% instruction) PHARM 229 Professional Practice 4 (device counselling assessor for 1 lab) PHARM 329 OSCE, Winter (OTC Case Lead & Assessor) PHARM 362 Advanced Patient Self-Care, Spring (course coordinator, 67% instruction) PHARM 228 Professional Practice 3, Fall (nonprescription aisle case writer and reviewer) PHARM 228 OSCE, Fall (OTC Case Writer, Lead & Assessor) PHARM 330 OSCE, Fall (OTC Case Writer, Lead & Assessor) PHARM 472 Community Practice in a Changing Environment (course coordinator, 27.8% instruction)
2016 PHARM 129 Professional Practice 1 (course coordinator, 80% instruction) PHARM 362 Advanced Patient Self-Care, Winter (course coordinator, 75% instruction) PHARM 362 Advanced Patient Self-Care, Summer (course coordinator, 75% instruction) PHARM 472 Community Practice in a Changing Environment (course creator & coordinator) PHARM 228 Professional Practice 3 (nonprescription aisle - 85% instruction/assessment) PHARM 491 Seminars in Pharmacy 3, Winter (6% instruction) PHARM 491 Seminars in Pharmacy 3, Summer (6% instruction) PHARM 120 Introduction to the Profession of Pharmacy (4% instruction) PHARM 229 Professional Practice 4 (device counselling assessor, 4% assessment) PHARM 366 Concepts in Nutritional Sciences, Winter (8% instruction) PHARM 497 PharmD Bridging Program – Clinical Rotation Course, Fall (case assessor) OSCEs assessor
2015 PHARM 129 Professional Practice I (course coordinator, 70% instruction) PHARM 362 Advanced Patient Self-Care, Winter (course coordinator, 80% instruction) PHARM 491 Seminars in Pharmacy 3, Winter (6% instruction) PHARM 366 Concepts in Nutritional Sciences, Winter (8% instruction) PHARM 120 Introduction to the Profession of Pharmacy (4% instruction)
2014 PHARM 129 Professional Practice I (course coordinator, 80% instruction) PHARM 362 Advanced Patient Self-Care, Winter (course coordinator, 80% instruction) PHARM 362 Advanced Patient Self-Care, Spring (course coordinator, 80% instruction) PHARM 228 Professional Practice 3 (course coordinator, 100% instruction) Page 230 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
PHARM 127 Professional Communication Skills (16% instruction) PHARM 366 Concepts in Nutritional Sciences, Spring (8% instruction) PHARM 366 Concepts in Nutritional Sciences, Fall (8% instruction) PHARM 490 Seminars in Pharmacy 3, Winter (8% instruction) PHARM 490 Seminars in Pharmacy 3, Spring (8% instruction) PHARM 120 Introduction to the Profession of Pharmacy (4% instruction) PHARM 237 Application of Analyses and Devices in Pharmacy and Medicine (assessor) OSCEs assessor
2013 PHARM 129 Professional Practice I (course coordinator, 70% instruction) PHARM 362 Advanced Patient Self-Care, Winter (course coordinator, 80% instruction) PHARM 362 Advanced Patient Self-Care, Spring (course coordinator, 80% instruction) PHARM 131 Professional Practice I Lab (course coordinator, 100% instruction) PHARM 291 Seminars in Pharmacy 2 (course coordinator, 20% instruction) PHARM 491 Seminars in Pharmacy 3, Spring (8% instruction) PHARM 366 Concepts in Nutritional Sciences, Winter (8% instruction) PHARM 366 Concepts in Nutritional Sciences, Spring (8% instruction) PHARM 127 Professional Communication Skills (5% instruction) OSCEs assessor
2012 PHARM 129 Professional Practice I (course developer & coordinator, 60% instruction) PHARM 362 Advanced Patient Self-Care, Winter (course developer & coordinator, 60% instruction) PHARM 362 Advanced Patient Self-Care, Spring (co-coordinator, 50% instruction) PHARM 291 Seminars in Pharmacy 2 (course coordinator, 25% instruction) PHARM 131 Professional Practice Lab I (interim course coordinator, 100% instruction for nonRx Aisle & other activities) PHARM 229 Professional Practice Lab II (case-writing for nonRx Aisle activities) PHARM 491 Seminars in Pharmacy 3, Spring (8% instruction) PHARM 127 Professional Communication Skills (5% instruction) PHARM 130 Professional Practice II (4% instruction) PHARM 366 Concepts in Nutritional Sciences, Winter (2% instruction) OSCEs assessor
2011 PHARM 291 Seminars in Pharmacy 2, Fall (course coordinator, 8% instruction) PHARM 131 Professional Practice Lab I (case-writing for nonRx Aisle; course overhaul) PHARM 130 Professional Practice II (8% instruction) PHARM 366 Nutrition (8% instruction) Mini Pharmacy School (course co-coordinator, 0% instruction) Page 231 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
OSCEs assessor
2010 PHARM 291 Seminars in Pharmacy 2 (course coordinator, 16% instruction) PHARM 129 Professional Practice I (teaching assistant, 25% facilitation/assessment) PHARM 131 Professional Practice Lab I (teaching assistant, 100% instruction for nonRx Aisle) PHARM 229 Professional Practice Lab II (teaching assistant, 25% instruction) PHARM 130 Professional Practice II (instructor, 8% instruction) Mini Pharmacy School (course co-coordinator, 0% instruction) OSCEs assessor
University of Toronto, Leslie Dan Faculty of Pharmacy
2018 PharmD Program: PHM388H1 Minor Ailments, Winter (course coordinator, 85% instruction)
2017 PharmD Program: PHM388H1 Minor Ailments, Winter (course coordinator, 85% instruction) PharmD Program: PHM330H1 Preparation for Advanced Pharmacy Practice Experience (APPE), Winter (course coordinator, 35% instruction) CPD Program (custom for Apotex): Practice Essentials for Today’s Pharmacist: Enhancing Clinical Skills, September 2017 (academic lead, 50% development, 50% facilitation) CPD Program: Assessing & Treating Minor Ailments, April 29 (academic lead, 50% instruction) CPD Program: PHRED Talks, academic lead IPG Program: CPSII Onsite Ambulatory Conditions, Winter (course co-coordinator, 50% instruction) IPG Program: CPSII Online Ambulatory Conditions, Spring (course co-coordinator, 50% instruction) IPG Program: CPSII Onsite Ambulatory Conditions, Summer (course co-coordinator, 50% instruction)
2016 PharmD Program: PHM388H1 Minor Ailments, Winter (course coordinator, 85% instruction) PharmD Program: PHM400H1 Transition to Advanced Pharmacy Practice Experience (APPE), Spring (course coordinator, 35% instruction) CPD Program: Assessing & Treating Minor Ailments, October 22 (academic lead, 50% instruction) IPG Program: CPSII Self-Care Course, Winter (course co-coordinator, 30% instruction) IPG Program: CPSII Self-Care Course, Fall Online (course co-coordinator, 30% instruction) IPG Program: Demystifying the PEBC’s Class, April 25 (75% instruction)
Page 232 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2015 CPD Program: Assessing & Treating Minor Ailments, February 28 & October 24 (academic lead, course developer & coordinator, 50% instruction) CPD Program: SDM Clinical Skills Workshop (2 days/offerings, 50% instruction) IPG Program: CPSII Self-Care Course, Winter (10% instruction) IPG Program: CPSII Prof Practice Lab (PPL), Winter (course co-coordinator, 50% instruction) IPG Program: CPSII Online PPL, Winter (course co-coordinator, 50% instruction)
2014 CPD Program: SDM Clinical Skills Workshop (8 days/offerings, 50% instruction) IPG Program: CPSII PPL, Winter (course coordinator, 100% instruction) IPG Program: CPSII Self-Care, Winter (10% instruction) IPG Program: CPSI PPL, Spring (course coordinator, 100% instruction) IPG Program: CPSI PPL, Fall (course co-coordinator, 50% instruction) IPG Program: CPSII Self-Care, Summer (10% instruction) IPG Program: PEBC Review, September 19 (instructor, 50% instruction)
2013 CPD Program: SDM Clinical Skills Workshop (14 days/offerings, 50% instruction) IPG Program: CPSII Self-Care, Winter (10% instruction) IPG Program: CPSII PPL, Winter (course co-coordinator, 50% instruction) IPG Program: CPSI Online PPL, Winter (course co-coordinator, 50% instruction) IPG Program: CPSI PPL, Spring (course co-coordinator, 50% instruction) IPG Program: CPSII Online PPL, Spring (course co-coordinator, 50% instruction) IPG Program: CPSII Self-Care, Summer (10% instruction) IPG Program: CPSII PPL, Summer (course co-coordinator, 50% instruction) IPG Program: CPSI Online PPL, Summer (course co-coordinator, 50% instruction) IPG Program: CPSI PPL, Fall (course co-coordinator, 50% instruction) IPG Program: CPSII Online PPL, Fall (course co-coordinator, 50% instruction)
2012 IPG Program: CPSI Online PPL, Summer (course co-coordinator, 50% instruction) IPG Program: CPSI PPL, Fall (course co-coordinator, 50% instruction) IPG Program: CPSII Online PPL, Winter (course co-coordinator, 50% instruction) h) 1. EXTERNAL RESEARCH FUNDING: past 7 years only, by year, indicating source (granting councils, industry, government, foundations, other); amount; principal investigator; purpose (research, travel, publications, etc...)
Year Source Type* Amount Purpose** Investigator 2017- Johnson & O submitted Research N Nakhla Johnson/University of Page 233 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Waterloo School of Pharmacy National Smoking Cessation Program: Enhancing Clinical Skills
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING: This includes university funds, SSHRC minor grants awarded through the University, etc.] Year Source Type* Amount per year Purpose**
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS: The Publications should be listed in the categories shown below and include the following information: books authored, books edited (a list of the chapters contributed by the editor must follow each title), chapters in books (other than those listed in the above category), papers in refereed journals, papers in refereed conference proceedings, technical reports, abstracts and/or papers read, and others. Each title must show the names of the authors in the order in which they appear in the original publication and inclusive page numbers. Publications submitted, but not yet accepted, must be listed separately within the various categories.
1) Life-time summary (count) according to the following categories:
- books and monographs……………………………………………………………………………………………….. 0 - edited book and monographs……………………………………………………………………………………… 0 - chapters in books and monographs ……………………………………………………………………………….2 - refereed journal articles………………………………………………………………………………………………….0 - refereed conference proceedings………………………………………………………………………………….. 0 - presentations at conferences………………………………………………………………………………………… 0 - technical reports…………………………………………………………………………………………………………… 0 - invited/keynote addresses …………………………………………………………………………………………… 44 - others (workshops presented)……………………………………………………………………………………… 5
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Chapters Books and Monographs: Page 234 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1. Nakhla N. Chapter 720: Self-Care/ Over-the-counter drugs/ Minor Ailments in Pharmacy Practice. In: Encyclopedia of Pharmacy Practice and Clinical Pharmacy. 1st ed. Elsevier. (in progress). Submitted December 29, 2017.
2. Nakhla N. Pharmacist Assessment of the Self-Treating Patient. In: Jovaisas B. Compendium of Therapeutics for Minor Ailments. 2nd ed. Ottawa, ON: Canadian Pharmacists Association; 2016:20-25. Available online, published April 1, 2016.
Peer Reviewed Invited Articles:
1. Nakhla N. Navigating fad diets for weight loss. Pharmacy Practice + Business. 2018:5(1):43-44. Available online, published January 26, 2018.
2. Nakhla N. Managing Allergic Rhinitis. Pharmacy Practice + Business. 2017:4(8):34-35. Available online, published October 25, 2017.
3. Nakhla N. New standards for nonprescription health claims and labels. Pharmacy Practice Plus. 2017:3(4):41. Available online, published May 9, 2017.
4. Nakhla N. QuEST: a quick and effective approach to OTC counselling. Pharmacy Practice Plus. 2017:4(1):35-37. Available online, published February 28, 2017.
5. Armstrong D, Nakhla N. Non-prescription proton-pump inhibitors for self-treating frequent heartburn: the role of the Canadian pharmacist. Pharmacy Practice. 2016 Oct- Dec;14(4):868. doi:10.18549/PharmPract.2016.04.868. Available online, accepted November 29, 2016.
6. Nakhla N. Helping new parents manage colic. Pharmacy Practice Plus. 2016:3(8):27-28. Available online, published October 21, 2016. 7. Nakhla N. Cold Sores: Treat at first Tingle. Pharmacy Practice Plus. 2016:3(4):41. Available online, published May 20, 2016.
8. Nakhla N, Austin Z. Prescriber Notebook: A resource to support your professional development. Ontario College of Pharmacists Optimizing Patient Care (OPC) Program. 2016; 1-74. Available online, published April 29, 2016.
9. Nakhla N. OTC Case Study: Fever in Children. Pharmacy Practice Plus. 2016:3(1):29. Available online, published February 22, 2016.
10. Nakhla N. Managing Heartburn in the Community Setting. Pharmacy Practice Plus. 2015:2(9):35. Available online, published November 30, 2015. Page 235 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
11. Nakhla N. Prevention and Management of Early Childhood Caries. Pharmacy Practice Plus. 2015:2(6):33-34. Available online, published August 25, 2015.
12. Nakhla N. Managing Premenstrual Syndrome. Pharmacy Practice Plus. 2015:2(4):43-44. Available online, published May 29, 2015.
13. Baer P, Beland A, Lin P, Nakhla N, Stern S. Colloquium- OTC pain medication in the polypharmacy era: what primary care physicians need to know. The Medical Post (supplement). Published April 7, 2015.
14. Nakhla N. Common Myths with the Common Cold. Toronto Star (MediaPlanet supplement). Available online, published November 22, 2014.
15. Nakhla N. Managing Aphthous Ulcers. Pharmacy Practice Plus. 2014:1(10):97. Available online, published November 17, 2014.
16. Nakhla N. Managing Dysmenorrhea: Look beyond the obvious. Pharmacy Practice Plus. 2014:1(8):35-36. Available online, published September 17, 2014.
17. Nakhla N. Promoting SAFE Acetaminophen Use. Pharmacy Practice Plus. 2014:1(6):22. Available online, published July 18, 2014.
18. Nakhla N. Benzocaine and Babies: A potentially lethal mix. Pharmacy Practice Plus. 2014:1(4):47. Available online, published May 23, 2014.
19. Nakhla N. OTC ISSUES: Vaginal infection screening tests- a valuable tool when used correctly. Pharmacy Practice Plus. 2014:1(1):57-60. Available online, published February 18, 2014.
Abstracts/Research Presentations:
1. Nakhla N, Lillie E. Differentiating how therapeutic information is communicated to patients and practitioners. Abstract selected for poster presentation at 2018 Annual Association of Faculties of Pharmacy of Canada (AFPC) Conference. Quebec City, QC. June 2-6, 2018.
2. Killeen R, Nakhla N, Pantazi F. Enhancing eye care through interprofessional collaboration – A joint pharmacist/optometrist initiative. Abstract selected for poster presentation at 2018 Annual Association of Faculties of Pharmacy of Canada (AFPC) Conference. Quebec City, QC. June 2-6, 2018.
Page 236 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Nakhla N, Lillie E. Assessing communication of therapeutic knowledge to patients and clinicians across courses. Abstract selected for poster presentation at The University of Waterloo Teaching and Learning Conference. Waterloo, Ontario. April 26, 2018.
4. Nakhla N, Sanderson M, Patel T. Community Pharmacists’ Knowledge, Skills, and Attitudes in the Management of Headache. Abstract selected for poster presentation at 2018 College of Psychiatric & Neurologic Pharmacists (CPNP) Conference. Indianapolis, Indiana. April 22-25, 2018.
5. Lillie E, Nakhla N. Integrating Assignments Across Courses to Enhance Therapeutic Knowledge and Communication. Poster presented at 2018 Nonprescription Medicines Academy (NMA) Conference. Long Beach, California. February 22-25, 2018.
6. Killeen R, Nakhla N, Pantazi F. Enhancing eye care through interprofessional collaboration – A joint pharmacist/optometrist initiative. Abstract submitted for poster presentation at 2018 Life Long Learning (LLL) in Pharmacy Conference. Brisbane, Australia. Submitted: January 30, 2018.
7. Lillie E, Nakhla N. Integrating Assignments Across Courses to Enhance Therapeutic Knowledge and Communication. Poster presented at 2017 Annual Association of Faculties of Pharmacy of Canada (AFPC) Conference. Quebec City, QC. June 2-6, 2017. Available online.
8. Nakhla N, Orr K. OTC’s Across Borders: New Paradigms for OTC use in the United States. Poster presented at American Association of Colleges of Pharmacy (AACP) Interim Meeting. Tampa, Florida. February 19, 2016.
9. Nakhla N. Education Strategies to Improve Access to Non-Prescription Medications. Abstract accepted for oral presentation at 74th International Pharmacy Federation (FIP) World Congress of Pharmacy and Pharmaceutical Sciences 2014. Bangkok, Thailand. September 2, 2014.
10. Nakhla N. An EBSCR (evidence-based self-care research) Project to Improve Student Literature Evaluation and Therapeutic Application Skills. Podium presentation at Nonprescription Medicines Academy Annual Meeting.
11. Cincinnati, Ohio. September 28, 2013. Abstract published in AACP Self-Care Therapeutics/ Nonprescription Medicines Special Interest Group Newsletter. Available online, published February 4, 2014.
12. Nakhla N, DeMarco M. Teaching, learning and assessment using an evidence-based research project in an advanced pharmacy elective. Abstract selected for oral Page 237 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
presentation at The Opportunities and New Directions (OND) Conference, University of Waterloo’s Centre for Teaching Excellence. Waterloo, Ontario. May 1, 2014.
13. Nakhla N. Schedule II & III Drugs in Ontario: Understanding the Nuances of the Canadian Drug Scheduling System. Podium presentation at Nonprescription Medicines Academy Annual Meeting. Cincinnati, Ohio. September 29, 2012. Abstract published in AACP Self-Care Therapeutics/Nonprescription Medicines Special Interest Group Newsletter. Available online, published March 1, 2013.
14. Nakhla N. Improving Pharmacy Students’ Learning in Literature Evaluation and Therapeutic Application Skills with a Self-Care Elective on Nonprescription Drug EBM. Poster presented at Nonprescription Medicines Academy Annual Meeting. Cincinnati, Ohio. October 14, 2011. Abstract Published in Nonprescription Medicines Academy Website, Faculty Development Section, January 2012.
Papers in Refereed Journals:
Invited Presentations:
1. Nonprescription drug access across the border. Pharmacy Practice Course for The University of Rhode Island. Live Webinar. January 30, 2018.
2. The Changing Face of Pharmacy. Proctor & Gamble. North York, Ontario. July 21, 2017.
3. Self-Care for Upper Respiratory Tract Infections. Canadian Association of Pharmacy Students and Interns (CAPSI). Kitchener, Ontario. July 6, 2017.
4. Finding Your Niche in Pharmacy. Ontario Pharmacists Association 2017 Conference. London, Ontario. June 17, 2017.
5. The Great Debate: Should Natural Health Products Be Sold in Pharmacies? Canadian Pharmacists Association 2017 Conference. Quebec City, Quebec. June 4, 2017.
6. Infant Assessment, Care & Nutrition. Pri-Med Canada Inter-Professional Conference. Toronto, Ontario. May 11, 2017.
7. Minor Ailment Bootcamp. Pri-Med Canada Inter-Professional Conference. Toronto, Ontario. May 11, 2017.
8. Pharmacist’s Scope Across Canada. Johnson & Johnson. Toronto, Ontario. April 27, 2017.
Page 238 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
9. Billion Dollar Idea: Expanding Pharmacy Services. Panelist for this Economic Club of Canada + Canadian Pharmacist’s Association event. Toronto, Ontario. April 25, 2017.
10. Providing Infant Care in Community Practice. 2017 Walmart Canada Professional Services Conference. Toronto, Ontario. April 1, 2017.
11. Pediatric JEOPARDY Event. Pharmacy Pediatric Initiative (PPI) Club. Toronto, Ontario. March 13, 2017.
12. A Two Billion Dollar Gut Check: Assessing the Value of Over-the-Counter Medicines to Canadian Healthcare. Panelist for this Consumer Health Products Canada & Economic Club of Canada event. Ottawa, Ontario. March 9, 2017.
13. My Journey as a Professor. Women in Science Society: Cheers to Science! Event. Waterloo, Ontario. February 9, 2017.
14. OTC’s Across Borders. Pharmacy Practice Course for The University of Rhode Island. Live Webinar. January 31, 2017.
15. OTC Jeopardy - Kids. UW Paediatrics Pharmacy Advocacy Group. Kitchener, Ontario. November 16, 2016.
16. A refresher on women’s reproductive health. 2016 Self-Care Symposium: providing pharmacy staff with research-based information on common OTC- and NHP-related issues. Toronto, Ontario. November 6, 2016.
17. Managing Allergies, Cough and Cold in Children. Canadian Association of Pharmacy Students and Interns (CAPSI). Kitchener, Ontario. July 6, 2016.
18. Infant Care: Fever, Teething, Nutrition & Colic. Ontario Pharmacists Association 2016 Conference. Toronto, Ontario. June 10, 2016.
19. Schedule II & III Drugs in Canada. Pharmacy Practice Course for the University of Rhode Island. Live Webinar. February 4, 2016.
20. Women’s Health: Vaginal Health Matters. 2015 Self-Care Symposium: A one-day live CE event to help pharmacists counsel on common OTC and NHP-related issues. Toronto, Ontario. November 8, 2015.
21. Understanding the Canadian Drug Scheduling System. Pharmacy Practice Course for the University of Rhode Island. Live Webinar. January 29, 2015.
Page 239 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
22. Update on Allergies, Cough and Cold in Children. 2014 Self-Care Symposium: A one-day live CE event to help pharmacists counsel on common OTC and NHP-related issues. Toronto, Ontario. November 9, 2014.
23. Management of Upper Respiratory Tract Infections. Canadian Association of Pharmacy Students and Interns (CAPSI). Kitchener, Ontario. June 23, 2014.
24. Vaginal Health: Differential Diagnosis of Vaginitis in Primary Care. Primary Care Today Inter-professional Annual Conference. Toronto, Ontario. May 8, 2014.
25. Schedule II ‘BTC’ drugs and Rx to OTC switches in Canada. Pharmacy Practice Course for the University of Rhode Island. Live Webinar. April 8, 2014.
26. Thinking outside the library: being embedded in a professional practice lab. The Super Conference, Ontario Library Association (OLA). Toronto, Ontario. January 31, 2014.
27. Vaginal Care, Infant Care, Oral Care. Ontario Pharmacists Association - Minor Ailments Continuing Education Certificate Program. Toronto, Ontario. December 14, 2013.
28. Infant Care, Vaginal Care, Oral Care. Ontario Pharmacists Association - Minor Ailments Continuing Education Certificate Program. London, Ontario. August 17-18, 2013.
29. Infant Care and Nutrition. Ontario Pharmacists Association - Online (Webinar) Infant Care Continuing Education Certificate Program. Toronto, Ontario. April 15, 2013.
30. Cough & Cold in Special Populations. Canadian Association of Pharmacy Students and Interns (CAPSI)- OTC Week. Kitchener, Ontario. July 16, 2012.
31. Vaginal Care, Infant Care, Oral Care. Ontario Pharmacists Association - Minor Ailments Continuing Education Certificate Program. Toronto, Ontario. April 13-14, 2012.
Workshops / Presentations Presented:
1. The Women in Health Care Leadership Panel: SOAPE (Students Optimizing and Advocating for Pharmacy Endeavours) Event for PAM 2018. University of Toronto. March 26, 2018.
2. Skills Lab SIG: University of Waterloo – Professional Practice Series. AFPC. March 6, 2018.
Page 240 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. HIPED by PharMed: Information Gathering/History Taking. McMaster Michael G. DeGroote School of Medicine + University of Waterloo School of Pharmacy. May 25, 2017.
4. Primary Care Today Inter-professional Conference. University of Toronto & Diversified. May 8-10, 2014.
5. 2013 Self-Care Symposium: An Accredited Live CE Event for Pharmacists. University of Toronto Leslie Dan Faculty of Pharmacy + Drugstore Canada. November 3, 2013.
DATE: May 1 2018
Page 241 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
PATEL, Tejal Assistant Clinical Professor, tenure-track Member of the Graduate Faculty: yes b) DEGREES:
PhrmD, University of Kentucky College of Pharmacy, Lexington, Kentucky, U.S., 1997 BScPhm, University of Kentucky College of Pharmacy, Lexington, Kentucky, U.S., 1996 c) EMPLOYMENT HISTORY:
2017- Assistant Clinical Professor (Part-time), Michael G. DeGroote School of Medicine, McMaster University 2014- Assistant Clinical Professor, University of Waterloo School of Pharmacy 2011-2017 Assistant Clinical Professor (Adjunct), Michael G. DeGroote School of Medicine, McMaster University 2011- Tutor, Evidence Based Medicine, Kitchener-Waterloo Site, Department of Family Medicine Residency Program, Michael G. DeGroote School of Medicine, McMaster University 2009- Clinical Pharmacy Specialist (Memory Clinic), The Centre for Family Medicine Family Health Team 2012-2014 Consultant Pharmacist (Mobility Clinic), The Centre for Family Medicine Family Health Team 2010-2014 Clinical Pharmacy Specialist (Neurology Clinic), The Centre for Family Medicine Family Health Team 2009-2014 Adjunct Clinical Assistant Professor, University of Waterloo School of Pharmacy 2008-2009 Clinical Pharmacy Specialist, Leader – Education & Academic Affairs, Pharmacy Department, St. Michael’s Hospital 2003-2007 Clinical Pharmacy Specialist, Neurosciences, Regina Qu’Appelle Health Region 2005-2006 Sessional Lecturer, College of Pharmacy and Nutrition, University of Saskatchewan 2000-2002 Clinical Associate, Department of Pharmacy, University of Illinois at Chicago College of Pharmacy 1999-2000 Clinical Pharmacy Specialist, Drug Information/Evaluation, Pharmacy Department, St. Michael’s Hospital 1997-1999 Research Pharmacist, Pharmacy Department and Health Sciences Research Center, St. Michael’s Hospital d) HONOURS:
Page 242 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2017 CAUCE Program Awards, Non-credit Programming under 48 Hours, Canadian Agency for University Continuing Education, British Columbia (Team award) 2016 Patient Care Achievement Award in Specialty Practice, Canadian Pharmacists Association 2013 Inter-professional Preceptor of the Year, KW and Area Family Medicine Residency Program, McMaster University 1997 Most Valuable Player, St. Michael’s Hospital e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2017 Journal Reviewer, Pharmacy 2017 Journal Reviewer, Archives of Physical Medicine and Rehabilitation 2017 Journal Reviewer, BMC Pharmacology and Toxicology 2017 Member, Graduate Studies and Research Committee 2015 Journal Reviewer, BMC Health Services Research 2015- Member, Parkinson Medical Advisory Council, Parkinson Society Canada 2015- Member, Steering Committee, Network for Aging Research, University of Waterloo 2011- Member, Admissions Committee, University of Waterloo School of Pharmacy 2011-2012 Member, Adjunct Faculty Task Force, University of Waterloo School of Pharmacy 2007-2009 Member, Stroke Prevention (TIA) Task Group, Canadian Stroke Strategy 2007-2009 Member, Acute Stoke Care Task Group, Canadian Stroke Strategy 2007-2009 Member, Best Practices Working Group, Canadian Stroke Network f) GRADUATE SUPERVISIONS:
Completed: 3 MSc, 0 PhD In Progress: 0 MSc, 0 PhD
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Haya Fernandez MSc, 2015-2017 Investigating the impact of vitamin D Complete supplementation on bone health in women with epilepsy Hamed Tabeefer MSc, 2015-2016 Chronic Pain Management by Complete Community Pharmacists: A Qualitative Analysis. Co-Supervision with Dr. Feng Chang Page 243 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Mo Chen MSc, 2015-2016 Chronic Pain Management by Complete Community Pharmacists: Phase II. Co- Supervision with Dr. Feng Chang
g) GRADUATE COURSES:
2018 Pharm 610: Topics in Drug Development h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2018 Women’s College O $15,000 Research Principal Research Institute Investigator: Tejal Patel 2018 Centre for Aging O $50,000 Research Principal and Brain Health Investigator: Innovation Tejal Patel 2017 Craig H. Neilson F $US 197,778 Research Principal Foundation Investigator: sara Guilcher 2016 Health Quality G $499,304 Research Principal Ontario Investigator: Linda Lee 2015 Canadian F $27,900 Research Principal Foundation of Investigator: Pharmacy Tejal Patel
2015 Women’s College O $14,906 Research Principal Research Institute Investigator: Tejal Patel 2015 Anti-Drug Strategy G $720,330/2years Research Principal Initiatives Investigator: Feng Chang 2014 AHRQ through O $11,260 Research Principal INSPIRE-PHC Investigator: Program Linda Lee 2014 College of Family O $9,972 Research Principal Physicians Janus Investigator: Research Grant Linda Lee 2014 Bruyere Research O $34,594 Research Principal
Page 244 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Institute Growth Investigator: Fund Grant Barbara Farrell
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2016 Waterloo Institute $9,950 Research of Complexity and Innovation 2015 University of O $10,000 Research Principal Waterloo Chronic Investigator: Tejal Disease Prevention Patel Initiative 2014 McMaster O $5,000 Research Principal University Health Investigator: Sciences Linda Lee Department of Family Medicine Pilot Research Project 2014 AHRQ through O $13,514.20 Research Principal Ontario Pharmacists Investigator: Research Linda Lee Collaboration (OPEN) 2010 McMaster O $5,000 Research Principal University Health Investigator: Sciences Linda Lee Department of Family Medicine Pilot Research Project 2009 University of O $14,194 Research Principal Waterloo Learning Investigator: Tejal Initiatives Fund Patel
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc.
Page 245 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
Books and monographs ...... 3 Edited book and monographs ...... 0 Chapters in books and monographs ...... 2 Referred journal articles ...... 24 Presentations at conferences ...... 96 Technical reports ...... 0 Invited/keynote addresses ...... 1 Others (workshops presented) ...... 0
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Conference Proceedings
1. Farooqi M, Carter C and Patel T. Electronic medication adherence technologies – Classification to guide use in older adults. Can Pharm J 2017; 150: S26.
2. Tabeefar H, Chang F and Patel T. Pharmacist experiences with providing care for patients with chronic pain in the community setting: A qualitative study. Can Pharm J 2017; 150: S67.
3. Chang F, Mohammed HT, Kluz A, Patel T, Killeen R. Opioid Education Partnership: Pilot test results for an interdisciplinary education initiative targeting prescription opioid misuse. Can Pain J 2017: 1: A50.
4. Fernandez H, Cooke M, Patel T. Behaviours beneficial to bone health among adults with and without epilepsy. Pharmacotherapy 2017:37: e52
5. Hu CD, Farooqi M, Patel S, Bauer J, Lee L, Schill C and Patel T. Polypharmacy and high risk medication use among frail elderly in primary care. Can Geriatrics J 2017; 20: 163
6. Lee J, Chen A, Locklin J, Lee L and Patel T. Is there an optimal cut-off MoCA score that can be used as an indicator of dementia? A systematic review. Can Geriatrics J 2017;20: 223
7. McDermott M, Patel T, Lee L and Slonim K. Recruitment for dementia-related research in primary care: barriers and facilitators. Can Geriatrics J 2017; 20: 224
Page 246 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
8. Pandey A, Suskin N, Patel T and Choudhry N. Lower educational levels may be an important determinant of adherence to evidence-based therapies in post-MI patients. J of Amer College of Cardio 2017; 11 (Suppl): 1847.
9. Pandey AK, Patel T, Suskin N and Choudhry N. Education as a determinant of adherence to pharmacological and lifestyle interventions post-myocardial infarction. Can J of Cardiology 2016; 32 (Suppl 1): S158.
10. Pandey AK, Patel T, Suskin N and Choudhry N. The impact of text message reminders on adherence to exercise and medications stratified by education. Circulation 2016; 134 (Suppl 1): A18266.
11. Patel T, Bauer J, Lee L and Schill C. Pharmacist intervention for a frail elderly population in primary care. Canadian Pharm J 2016; 149: S27.
12. Patel T, Chang F, Mohammed HT, Lyon J. Expectations and needs assessment of women with epilepsy: community pharmacist assistance with antiepileptic medications (work in progress). J. Pharm Prac 2016; 29: 307.
13. Cheng R, Yang YD, Patel T. Medication incidents involving antiepileptic drugs in Canadian hospitals: a multi-incident analysis. J. Pharm Prac 2016; 29: 282.
14. Fernandez H and Patel T. Lifestyle behaviours related to bone health in adults with epilepsy (work in progress). J. Pharm Prac 2016; 29: 314.
15. Fernandez H and Patel T. Vitamin D and bone health in adults with epilepsy: a systematic review (work in progress). J. Pharm Prac 2016; 29: 328.
16. Vuong V, Lee L and Patel T. Pharmacist interventions in an interdisciplinary Memory Clinic: a retrospective chart review (work in progress). J. Pharm Prac 2016; 29: 319.
17. Lee L, Molnar F, Hillier LM, Patel T, Slonim K. Collaborative dementia care in primary care: how collaborative is it? Can Geriatr J 2016; 19: 147
18. Patel T, Chang F, Khan A, Raman-Wilms L, Jurcic J, Coulston B and Sproule B. Survey of community pharmacists: Knowledge, perceptions and practice related to chronic pain. Can Pharm J 2015; 148: S46
19. Khan A, Vuong V, Iftikhar N, Patel T and Chang F. Implementation of programs and services by community pharmacists: Barriers, facilitators and operational requirements. Can Pharm J 2015; 148: S45
Page 247 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
20. Chang F, Khan A, Wong K and Patel T. Emerging chronic disease prevention or management programs by community pharmacists: A systematic review. Can Pharm J 2015; 148: S44
21. Dolovich L, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K and Waite N. Barriers and facilitators to implementing an evaluation framework for pharmacy services. Can Pharm J 2015; 148: S28
22. Dolovich L, Babaei-Rad R, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T and Slonim K. Evaluation of pharmacy services: Capturing the patient perspective. Can Pharm J 2015; 148: S13
23. Patel T, Klie M, Milligan J and Lee FJ. Medication-related problems among spinal cord injury patients at a primary care based interdisciplinary clinic. J Spinal Cord Med 2014; 37: 5.
24. Patel T, Lee L, Rojas-Fernandez C and Meginnis H. Application of screening criteria to determine need for pharmacist intervention in a frail elderly population in primary care. Can J Hosp Pharm 2014; 67: 317.
25. Lee M, Patel T and Lee L. Non-pharmacological outpatient interventions for benzodiazepine discontinuation in elderly persons: a systematic review. Can Family Physician 2014; 61: S55.
26. Dolovich L, Slonim K, MacKeigan L, Patel T, Waite N, Chang F and Farrell B. Capturing the perspectives of academics, policy makers, physicians and pharmacists about the evaluation of pharmacy services. Can Pharm J 2014; 147: S27.
27. Chang F, Khan A, Patel T, Grindrod K, Chen K, Milic A, Aoki K, Mercer K and Sproule B. Chronic pain stakeholder engagement workshop. Can Pharm J 2014;147: S11.
28. Patel T, Lillie E, Roberts-Smith J and Waite N. Investigating the effectiveness of drama as an engagement learning methodology in an integrated therapeutics course. Am J Pharma Education 2012; 76 (5): 68.
29. Semchuk W, Martinson A, Evans C, Blackburn D, Zimmerman R, Patel T. Impact of a collaborative care model in a Medication-Optimization Program, the Saskatchewan Medication Assessment for Risk Reduction Target Therapies (SMART2) Program: A prospective, randomized, controlled study. Can J Cardiol 2011; 27: 216 – 217.
30. Rojas-Fernandez CH, Patel T, Lee L. A novel practice setting for pharmacists: practicing in an interdisciplinary, family health team based Memory Clinic. Can Pharm J 2011; 144: e42
Page 248 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
31. Patel T, Rojas-Fernandez C, Mikhail M, Lee L. Optimising medications in older people with cognitive impairment presenting to a family health team based Memory Clinic. Can J Hosp Pharm 2011; 64: 68.
Papers in Refereed Journals
1. Foong AI, Patel T, Kellar J, Grindrod K. The scoop on serotonin syndrome. Can Pharm J. In press.
2. Foong AI, Patel T, Kellar J, Grindrod K. Demystifying serotonin syndrome. Can Fam Physician. In press.
3. Lee L, Patel T, Molnar F, Seitz D. Optimizing medications in cognitively impaired older adults: considerations for primary care clinicians. Can Fam Physician. In press.
4. Fernandez H, Mohammed H, Patel T. Vitamin D supplementation for bone health in adults with epilepsy: A systematic review. Epilepsia 2018; 00: 1 - 12. DOI: https://doi.org/10.1111/epi.14015
5. Cheng R, Yang YD, Chan M and Patel T. Medication incidents involving antiepileptic drugs in Canadian hospitals: A multi-incident analysis. Healthcare Quarterly 2017; 20: 54 - 62.
6. Pandey A, Krumme A, Patel T and Choudhry N. The impact of text messaging on medication adherence and exercise among post-myocardial infarction patients. JMIR mHealth and uHealth 2017; 5 (8): e110 (p1-10). DOI: https://doi.org/10.2196/mhealth.7144
7. Lee L, Patel T, Hillier L, Maulkhan N, Slonim K and Costa A. Identifying frailty in primary care: A systematic review. Geriatr & Gerontol Int. 2017; 17: 1358 - 1377. DOI: https://doi.org/10.1111/ggi.12955
8. Patel T, Slonim K, Lee L. Use of potentially inappropriate medications among ambulatory home-dwelling elderly patients with dementia: A review of the literature. Can Pharm J 2017; 150: 169 – 183. DOI: https://doi.org/10.1177/1715163517701770
9. Maximos M, Chang F, Patel T. Risk of falls associated with antiepileptic drug use in ambulatory elderly population: A systematic review. Can Pharm J 2017; 150: 101 – 111. DOI: https://doi.org/10.1177/1715163517690744
10. Duong S, Patel T, Chang F. Dementia: What pharmacists need to know. Can Pharm J 2017; 150: 118 – 129. DOI: https://doi.org/10.1177/1715163517690745
Page 249 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
11. Lee L, Patel T, Costa A, Bryce E, Hillier LM, Slonim K, Hunter SW, Heckman G, Molnar FJ. Accuracy of gait speed and handgrip strength as a screen for frailty in primary care. Can Fam Physician 2017; 63: e51 – e57.
12. Patel T, Milligan J and Lee FJ. Medication problems in individuals with spinal cord injury in a primary care-based clinic. J of Spinal Cord Med 2017; 40: 54 - 61. DOI: 10.1179/2045772315Y.0000000055
13. Lee L, Patel T, Hillier L, Milligan J. Office-based case finding for chronic obstructive pulmonary disease in older adults in primary care. Can Respiratory J 2016; article ID 1083270. DOI: https://doi.org/10.1155/2016/1083270
14. Patel T, Chang F, Mohammed HT, Raman-Wilms L, Jurcic J, Khan A, Sproule B. Knowledge, perceptions and attitudes toward chronic pain and its management: A cross-sectional survey of frontline pharmacists in Ontario, Canada. PLoS One 2016; 11 (6): e0157151. DOI: https://doi.org/10.1371/journal.pone.0157151
15. Chang F, Patel T, and Schulz ME. The “Rising Tide” of dementia in Canada: what does it mean for pharmacists and the people they care for? Can Pharm J 2015; 148: 193 – 199.
16. Patel T and Chang F. Assessment and management of patients with Parkinson’s disease by community pharmacists. Can Pharm J 2015; 148: 142 – 149.
17. Bauman CA, Milligan JD, Patel T, Pritchard S, Labreche T, Dillon-Martin S, Ilich A and Riva JJ. Community-based falls prevention: lessons from an interprofessional Mobility Clinic. J Can Chiropr Assoc 2014; 58: 300 – 311.
18. Patel T and Chang F. Parkinson’s disease guidelines for pharmacists. Can Pharm J 2014; 147: 161 – 170.
19. Rojas-Fernandez C, Patel T and Lee L. An interdisciplinary memory clinic: a novel practice setting for pharmacists in primary care in Ontario, Canada. Ann Pharmacother 2014; 48; 785 - 795.
20. Seymour N, Patel T and Dixon H. Worsening of myasthenia gravis following the addition of gabapentin for essential tremor. J Pharm Technology 2013; 29: 191 - 3.
21. Lee J, Alfieri M, Patel T and Lee L. Choosing family medicine residency programs: what factors influence residents’ decisions? Can Fam Physician 2011; 57: e113 – 21.
Podium Presentations
Page 250 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1. Lee L and Patel T. Beyond cognitive enhancers: Practical tips to optimize medications for persons with dementia in primary care. Memory Clinic Booster Days. Cambridge, Ontario., September 22, and October 01, 2017; London, Ontario, September 25, 2017; Ottawa, Ontario, October 5, 2017; Thunder Bay, Ontario, October 13, 2017; Keene, Ontario, October 16, 2017; Sudbury, Ontario, October 18, 2017 2. Canadian Congress on Dementia, Toronto, Ontario. November 4, 2017.Annual Scientific Assembly, Ontario College of Family Physicians, Toronto, Ontario. November 24, 2017
3. Patel T. Women and Epilepsy. Epilepsy South Central Ontario Retreat. Brantford, Ontario. September 16, 2017
4. Patel T. Pharmacist activities in neurological disorders.* Parkinson Canada Building Your Healthcare Team. Kitchener, Ontario. June 12, 2017
5. Lee L and Patel T. Managing complexity in advanced brain disease. 2017 Update in Geriatrics for Primary Care! Beyond the Guidelines: Managing Complexity in Advanced Disease. Ottawa, Ontario. June 2, 2017
6. Patel T. Medication use by the older adult: Practical tips for deprescribing inappropriate and unnecessary medications.* Pri-Med Conference. Toronto, Ontario. May 12, 2017
7. Patel T. Treatment of Parkinson’s disease with medications: which, when, how and why.* Parkinson’s Medication and You Symposium. Parkinson Canada, Montreal, Quebec. April 26, 2017. Keynote Address.
8. Patel T. Dopaminergic agents for the treatment of Parkinson’s disease.* Memory Clinic Booster Day, London, Ontario. October 3, 2016. Cambridge, Ontario. Memory Clinic Booster Day, October 12, 2016.
9. Patel T. The older adult and capacity to manage medications.* Pharmacy Learning and Leadership Symposium. 16th Annual Summer Conference, London, Ontario. August 17, 2016.
10. Patel T, Donaldson L, Lee L, Bauer J and Schill C. Development and implementation of a pharmacist intervention for frail elderly patients in an interdisciplinary primary care team: a qualitative analysis. Canadian Pharmacists Conference 2016, Calgary, Alberta.
11. Chang F, Chen M and Patel T. Effectiveness of a community-based pharmacist intervention in chronic non-cancer pain: a systematic review. Canadian Pharmacists Conference 2016, Calgary, Alberta. June 26, 2016.
Page 251 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
12. Patel T. The management of Parkinson’s disease. Integrated Health Professionals Meeting. Centre for Family Medicine, Kitchener, Ontario. February 2010
13. Patel T. History of epilepsy Mini-Pharmacy School, University of Waterloo School of Pharmacy, Kitchener, Ontario. October 2009
14. Patel T. What can pharmacists do to optimize the care of stroke patients? – A best practices primer. Professional Practice Conference, Canadian Society of Hospital Pharmacists, Toronto, Ontario. February 2009
Poster Presentations (Underlined names indicate presenters)
1. Guilcher SJT, Lofters A, Calzavara A, Hogan ME, Hitzig SL, Packer T and Patel T. Examination of prescription drug use following a traumatic spinal cord injury using Ontario administrative health data. 7th National Spinal Cord Injury Conference, Niagara Falls, Ontario. November 9 – 11, 2017. Award: 1st Prize in Knowledge Generation
2. Cadel L, De Luca C, Hitzig SL, Packer T, Lofters A, Patel T and Guilcher SJT. Self-management of pain and depression in adults with spinal cord injury: a scoping review. 7th National Spinal Cord Injury Conference, Niagara Falls, Ontario. November 9 – 11, 2017.
3. Farooqi M, Carter C and Patel T. Electronic medication adherence technologies – Classification to guide use in older adults. Canadian Pharmacists Conference 2017, Quebec City, Quebec. June 4, 2017.
4. Tabeefar H, Chang F and Patel T. Pharmacist experiences with providing care for patients with chronic pain in the community setting: A qualitative study. Canadian Pharmacists Conference 2017, Quebec City, Quebec. June 4, 2017.
5. Chang F, Mohammed HT, Kluz A, Patel T, Killeen R. Opioid Education Partnership: Pilot test results for an interdisciplinary education initiative targeting prescription opioid misuse. Canadian Pain Society Annual Scientific Meeting 2017, Halifax, Nova Scotia. May 24, 2017.
6. Fernandez H, Cooke M, Patel T. Behaviours beneficial to bone health among adults with and without epilepsy. American College of Clinical Pharmacy Virtual Symposium, May 17 – 18, 2017. Abstract: Pharmacotherapy 2017:37: e52
7. Hu CD, Farooqi M, Patel S, Bauer J, Lee L, Schill C and Patel T. Polypharmacy and high risk medication use among frail elderly in primary care. Canadian Frailty Network Conference 2017, Toronto, Ontario. April 23 – 24, 2017.
Page 252 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
8. Lee J, Chen A, Locklin J, Lee L and Patel T. Is there an optimal cut-off MoCA score that can be used as an indicator of dementia? A systematic review. 2017 Canadian Geriatrics Society’s Annual Scientific Meeting, Toronto, Ontario. April 20 – 22, 2017.
9. McDermott M, Patel T, Lee L and Slonim K. Recruitment for dementia-related research in primary care: barriers and facilitators. 2017 Canadian Geriatrics Society’s Annual Scientific Meeting, Toronto, Ontario. April 20 – 22, 2017.
10. Pandey A, Suskin N, Patel T and Choudhry N. Lower educational levels may be an important determinant of adherence to evidence-based therapies in post-MI patients. American Cardiology Conference 17: 66th Annual Scientific Session and Expo. Washington, District of Columbia. March 17 – 19, 2017. 11. Pandey AK, Patel T, Suskin N and Choudhry N. Education as a determinant of adherence to pharmacological and lifestyle interventions post-myocardial infarction. Canadian Cardiovascular Congress 2016: 69th Annual Meeting of the Canadian Cardiovascular Society, Montreal, Quebec. October 22 – 26, 2016.
12. Pandey AK, Patel T, Suskin N and Choudhry N. The impact of text message reminders on adherence to exercise and medications stratified by education. American Health Association’s 2016 Scientic Sessions and Resuscitation Science Symposium, New Orleans, Louisiana. November 12 – 16, 2016.
13. Patel T, Bauer J, Lee L and Schill C. Pharmacist intervention for a frail elderly population in primary care. Canadian Pharmacists Conference, Calgary, Alberta. June 24 – 25, 2016.
14. Lee L, Maulkhan N, Staples C, Hillier L, Slonim K, Aiken S, Patel T. Challenges in recruitment of persons with dementia for a study on hearing aids and cognition: lessons learned. 2016 Trillium Primary Health Care Research Day, Toronto, Ontario. June 1, 2016.
15. Chang F, Sproule B, Patel T, Jurcic J, Raman-Wilms L. Opioid management in chronic pain by pharmacists providing care in the community settings in Ontario. Canadian Pain Society 37th Annual Scientific Program, Vancouver, British Columbia. May 24 – 27, 2016.
16. Chang F, Patel T, Kluz A, Kileen R. Opioid education partnership: pharmacists as collaborators in reducing prescription opioid misuse. Canadian Pain Society 37th Annual Scientific Program, Vancouver, British Columbia. May 24 – 27, 2016.
17. Chang F, Chen M, Kulkarni T, Patel T. Effectiveness of community-based pharmacist interventions in chronic non-cancer pain: a systematic review. Canadian Pain Society 37th Annual Scientific Program, Vancouver, British Columbia. May 24 – 27, 2016.
Page 253 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
18. Patel T, Hasan S, MacFarlane T, Chang F. Handling of controlled substances in hospices in Ontario: a cross-sectional survey. Canadian Association for Health Services and Policy Research Conference 2016, Toronto, Ontario. May 9, 2016.
19. Patel T, Hu CD, Farooqi M, Chang F, Mohammed HT, Lyon L. Expectations and needs assessment of women with epilepsy: community pharmacist assistance with antiepileptic medications. Women’s Xchange Spring 2016 Event, Women’s College Hospital. May 6, 2016. Video presentation.
20. Patel T, Chang F, Mohammed HT, Lyon J. Expectations and needs assessment of women with epilepsy: community pharmacist assistance with antiepileptic medications (work in progress). College of Psychiatric and Neurologic Pharmacists Annual Meeting 2016, Colorado Springs, Colorado, US. April 18, 2016.
21. Cheng R, Yang YD, Patel T. Medication incidents involving antiepileptic drugs in Canadian hospitals: a multi-incident analysis. College of Psychiatric and Neurologic Pharmacists Annual Meeting 2016, Colorado Springs, Colorado, US. April 18, 2016.
22. Fernandez H and Patel T. Lifestyle behaviours related to bone health in adults with epilepsy (work in progress). College of Psychiatric and Neurologic Pharmacists Annual Meeting 2016, Colorado Springs, Colorado, US. April 18, 2016.
23. Fernandez H and Patel T. Vitamin D and bone health in adults with epilepsy: a systematic review (work in progress). College of Psychiatric and Neurologic Pharmacists Annual Meeting 2016, Colorado Springs, Colorado, US. April 18, 2016.
24. Vuong V, Lee L and Patel T. Pharmacist interventions in an interdisciplinary Memory Clinic: a retrospective chart review (work in progress). College of Psychiatric and Neurologic Pharmacists Annual Meeting 2016, Colorado Springs, Colorado, US. April 18, 2016.
25. Lee L, Molnar F, Hillier LM, Patel T, Slonim K. Collaborative dementia care in primary care: how collaborative is it? 36th Annual Meeting of the Canadian Geriatrics Society, Vancouver, British Columbia. April 15 – 16, 2016.
26. Sproule B, Chang F, Patel T, Jurcic J, Raman-Wilms L. Opioid management in chronic pain by pharmacists providing care in the community settings in Ontario. OPEN Summit, Toronto, Ontario. January 20, 2016.
27. Chang F, Patel T, Kluz A, Kileen R. Opioid education partnership: pharmacists as collaborators in reducing prescription opioid misuse. OPEN Summit, Toronto, Ontario. January 20, 2016.
Page 254 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
28. Thompson W, Farrell B, Black C, Archibald D, Weaver L, Raman-Wilms L, Patel T, Grassau P, Eid K, Winslade N. Team management of polypharmacy in older persons: a modified Delphi approach. Annual Meeting of the North American Primary Care Research Group, Cancun, Mexico. October 27, 2015.
29. Khan A, Vuong V, Iftikhar N, Patel T and Chang F. Implementation of programs and services by community pharmacists: barriers, facilitators and operational requirements (review). Canadian Pharmacists Conference, Ottawa, Ontario. May 28 – 31, 2015.
30. Chang F, Khan A, Wong K and Patel T. Emerging chronic disease prevention or management programs by community pharmacists: A systematic review. Canadian Pharmacists Conference, Ottawa, Ontario. May 28 - 31 2015. OPEN Summit, Toronto, Ontario. October 7 – 8, 2014.
31. Patel T, Chang F, Khan A, Raman-Wilms L, Jurcic J, Coulston B and Sproule B. Survey of community pharmacists: Knowledge, perceptions and practice related to chronic pain. Canadian Pharmacists Conference, Ottawa, Ontario. May 28 - 31 2015.
32. Dolovich L, Babaei-Rad R, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T and Slonim K. Evaluation of pharmacy services: Capturing the patient perspective. Canadian Pharmacists Conference, Ottawa, Ontario. May 28 – 31, 2015.
33. Dolovich L, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K and Waite N. Barriers and facilitators to implementing an evaluation framework for pharmacy services. Canadian Pharmacists Conference, Ottawa, Ontario May 28 - 31 2015.
34. Chan A, Lee L, Slonim K, and Patel T. Behavioural and psychological symptoms of dementia in a primary care Memory Clinic. 34th Annual Ontario Gerontology Association Conference, Toronto, Ontario. April 22, 2015.
35. Patel T, Klie M, Milligan J and Lee FJ. Medication-related problems among spinal cord injury patients at a primary care based interdisciplinary clinic. 6th Annual Spinal Cord Injury Conference, Toronto, Ontario. October 3, 2014.
36. Patel T, Lee L, Rojas-Fernandez C and Meginnis H. Application of screening criteria to determine need for pharmacist intervention in a frail elderly population in primary care. Summer Educational Sessions Meeting of the Canadian Society of Hospital Pharmacists, St. John’s Newfoundland. August 10, 2014. Invited Facilitated Presentation.
Page 255 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
37. Lee M, Patel T and Lee L. Non-pharmacological outpatient interventions for benzodiazepine discontinuation in elderly persons: a systematic review. Family Medicine Forum, College of Physicians and Surgeons, Quebec City, Quebec.
38. Maximos M and Patel T. Risk of falls associated with anticonvulsant use in the ambulatory elderly population: a systematic review. First Annual Waterloo-Wellington Clinical Research and Quality Improvement Symposium, Kitchener, Ontario. June 2014.
39. Dolovich L, Slonim K, MacKeigan L, Patel T, Waite N, Chang F and Farrell B. Capturing the perspectives of academics, policy makers, physicians and pharmacists about the evaluation of pharmacy services. Canadian Pharmacists Conference, Saskatoon, Saskatchewan. May 31 – June 3 2014.
40. Chang F, Khan A, Patel T, Grindrod K, Chen K, Milic A, Aoki K, Mercer K and Sproule B. Chronic pain stakeholder engagement workshop. Canadian Pharmacists Conference, Saskatoon, Saskatchewan. May 31 – June 3 2014.
41. Okuka J and Patel T. Achievement and maintenance of therapeutic stability of warfarin therapy in persons with cognitive impairment or dementia. The Banff Seminar. Canadian Society of Hospital Pharmacists, Banff, Alberta. March 2013.
42. Patel T, Lee L, Narayan A, MacMillan C, Dillon-Martin S. Outreach screening for medication safety concerns among elderly marginalized population. Family Medicine Forum, Toronto, Ontario. November 16, 2012.
43. Patel T, Lillie E, Roberts-Smith J and Waite N. Investigating the effectiveness of drama as an engagement learning methodology in an integrated therapeutics course. American Academy of Colleges of Pharmacy, Kissimmee, Florida. July 16, 2012.
44. Semchuk W, Martinson A, Evans C, Blackburn D, Zimmerman R, Patel T. Impact of a collaborative care model in a Medication-Optimization Program, the Saskatchewan Medication Assessment for Risk Reduction Target Therapies (SMART2) Program: A prospective, randomized, controlled study. Canadian Cardiovascular Congress, Victoria, British Columbia. October 24, 2011.
45. Patel T, Lee L, McMillan C. Change in attitude and perspective among health care learners in a pilot inter-professional model in a primary care Memory Clinic. Canadian Pharmacy Education and Research Conference/Association of Faculties of Pharmacy Annual Conference, Winnipeg, Manitoba. June 2011.
Page 256 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
46. Rojas-Fernandez CH, Patel T, Lee L. A novel practice setting for pharmacists: practicing in an interdisciplinary, family health team based Memory Clinic. Canadian Pharmacist’s Association Conference 2011, Montreal, Quebec. May 2011.
47. Patel T, Rojas-Fernandez C, Mikhail M, Lee L. Optimising medications in older people with cognitive impairment presenting to a family health team based Memory Clinic. Professional Practice Conference, Canadian Society of Hospital Pharmacist, Toronto, Ontario. January 2011.
Date: April 5, 2018
Page 257 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
NEKKAR, Praveen Rao Associate Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
PhD Pharmaceutical Sciences, University of Alberta, 2004 MPharm, Pharmaceutical Sciences, University of Mangalore, 1998 BPharm, Pharmaceutical Sciences, University of Mangalore, 1995 c) EMPLOYMENT HISTORY:
2017- Associate Professor & Graduate Officer, School of Pharmacy, University of Waterloo 2015- Associate Professor, School of Pharmacy, University of Waterloo 2008- Cross Appointed Faculty, Department of Chemistry, University of Waterloo 2008- Cross Appointed Faculty, Department of Biology, University of Waterloo 2008-14 Assistant Professor, School of Pharmacy, University of Waterloo 2005-06 Research Scientist, NAEJA Pharmaceuticals, Edmonton, Canada 2006-08 Postdoctoral Research Associate, Department of Chemistry, The Scripps Research Institute, La Jolla, USA 2004-2005 Postdoctoral Research Associate, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, Canada d) HONOURS:
2015 Dean’s Reception, Faculty of Science, University of Waterloo 2015 Media Event, University of Waterloo e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2017- Member, Editorial Board, Heliyon, Elsevier Publishers 2017- Guest Editor, Molecules – Special Issue 2017 Reviewer, Canada Research Chairs (CRC) Program, Government of Canada 2012- Member, Editorial Board, Open Journal of Medicinal Chemistry 2011- Member, Editorial Board, ISRN Pharmaceutics 2011-2014 Member, Editorial Board, Journal of Pain Research Page 258 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011-2017 Member, Awards Committee, AFPC 2012-2016 Member, Curriculum Committee, School of Pharmacy, University of Waterloo 2013-14 Co-Chair, Health and Safety Committee, School of Pharmacy, University of Waterloo 2011-2014 Chair, Course Evaluation Task Force, School of Pharmacy, University of Waterloo 2015- Member, Graduate Studies and Research Committee, School of Pharmacy, University of Waterloo 2012- Grant Reviewer, Alzheimer's Association, USA 2014 Grant Reviewer, ISTP, Federal Government, Canada 2013, 2015 Grant Reviewer, Government of Chile 2012 Grant Reviewer, MRC, United Kingdom f) GRADUATE SUPERVISIONS:
Completed: 7 MSc, 1 Ph.D. In progress: 2 MSc, 1 Ph.D.
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Alanna McEneny (MSc), 2013-2015 Metabolism, transport, and Completed (Co-supervision) physiologically based pharmacokinetic modeling of novel tacrine derivatives Gary Tin (MSc), 2012-2014 Design, synthesis and biological Completed evaluation of novel tricyclics as dual cholinesterase and amyloid aggregation inhibitors with antioxidant properties Karan Teckwani (MSc), 2011-2014 Synthesis of multiply deuterated Completed (Co-supervision) cephalosporin
Wesseem Osman (MSc), 2011-2013 Design, synthesis and evaluation of Completed tacrine-based agents to treat Alzheimer’s disease Tarek Mohamed (MSc), 2009-2011 Design, synthesis and biological Completed evaluation of 2,4-disubstituted pyrimidine derivatives: Page 259 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
multifunctional candidates as potential treatment options for Alzheimer’s disease Arash Shakeri (MSc), 2014-2016 Novel adamantane derivatives as Completed dual beta-amyloid and tau- aggregation inhibitors Sarbjeet Singh (MSc), 2015-2017 3-Phenylpyrazino[1,2-a]indol-1(2H)- Completed Gujral ones as dual cholinesterase and amyloid aggregation inhibitors Jonathan Sutley (MSc), 2016-2018 Phenoselenazines as disease- In Progress modifying agents to treat Alzheimer’s disease Tarek Mohamed (PhD), 2011-2016 Development and Biological Completed Evaluation of Novel Quinazoline Derivatives: A Multi-targeted Approach for the Treatment of Alzheimer’s Disease Amna El Shatshat (MSc), 2017- Novel approaches to study protein In Progress aggregation Amy Pham (PhD), 2016- Design, synthesis and evaluation of In Progress novel class of agents to study protein aggregation g) GRADUATE COURSES: past 7 years, by year
PHARM 607: Advanced Pharmaceutical Analysis (instructor and coordinator) PHARM 608: Special Topics in Pharmaceutical Science (instructor and coordinator) PHARM 610: Topics in Drug Development (instructor) h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2015-20 Early Researcher Award G $30,000 Research Principal Ministry of Research investigator: P. and Innovation Nekkar Rao Award 2014- NSERC-Discovery C $41,000 Research Principal 2019 Federal Government investigator: P. Nekkar Rao 2018 NSERC-Engage C $33,000 Research Principal investigator: P.
Page 260 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Nekkar Rao 2017 NSERC-Engage C $31,300 Research Principal investigator: P. Nekkar Rao 2015-16 JELF-CFI Canada O $26,800 Research Principal Foundation for investigator: P. Innovation Nekkar Rao 2015-16 ORF Ministry of O $26,800 Research Principal Research investigator: P. and Innovation Nekkar Rao
2014 Mitcas, Canada C $15,000 Research Principal investigator: P. Nekkar Rao 2012-14 JELF-CFI Canada O $75,252 Research Principal Foundation for investigator: P. Innovation Nekkar Rao
2012-14 ORF Ministry of O $75,252 Research Principal Research investigator: P. and Innovation Nekkar Rao
2013-16 IOF Canada Foundation O $22,576 Research Principal for Innovation investigator: P. Nekkar Rao 2014- NSERC-RTI Federal O $51,188 Research Principal 2015 Government investigator: Dr. Lyndon Jones 2012- NSERC-RTI Federal O $150,000 Research Principal 2013 Government investigator: Dr. Honek
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2018-2019 Bordeaux-Waterloo O $25,000 Reserach Principal Grant, Universities of investigator: P.
Page 261 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Bordeaux & Waterloo Nekkar Rao
2016 UW-RIF, CIHR O $8,000 Reserach Principal investigator: P. Nekkar Rao 2016 UW Network of Aging O $10,000 Research Principal Research investigator: P. Nekkar Rao 2013-15 UW-RIF NSERC O $15,000 Research Principal investigator: P. Nekkar Rao 2008-14 UW S $50,000 Research Principal investigator: P. Nekkar Rao 2010-11 UW-RIF CIHR O $8,000 Research Principal investigator: P. Nekkar Rao 2010-11 UW-International O $10,000 Travel Principal investigator: P. Nekkar Rao 2010-12 UW-VP Funds O $24,000 Research Principal investigator: P. Nekkar Rao
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 1 - refereed journal articles ...... 79 - refereed conference proceedings...... 68 - presentations at conferences ...... 40 - technical reports ...... 3 - invited/keynote addresses ...... 10 - others (workshops presented) ...... 0
Page 262 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Books Authored:
NA
Books Edited:
NA
Chapters in Books:
1. Praveen P. N. Rao., Deguo Du. In silico strategies to design, small molecules to study beta- amyloid aggregation. In: Roy K. (eds) Computational Modeling of Drugs Against Alzheimer's Disease. Neuromethods, Vol 132. Humana Press, New York, 2018.
Papers in refereed Journals:
40. Tarek Mohamed., Sarbjeet Singh Gujral., Praveen P. N. Rao. Tau derived hexapeptide AcPHF6 promotes beta-amyloid (Aβ) fibrillogenesis. ACS Chemical Neuroscience 2018, DOI: 10.1021/acschemneuro.7b00433.
41. Tarek Mohamed., Mandeep Mann., Praveen P. N. Rao., Application of quinazoline and pyrido[3,2-d]pyrimidine templates to design multi-targeting agents in Alzheimer’s disease. RSC Advances 7:22360-22368, 2017.
42. Alanna McEneny-King., Andrea N. Edginton., Praveen P. N. Rao. Cytochrome P450 binding studies of novel tacrine derivatives: predicting the risk of hepatotoxicity. Bioorganic and Medicinal Chemistry Letters 27:2443-2449, 2017.
43. Tarek Mohamed., Praveen P. N. Rao., 2,4-Disubstituted quinazolines as amyloid-beta aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies. European Journal of Medicinal Chemistry 126:823-843, 2017.
44. Courtney Matthew., Chen Xiaoming., Chan Sarah., Tarek Mohamed., Praveen P. N. Rao., Carolyn Ren. A droplet microfluidic system with on-demand trapping and releasing of droplet for drug screening applications. Analytical Chemistry 89:910-915, 2017.
Page 263 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
45. Muslim, A. A., Ayyash D., Sarbjeet Singh Gujral., Mekhail, G. M., Praveen P. N. Rao., Shawn D. Wettig. Synthesis and characterization of asymmetrical gemini surfactants. Physical Chemistry Chemical Physics 19:1953, 2017.
46. Tiago Silva., Tarek Mohamed., Arash Shakeri., Praveen P. N. Rao., Loreto Martinez-Gonzalez., Daniel I. Perez., Ana Martinez., Maria Joao Valente., Jorge Garrido., Eugenico Uriarte., Paula Serrao., Patricia Soares da Silva., Fernando Remiao., Fernanda Borges. Development of blood-brain barrier permeable nitrocatechol-based catechol-O-methyltransferase inhibitors with reduced potential for hepatotoxicity Journal of Medicinal Chemistry 59:7584-7597, 2016.
47. Wesseem Osman., Tarek Mohamed., Victor, M. S., Vasefi M. S., Beazely, M. A., Praveen P. N. Rao. Structure-activity relationship studies of benzyl, phenethyl and pyridyl substituted tetrahydroacridin-9-amines as multi-targeting agents to treat Alzheimer's disease. Chemical Biology and Drug Design 88:710-723, 2016.
48. Tarek Mohamed., Arash Shakeri., Praveen P. N. Rao. Structure-activity relationship studies of isomeric 2,4-diaminoquinazolines on β-amyloid aggregation kinetics. ACS Medicinal Chemistry Letters 7:502-507, 2016 (Cover Page article).
49. Tarek Mohamed., Arash Shakeri., Praveen P. N. Rao. Amyloid cascade in Alzheimer's disease: recent advances in Medicinal Chemistry. European Journal of Medicinal Chemistry 113:258- 272, 2016.
50. Tarek Mohamed, Praveen P. N. Rao., Facile approaches toward the synthesis of N4- monosubstituted quinazolin-2,4-diamines. Tetrahedron Letters 56: 6882-6885, 2015.
51. Angeles Ramirez-Cisneros M, Berenice Aguilar-Guadarrama A, Praveen P. N. Rao, Rodriguez- Lopez V, Yolanda Rios M. In vitro COX-1 and COX-2 enzyme inhibitory activities of iridoids from Penstemon barbatus, Castilleja tenuiflora, Cresentia alata and Vitex mollis. Bioorganic and Medicinal Chemistry Letters 25:4505-4508, 2015.
52. Tin G, Mohamed T, Gondora N, Beazely M. A. Praveen P. N. Rao. Tricyclic phenothiazine and phenoselenazine derivatives as potential multi-targeting agents to treat Alzheimer’s disease. Medicinal Chemistry Communications 6:1930-1941, 2015 (Cover Page article).
53. Liu H, Ojha B, Morris C, Jiang M, Wojcikiewicz E. P, Praveen P. N. Rao., Du D. Positively charged chitosan and N-trimethylchitosan inhibit Aβ40 fibrillogenesis. Biomacromolecules 16, 2363-2373, 2015. 54. Xian-Le Bu, Praveen P. N. Rao., Yan-Jiang Wang. Anti-amyloid aggregation activity of natural compounds: Implications for Alzheimer's drug discovery. Molecular Neurobiology 53:3565- 3575, 2015. Page 264 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
55. Praveen P. N. Rao., Tarek Mohamed, Karan Teckwani, Gary Tin. Curcumin binding to beta- amyloid: A computational study. Chemical Biology and Drug Design 86: 813-820, 2015.
56. Alanna McEneny-King, Andrea N. Edginton, Praveen P. N. Rao. Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. Bioorganic and Medicinal Chemistry Letters 25, 297-301: 2015.
57. Vannini F, Chattopadhyay M, Kodela R, Praveen P. N. Rao., Khosrow, K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biology 6, 318-325: 2015.
58. Mostafa Y. A, Kralt B, Praveen P. N. Rao, Taylor S. D. A-ring substituted 17β-arylsulfonamides of 17β-aminoestra-1,3,5(10)-trien-3-ol as highly potent reversible inhibitors of steroid sulfatase. Bioorganic and Medicinal Chemistry 23: 5681-5692, 2015.
59. Tarek Mohamed, Abdeljalil Assoud, Praveen P. N. Rao. N-benzyl-2-chloroquinazoline-4- amine. Acta Crystallographica Section E, E70: o554, 2014.
60. Tarek Mohamed, Tuan Hoang, Masoud Jelokhani-Niaraki, Praveen P. N. Rao. Tau-derived- hexapeptide 306VQIVYK311 aggregation inhibitors: Nitrocatechol moiety as a pharmacophore in drug design. ACS Chemical Neuroscience 4: 1559-1570, 2013.
61. Ojha B, Liu H, Dutta S, Praveen P. N. Rao. Wojcikiewicz E. P, Du D. Poly(4-styrenesulfonate) as an inhibitor of Aβ40 amyloid fibril formation. Journal of Physical Chemistry B 117: 13975- 13984, 2013.
62. Tarek Mohamed, Wesseem Osman, Gary Tin, Praveen P. N. Rao. Selective inhibition of human acetylcholinesterase by xanthine derivatives: In vitro inhibition and molecular modeling investigations. Bioorganic and Medicinal Chemistry Letters 23: 4336-4341, 2013.
63. Ravinder Kodela, Mitali Chattopadhyay, Satindra Goswami, Zong, Yuan Gan, Praveen P N Rao, Kamran V Nia, Carlos A. Velázquez-Martínez, Khosrow Kashfi. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: Differences in mode of cyclooxygenase inhibition. Journal of Pharmacology and Experimental Therapeutics 345: 85- 94, 2013.
64. Praveen P N Rao., Tarek Mohamed, Wesseem Osman. Investigating the binding interactions of galantamine with β-amyloid peptide. Bioorganic and Medicinal Chemistry Letters 23: 239- 243, 2013.
Page 265 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
65. Tarek Mohamed, Jacky C K Yeung, Maryam S Vasefi, Michael A Beazely, Praveen P N Rao. Development and evaluation of multifunctional agents for potential treatment of Alzheimer's Disease: Application to a pyrimidine-2,4-diamine template. Bioorganic and Medicinal Chemistry Letters 22: 4707-4712, 2012.
66. Keriman Özadalı, Fügen Özkanlı, Sarthak Jain, Praveen P N Rao. Carlos A. Velázquez-Martínez Synthesis and biological evaluation of isoxazolo[4,5-d]pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents. Bioorganic and Medicinal Chemistry 20: 2912-2922, 2012.
67. Tarek Mohamed, Praveen P N Rao. Alzheimer’s disease:Emerging trends in small molecule therapies. Current Medicinal Chemistry 18: 4299-4320, 2011.
68. Praveen P N Rao., Tarek Mohamed. Current and emerging at-site pain medications: A review. Journal of Pain Research 4: 279-286, 2011.
69. Rahim, M. R., Praveen P N Rao., Bhardwaj, A., Kaur, J., Huang, Z., Edward E. Knaus. Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors. Bioorganic and Medicinal Chemistry Letters 21: 6074-6080, 2011.
70. Tarek Mohamed, Jacky C K Yeung, Praveen P N Rao. Development of 2-substituted-N- (naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and A- aggregation inhibitors: synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters 21:5881-5887, 2011.
71. Tarek Mohamed, Zhao X, Habib L K, Yang J, Praveen P N Rao. Design, synthesis and evaluation of 2,4-disubstituted pyrimidines derivatives: dual activity as cholinesterase and A-aggregation inhibitors. Bioorganic and Medicinal Chemistry 19: 2269-2281, 2011.
Papers in Refereed Conference Proceedings
1. Praveen P N Rao, Tarek Mohamed, Arash Shakeri. Interactions of quinazoline derivatives with beta-amyloid. Biophysical Society 62nd Annual Meeting, San Francisco, USA 2018.
2. Praveen P N Rao, Quinazoline scaffolds are pharmacological tools to study amyloid aggregation. 100th Canadian Chemistry Conference and Exhibition (CSC-2017), Toronto 2017 (oral presentation).
3. Jonathan K. L. Sutley, Praveen P N Rao. Investigating the effects of levothyroxine and liothyronine on beta-amyloid aggregation. Alzheimer’s Association International Conference (AAIC 2017), London, United Kingdom 2017.
Page 266 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
4. Selina Manji, Praveen P N Rao. Evaluation of oxicam derivatives as amyloid aggregation inhibitors. Association of Faculties of Pharmacy of Canada and Canadian Pharmacists Conference (AFPC-CPERC/CPC 2017), Quebec City, Canada 2017.
5. Praveen P N Rao, Kinetics of tau-hexapeptide promoted β-amyloid fibrillogenesis. American Chemical Society (ACS) Regional meeting (NERM-2016), Binghamton, New York, USA 2016 (oral presentation).
6. Praveen P N Rao, Tarek Mohamed, Arash Shakeri. Designing small molecules as pharmacological tools to study Alzheimer's disease. Alzheimer’s Association International Conference (AAIC 2016), Toronto, Canada 2016.
7. Arash Shakeri, Praveen P N Rao. Evaluation of novel adamantane derivatives as potential dual inhibitors of amyloid beta and tau aggregation. Alzheimer’s Association International Conference (AAIC 2016), Toronto, Canada 2016.
8. Tarek Mohamed, Praveen P N Rao. Rational-based design and development of quinazoline- based small-molecules: multi-targeting potential for Alzheimeric pathologies. Alzheimer’s Association International Conference (AAIC 2016), Toronto, Canada 2016.
9. Praveen P N Rao, Jonathan K. L. Sutley. Design, synthesis, and evaluation of novel phenoselenazine (PSZ) based tricyclic compounds as potential agents to treat Alzheimer’s disease. Alzheimer’s Association International Conference (AAIC 2016), Toronto, Canada 2016.
10. Sarbjeet Singh Gujral, Praveen P N Rao. Tricyclic indole-based compounds in the prevention of Alzheimer’s disease. Alzheimer’s Association International Conference (AAIC 2016), Toronto, Canada 2016.
11. Rota, S. G., Spagnuolo, P. A., Angka, L., Doxey, A., Praveen P N Rao, Minden, M. D. Estrogen receptor beta is a novel target in acute myeloid leukemia. American Society of Hematology, 57th Annual Meeting & Exposition, Orlando, FL, USA 2015.
12. Alanna McEneny, Andrea N Edginton, Praveen P N Rao. CYP1A2 binding studies of novel tacrine derivatives. Association of Faculties of Pharmacy of Canada (CSPS-AFPC 2015), Toronto, Canada 2015.
13. Alanna McEneny, Andrea N Edginton, Praveen P N. Rao. CYP1A2 binding studies of novel tacrine derivatives. Laurier Protein Science Symposium, Wilfrid Laurier University, Waterloo, Canada 2015.
Page 267 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
14. Gary T, Mohamed T, Praveen P N Rao. Design, synthesis and biological evaluation of novel phenothiazines: dual cholinesterase, amyloid aggregation inhibitors with antioxidant properties. 97th Canadian Chemistry Conference and Exhibition (CSC 2014), Quebec, Canada 2014.
15. Alanna McEneny, Andrea N Edginton, Praveen P N. Rao. Chemical structure modification of tacrine and its effect on CYP1A2 binding: in vitro and in silico investigations. Canadian Alzheimer’s Disease Research Symposium, Quebec City, Quebec. 2014.
16. Mohamed T, Praveen P N Rao, Rational design and development of small bioactive molecules for the multi-targeted approach to Alzheimer’s pathology. 13th International Geneva symposium on advances in Alzheimer's therapy, Geneva, Switzerland 2014.
17. Praveen P N Rao, Mohamed T, Osman W. Fused bicyclic and tricyclic rings as bioactive ring scaffolds: Potential application to treat Alzheimer’s disease. 96th Canadian Chemistry Conference and Exhibition (CSC 2013), Quebec, Canada 2013.
18. Osman W, Zhou W, Sit V. M, Mohamed T, Praveen P N Rao. Design, synthesis and biological evaluation of novel fused-ring systems to treat Alzheimer’s disease. Association of Faculties of Pharmacy of Canada (AFPC-CPERC 2013), Niagara-on-the-Lake, Canada 2013 (Best poster award).
19. Mohamed T, Praveen P N Rao, Rational-based design of multi-targeted small molecules for the treatment of Alzheimer’s disease. Alzheimer’s Drug Discovery Foundation (ADDF 2013), San Francisco, USA 2013.
20. Osman W, Sit V. M, Mohamed T, Praveen P N Rao. Acridine derivatives as multi-target therapies for treatment of neurodegenerative disease. Alzheimer’sDrug Discovery Foundation (ADDF 2013), San Francisco, USA 2013.
21. Praveen P N Rao, Mohamed T, Deguo Du, Hijazi, A. Alzheimer's Disease: Small molecules as disease-modifying agents. Alzheimer’s Association International Conference (AAIC 2012), Vancouver, Canada 2012.
22. Mohamed T, Praveen P N Rao, Targeting Alzheimeric pathologies with small molecules: A multi-targeted approach. Alzheimer’s Association International Conference (AAIC 2012), Vancouver, Canada 2012.
23. Osman W, Zhou W, Sit V. M, Mohamed T, Praveen P N Rao. Design, synthesis and biological evaluation of novel fused-ring systems to treat Alzheimer’s disease. Alzheimer’s Association International Conference (AAIC 2012), Vancouver, Canada 2012.
Page 268 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
24. ldawsari, F., Chattopadhyay, M, Yoo, J., Praveen P N Rao, Medina-Franco, J., Kashfi, K., Velazquez-Martinez, C. A. Design, synthesis, and biological evaluation of resveratrol analogues as anti-inflammatory and potential chemopreventive agents (poster presentation). Cancer Research Conference 2012, Alberta Cancer Foundation, Banff, Alberta, 2012.
25. Praveen P N Rao., Mohamed T, Yeung C. K, Yang J. Rational design and evaluation of substituted-pyrimidines as dual cholinesterase and amyloid aggregation inhibitors. The 243rd American Chemical Society National Meeting (ACS 2012), San Diego, USA 2012.
26. Praveen P N Rao., Mohamed T, Yeung C. K, Zhao X, Habib L, Yang J.Development of 2,4- disubstituted pyrimidine ring templates: dual cholinesterase and amyloid-βinhibitors. The 94th Canadian Chemistry Conference and Exhibition (CSC 2011), Montreal, Canada 2011.
27. Tarek Mohamed, Yeung, C. K, Zhao X, Habib L, Yang Y, Praveen P N Rao. Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: Multi-functional small molecules for the potential treatment of Alzheimer’s disease. Association of Faculties of Pharmacy of Canada (AFPC 2011), Winnipeg, Canada 2011 (Best poster award).
28. Fahad A, Chattopadhyay M, Yoo J, Praveen P N Rao., Medina-Franco J, Kashfi K,Velázquez, C. Design, synthesis and biological evaluation of resveratrol analogues as anti-inflammatory and potential chemopreventive agents. Research Day, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada 2011 (Best poster award).
Invited Oral Presentations
1. Praveen P N Rao, Small molecule design and development: application to Alzheimer’s disease. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto 2017.
2. Praveen P N Rao. Alzheimer’s disease and amyloid cascade hypothesis. Manipal College of Pharmaceutical Sciences, Manipal, India, Aug 27th, 2015.
3. Praveen P N Rao. Targeting beta amyloid using small and large molecules. Laurier Protein Science Symposium, Waterloo, Canada, May 29th, 2015.
4. Praveen P N Rao. Alzheimer’s disease: A medicinal chemistry approach. School of Pharmacy, Seminar series, University of Waterloo, Kitchener, March 25th, 2015.
5. Praveen P N Rao. Discovering novel pharmacophores with anti-tau aggregation properties. Target Meeting 3rd World Neuroscience Online conference, Houston, June 17-19, 2014. Page 269 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
6. Praveen P N Rao, Novel molecules for treatment of atherosclerosis. Biotransfer 2014, National Research Council, 6th edition, Toronto, March 18, Canada 2014.
7. Praveen P N Rao. The role of Medicinal Chemistry in Canadian Pharmacy Curriculum. Association of Faculties of Pharmacy of Canada (AFPC-CPERC 2013), Niagara-on-the-Lake, Canada 2013 (oral presentation).
8. Praveen P N Rao, Multifunctional tacrine derivatives as potential agents to treat Alzheimer's disease. Target Meeting 2nd World Neuroscience Online conference, Houston, June 18-20, USA 2013.
9. Praveen P N Rao, Drug Discovery: Alzheimer’s Disease, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India 2012.
10. Praveen P N Rao, Developing novel molecules as disease-modifying agents to treat Alzheimer’s disease. Target Meeting 1st World Neuroscience Online conference, Houston, June 14-16, USA 2012.
11. Praveen P N Rao, My research in Medicinal Chemistry, Department of Biology, University of Waterloo, Waterloo, Dec 5th , Canada 2010.
DATE: April 2018
Page 270 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
RICHARD, Cynthia Clinical Lecturer, Teaching Fellow; definite term Member of the Graduate Faculty: yes b) DEGREES:
PhD, Dalhousie University, Pharmacology, 2006 BScPh, Dalhousie University, Pharmacy, 2001 c) EMPLOYMENT HISTORY:
2013- Clinical Lecturer, School of Pharmacy, University of Waterloo 2009-2013 Adjunct Clinical Assistant Professor, School of Pharmacy, University of Waterloo 2007-2009 Sessional Lecturer, Human Health and Nutritional Sciences, University of Guelph 2001-2004 Relief Pharmacist, Lawtons Drugs d) HONOURS:
2017 Student Support Recognition Award, School of Pharmacy, University of Waterloo 2017 AFPC/PEBC Award for Excellence in Research or Innovation in Assessment of Competence (awarded to UW Assessment Committee, of which I am a member) 2012 Excellence in Science Teaching Award, University of Waterloo 2011 Student Support Recognition Award, School of Pharmacy, University of Waterloo e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2018- FAUW appointee, University of Waterloo Complementary Teaching Assessment Project Team (CTAPT) 2017- Chair, Chair, Canadian Pharmacy Education and Research Conference (CPERC) 2018 Working Group 2017- Vice Chair, Association of Faculties of Pharmacy of Canada (AFPC) Council of Faculty 2016- Chair, Association of Faculties of Pharmacy of Canada (AFPC) Skills Lab SIG 2016- Member, Southwest Academic Health Network (SWAHN) Nutrition Working Group 2011- Chief Administrator, Pharmacy Examining Board of Canada Qualifying Examination, Part II (OSCE), Kitchener-Waterloo
Page 271 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2012-2013 Conference program planning co-chair, 2013 Canadian Pharmacy Education and Research Conference, Association of Faculties of Pharmacy of Canada, Niagara-on-the-Lake f) GRADUATE SUPERVISIONS:
N/A g) GRADUATE COURSES:
N/A h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2009 CIHR C $11,035 Meetings Principal dissemination plannings investigator: NM Waite
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2017 UW LITE SEED C $5,000 Research PI: J Nagge grant 2016 UW LITE SEED O $4963 Research PI: C. Richard grant i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 1 - refereed journal articles ...... 14 - refereed conference proceedings...... 31 - presentations at conferences ...... 9 - technical reports ...... 0 - invited/keynote addresses ...... 0 Page 272 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
- others (workshops presented) ...... 0
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Chapters in Books:
1. Richard CL, Spagnuolo P. Complementary and Alternative Therapies. Compendium of Therapeutics for Minor Ailments, 2nd edition (CTMA 2). Appendix I, p. 1242-1261. Canadian Pharmacists Association. 2016.
Submitted: Richard CL. Overview of herbal supplements and natural remedies. Essential Guide for Renal Dietitians. Canadian Association of Nephrology Dietitians.
Papers in Refereed Journals:
1. Richard CL, Lillie E, Mathias K, McFarlane T. Peer review of teaching in a Canadian pharmacy school: attitudes and impact on teaching practice. American Journal of Pharmaceutical Education 2018; accepted and published online in draft form. 2. Nagge J, Lee-Poy MF, Richard CL Evaluation of a unique interprofessional education program involving medical and pharmacy students. American Journal of Pharmacy Education 2017; 81: Article 6140. 3. Cutler MJ, Lowthers EL, Richard CL, Hajducek DM, Spagnuolo PA, Blay J. Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4- negative cells and increasing peptidase CD26.BMC Cancer 2015 Nov10; 15:882. 4. Monk JM, Richard CL, Woodward B. A non-inflammatory form of immune competence prevails in acute pre-pubescent malnutrition: new evidence based on critical mRNA transcripts in the mouse. British Journal of Nutrition 2011 Sep 27:1-5.
Abstracts
1. Richard C, Lillie E, Mathias K, Power M, McFarlane T. Peer review of teaching: can it motivate instructors to make changes to teaching? Accepted for oral presentation at University of Waterloo Teaching and Learning Conference 2018. April 2018. Waterloo, ON, Canada.
2. Nagge J, Houle S, Killeen R, Richard C, Lippens M. Measuring the value of including experiential opportunities as part of a blended learning continuing professional development program for prospective providers of anticoagulation services. Accepted,
Page 273 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
University of Waterloo Teaching and Learning Conference 2018. April 2018. Waterloo, ON, Canada.
3. Kennie-Kaulbach N, Richard C, Charrois T, Cassidy J, Jorgenson D. Survey of skills lab courses for pharmacy programs in Canada. Accepted for oral presentation at Canadian Pharmacy Education and Reference (CPERC) 2018. June 2018. Ottawa, Canada.
4. Richard CL, Lillie E, Mathias K, McFarlane T, Power M. Does peer review of teaching impact teaching practice and perceptions in pharmacy? Canadian Pharmacy Education and Reference (CPERC) 2017. June 2017. Quebec City, Canada.
5. Richard CL, Rigby AH, Edginton AN. Establishment of a 2nd year midpoint assessment to identify students for remediation. Canadian Pharmacy Education and Reference (CPERC) 2016. June 2016. Richmond, BC, Canada
6. Richard C, Rigby A, Edginton A. 2nd year midpoint assessment to identify students for remediation. Oral presentation at University of Waterloo Teaching and Learning Conference Opportunities and New Directions 2016. April 2016. Waterloo, ON, Canada.
7. Lille E, Nagge J, Richard C, Waite N. A prescription for success: creating a safe environment for curricular innovation. Oral presentation at University of Waterloo Teaching and Learning Conference Opportunities and New Directions 2016. April 2016. Waterloo, ON, Canada. Richard C, Spagnuolo P. Nutrition education in the PharmD curriculum at the University of Waterloo school of Pharmacy. Breaking Bread with SWAHN: Nutrition Research and Innovation Symposium. April 2015. London ON, Canada. Oral presentation.
8. Schneider EF, Richard CL, Lillie E. Performance-based assessment using Objective Structured Clinical Exams (OSCEs) at the University of Waterloo School of Pharmacy. AACP/AFPC Annual Meeting 2015. July 2015. National Harbor, MD, United States. Poster presentation.
9. Schneider EF, Richard CL, Lillie E. Performance of a high-stakes OSCE at a Canadian pharmacy school. AACP/AFPC Annual Meeting 2015. July 2015. National Harbor, MD, United States. Poster presentation.
10. Schneider E, Lillie E, Richard C. What have pharmacy students learned? An Objective Structured Clinical Exam (OSCE) for measurement of skill application in real time. University of Waterloo Teaching and Learning Conference Opportunities and New Directions 2015. April 2015. Waterloo, ON, Canada. Oral presentation.
Page 274 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
11. Cutler MJ, Lowthers EL, Richard CL, Spagnuolo P, Blay J. Treatment of colon cancer cells with diverse anticancer agents decreases CXCR4 and CD133 and increases CD26 and CD44 while reducing CXCL12-induced migration. 2013 Canadian Cancer Research Conference, Toronto, November 2013.
DATE: April 2018
Page 275 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
SIAN, Preet Adjunct Clinical Assistant Professor, Contract Member of the Graduate Faculty: no b) DEGREES: designation, institution, department, year
Masters of Pharmacy, University of Brighton, Brighton, United Kingdon ON, 2008 Bachelor of Science, University of Waterloo, Waterloo ON, 2004
ADDITIONAL CERTIFICATIONS 2015-2019 Health Care Provider CPR/AED 2013 OPA Geriatric Certificate Program 2013 OCP Certified Preceptor 2013 OCP registered Authorized Injector 2013 Registered Diabetes Educator (CDE) 2012 Cardiovascular Patient Care Certificate Program 2012 OPA Smoking Cessation Program 2012 OPA Nutrition for Pharmacists Certificate Program 2011 Management of Oral Anticoagulation Therapy Primary Care Certificate Course, University of Waterloo c) EMPLOYMENT HISTORY: dates, rank/position, department, institution/firm
2014 – Adjunct Clinical Assistant Professor, School of Pharmacy, University of Waterloo, ON 2013 – Pharmacist Manager, Loblaw Pharmacy, Waterloo, ON 2012 – 2013 Teaching Assistant/Lecturer, School of Pharmacy, University of Waterloo, ON 2010 – 2012 Staff Pharmacist, DRUGStore Pharmacy, Guelph, ON 2010 Pharmacy Intern, DRUGStore Pharmacy, Guelph, ON 2010 Studentship, Shoppers Drug Mart Pharmacy, Waterloo, ON 2008 – 2009 Hospital Residency, Pre-registration Pharmacist, Princess Alexandra Hospital, Harlow, United Kingdom d) HONOURS: (F.R.S., F.R.S.C., Governor Generals Award, honorary degree, etc...) e) SCHOLARLY AND PROFESSIONAL ACTIVITIES: past 7 years only (eg. executive and editorial positions but not memberships in societies)
2016 Vice President, Region of Waterloo Pharmacist Association Page 276 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
yyyy – present Course Coordinator and Instructor, PHARM 130: Professional Practice II (core), School of Pharmacy, University of Waterloo yyyy – present Course Coordinator and Instructor, PHARM 377: Drug Induced Disease (elective), School of Pharmacy, University of Waterloo yyyy – present Guest Lecturer, PHARM 222: Integrated Patient Focused Care 3 (Female contraception), School of Pharmacy, University of Waterloo yyyy – present Guest Lecturer, PHARM 321: Integrated Patient Focused Care 6 (PUD and GERD) yyyy Developed and recorded online content for OPA online program: Assessing and Prescribing for Minor Ailments (Patient Triage & Assessment) yyyy- Content Developer & Assessor, OSCE final examinations, School of Pharmacy, University of Waterloo yyyy – Content developer, PHARM 229: Professional Practice 4, School of Pharmacy, University of Waterloo yyyy – Content developer, PHARM 329: Professional Practice 5 (Vaccines), School of Pharmacy, University of Waterloo yyyy – Coordinator, PHARM 401: Independent Study, School of Pharmacy, University of Waterloo yyyy – Teaching Assistant, PHARM 425: Symposium, School of Pharmacy, University of Waterloo 2010 - Member, Ontario Pharmacist Association 2010 - Member, Ontario College of Pharmacists f) GRADUATE SUPERVISIONS: master’s, doctoral, postdoctoral - completed/in progress
None
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion: g) GRADUATE COURSES: past 7 years, by year
None h) 1. EXTERNAL RESEARCH FUNDING: past 7 years only, by year, indicating source (granting councils, industry, government, foundations, other); amount; principal investigator; purpose (research, travel, publications, etc...)
Year Source Type* Amount per year Purpose**
Page 277 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants) ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING: This includes university funds, SSHRC minor grants awarded through the University, etc.] Year Source Type* Amount per year Purpose**
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS: The Publications should be listed in the categories shown below and include the following information: books authored, books edited (a list of the chapters contributed by the editor must follow each title), chapters in books (other than those listed in the above category), papers in refereed journals, papers in refereed conference proceedings, technical reports, abstracts and/or papers read, and others. Each title must show the names of the authors in the order in which they appear in the original publication and inclusive page numbers. Publications submitted, but not yet accepted, must be listed separately within the various categories.
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 0 - refereed journal articles ...... 0 - refereed conference proceedings...... 0 - presentations at conferences ...... 0 - technical reports ...... 0 - invited/keynote addresses ...... 0 - others (workshops presented) ...... 0
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
DATE: April 2018
Page 278 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
SLAVCEV, Roderick Associate Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
MBA, Biotechnology Management, University of Saskatchewan, 2006 PhD, Microbial Genetics, University of Saskatchewan, 2002 HBSc, University of Toronto, 1995 c) EMPLOYMENT HISTORY:
2015- Associate Professor, School of Pharmacy, University of Waterloo 2007-2015 Assistant Professor, School of Pharmacy, University of Waterloo 2006- Lecturer, Science and Business, University of Waterloo 2006- Medical Science Liaison, Clinical Affairs, Janssen-Ortho, Inc. 2002- Research Associate, Medical Genetics and Microbiology, University of Waterloo d) HONOURS:
2011 Association of Faculties of Pharmacy of Canada Janssen Innovation Award 2010 C.Biol, Chartered Biologist status, Society of Biology Accepted Member, Royal Society of Biology e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2014- Editorial Team, Canadian Foundation for Pharmacy; Pharmacy Management Textbook 2011- Member, Editorial Board, Journal of Pharmaceutical Technology and Drug Research, Herbert Publications Ltd. 2011-12 Member, Editorial Board, International Journal of Virology and Molecular Biology, SAP Publishing Group 2011-12 Member, Editorial Board, Pharmaceutical Regulatory Affairs, OMICS Publishing Group 2010-12 Member, Editorial Board, Pharmaceutica Analytica Acta, OMICS Publishing Group
Page 279 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
f) GRADUATE SUPERVISIONS:
Completed: 6 MSc, 1 PhD In progress: 3 PhD
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Nafiseh Nafissi (PhD), 2009-2014 Construction and Completed optimization of an in vivo linear covalently closed Safe DNA vector gene delivery system Katlyn Sheldon (MSc), 2008-2013 Construction and Completed characterization of a fine- tunable phage display system Chi Hong Sum (MSc; cosupervised Construction and Completed with S. Wettig), characterization of a 2011-2014 targeted linear covalently closed DNA-VLP HIV vaccine Jessica Nicastro (MSc), 2011-2014 Characterization of a Completed bidimensional genetic system for the display of proteins on the surface of phage Lambda Farah El-zarkout (MSc), 2011-2013 Application of a lytic Completed phage display system toward the development of a super-lytic nanoparticle Heba Allattas (MSc), 2012-2015 Elucidation of the Completed bacteriophage Lambda T4rII exclusion system Shirley Wong (MSc/PhD), 2013- Application of DNA In Progress ministring technology to a ovarian cancer therapeutic
Page 280 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Jessica Nicastro (PhD) 2014- Development of a novel In Progress phage display Heba Allattas (PhD) 2015- Advancing understanding In Progress of the bacteriophage lambda () T4rII exclusion (Rex) phenotype Jesse St. Jean (PhD) 2017- Use of bacteriophage as In Progress vaccine/gene hybrid delivery vehicle in treatment of Alzheimer’s disease Shaker Alsharif (PhD) 2018- TBD In Progress g) GRADUATE COURSES:
2014 – Pharm 608A Special topics in biopharma technology management 2014 – Pharm 608A Special topics in bacteriophage genetics 2011 – Pharm 604 Gene Therapy
Directed Studies: 2010 – Katlyn Sheldon (MSc), Nafiseh Nafissi (PhD) h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2015 AVT O $163,000 Research 2015 NSERC C $150,000 Research 2014 NSERC C $150,000 Research 2014 HRSDC G $60,000 Research 2013 NSERC C $30,000 Research 2013 HRSDC G $45,000 Research 2012 HRSDC G $20,000 Research 2011 HRSDC G $30,000 Research 2010 HRSDC G $15,000 Research
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator
Page 281 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011 NSERC C $24,000 Research Bridge i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 2 - edited book and monographs ...... 0 - chapters in books and monographs ...... 7 - refereed journal articles ...... 31 - refereed conference proceedings...... 0 - presentations at conferences ...... 0 - technical reports ...... 1 - invited/keynote addresses ...... 0 - others (patents) ...... 3
2) Details for past seven (7) years same categories as above:
Books Authored:
1. Slavcev, Roderick. Tackling the Classical Genetic Mystery of the Bacteriophage λ Rex Phenotype, Lambert Academic Publishing, Köln, 2010.
2. Slavcev, Roderick A. Alan Low, Jason Perepelkin, Rita Winn, Kevin Hall, Mike Jaczko, Dayle Acorn, , ed. Pharmacy Management in Canada. Vol. 1. Toronto: Brush Publishing, 2015.
Chapters in Books:
1. Slavcev, R.A. 2015. Microenvironmental, industry analysis. In: Pharmacy Management in Canada, Canadian Foundation for Pharmacy, Brush Publishing.
2. Slavcev, R.A. 2015. Assessing the critical attributes of a new venture. In: Pharmacy Management in Canada, Canadian Foundation for Pharmacy, Brush Publishing.
3. Slavcev, R.A. 2015. The Pharmacy Industry Landscape—Where are we? Where do we need to go and how do we get there? In: Pharmacy Management in Canada, Canadian Foundation for Pharmacy, Brush Publishing.
4. Kaur, T., and R.A. Slavcev*. 2012. Solid Lipid Nanoparticles: “Tuneable Anti-Cancer Gene/Drug Delivery Systems”. In: Gene Therapy/Book 1, InTech Open Access Publisher. Page 282 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
5. Slavcev, R.A, Kaur, T. and S. Wettig. 2011. Nanomedicine-based approaches to cancer diagnosis and therapy. In: X. Yuan (ed.) Non-viral gene therapy, InTech Open Access Publisher, pp. 515-546.
6. Wettig, S., Kaur, T., and Slavcev, R. 2011. Calorimetric investigations of non-viral DNA transfection systems. In: J. Piraján (ed.) Thermodynamics - Kinetics of Dynamic Systems, InTech Open Access Publisher, pp. 255-276.
Papers in Refereed Journals:
1. Barati N, Razazan A, Nicastro J, et al. Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Letters. 2018; 424:109-116. https://doi.org/10.1016/j.canlet.2018.03.030
2. Arab A, Nicastro J, Slavcev R, et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunol Res. 2018; 66(1):200-206. https://doi.org/10.1007/s12026-017-8969-0
3. Slavcev R, Waite NM, Jennings B. Shaping pharmacy students’ business and management aptitude and attitude. Curr Pharm Teach Learn. 2016; 8(5):672-680. https://doi.org/10.1016/j.cptl.2016.06.003
4. Wong S, Lam P, Nafissi N, Denniss S, Slavcev R. Production of double-stranded DNA ministrings. J. Vis. Exp. 2016; (108): e53177. doi:10.3791/53177.
5. Sum, C., Nafissi, N., Slavcev, R.A.* and S. Wettig. Transfection and physical characterization of DNA/16-3-16/DOPE gemini surfactant based vectors for the delivery of LCC DNA ministrings. PLoS One
6. Wong, S., and R. A. Slavcev.* 2015. "DNA ministrings: Linear-covalently closed minivectors for use in non-viral gene therapy with applications toward ovarian cancer." Molecular Therapy 23: 75.
7. Wong, S., and R.A. Slavcev.* 2015. The infection of cancer: Bacterial cancer therapy. Letters in Applied Microbiology. 61: 107-112.
8. Wong. S., Lam, P., Nafissi, N., Denniss, S. and R.A. Slavcev.* 2015. Production of Double- stranded DNA Ministrings. Journal of Visualized Experiments. (In Press)
Page 283 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
9. Nafissi, N., Alqawlaq, S., Lee, E., Spagnuolo, P., Foldvari, M. and R.A. Slavcev*. 2014. Ministring DNA: Highly safe and effective DNA transgene delivery vectors. Molecular Therapy Nucleic Acids 3: e165 IF, 6.23
10. Sum, C., Wettig, S. and R.A. Slavcev*. 2014. DNA vector influence on non-viral gene therapeutic safety and efficacy. Current Gene Therapy 14: 309-329.
11. Sum, C., Chong, J., Wettig, S. and R.A. Slavcev*. 2014. Purification of Linear Covalently Closed (LCC) DNA ministrings by Q-anion exchange membrane chromatography. Chromatography A 1339: 214-218.
12. Nafissi, N., Sum, C., Wettig, S. and R.A. Slavcev*. 2014. Optimization of a one-step inducible in vivo mini DNA vector production system. PLOS One 9: e89345.
13. Slavcev, R.A.*, Sum, C.H. and N. Nafissi. 2014. Optimized production of a safe and efficient gene therapeutic vaccine versus HIV via a linear covalently closed DNA minivector. Infectious Diseases (Supplement) 14: P74.
14. Grindrod, K.*, Gates, A, Leat, S., Dolovich, L., Slavcev, R.A., Drimmie, R., Aghaei, B. Poon, C. and S. Khan. 2014. A rapid prototyping project to build a mobile screening tool to identify adults 55 and over who have difficulty reading medication labels. Journal of Medical Internet Research 15;2(3):e35. doi: 10.2196/mhealth.3250
15. Nicastro, J., Sheldon, K., and R.A. Slavcev*. 2014. Phage display applications. Applied Microbiology and Biotechnology 98: 2853-66.
16. Nafissi, N., and R.A. Slavcev*. 2014. Bacteriophage recombination systems and biotechnological applications. Applied Microbiology and Biotechnology 98: 2841-51.
17. Nicastro, J., Sheldon, K., El-zarkout, F., Sokolenko, S., Aucoin, M., and R.A. Slavcev*. 2013. Construction and analysis of a genetically tuneable lytic phage display system. Applied Microbiology and Biotechnology 97:7791-7804.
18. Kaur, T., and R.A. Slavcev*. 2013. Solid Lipid Nanoparticles: “Tuneable Anti-Cancer Gene/Drug Delivery Systems”. In: Gene Therapy/Book 1, InTech Open Access Publisher. DOI: 10.5772/54781.
19. Nafissi, N., and R.A. Slavcev*. 2012. Construction and Characterization of an in vivo linear covalently closed DNA vector production system. Microbial Cell Factories 11:154-167.
Page 284 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
20. Sokolenko, S., Nicastro, J., Slavcev, R., and M. Aucoin*. 2012. Graphical analysis of flow cytometer data for characterizing controlled fluorescent protein display on λ phage. Cytometry A (E-Published Ahead of Print).
21. Kaur, T., and R.A. Slavcev*. 2012. Solid Lipid Nanoparticles: “Tuneable Anti-Cancer Gene/Drug Delivery Systems”. In: Gene Therapy/Book 1, InTech Open Access Publisher. (In Press).
22. Kaur, T., Nafissi, N., Wasfi, O., Sheldon, K., Wettig, S., and R.A. Slavcev*. 2012. Immunocompatibility of Bacteriophages as Nanomedicines. Journal of Nanotechnology, 2012: 1-
23. Kaur, T., Nafissi, N., Wasfi, O., Sheldon, K., Slavcev, R. 2012. Phage Nanomedicine and Mammalian Host Immune Responses Journal of Nanotechnology (In press)
24. Slavcev, R., Kaur, T., Nafissi, N., Ng, L. 2012. SSINCC: Simple Separation of Interacting Nucleoprotein Complex Components. Advances in Biological Chemistry (In press)
25. Slavcev, R. 2012. The Disparity of Motivational Drivers in International Health Care Systems. Pharmaceutical Regulatory Affairs 1: 1-2
26. Slavcev, R.A., Al Abdallah, Q., Kaur, T., Funnell, B., and S. Wettig. P1 ParAB-mediated intermolecular association of P1 parS sites. 2011. Virology 421: 192-201
27. Slavcev, R.A. 2011. Optimizing Healthcare Access through the Alignment of Economic and Ethical Imperatives. Healthcare Quarterly 14: 44-46.
28. Wasfi, O., Power, M., and R. Slavcev. 2011. An Outcomes Based Model for Medical Microbiology Curricular Assessment and Design in Pharmacy at the University of Waterloo. Opportunities and New Directions 2: 91-99.
Technical Reports
1. Slavcev, R.A. 2011. Moving toward international access to healthcare: Aligning ethics and economics. Management Ethics, Spring: p.3-5
Patents
1. Slavcev, R. and J. Nicastro. 2015. A Fine-tuned Lytic Phage Display System. USPTO serial #: 61/815467 (http://www.freepatentsonline.com/y2015/0031583.html)
Page 285 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2. Slavcev, R. and N. Nafissi. 2014. In vivo linear covalently closed DNA vector production system. USPTO serial #: 61/729,384 (http://www.google.com/patents/US20140206037)
3. Slavcev, R., Kaur, T., Nafissi, N. and S. Wettig. 2010. Safe and Efficient Gene Therapeutics: A Novel Polyplexed Mini-Linear Covalently Closed Transgene Delivery System with Application to Cancer Gene Therapy. USPTO serial #: 61/344,851 (provisional abandoned).
DATE: April 5, 2015
Page 286 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
WAITE, Nancy Madeline Professor, tenured Associate Director, Clinical Education Ontario College of Pharmacists Professor in Pharmacy Innovation Member of the Graduate Faculty: yes b) DEGREES:
Postdoctoral Fellowship, Pharmacokinetic fellow, College of Pharmacy and Allied Health Professionals, Wayne State University, Detroit, MI, 1989 PharmD, College of Pharmacy and Allied Health Professionals, Wayne State University, Detroit, MI, 1988 BScPhm, Faculty of Pharmacy, University of Toronto, Toronto, ON, 1986 c) EMPLOYMENT HISTORY:
2015- Associate Director, Clinical Education, School of Pharmacy, University of Waterloo, Waterloo, ON 2014- Full Professor (tenured),* School of Pharmacy, University of Waterloo, Waterloo, ON 2012- Research Associate, Waterloo Centre for the Advancement of Cooperative Education, University of Waterloo, Waterloo, ON 2012- Ontario College of Pharmacists Professor in Pharmacy Innovation, School of Pharmacy, University of Waterloo, Waterloo, ON 2007-2015 Associate Director, Practice-Based Education and Professional Outreach, School of Pharmacy, University of Waterloo, Waterloo, ON 2010-2011 Interim Hallman Director, School of Pharmacy, School of Pharmacy, University of Waterloo, Waterloo, ON 2010-2011 Interim Health Science Campus Director, School of Pharmacy University of Waterloo, Waterloo, ON 2010-2011 Interim Associate Dean Pharmacy, School of Pharmacy University of Waterloo, Waterloo, ON 2007-2014 Associate Professor (tenured), School of Pharmacy University of Waterloo, Waterloo, ON 2005-2007 Associate Professor, Leslie Dan Faculty of Pharmacy University of Toronto, Toronto, ON 2005-2007 Director of Educational Development, Leslie Dan Faculty of Pharmacy University of Toronto, Toronto, ON
Page 287 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2002-2005 Manager, Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany NY 1996-2007 Associate Professor (tenured), Department of Pharmacy Practice Albany College of Pharmacy and Health Sciences, Albany, NY 1989-1996 Research Coordinator, Pharmacy Department, St. Michael’s Hospital, Toronto, ON 1989-1993 Assistant Professor, Leslie Dan Faculty of Pharmacy University of Toronto, Toronto, ON d) HONOURS
2017 OPEN selected by the Research, Analysis and Evaluation Branch, Strategic Policy and Planning Division, Ministry of Health and Long-term Care to showcase the impact that HSRF funding can have on policy and practice: “placemat” created to be shared within Ministry and with the Minister of Health 2016 Best Paper award from the Research in Social and Administrative Pharmacy Journal for: Wenger LM, Rosenthal M, Sharpe JP, Waite N. Confronting inequities: A scoping review of the literature on pharmacist practice and health-related disparities. Res Social Adm Pharm. 2016;12(2):175–217 Impact Factor 1.936. (This journal is the #1 ranked pharmacy journal.) The award was received based on methodological rigour, comprehensiveness and salience of subject matter. As well the paper featured on Research in Social and Administrative Pharmacy’s Facebook feed as “A comprehensive and eloquently written review on pharmacists’ practice in the face of health disparities. Tremendous article!” 2016 “A literature review of the impact of pharmacy students inimmunization initiatives” selected as a highlighted article for May/June 2016 issue of Can Pharm J, Can Pharm J issued a press release and provided open access to increase dissemination 2015 Best Pharmacy Practice Research, oral presentation, 2015 Canadian Pharmacists Conference 2015 Journal Award, 2015 Canadian Association for University Continuing Education annual conference 2014 Best Pharmacy Practice Research, oral presentation, 2014 Canadian Pharmacists Conferenc 2012 Ontario College of Pharmacists Professorship in Pharmacy Innovation 2012 Award for Program Excellence, Canadian Association from University Continuing Education (CAUCE) 2011 Association of Faculties of Pharmacy in Canada, Bristol-Meyers Squibb Pharmacy Educator Award Page 288 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
Reviewer Journals
1997- American Journal of Pharmaceutical Education 2006- Canadian Pharmacists Journal 2012 International Journal of Pharmacy Teaching
Committee Participation
University of Waterloo, 2007–present
2011 Anatomy Teaching Facility Committee 2007-2009 Community Service Learning Special Interest Group, member 2011 Dean of Science Nominating Committee (elected by Pharmacy), member 2011 Faculty of Science Dean’s Administrative Committee, member 2007-2012 Faculty of Science Tenure and Promotion Committee, member (voted to represent Pharmacy) 2007-2009 Science Faculty Council Executive, member 2007-2009 Teaching Based Research Group, member 2012 WatCACE Research Committee 2015 Accreditation and Program Review, School of Social Work, internal reviewer 2016-17 HeForShe: Equity grant Committee 2018 Senior Women Academic Administrators of Canada (SWAAC) 2018 Annual Meeting Planning Committee 2017 Wolfe and Waterloo Chairs Renewal Committee, Faculty of Arts 2017 Member, Director of Optometry Nominating Committee
School of Pharmacy, University of Waterloo, 2007–present
2015-2016 Tenure and Promotion Committee 2007-2009, 2015 Curriculum Committee, chair 2012, 2015 Faculty Performance Review Committee, member 2011 Pharmacy Executive Committee, chair 2011 Accreditation Self-Study lead 2011 Adjunct Faculty Task Force 2007-2009 Admissions Committee, member 2007- Curriculum Committee, member
2007- Pharmacy Executive Committee, member 2012 Pharmacy Liaison Librarian Hiring Committee, member Page 289 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011- Pharmacy Practice Research Group, member 2011- Residency/Clinical Master’s Task Force, member 2011 School Advisory Committee for Appointments (clinical/social administrative tenure-track faculty), chair 2011 School Advisory Committee for Appointments (pharmaceutical science tenure-track faculty), member 2011-2012 School Advisory Committee for Appointments (Associate Director of Research and Graduate Studies), member 2012 Strategic Planning Committee, member 2011-2012 Teaching Evaluation Task Force, member
OPEN: Ontario Pharmacy Research Collaboration, 2013–present
2014- Scientific Advisory Committee, member 2013- Advisory Committee, member 2013- Capacity Building Committee, lead 2013- Executive Committee, team lead 2013- Project Lead Committee, member 2013- Gender and Vulnerable Populations, lead 2013- Pharmacists as Immunizers, lead
External (1992–present)
2011- Ontario College of Pharmacists Registration Committee, member (Jan-Jun 2011) Structured Practical Training Advisory Committee, member (2011-2014) 2011-2013 Centre for Family Medicine, Kitchener, ON Advisory Board, member (2011-2013) 2011- Gateway Centre of Excellence in Rural Health, Seaforth, ON Board of Directors, member (2011-) Research Coordinator (2012-2013) 2011- Vanguard Group (local group raising money for community-based research initiatives) , member (2010–2013) 2011 Association of Deans of Pharmacy of Canada (ADPC) Dean/Director representative, member (Jan–Jun 2011) 2008-2009 Accreditation of Interprofessional Health Education (AIPHE) Advisory Council, member (2008–2009) 2008 AFPC/AACP Annual Meeting Joint Programming Committee in Chicago, IL, member 2011-2012 AFPC/ADPC Governance Review Task Force, member 2007-2013 AFPC Council of Faculties, Pharmacy-elected representative, member 2012-2013 Board of Directors (elected from Council of Faculties), member Page 290 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011-2012 Canada Health Infoway, Health Informatics Curriculum Steering Committee, member 2012-2013 CPERC 2013 Educational Planning Committee, co-chair Education Committee, chair (2007–2009) 2007-2012 Canadian Society of Hospital Pharmacists (CSHP) and Canadian Pharmacists Association (CPhA) CPhA–CSHP Primary Care PSN, founding member (2007) Primary Health Care Skills Training Mentorship Program Working Group, member (2007–2009) CPhA Blueprint for Pharmacy Education and Continuing Professional Development Working Group, invited member (2007–2009) ADAPT Advisory Council, member (2011–2012) 2007-2009 Ontario Ministry of Health and Long-term Care Quality Management Collaborative Pharmacy Steering Committee, member (2007–2009) Pharmacy Travel Vaccine Working Group, advisor (2015-present) Provided information on pharmacists’ role as immunizers f) GRADUATE SUPERVISIONS:
Summary of Clinical Supervision of Graduate and Post-graduate trainees
In Progress: 0 MSc, 2 PhD Completed: 0 MSc, 0 PhD, Post-doctoral residency: 7; Fellowships: 1
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Gokul Raj Pullagura (MSc), 2015- Vaccine Hesitance Transfer from 2016 MSc to PhD in (PhD), 2016- 2016; PhD In Progress Fahad Alzahrani (PhD), 2015- The relationship between In Progress pharmacists’ explicit and implicit bias in visible minority patients’ perception of pharmacy care services
Page 291 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
g) GRADUATE COURSES: past 7 years, by year
None.
h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2017- Health Systems Research G $695,797 Research 2020 Fund Program (HSRF): Ontario Ministry of Health and Long Term Care 2017- Merck O $35,200 Research Principal 2020 Investigator: Nancy Waite 2016- Neighbourhood Pharmacy F $79,992 Research Co- Investigator: 2020 Association of Canada Nancy Waite 2016- CIHR: Planning and C $19,988 Co- Investigator: 2017 Dissemination Grant Nancy Waite 2014- Canadian Immunization C $550,000 Research Principal 2017 Research Network (CIRN) investigator: Scott Halperin, Co-applicant: Nancy Waite 2013- Health System Research G $1,924,538 Research Principal 2016 Fund Program *funding investigators: Ontario Ministry of Health amounts Nancy Waite and and Long-Term Care below Lisa Dolovich Fostering innovation and included in evaluating the this effectiveness of Ontario program pharmacist-led total medication management programs; OPEN: Ontario Pharmacy REsearch CollaboratioN 2013- Health System Research G $29,050* Research Principal 2016 Fund Program investigators: Ontario Ministry of Health Nancy Waite and and Long-Term Care Beth Sproule Capacity building: Cross- cutting theme in “Fostering innovation and Page 292 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
evaluating the effectiveness of Ontario pharmacist-led medication management programs” 2013- Health System Research G $105,502* Research Principal 2016 Fund Program investigators: Ontario Ministry of Health Nancy Waite and and Long-Term Care Sherilyn Houle Pharmacists’ role as immunizers (influenza prevention): Research project in “Fostering innovation and evaluating the effectiveness of Ontario pharmacist-led medication management programs” 2013- Health System Research G $70,360* Research Principal 2016 Fund Program investigators: Lisa Ontario Ministry of Health McCarthy and and Long-Term Care Nancy Waite Pharmacist prescribing: Research project in “Fostering innovation and evaluating the effectiveness of Ontario pharmacist-led medication management programs” 2013- Health System Research G $47,419* Research Principal 2016 Fund Program investigators: Ontario Ministry of Health Martin Cooke and Long-Term Care and Nancy Waite Gender and vulnerable populations: Cross-cutting theme in “Fostering innovation and evaluating the effectiveness of Ontario pharmacist-led medication management programs” Page 293 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2013- Health System Research G $93,536* Research Principal 2016 Fund Program investigators: Ontario Ministry of Health Kelly Grindrod and Long-Term Care and James Knowledge translation Conklin, co- and exchange: Cross- investigator: cutting theme in Nancy Waite “Fostering innovation and evaluating the effectiveness of Ontario pharmacist-led medication management programs” 2012 Health Professional C $4,251 Research Principal Student Research Award supervisor: CIHR Nancy Waite 2011- Research and Education F $5,313 Research Principal 2012 Foundation investigator: Barb Canadian Society of Farrell, co- Hospital Pharmacists investigator: Content analysis of a Nancy Waite primary care pharmacy specialty network listserv archive 2010 Pfizer O $35,000 Research Principal Exploring the barriers and investigator: enablers of community Nancy Waite pharmacist-delivered smoking cessation interventions
2009 Health Professional C $4,251 Research Principal Student Research Award supervisor: CIHR Nancy Waite 2009 Meetings, Planning and C $11,035 Research Principal Dissemination Grant investigator: CIHR Nancy Waite Nutraceuticals: Establishing a researcher, pharmacist, dietitian and educator network 2009- Health Care Policy G $266,666 Research Principal Page 294 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011 Contribution Program investigator: Health Canada Canadian ADAPTS: Access to quality Pharmacists Drug therapy–Applying Association, Pharmacists’ knowledge Collaborator: to The primary care Nancy Waite System 2009 Boehringer Ingelheim O $5,000 Research Principal (unrestricted educational investigator: grant) Nancy Waite Continuing professional development needs assessment project 2009-10 Interprofessional G $226,281 Research Principal Care/Education Fund (funding investigator: Joe Renewal Grant period: 18 Lee, Co- Health Force Ontario months) investigator: The Memory Clinic: Nancy Waite Translating inter- professional care into inter-professional education
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
Page 295 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** Investigator 2015- Seed grant: Chronic O $10,000 Research Principal 2016 Disease Prevention investigator: Initiative Nancy Waite Propel Centre for Population Health Impact Mapping health geography data and pharmacy access 2015- Learning Innovation and O $19,925 Education Principal 2016 Teaching Enhancement investigator: (LITE) Nancy Waite University of Waterloo Communities of practice: An innovation in experiential education 2012- WatCACE Co-op Research O $9,500 Research Principal 2014 Program investigator: University of Waterloo Anson Tang, Co- The use of experiential investigator: learning in Nancy Waite undergraduate pharmacy to spur curricular reform 2010- WatCACE Co-op Research O $19,500 Research Principal 2013 Program investigator: (delayed University of Waterloo Nancy Waite to start Pharmacist coaches to 2011) enhance student development into reflective practitioners 2010 Program Initiatives Fund O $14,970 Research Principal University of Waterloo investigator: Pia Online experiential Marks, Co- learning and real-world investigator: transfer: Intersections Nancy Waite 2010- WatCACE Co-op Research O $9,442 Research Principal 2013 Program investigator: University of Waterloo Certina Ho, Co- (delayed Experiential learning in investigator: to start undergraduate pharmacy Nancy Waite Page 296 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2011) curriculum at the University of Waterloo: A case study of skills development during co- operative experience of pharmacy students 2008– Program Initiatives Fund O $10,000 Research Principal 2010 University of Waterloo investigator: Learning to serve, serving Nancy Waite to learn: The beginning of a cross-campus community service learning initiative 2008– WatCACE Co-op Research O $19,400 Research Principal 2010 Program investigator: University of Waterloo Nancy Waite Making patient safety real: An outcome-driven “classroom to co-op and back again” research initiative
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories: Papers in refereed journals ...... 39 Technical reports ...... 0 Abstracts and/or papers read ...... 127 Invited presentations ...... 93
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Journals:
1. Pereira J, Gilca V, Waite N, Andrew MK. Canadian seniors’ perceptions of effectiveness and value of regular and high-dose influenza vaccines. BMC Geriatrics (submitted Feb 2018)
Page 297 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2. Waite N, McCarthy L, Milne E, Hillier C, Houle S, Dolovich L. Recent Doctor of Pharmacy Graduates Perceived Preparedness for Expanded Pharmacist Services. J Am Pharm Assoc (submitted Jan 2018)
3. Andrew MK, Gilca V, Waite N, Pereira J. EXamining the Knowledge, Attitudes and Experiences of Canadian Seniors Towards Influenza (the EXACT survey) BMC Geriatrics (accepted Nov 2017 with revisions)
4. Alsabaggh W, Wenger L, Raman-Wilms L, Schneider E, Church D, Waite N. Pharmacists as immunizers, their pharmacies and immunization services: A survey of Ontario community pharmacists. Can Pharm J (accepted Feb 2018)
5. Alsabaggh W, Church D, Wenger L, Papastergiou J, Raman-Wilms L, Schneider E, Waite N. Pharmacy patron perspectives of community pharmacist administered influenza vaccinations Res Soc Adm Pharm (accepted with revisions Feb 2018)
6. O’Reilly DJ, Blackhouse G, Burns S, Bowen J, Burke N, Mehltretter J, Waite N, Houle S. Economic analysis of pharmacist-administered vaccines in Ontario. Int J Pharm Pract (submitted Nov 2017)
7. Nemutlu G, Erenay F, Ozaltin O, Papastergiou J, Waite N. Optimal Vaccine Administration Policies Using Multi-dose Vials of Different Sizes. Production and Operations Management (accepted with revisions Jan 2018)
8. Cooke M, Waite N, Cook K, Milne E, Chang F, McCarthy, Sproule B. Incorporating sex, gender and vulnerable populations in a large multisite health research program: The Ontario Pharmacy Research Collaboration as a Case Study Health Research Policy and Systems (2017) 15:20 DOI 10.1186/s12961-017-0182-z.
9. McCarthy L, Milne E, Waite N, Cooke M, Cook K, Chang F, Sproule B. Sex and gender- based analysis in pharmacy practice research: A scoping review. Res Soc Adm Pharm. https://doi.org/10.1016/j.sapharm.2016.11.007
10. Buchan SA, Rosella L, Finkelstein M, Juurlink D, Isenor J, Marra F, Patel A, Russell M, Quach S, Waite N, Kwong J for the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group. Impact of pharmacist administration of influenza vaccines on uptake in Canada. CMAJ August 8, 2016 cmaj.151027.
11. Slavcev RA, Waite NM, Jennings B. Shaping pharmacy students’ business and management aptitude and attitude. Curr Pharm Teach Learn. 2016;8(5):672–80.
Page 298 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
12. Ziegler B, Alsabbagh W, Houle S, Wenger L, Church D, Waite N. Protecting our patients by protecting ourselves: An analysis of the personal influenza immunization rate of Ontario community pharmacists. Can Pharm J. 2016;149(4):246–55.
13. Church D, Johnson S, Raman-Wilms L, Pearson-Sharpe J, Schneider E, Waite N. A literature review of the impact of pharmacy students as immunizers on public outcomes. Can Pharm J 2016;149(3):153-65.
14. Wenger LM, Rosenthal M, Pearson-Sharpe J, Waite NM. Confronting inequities: A scoping review of the literature on pharmacist practice and health-related disparities. Res Social Adm Pharm. May 29, 2015 doi: 10.1016/j.sapharm.2015.05.011.
15. Armstrong L, Rosenthal M, Waite NM. Supporting student development through a cooperative education coaching program. Asia-Pacific Journal of Cooperative Education. 2015;16(4):255–65. Available online at http://www.apjce.org/files/APJCE_16_4_255_265.pdf.
16. Trinacty M, Farrell B, Schindel TJ, Sunstrum L, Dolovich L, Kennie N, Russell G, Waite N. Learning and networking: Utilization of a primary care listserv by pharmacists. Can J Hosp Pharm. 2014;67(5): 343–52.
17. Marks PZ, Jennings B, Farrell B, Kennie-Kaulbach N, Jorgenson D, Pearson-Sharpe J, Waite N. “I gained a skill and a change in attitude”: A case study describing how an online continuing professional education course for pharmacists supported achievement of its transfer-to-practice outcomes. Canadian J of University Continuing Ed. 2014;40(2): 1–18. (This CAUCE publication was selected to receive the Journal Award at the 2015 Canadian Association for University Continuing Education annual conference.)
18. Kennie-Kaulbach N, Farrell B, Ward N, Johnston S, Gubbels A, Eguale T, Dolovich L, Jorgenson D, Waite N, Winslade N. Pharmacist provision of primary health care: a modified Delphi validation of pharmacists’ competencies. BMC Fam Pract. 2012; 13:27.
19. Farrell B, Dolovich L, Emberley P, Gagne M, Jennings B, Jorgenson D, Kennie N, Marks P, Papoushek C, Waite N, Woloschuk D. Designing a novel continuing education program for pharmacists: lessons learned. Can Pharm J. 2012; 145(4): e7–e16. http://cph.sagepub.com/content/145/4/e7.full.pdf+html
Abstracts and/or Papers Read
Asterisk denotes abstracts for which I was the presenter; (O) denotes oral presentation
Page 299 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1. Nemutlu, G.S.*, Erenay, F.S., Ozaltin O.Y., Waite, N., Papastergiou, J. Determining the optimal vaccine administration policies with multi-dose vials, POMS Seattle, WA, USA 2017 (O)
2. Nemutlu, G.S.*, Erenay, F.S., Ozaltin O.Y., Waite, N., Papastergiou, J. Optimal vaccine administration policies using multi-dose vials of different, Session of CORS Student Paper Award Finalists, IFORS Quebec City, QC, Canada 2016 (O)
3. Houle SKD, O'Reilly D, Blackhouse G, Burns S, Bowen J, Burke N, Mehltretter J, Waite N. Economic analysis of community pharmacists providing influenza vaccination in Ontario. 2017 Canadian Pharmacists conference, Quebec City, QC, June 2-5, 2017 (O)
4. Pullagura GR, Waite N, Violette R, Houle SKD. Assessment of practicing community pharmacists’ knowledge, attitudes and behaviour towards influenza vaccine hesitancy in Ontario – An exploratory study. 2017 Canadian Pharmacists conference, Quebec City, QC, June 2-5 2017 (O)
5. Violette R, Meyer S, Simeoni M, Aggarwal R, Waite N, MacDougall H. Influenza- and pharmacy-specific factors of vaccine hesitancy: A web 2.0 analysis. 2017 Canadian Pharmacists conference, Quebec City, QC, June 2-5 2017 (O)
6. Violette R, Waite N, Papastergiou J, Houle SKD, Pearson-Sharpe J, Milne E. Distribution of influenza vaccine to community pharmacies in Ontario: the 2015-16 flu season experience. 2017 Canadian Pharmacists conference, Quebec City, QC, June 2-5 2017 (O)
7. O'Reilly D, Blackhouse G, Burns S, Bowen J, Burke N, Mehltretter J, Waite N, Houle S. Economic Analysis of Pharmacist-Administered Influenza Immunizations in Ontario. 2017 CADTH Symposium, Ottawa, ON, April 23-25, 2017 (O)
8. Houle S, Waite NM, Violette R, Mehltretter J. Economic analysis of community pharmacists providing influenza vaccination in Ontario. Canadian Immunization Conference. Ottawa, ON. December 6–8, 2016. (O)
9. Waite NM. Research as a driver for improving practice and health policy: Emerging findings from the Ontario Pharmacy Research Collaboration (OPEN). Social and Administration Pharmacy Educators of Canada Conference. Montreal, QC. October 12–14, 2016. (O)
10. Waite N, Cooke M, Milne E. The consideration of sex/gender and vulnerable populations in pharmacy practice research. 2016 Canadian Pharmacists Conference. Calgary, AB. June 24– 27, 2016. (O)
Page 300 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
11. Tolmie A, Waite N, Milne E. “Communities of Practice: An Innovation in Experiential Education.” Poster presentation at the Association of Faculties of Pharmacy of Canada Annual Conference and Meetings. Richmond, BC, Canada., June 2016.
12. Waite N, Church D, Johnson S, Raman-Wilms L, Pojskic N, Pearson-Sharpe J, Schneider E, Houle S. Pharmacists’ expanded immunization authority: A regulatory review. OPEN 2016 Summit. Toronto, ON. January 20–21, 2016.
13. Dolovich L, MacKeigan L, Marshall S, Waite N. Expanding pharmacy practice research capacity in Canada: The making of a stakeholder-engaged, multi-institutional, multi- disciplinary collaboration. OPEN 2016 Summit. Toronto, ON. January 20–21, 2016.
14. Waite N, Wenger L, Cooke M, Grindrod K, Jennings B, MacKeigan L, Marshall S, Sproule B, Dolovich L, Milne E. Understanding the value of collaboration in health services research. OPEN 2016 Summit. Toronto, ON. January 20–21, 2016.
15. McCarthy L, Bojarski E, Guirguis L, Pojskic N, Grindrod K, Dolovich L, Waite N. The Ontario pharmacist prescribing survey: Understanding the uptake of prescriptive authority among community pharmacists. 43rd North American Primary Care Research Group Annual Meeting. Cancun, Mexico. October 24–28, 2015.
16. MacKeigan L, Waite N, Wenger L, Cooke M, Grindrod K, Jennings B, Sproule B, Marshall S, Dolovich L. Understanding the value of collaboration in health services research. 75th FIP World Congress of Pharmacy and Pharmaceutical Sciences. Dusseldorf, Germany. September 29–October 3, 2015.
17. MacKeigan L, Dolovich L, Waite N, Marshall S. Expanding pharmacy practice research capacity in Canada: The making of a stakeholder-engaged, multi-institutional, multi- disciplinary collaboration. 75th FIP World Congress of Pharmacy and Pharmaceutical Sciences. Dusseldorf, Germany. September 29–October 3, 2015.
18. Waite N, Jennings B, Sproule B, Dolovich L, Houle S, MacKeigan L, Austin Z, Blay J, Wenger LM. Building pharmacy practice research skills in a large research collaborative: Reflections at the halfway point. American Association of Colleges of Pharmacy Annual Meeting. National Harbor, MD. July 11–15, 2015.
19. Dolovich L, Babaei-Rad R, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K, Waite N. Evaluation of pharmacy services: Capturing the patient perspective. 2015 Trillium Primary Health Care Research Day, Toronto, ON, June 4, 2015 (O).
Page 301 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
20. Dolovich L, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K, Waite N. Results of the evaluation framework scoping review. 2015 Trillium Primary Health Care Research Day, Toronto, ON, June 4, 2015.
21. Buchan S, Rosella L, Finkelstein M, Juurlink D, Quach S, Russell M, Waite N, Kwong J. Impact of pharmacist delivery of influenza vaccines on uptake in Canada. 2015 Canadian Society for Epidemiology and Biostatistics Conference. Mississauga, ON. June 1–4, 2015.
22. *Kwong J, Cadarette S, Schneider E, Campitelli M, Church D, Consiglio G, Pojskic N, Houle S, Alsabbagh W, Waite N. Community pharmacies providing influenza vaccines in Ontario: A descriptive analysis using administrative data. 2015 Canadian Pharmacists Conference. Ottawa, ON, May 28–31, 2015. (O) (This oral presentation received the award for best pharmacy practice research oral presentation.)
23. Dolovich L, Babaei-Rad R, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K, Waite N. Evaluation of pharmacy services: Capturing the patient perspective. 2015 Canadian Pharmacists Conference. Ottawa, ON, May 28–31, 2015. (O)
24. Alsabbagh W, Wenger L, Papastergiou J, Pojskic N, Raman-Wilms L, Schneider E, Waite N. Facilitators and barriers of Ontario pharmacists as providers of influenza vaccination: Surveys of pharmacists and patrons of community pharmacies. 2015 Canadian Pharmacists Conference, Ottawa, ON, May 28–31, 2015. (O)
25. Ziegler B, Alsabbagh W, Houle S, Wenger L, Waite N. Understanding Ontario pharmacists’ personal influenza vaccination rates. 2015 Canadian Pharmacists Conference, Ottawa, ON, May 28–31, 2015. (O)
26. Alsabbagh W, Wenger L, Papastergiou J, Pojskic N, Raman-Wilms L, Schneider E, Waite N. Effect of age of Ontario community pharmacy patron’s perspective of pharmacists as influenza immunizers. 2015 Canadian Pharmacists Conference, Ottawa, ON, May 28–31, 2015. (O)
27. Wenger L, Pearson-Sharpe J, Rosenthal M, Waite N. Confronting inequities: A review of the literature on pharmacist practice and health care disparities. 2015 Canadian Pharmacists Conference, Ottawa, ON, May 28–31, 2015.
28. Dolovich L, Akram S, Rietkoetter S, Chang F, Farrell B, MacKeigan L, Nainifard A, Patel T, Slonim K, Waite N. Barriers and facilitators to implementing an evaluation framework for pharmacy services. 2015 Canadian Pharmacists Conference, Ottawa, ON, May 28–31, 2015.
Page 302 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
29. Kwong K, Cadarette S, Schneider E, Campitelli M, Church D, Consiglio G, Pojskic N, Alsabbagh W, Houle S, Waite N. Community pharmacies providing influenza vaccines in Ontario: A descriptive analysis using administrative claims data. CIRN Annual General Meeting, Montréal, QC, May 6–7, 2015. (O)
30. *Waite N, Church D, Johnson S, Raman-Wilms L, Pojskic N, Pearson-Sharpe J, Schneider E, Houle S. Pharmacists’ expanded immunization authority: A regulatory review. CIRN Annual General Meeting, Montréal, QC, May 6–7, 2015.
31. Wenger L, Sergeant O, Schneider E, Pojskic N, Raman-Wilms L, Papastergiou J, Waite NM. Pharmacists as immunizers: Understanding the patient perspective. Ontario Public Health Convention, Toronto, ON, March 25–27, 2015. (O)
32. Kwong J, Cadarette S, Schneider E, Campitelli M, Church D, Consiglio G, Pojskic N, Houle S, Waite N. Community pharmacies providing influenza vaccines in Ontario: A descriptive analysis using administrative data. Ontario Public Health Convention, Toronto, ON, March 25–27, 2015. (O)
33. *Waite NM. Expanding roles for pharmacists in Canada: Lessons for educators and the profession. Australasian Pharmaceutical Sciences Association 2014 Conference, Brisbane, Australia, December 5–7, 2014. (O — keynote address)
34. *Waite NM. Pharmacists as prescribers: Canadian update. Australasian Pharmaceutical Sciences Association 2014 Conference, Brisbane, Australia, December 5–7, 2014. (O)
35. Church D, Johnson S, Raman-Wilms L, Schneider E, Waite NM. Pharmacy students as immunizers: A scoping review of the literature. 2014 Canadian Immunization Conference, Ottawa, ON, December 2–4, 2014.
36. Wenger L, Sergeant O, Schneider E, Pojskic N, Raman-Wilms L, Papastergiou J, Waite NM. Patient perspectives on pharmacists as immunizers: A scoping review. 2014 Canadian Immunization Conference, Ottawa, ON, December 2–4, 2014. (O)
37. Church D, Johnson S, Raman-Wilms L, Pojskic N, Schneider E, Houle S, Waite N. Pharmacists’ expanded immunization authority: A global regulatory review. 2014 Canadian Immunization Conference, Ottawa, ON, December 2–4, 2014.
38. Church D, Waite N, Schneider E, Houle S, Pearson-Sharpe J, Pojskic N. Expanding pharmacists’ immunization authority in Ontario: A jurisdictional and scoping review. Canadian Association for Population Therapeutics: 2014 Annual Conference, Toronto, ON, November 2–4, 2014.
Page 303 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
39. Johnson S, Waite N, Schneider E. Pharmacy students-as-immunizers: A scoping and jurisdictional review. Canadian Society for Pharmaceutical Sciences, Montréal, QC, June 10–13, 2014. Sarah Johnson, a fourth-year BScPhm candidate under my supervision as an independent study student, was nominated for GlaxoSmithKline 2014 National Summer Student Research Award for this poster presentation.
40. Killeen R, Waite N, Schneider E. Developing a recognition of prior learning (RPL) process for implementation in a PharmD bridging program. Canadian Pharmacists Conference 2014 / Association of Faculties of Pharmacy of Canada Annual General Meeting, Saskatoon, SK, May 31–June 3, 2014.
41. *Chang F, Cook KM, Cooke M, McCarthy L, Sproule B, Waite N. Developing and implementing more inclusive demographic survey questions. Canadian Pharmacists Conference 2014 / Association of Faculties of Pharmacy of Canada Annual General Meeting, Saskatoon, SK, May 31–June 3, 2014. (O)
42. *Sergeant O, Wenger L, Schneider E, Waite N. Patient perspectives on pharmacists as immunizers: A scoping review. Canadian Pharmacists Conference 2014 / Association of Faculties of Pharmacy of Canada Annual General Meeting, Saskatoon, SK, May 31–June 3, 2014. (O)
43. *Johnson S, Waite NM, Schneider E. Pharmacy students as immunizers: Review and policy recommendations. Canadian Pharmacists Conference 2014 / Association of Faculties of Pharmacy of Canada Annual General Meeting, Saskatoon, SK, May 31–June 3, 2014. (O)
44. Winslade NE, Fernandes OA, Vercaigne L, Waite NM, Dillon CM, Pharand CC, Leonard P. Integrating CPSI’s safety competencies into undergraduate health professions programs: A comparison of five Canadian faculties of pharmacy. Canadian Pharmacists Conference 2014 / Association of Faculties of Pharmacy of Canada Annual General Meeting, Saskatoon, SK, May 31–June 3, 2014.
45. Dolovich L, Slonim K, MacKeigan L, Patel T, Waite NM, Chang F, Farrell B. Capturing the perspectives of policy makers, physicians and pharmacists about the evaluation of pharmacy services. Trillium Primary Health Care Research Day, Toronto, ON, May 28, 2014.
46. Winslade N, Brown T, Mailhot C, Schindel T, Waite N. National educational outcomes for pharmacy programs in Canada. International Pharmaceutical Federation World Congress, Dublin, Ireland, August 31–September 5, 2013. (O)
Page 304 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
47. Cook K, Waite N. Is university-based community service learning a win-win for academia and the community? The “PHarmacy innovation Garden” as a research case study. CU Expo 2013: Engaging Shared Worlds, Corner Brook, NL, June 12–15, 2013. (O)
48. *Waite NM, Cook KM. Measuring student and community outcomes achieved with the “PHarmacy innovation Garden,” a community service-learning initiative. 4th annual Canadian Pharmacy Education and Research Conference and 70th Association of Faculties of Pharmacy of Canada Annual General Meeting, Niagara-on-the-Lake, ON, June 11–13, 2013. (O)
49. Waite N, Agro K, Malian N. Overcoming MedsCheck barriers: Are we there yet? 2013 Canadian Pharmacists Association National Conference and Trade Show, Charlottetown, PEI, June 1–4, 2013. (O)
50. *Waite NM, Cook KM. Achieving a win-win balance with community service-learning: Are we there yet? 2013 Opportunities and New Directions Conference, The Centre for Teaching Excellence, University of Waterloo, Waterloo, ON, April 25, 2013. (O)
51. Trinacty M, Farrell B, Schindel T, Sunstrum L, Dolovich L, Kennie N, Russell G, Waite N, Kak K. Exploration of a primary care listserv specialty network archive using content analysis. Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, ON, February 4, 2013.
52. Farrell B, Trinacty M, Schindel T, Sunstrum L, Dolovich L, Kennie N, Russell G, Waite N, Kak K. Exploration of a primary care pharmacy specialty network listserv archive using content analysis. Annual meeting of the International Pharmaceutical Federation, Amsterdam, Netherlands, October 3–8, 2012. (O)
53. *Waite NM, Tang A, Chase H, Roach R, Schneider E. Implementing a new experiential model — co-operative learning: A four-year success story. American Association of Colleges of Pharmacy Annual Meeting, Kissimmee, FL, July 14–18, 2012.
54. *Schneider E, Waite NM, Beechinor D, Bowles-Jordan J. Longitudinal high stakes fourth year summative clinical assessment. American Association of Colleges of Pharmacy Annual Meeting, Kissimmee, FL, July 14–18, 2012.
55. Patel TV, Lillie E, Roberts-Smith J, Waite NM. Investigating the effectiveness of drama as an engagement learning methodology in an integrated therapeutics course. American Association of Colleges of Pharmacy Annual Meeting, Kissimmee, FL, July 14–18, 2012. Abstract also published in Am J Pharm Educ. 2012; 76 (5): 68–9.
Page 305 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
56. *Waite N, Tang A, Schneider E, Roach R, Fondacaro R, Jarvie P, Chase H. Lessons learned from starting a cooperative education health care program in an economically and professionally challenging environment. World Association of Cooperative Education Conference, Istanbul, Turkey, June 20–22, 2012. (O)
57. *Waite N, Schneider E, Tang A, Farrell B. Tracking student professional outcome achievement while on co-op. World Association for Cooperative Education Conference, Istanbul, Turkey, June 20–22, 2012.
58. Trinacty M, Farrell B, Schindel T, Sunstrum L, Dolovich L, Kennie N, Russell G, Waite N, Kak K. Exploration of a primary care listserv specialty network archive using content analysis. Canadian Pharmacists Association Annual Conference, Whistler, BC, June 2–3, 2012.
59. Waite N, Cook K, Abraham A. A multi-tiered qualitative analysis of pharmacy student learning in a unique community service-learning program. The Centre for Teaching Excellence, University of Waterloo, Waterloo, ON, May 2012.
60. Cook K, Waite N. Unique partnerships in researching and understanding community service-learning in pharmacy education: A brief case study. Canadian Community Psychology Conference, Waterloo, ON, May 2012.
61. Marks P, Jennings B, Farrell B, Sharpe JP, Kennie N, Waite N. Online experiential learning and the real-world transfer: Results from a pharmacy CE Program. Canadian Society for the Study of Higher Education Annual Meeting, Waterloo, ON May 2012.
62. *Waite N, Cook K, Abraham A. Measuring community service student learning: A professional program’s findings. Community-Campus Partnerships for Health’s 15th anniversary conference, Community-Campus Partnerships as a Strategy for Social Justice: Where We’ve Been & Where We Need to Go, Houston, TX, April 18–21, 2012.
63. Farrell B, Ward N, Dolovich L, Jorgenson D, Kennie N, Gubbels A, Jennings B, Marks P, Waite N. Pharmacists ADAPTing to change: The who’s who of the pilot cohort of an e- learning primary health care program. Canadian Pharmacists Association Annual Conference, Montreal, QC, May 28–30, 2011.
64. Farrell B, Ward N, Kennie N, Jorgenson D, Eguale T, Dolovich L, Winslade N, Johnston S, Gubbels A, Waite N. Validating primary health care pharmacist competencies: Checking our aim. Canadian Pharmacists Association Annual Conference, Montreal, QC, May 28– 30, 2011.
Page 306 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
65. *Waite N. Bold and unique approach to community partnerships in pharmacy education. Community-University Partnerships: Bringing Global Perspectives to Local Action, CU Expo 2011, Waterloo, ON, May 10–14, 2011. (O)
66. *Waite N. Two sides of the experiential learning coin: The benefit to students and the community. Community–University Partnerships: Bringing Global Perspectives to Local Action, CU Expo 2011, Waterloo, ON, May 10–14, 2011.
67. Marks P, Jennings B, Waite N, Cook K, Farrell B, Ward N, Dolovich L, Jorgenson D, Kennie N. Towards methodological rigor in qualitative research: A case study. Poster session presented at the Opportunities and New Directions Conference, The Centre for Teaching Excellence, University of Waterloo, Waterloo, ON, April 27–28, 2011.
68. Kennie N, Farrell B, Dolovich L, Ward N, Jorgenson D, Johnston S, Waite N, Eguale T, Gubbels A, Winslade N. Validating primary health care competencies: Checking our aim. Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, Ontario, January 31, 2011.
69. Farrell B, Ward N, Dolovich L, Jorgenson D, Kennie N, Gubbels A, Jennings B, Marks P, Waite N. Pharmacists adapting to change: The who’s who of the pilot cohort of an e- learning primary health care program. Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, Ontario, January 31, 2011.
70. Lillie E, Cadell S, Finch P, Spafford M, Stalker C, Waite N. No teaching hospital, no IPE office to foster collaboration across the region — no problem. Inter-institutional IPE in Waterloo Region, Interprofessional Education Ontario 2011 Conference, Toronto, ON, January 23–25, 2011.
Invited Presentations
1. Can we improve choosing, using and removing medications? Emerging findings from the Ontario Pharmacy Evidence Network (OPEN) Otago University, Dunedin, New Zealand, Nov 2017; Queensland University of Technology Nov 2017; Griffith University – Nathan Campus, Brisbane, Australia Nov 2017; James Cook University, Townsville, Australia Oct 2017.
2. Novel experiential models: The courage to make practice and education needs work together. Griffith University – Gold Coast Campus, Gold Coast, Australia Nov 2017.
Page 307 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
3. Research as a driver for improving practice and health policy: Emerging findings from the Ontario Pharmacy Research Collaboration (OPEN), Social and Administrative Pharmacy Education Conference, Montreal, QC, October 17, 2016.
4. Shot in the Arm: Did we hit our influenza immunization targets?, School of Pharmacy, University of Waterloo Alumni Event, Kitchener, ON, October 1, 2016.
5. Integrating Co-operative Education and Regional Patient Care Rotations: A Novel Approach to Experiential Learning, Canadian Association for Cooperative Education National Conference, Fredericton, NB August 8, 2016.
6. A Prescription for Success: Creating a Safe Environment for Curricular Innovation, Opportunities and New Direction Teaching Conference, Waterloo, ON April 28, 2016.
7. OPEN findings – Update 2016, Canadian Foundation for Pharmacy Gala, April 14, 2016.
8. OPEN: An overview and program milestones, 3rd Bilateral Workshop between Soochow University and the University of Waterloo, Soochow University, Suzhou, China, March 24, 2016.
9. Pharmacists as Immunizers: A Shot in the Arm: Uptake and Outcome of Ontario's Pharmacists-as-Immunizers Policy, 3rd Bilateral Workshop between Soochow University and the University of Waterloo, Soochow University, Suzhou, China, March 24, 2016
10. What does pharmacy practice research tell us about the patient experience? OPEN’s findings. Shoppers Drug Mart. Calgary, Alberta, Ontario, October 4, 2015 (invited conference participant).
11. What does pharmacy practice research tell us about the patient experience? OPEN’s findings. Shoppers Drug Mart. Toronto, Ontario, October 4, 2015 (invited conference participant).
12. Survey of public and pharmacists regarding influenza vaccination uptake at community pharmacies: What the data show. Vaccine Acceptance and Uptake Task Group. Public Health Agency of Canada, July 15, 2015 (invited participant).
13. Ontario College of Pharmacists. Council Meeting. Ontario Pharmacy Research Collaboration: Overview and selected research findings + OCP Professorship report. Toronto, ON, June 15, 2015.
Page 308 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
14. Ontario Pharmacy Research Collaboration: Overview and selected research findings. Ontario Pharmacists Association Annual General Meeting. Ottawa, ON, May 29, 2015 (part of the 2015 Canadian Pharmacists Conference).
15. 2015 Quality Assurance Key Contact Meeting. Ontario Universities Council on Quality Assurance. Ministry of Training, Colleges and Universities. Toronto, ON, April 17, 2015.
16. Protecting Ontario residents from influenza by pharmacist-administered flu vaccine: Evidence of policy change impact. Ministry of Health and Long Term Care. Health Services Research Fund Showcase, February 23, 2015.
17. Expanding roles for pharmacists in Canada — Lessons for educators and the profession. Australasian Pharmaceutical Sciences Association (APSA) 2014 Conference. Queensland University of Technology. Brisbane, Australia, December 5–7, 2014. Keynote address.
18. Pharmacists as prescribers: Canadian update. Australasian Pharmaceutical Sciences Association (APSA) 2014 Conference. Queensland University of Technology. Brisbane, Australia, December 5–7, 2014.
19. The PharmD in Australia/New Zealand — Panel discussion. Australasian Pharmaceutical Sciences Association (APSA) 2014 Conference. Queensland University of Technology. Brisbane, Australia, December 5–7, 2014.
The following oral presentations were made at the Ontario Pharmacy Research Collaboration’s 2014 Summit. (The presenter is in underline.)
11. Waite N, Dolovich L, Cook K, Cooke M, Grindrod K, Jennings B, Sproule B, Marshall S, Wenger L. OPEN collaboration research: Experience and impact. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
12. Chang F, Cook K, Cooke M, McCarthy L, Sproule B, Waite N. Sex- and gender-based analysis in the pharmacy research literature. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
13. McCarthy L, Bojarski E, Grindrod K, Dolovich L, Pojskic N, Waite N. Pharmacists’ authority to renew and adapt prescriptions: Project overview. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
14. Church D, Pojskic N, Schneider E, Houle S, Waite N. Pharmacist immunization authority beyond influenza: A scoping review. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
Page 309 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
15. Johnson S, Church D, Raman-Wilms L, Waite N, Pearson-Sharpe J, Schneider E. Pharmacy students as immunizers: A scoping review of the literature. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
16. Wenger L, Sergeant O, Papastergiou J, Pearson-Sharpe J, Pojskic N, Raman-Wilms L, Schneider E, Waite N. Patient perspectives on pharmacists as immunizers. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
17. Wenger L, Pearson-Sharpe J, Waite N. Bias in pharmacist interactions with patients. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
18. Schneider E, Wenger L, Pojskic N, Raman-Wilms L, Waite N. Pharmacists’ perspectives on pharmacists as immunizers. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
19. Dolovich L, Akram S, Rietkoetter S, Slonim K, Nainifard A, MacKeigan L, Patel T, Waite N, Chang F, Farrell B. Capturing the perspectives of academics, policy makers, physicians and pharmacists about the evaluation of pharmacy — Preliminary results. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
20. Kwong J, Cadarette S, Schneider E, Campitelli M, Church D, Consiglio G, Pojskic N, Houle S, Waite N. Impact of pharmacists on influenza vaccination uptake in Ontario: A descriptive analysis using administrative claims data. OPEN 2014 Summit, Toronto, ON, October 7–8, 2014.
21. Ontario Pharmacy Research Collaboration: Overview and milestones. Ontario Pharmacy Council. Toronto, ON, March 20, 2014.
22. Fostering innovation and evaluating the effectiveness of Ontario pharmacist-led medication management programs. Ontario College of Pharmacists. Toronto, ON, September 20, 2013.
23. Curricular revision: Shifting paradigms and experience from the edge, Teaching/learning retreat. Faculty of Pharmacy, University of Alberta, Edmonton, AB, May 2013.
24. Educational outcomes for Canadian residency programs, Canadian Hospital Residency Board Workshop, Ottawa, ON, February 2013.
25. Integrating teaching into your family health team. Association of Family Health Teams of Ontario Annual Meeting, Toronto, ON, October 2012.
26. Ontario residencies: Accreditation, outcomes and levels. Hospital Pharmacy Residency Forum of Ontario Annual Meeting, Toronto, ON, June 2012. Page 310 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
27. Bold and unique approach to community partnerships in pharmacy education. Community–University Partnerships: Bringing Global Perspectives to Local Action. CU Expo 2011, Waterloo, ON, Canada, May 10–14, 2011.
28. Student practical experiences: To pay or not to pay. Professional Practice Conference, Canadian Society of Hospital Pharmacists, Toronto, ON, February 2011.
29. Leadership pearls. Professional Practice Conference, Canadian Society of Hospital Pharmacists, Toronto, ON, February 2011.
DATE: April 9, 2018
Page 311 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
WETTIG, Shawn David Associate Professor, tenured Member of the Graduate Faculty: yes b) DEGREES:
PhD, Physical Chemistry, University of Saskatchewan, Saskatoon, SK, 2000 BSc, Chemistry and Physics, University of Lethbridge, Lethbridge, AB, 1994 c) EMPLOYMENT HISTORY:
2014- Associate Professor, School of Pharmacy, University of Waterloo 2007-2013 Assistant Professor, School of Pharmacy, University of Waterloo 2002- Research Associate, College of Pharmacy and Nutrition 2007 University of Saskatchewan, Saskatoon, SK 2001- Research Associate, Department of Biochemistry 2004 University of Saskatchewan, Saskatoon, SK 2003 Sessional Lecturer, Department of Biochemistry University of Saskatchewan, Saskatoon, SK 1998- Consultant, Wettig Consulting Services 2000 Saskatoon, SK d) HONOURS: N/A e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
2015- Associate Director (Graduate Studies and Research) – School of Pharmacy, University of Waterloo, 2014- Associate Editor – Journal of Surfactants and Detergents, 2013- Associate Editor – Journal of Pharmacy & Pharmaceutical Sciences 2011-2012 Organizing Committee Member – 19th Annual Symposium on Surfactants in Solution (SIS2012) Journal Reviewing - Currently review approximately 12 articles annually for journals including Phys Chem, Chem Phys, Chem Comm, Langmuir, Thermochimica Acta, Bioconjucate Chem, J. Colloid, Int. Sci, Colloids and Surfaces A, J. Phys. Chem, Soft Matter Grant Reviewing – NSERC Discovery (Evaluation Group 1504) f) GRADUATE SUPERVISIONS:
Completed: 8 MSc, 5 PhD In progress: 2 MSc, 5 PhD Page 312 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
NAME OF STUDENTS supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Status supervision) Project Javed Akbar (MSc), 2008-2010 Stability studies of Completed gemini surfactant liposome delivery systems Barb Dobson (MSc), 2009-2010 Polymeric Completed Nanoparticles for DNA Transfection Chi Hong Sum (MSc), 2011-2014 Development of Completed Endogenous HIV Vaccine Through Gemini Surfactant Mediated Transfection of Linear Mini-Plasmid Vector Posessing a Chimeric Gag-Env Gene Construct Mehrnoosh Bahmani (MSc), 2011-2013 Effect of gemini Completed surfactants on beta- Amyloid aggregation Osama Madkhali (MSc), 2011-2013 Pluronic-based Completed nanoparticles for gene therapy applications Muhammad Shahidul (MSc), 2012-2015 Characterization of Completed Islam counterion effects of gemini surfactants and in vitro studies of transfection efficiency for gene therapy in epithelial ovarian cancer
Page 313 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Taksim Ahmed (MSc), 2013- Langmuir-Blodgett Monolayer Completed 2015 Studies of Mixed Gemini Surfactant – Phospholipid Monolayers for Gene Therapy Applications Robert Henderson (PhD), 2011- AFM and KPFM investigation of Completed 2015 mixed gemini surfactant – lipid monolayers (co-supervised with Physics) Mohamed Chan (MSc) 2014- The effect of a source change for Completed 2016 an Active Pharmaceutical Ingredient (API) or Excipient on the finished Drug Product Lizzie (Haitang) (PhD) 2008- Novel gemini surfactant Completed Wang 2013 nanoparticles for targeted gene therapy application in ovarian cancer Aula al Muslim (PhD), 2011- Dissymmetric gemini surfactants Completed 2017 designed for improved DNA transfection Samantha Shortall (PhD), 2011- Folate-receptor targeted Pluronic In Progress nanoparticles for ovarian cancer gene therapy Gregor Kemper (PhD), 2013- Bone tissue engineering by gene Completed 2017 delivery: a new route for the Joint degree synthesis of non-viral vectors program with the University of Bordeaux) Shannon Callender (PhD), 2013- Development of a Prenatal Soft- In Progress gel George Mekhail (PhD), 2014- Surface decorated Nanocarrier Completed 2017 systems for cancer therapy with (Joint with Ain high targeting efficacy Shams University, Cairo) Osama Madkhali (PhD), 2014- Cationic gelatin based In Progress nanoparticles for gene therapy applications Tranum Kaur (Post doc), Safe DNA plasmid treatment of In Progress
Page 314 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2009-2011 ovarian cancer Jiahao Huang (PhD) 2016- Formulation Development for In Progress Botanical Drugs Scott Gillis (PhD) 2017- Langmuir monolayer studies of In Progress model membranes in the presence of gemini surfactants Mohamed Aborig (MSc) 2017- Gold Nanoparticles for Prostate In Progress Cancer Therapy Gurmeet Lall (MSc) 2017- Langmuir Monolayer studies of In Progress gelatin based gene therapy formulations
g) GRADUATE COURSES: past 7 years, by year
2017 Pharm 605 — Physical Chemistry of Surfactant Systems 2016 Pharm 617 — Formulations 2014 Pharm 605 — Physical Chemistry of Surfactant Systems 2014 Pharm 608A — Selected Topics in Pharmaceutical Sciences: Soft-gelatin Capsules 2013 Pharm 608A — Selected Topics in Pharmaceutical Sciences: Non-viral Gene Delivery for Gene Therapy Applications 2012 Pharm 605 — Physical Chemistry of Surfactant Systems 2011 Pharm 605 — Physical Chemistry of Surfactant Systems 2011 Pharm 604 — Gene Therapy 2009 Pharm 604 — Gene Therapy 2009 Chem 750 — Physical Chemistry of Surfactant Systems h) 1. EXTERNAL RESEARCH FUNDING
Year Source Type* Amount Purpose** Investigator 2016- 2020 NSERC Discovery C $27,000 Research S. Wettig 2015-2016 Ride for Dad, C $105,000 Principal Prostate Cancer Research Investigator: E. Fight Foundation Osei; Co-PIs: S. Wettig, A. Fleck, J. Darko, F. Damian, T. Mutsaers 2013-2016 Erasmus Mundus C €34,600 Principal IDS-FunMat Research Investigator: S. Wettig; Co-PIs: R.
Page 315 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Oda, M-C. Durrieu 2014-2017 MITACS (Accelerate) C $40,000 Research Principal Investigator: S. Wettig; Co-PI: V. Quiquero 2012-2015 Accucaps Industries C $35,000 Research Principal Inc. Investigator: S. Wettig; Co-PI: V. Quiquero 2012-2015 Accucaps Industries C $35,000 Research Principal Inc. Investigator: S. Wettig
2013 ORF C $75,252 Equipment Principal Investigator: P. Nekkar; Co-PI: S. Wettig 2013 CFI – LOF C $75,252 Equipment Principal Investigator: P. Nekkar; Co-PI: S. Wettig 2013 ORF C $187,505 Equipment Principal Investigator: S. Wettig; Co-PIs: L. Jones, Z. Leonenko 2013 CFI – LOF C $187,505 Equipment Principal Investigator: S. Wettig; Co-PIs: L. Jones, Z. Leonenko 2012-2017 Ontario MRI ERA C $38,000 Research Principal Investigator: S. Wettig 2011-2016 NSERC (Discovery) C $21,000 Research Principal investigator: S. Wettig 2008-2009 CIHR (Proof-of- C $150,000 Research Principal Principal Program) investigator: M. Foldvari; Co-PIs: S. Wettig, I. Badea and R. Verrall
Page 316 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
*Type: C-Granting councils; G-Government; F-Foundations; O-Other ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING: 3. Year Source Type* Amount Purpose** Investigator 2007 University of O $200,000 Research Principal Waterloo (Start-up investigator: S. funds) Wettig
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc. i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories Papers in refereed journals ...... 61 Books and/or book chapters ...... 3 Papers in refereed conference proceedings...... 1 Abstracts and/or papers read ...... 34 Invited presentations ...... 11 Patents ...... 5
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Papers in Refereed Journals:
Page 317 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
1. S Nambiara, E Osei, A Fleck, J Darko, AJ Mutsaers, and SD Wettig (2018) Synthesis of curcumin functionalized gold nanoparticles and cytotoxicity studies in human prostate- cancer cell line. Applied Nanoscience DOI: 10.1007/s13204-018-0728-6.
2. SM Shortall and SD Wettig (2018) Cationic Gemini Surfactant–Plasmid Deoxyribonucleic Acid Condensates as a Single Amphiphilic Entity. J. Phys. Chem. B, 122, 194–199.
3. SP Callender, JA Matthews, K Kobernyk, SD Wettig (2017) Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery. International Journal of Pharmaceutics, 526, 425-442.
4. MS Islam, SM Shortall, GM Mekhail, SP Callender, O Madkhali, Z Bharwani, D Ayyash, K Kobernyk, and SD Wettig (2017) Self-assembly, Aggregation, Micellization studies of Cationic Gemini Surfactants associated with Various Counterions. Phys Chem Chem Phys, 17, 10825-10834. COVER ARTICLE
5. A Al Muslim, D Ayyash, SS Gujrala, PPN Rao, and SD Wettig (2017) Synthesis and Characterization of Asymmetrical Gemini Surfactants. Phys Chem Chem Phys, 19, 1953- 1962.
6. TF Moghadama, S Azizian, and SD Wettig (2017) Effect of Spacer Length on the Interfacial Behavior of N,N΄-Bis(dimethylalkyl)-,-Alkanediammonium Dibromide Gemini Surfactants in the Absence and Presence of ZnO Nanoparticles. Journal of Colloid and Interface Science, 486, 204-210.
7. F Damian, M Harati, V Pathak, J Schwartzenhauer, D Durham, V Quiquero, O van Cauwenberghe, SD Wettig (2016) Development of a Discriminating Dissolution Method that Demonstrates In Vitro-In Vivo Correlation for an Immediate Release Soft Gelatin Capsules Containing a BCS Class II Compound. Dissolution Technologies, 23, 6 – 13.
8. GM. Mekhail, AO Kamel, GAS Awad, ND Mortada, RL Rodrigo, PA Spagnuolo, and SD Wettig (2016) Synthesis and evaluation of alendronate-modified gelatin biopolymer as a novel osteotropic nanocarrier for gene therapy. Nanomedicine (Lond.) 11, 2251-2273.
9. T Ahmed, AO Kamel, SD Wettig (2016) Interactions between DNA and Gemini surfactant: impact on gene therapy: part I. Nanomedicine (Lond.) doi:10.2217/nnm.15.203 (2016) (Epub ahead of print).
Page 318 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
10. T Ahmed, AO Kamel, SD Wettig (2016) Interactions between DNA and Gemini surfactant: impact on gene therapy: part II. Nanomedicine (Lond.) doi:10.2217/nnm.15.204 (2016) (Epub ahead of print).
11. CH Sum, N Nafissi, RA Slavcev, and SD Wettig (2015) Physical Characterization of Gemini Surfactant-Based Synthetic Vectors for the Delivery of Linear Covalently Closed (LCC) DNA Ministrings. PLoS ONE 11, e0142875.
12. TF Moghadam, S Azizian, and SD Wettig (2015) Synergistic behaviour of ZnO nanoparticle and gemini surfactants on the dynamic and equilibrium oil/water interfacial tension. Physical Chemistry, Chemical Physics, 17, 7122 – 7129.
13. CH Sum, SD Wettig, R Slavcev (2014) Impact of DNA Vector Topology on Non-Viral Gene Therapeutic Safety and Efficacy. Current Gene Therapy, 4, 309-329 (2014)
14. CH Sum, J Chong, SD Wettig, R Slavcev (2014) Separation and Purification of Linear Covalently Closed (LCC) DNA by Q-Anion Exchange Membrane Chromatography. Journal of Chromatography A, 1339, 214-218.
15. N Nafissi, CH Sum, SD Wettig, R Slavcev (2014) Optimization of a One-Step Heat- Inducible in vivo Mini DNA Vector Production System. PLoS ONE 9, e89345.
16. H Wang, T Kaur, N Tavakoli, JW Joseph, SD Wettig (2013) Transfection and structural properties of phytanyl substituted gemini surfactant-based vectors for gene delivery. Physical Chemistry, Chemical Physics, 15, 20510-20516.
17. S Moghadam, E Saliaj, SD Wettig, C Dong, M Ivanova, JT Huzil, M Foldvari (2013) Effect of Chemical Permeation Enhancers on Stratum Corneum Barrier Lipid Organizational Structure and Interferon Alpha Permeability. Molecular Pharmaceutics, 10, 2248-2260.
18. T Kaur, T, N Nafissi, O Wasfi, K Sheldon, SD Wettig, and RA Slavcev (2012) Immunocompatibility of Bacteriophages as Nanomedicines. Journal of Nanotechnology, 5, 1-13.
19. M Donkuru, SD Wettig, RE Verrall, I Badea, and M Foldvari (2012) Designing pH-sensitive gemini nanoparticles for non-viral gene delivery into keratinocytes. Journal of Materials Chemistry, 22, 6232 – 6244.
20. J Akbar, N Tavakoli, DG Marangoni and SD Wettig (2012) Mixed aggregate formation in gemini surfactant/1,2-dialkyl-sn-glycero-3-phosphoethanolamine systems. Journal of Colloid and Interface Science, 377, 237-243.
Page 319 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Books/Book Chapters
1. Nanomedicine - Gene delivery, imaging and evaluation systems, RA Slavcev, SD Wettig, and Z Zeng, Eds. Springer Nature Publishing Group, New York, NY (2018; in press)
Abstracts/Papers Read
1. T Ahmed, and SD Wettig “Disruption of Model Membranes by Drug Delivery Systems: A Langmuir Monolayer Study” CENIDE-WIN joint workshop on Nano-science and –technology, 19 – 20 June, 2017, Duisburg, Germany
2. O Madkhali and SD Wettig “Understanding the interaction of Gelatin/Pluronic/DNA system with Model Membrane: Langmuir Monolayer Study” 100th Canadian Chemistry Conference and Exhibition, 28 May – 1 June, 2017, Toronto, ON.
3. S Callender and SD Wettig “Microemulsions: A modern day panacea?” 100th Canadian Chemistry Conference and Exhibition, 28 May – 1 June, 2017, Toronto, ON.
4. T Ahmed and SD Wettig “Disruption of Model Membranes by Drug Delivery Systems: A Langmuir Monolayer Study” 100th Canadian Chemistry Conference and Exhibition, 28 May – 1 June, 2017, Toronto, ON.
5. T Ahmed and SD Wettig “Monolayer studies of interactions between gemini surfactants and model cellular membranes” 99th Canadian Chemistry Conference and Exhibition, 5 – 9 June 2016, Halifax, NS.
6. S Callender, SD Wettig “Polysorbate 80 and Cremophor RH 40 as a Novel, Non-ionic Surfactant Pair for Complex, Multi-API Microemulsion Drug Delivery” AAPS 2015 Annual Meeting, 25-29 October, 2015, Orlando FL
7. G Kemper, Lt Plawinski, E Pouget, SD Wettig, R Oda, MC Durrieu “Bioactive Helical Nanomaterials and their Influence on Stem Cell Differentiation” 27th European Conference on Biomaterials, Cracow, Poland, 30 August – 3 September, 2015.
8. S Shortall, SD Wettig “Folate Receptor-Targeted Pluronic Nanoparticles for Ovarian Cancer Gene Therapy” 1st Annual Meeting of the Biophysical Society of Canada, June 17-19, 2015, Toronto, Ontario, Canada.
9. T Ahmed, J Chau, R Henderson, SD Wettig “Characterization of the Novel Gene Transfection Formulations Consist of Gemini Surfactant-DNA Using Langmuir-Blodgett Monolayer Technique: Redefining the Role Helper Lipid” 1st Annual Meeting of the Biophysical Society of Canada, June 17-19, 2015, Waterloo, ON, Canada. Page 320 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
10. S Callender, SD Wettig “Microemulsions as a Unique Tool for Single-Dose, Multi-API Delivery: Emusifying Agent Selection” 1st Annual Biophysical Society of Canada Conference, June 17-19, 2015, Waterloo, ON, Canada.
11. A Al Muslim, SD Wettig “Dissymmetric gemini surfactants and model membranes” 1st Annual Biophysical Society of Canada Conference, June 17-19, 2015, Waterloo, ON, Canada.
12. S Shortall, SD Wettig “Gene Delivery Nanoparticles Targeting Ovarian Cancer using Folic Acid” 18th Annual Canadian Society for Pharmaceutical Sciences/ Canadian Chapter of the Controlled Release Society (CSPS/CC-CRS) Conference 2015, May 26-28, 2015, Toronto, Ontario, Canada.
13. S Callender, SD Wettig ”Polysorbate 80 & Cremophor RH 40 as a Unique, Non-ionic Surfactant Pair for Multi Drug Delivery” 18th Annual Canadian Society for Pharmaceutical Sciences/ Canadian Chapter of the Controlled Release Society (CSPS/CC-CRS) Conference 2015, May 26-28, 2015, Toronto, Ontario, Canada.
14. O Madkhali, SD Wettig “Gemini Surfactant/Pluronic™ Based Vectors for Gene Delivery” AAPS 2014 Annual Meeting, 2-6 November, 2014, San Diego CA
15. A Al Muslim, SD Wettig “Synthesis and Characterization of Dissymmetric Gemini Surfactant Nanoparticles” 97th Canadian Chemistry Conference and Exibition , 1 – 5 June, 2014, Vancouver, BC
16. S Shortall, O Madkhali, SD Wettig “Folate Receptor-Targeted Pluronic Nanoparticles for Ovarian Cancer Gene Therapy” 97th Canadian Chemistry Conference and Exhibition , 1 – 5 June, 2014, Vancouver, BC
17. O Madkhali, SD Wettig “Pluronic-Based Nanoparticles for Gene Therapy Applications” 97th Canadian Chemistry Conference and Exhibition , 1 – 5 June, 2014, Vancouver, BC
18. H Walther, L Subbaraman, SD Wettig, L Jones “ARVO (In Vitro Surface Pressure Measurements of Various Tear Film Lipids” Association for Research in Vision and Ophthalmology, May 2014, Orlando, FA
19. F Damian, J Schwartzenhauer, V Pathak, O Van Cauwenberghe and SD Wettig “Development of a Discriminating Dissolution Method That Demonstrates in Vitro - in Vivo Correlation for an Immediate Release Soft Gelatin Capsules Containing a BCS Class II Compound” AAPS 2013 Annual Meeting, 10-14 November, 2013, San Antonio TX
Page 321 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
20. M Bahmani, SD Wettig “Effect of gemini surfactant on amyloid beta aggregation” CSPS 2013 Annual Meeting, June 11-14, 2013, Vancouver, BC, attendee
21. CH Sum, N Nafissi, RA Slavcev, and SD Wettig “Enhanced gene delivery through gemini surfactant mediated transfection of linear covalently closed (lcc) miniplasmids” 19th International Symposium on Surfactants in Solution, June 24 – 29, 2012, Edmonton, AB Canada
Invited Presentations
1. SD Wettig “Studies in self-assembling drug delivery systems” University of Waterloo School of Pharmacy Seminar Series, 22 September 2017, Waterloo, ON.
2. SD Wettig et al. “Functionalized gold nanoparticles for multi-modal treatment of prostate cancer.” University of Saskatchewan College of Pharmacy and Nutrition Seminar Series, 8 June, 2017, Saskatoon, SK.
3. SD Wettig et al. “Clinical Translation of a gold nanoparticle based radiotherapy for canine prostate cancer treatment” 10th annual ICCI Cancer Research Symposium, 25 May, 2017, Guelph ON.
4. SD Wettig “Monolayer studies of interactions between gemini surfactants and model cellular membranes” 2nd Bilateral Workshop between the University of Bristol and the University of Waterloo, 20 – 24 June 2016, Bristol, UK.
5. SD Wettig “Monolayer studies on model cellular membranes” 3rd Bilateral Workshop between Soochow University and the University of Waterloo, 22 – 24 March 2016, Suzhou, China.
6. SD Wettig “Vison for the Associate Dean of Research & Graduate Affairs” College of Pharmacy and Nutrition, University of Saskatchewan, 14 March 2016, Saskatoon SK
7. J Akbar, N Tavakoli, DG Marangoni and SD Wettig “Surface tension studies of gemini surfactant/DNA/neutral lipid complexes: Implications for DNA transfection” 19th International Symposium on Surfactants in Solution, June 24 – 28, 2012, Edmonton, AB Canada
Patents
Application#: 62/606,229; Date: 15th September 2017 Title: Arterial embolization facilitated multimodal gold nanomaterial for cancer therapy
Page 322 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Inventors: Andre Fleck, Ernest Osei, Shruti Nambiar, Johnson Darko, Shawn Wettig, Anthony Mutsaers, Pierre Fortin
DATE: 6 APR 2018.
Page 323 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
a) NAME:
WONG, William W.L. Assistant Professor, tenure-track Member of the Graduate Faculty: yes
b) DEGREES:
PhD, Computer Science (Pharmacoinformatics), University of Waterloo, ON, 2009 MMath, Computer Science (Database), University of Saskatchewan, 2000 BSc, Computer Science and Statistics, York University, Ontario, Canada, 1999
c) EMPLOYMENT HISTORY:
2016- Assistant Professor, School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, Ontario, Canada 2013- Assistant Professor (status-only), Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
d) HONOURS:
2018 – 2023 Early Researcher Award, Ontario Ministry of Research and Innovation and Science
e) SCHOLARLY AND PROFESSIONAL ACTIVITIES:
Member of the Ontario Health Technology Advisory Committee (OHTAC), Health Quality Ontario (HQO) Member of the pan-Canadian Oncology Drug Review (pCODR) Economic Guidance Panel Member of a recently CIHR funded team grant for Canadian Network on Hepatitis C.
f) GRADUATE SUPEVISIONS: Completed: 0 MSc, 0 PhD In Progress: 1 MSc, 0 PhD
NAME OF STUDENTS: supervised within the past seven years, title of thesis of project, year of first registration and year of completion:
Name of Student Type (years of Title of Thesis or Project Status supervision) Kristina Ellis MSc (2017- ) Towards developing policy model In progress for chimeric antigen receptor T- Page 324 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
cells therapy Feng Tian MSc (2017 - ) Modeling Chronic Hepatitis B In progress Epidemics in Canada Using Agent- based Model Yasmin Saeed PhD (Co-supervision Cross sectional and longitudinal In Progress (University of since 2014) measures of quality of life and in Toronto) utility among patients with University chronic hepatitis C virus of Toronto infection
g) GRADUATE COURSES: past 7 years, by year
2017 PHARM 611, Applied Health Economics and Pharmacoeconomics
h) 1. EXTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** 2018 - Early Researcher G, PI $150,000 Research 2023 Award, Ontario Ministry of Research and Innovation 2018 - CIHR Project C, co-I $ 1,197,225 Research 2021 Grant 2016 - NSERC Discovery C, PI $90,000 Research 2021 Grant 2015 - CIHR National C, co-I $4,500,000 Research 2020 Hepatitis C Collaborative Network 2017 - Canadian Liver F, PI $1,000,000 Research 2020 Foundation Research Partnership 2016-2019 CIHR Team Grant: C, co-I $1,000,000 Research Canada-Latin America- Caribbean Zika Virus Program
Page 325 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
2016-2019 CIHR Project C, PI $470,169 Research Grant
2016 - Heart and Stroke F, co-I $204,600 Research 2019 Foundation of Canada (HSFC) Grants-in-Aid program 2018-2019 CIHR Project C, co-I $100,000 Research Grant
2016-2018 Prostate Cancer F, co-I $425,437 Research Canada Operating Grant 2014-2015 CIHR Operating C, PI $100,000 Research Grant 2011-2013 CIHR Operating C, co-I $133,475 Research Grant
*Type: C-Granting councils; G-Government; F-Foundations; O-Other (eg. Equipment, CFI, ORF, NSERC RTI, External travel grants); PI- principle investigator; co-I- co-investigator ** Purpose: research, travel, publication, etc.
2. INTERNAL RESEARCH FUNDING:
Year Source Type* Amount Purpose** 2016 UW Start up S $115,000 Research
*Type: S – Startup, O-Other (eg. UW RIF, UW SSHRC, Internal travel grants) ** Purpose: research, travel, publication, etc.
i) PUBLICATIONS:
1) Life-time summary (count) according to the following categories:
- books and monographs ...... 0 - edited book and monographs ...... 0 - chapters in books and monographs ...... 0 - refereed journal articles ...... 24 - refereed conference proceedings...... 36 - presentations at conferences ...... 21 Page 326 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
- technical reports ...... 5 - invited/keynote addresses ...... 7 - others (workshops presented) ...... 1
2) Details for past seven (7) years same categories as above: books, chapters in books, papers in refereed journals.
Refereed Journal Articles:
1. Saluja R, Arciero VS, Cheng S, McDonald E, Wong W.W.L., Cheung MC, Chan K.K. (2018). Examining trends in cost and clinical benefit of novel anti-cancer drugs over time. Journal of Oncology Practice, in press.
2. Wong W.W.L., Haines A., Zangneh H., Shah H. (2018) Can we afford not to screen and treat HCV infection in Canada Canadian Liver Journal, in press.
3. Zargar M, McFarlane T, Chan KK, Wong WWL. (2018) Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma in Canada. The Oncologist, v23,2:225-233.
4. Bolotin S, Feld J, Garber G, Wong WWL, Guerra F, Mazzulli T. Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. (2018) PLOS ONE, v13, 1:e0191184.
5. Wong WWL, Erman A, Feld J, Krahn M. Model-Based Projection of Health and Economic Effects of Screening Hepatitis C: Informing on Screening Recommendations in Canada. (2017) CMAJ Open, v5, 3:E662-E672.
6. Erman A, Sathya A, Nam A, Bielecki J, Feld J; Thein HH, Wong WWL, Grootendorst P, Krahn M. Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis. (2017) Journal of Viral Hepatitis, in press
7. Wong W.W.L., Lee K., Singh S., Wells G., Feld J., Krahn M. (2017) Drug therapies for Chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open, v5, 1:E97-E108.
8. Wong W.W.L., Feng Z.Z, Thein H-H. (2016). A parallel sliding region algorithm to make agent-based modeling possible for large-scale simulation: modelling hepatitis C epidemics in Canada. IEEE Journal of Biomedical and Health Informatics, v20,6:1538- 1544.
Page 327 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
9. Sander B., Wong W.W.L., Ormanidhi O., Atkin, K., Murphy, J., Krahn M., and Deeks S. L. (2016). The Cost-Effectiveness of Integrated Cervical Cancer Prevention Strategies in the Ontario Setting – Can We Do Better? Vaccine, in press.
10. Riesco-Martinez M.C., Berry S., Ko Y., Mittmann N., Giotis A., Lien K., Wong W.W.L., and Chan K.K. (2016). Cost effectiveness analysis of the use of EGFR inhibitors for wild type (WT) KRAS unresectable metastatic Colorectal Cancer (mCRC). Journal of Oncology Practice, accepted.
11. Wong W.W.L., Hicks L.K., Tu H-A, Pritchard K.I., Krahn M.D., Feld, J., Chan K.K.. (2015). Hepatitis B Virus Screening before Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer: A Cost-Effectiveness Analysis. Breast Cancer Research and Treatment, v151 3:639-652.
12. Lee E.K, Wong W.W.L., Trudeau M.E., Chan K.K. (2015). Cost-Effectiveness of Prophylactic Granulocyte Colony-Stimulating Factor for Febrile Neutropenia in Breast Cancer Patients Receiving FEC-D. Breast Cancer Research and Treatment, v150 1:169- 180.
13. Wong W.W.L., Tu H-A., Feld, J., Wong, T., Krahn M. (2015). Cost-Effectiveness of Screening Hepatitis C in Canada. Canadian Medical Association Journal (CMAJ), v187, 3:E110.
14. Wijeysundera H., Wong W.W.L., Bennell M., Fremes S. E., Radhakrishnan S., Peterson M., Ko, D.T. (2014). Impact of increasing wait times on the effectiveness of transcatheter aortic-valve replacement (TAVR) in high-risk and inoperable patients with severe aortic disease: a discrete event simulation model. The Canadian Journal of Cardiology, v30 10:1162-1169.
15. Wong W.W.L., Griesman, J., Feng, Z. (2014). Imputing Genotypes Using Regularized Generalized Linear Regression Models. Statistical Applications in Genetics and Molecular Biology, v13 5:519-529.
16. Wong W.W.L., Woo, G., Heathcote J.E., Krahn M. (2013). Disease Burden of Chronic Hepatitis B among Immigrants in Canada. Canadian Journal of Gastroenterology, v27, 3:137-147.
17. Oliverira C., Nguyen V.H., Wijeysundera H., Wong W.W.L., Woo, G., Grootendorst P., Liu P., Krahn M. (2013). Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. CMAJ Open, v1, 2:E83:E90.
Page 328 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
18. Nguyen V.H., Oliverira C., Wijeysundera H., Wong W.W.L., Woo, G., Grootendorst P., Liu P., Krahn M. (2013). Canada's Contribution to Global Research in Cardiovascular Diseases. The Canadian Journal of Cardiology, v29, 6:742-746.
19. Oliverira C., Nguyen V.H., Wijeysundera H., Wong W.W.L., Woo, G., Liu P., Krahn M. (2012). How Much Are We Really Spending? The Estimation of the Expenditures on Cardiovascular Disease Research in Canada. BMC Health Services Research, v12:281.
20. Wong W.W.L. and Burkowski F. J. (2011). Using Kernel Alignment to Select Features of Molecular Descriptors in a QSAR study, IEEE Transactions on Computational Biology and Bioinformatics, v8, 5:1373–1384.
21. Feng Z., Wong W.W.L., Gao X., Schenkel F. (2011). Generalized Genetic Association Study with Samples of related subjects, Annals of applied statistics, v5, 3:2109–2130.
22. Wong W.W.L., Woo, G., Heathcote J.E., Krahn M. (2011). Cost Effectiveness of Screening Immigrants to Canada for Hepatitis B. Liver International, v31, 8:1179–1190.
23. Wong W.W.L. and Burkowski F. J. (2009). Predicting Multiple Binding Modes Using a Kernel Method Based on a Vector Space Model Molecular Descriptor, International Journal of Computational Biology and Drug Design, v2, 1:58–80.
24. Wong W.W.L. and Burkowski F. J. (2009). A Constructive Approach for Discovering New Drug Leads: Using a Kernel Methodology for the Inverse-QSAR Problem, Journal of ChemInformatics, v1:4
Refereed Government Reports
1. Wong W.W.L., Erman A*, Krahn M. (2017). Model-based Projection of Health and Economic Effect of Screening Hepatitis C in Canada: 2016 update. Canadian Task Force on Preventive Health Care, Calgary
2. Wong W.W.L., Lee K., Krahn M. (2016). CADTH THERAPEUTIC REVIEW 8: Pharmacoeconomic Report: Drugs for Chronic Hepatitis C. Canadian Agency for Drugs and Technologies in Health, Ottawa.
3. Wong W.W.L., Pechlivanoglou P., Erman A., Saeed Y., Younis M., Rayad N., Bielecki J., Rac V., Krahn M.. (2015). Treatment for chronic hepatitis B: Systematic Review and Network Meta-Analysis. Ontario Drug Policy Research Network
Page 329 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
4. Wong W.W.L, Khoo E., Deeks S.L., Murphy J. and Sander B.. (2014). The Cost- Effectiveness of Integrated Cervical Cancer Prevention Strategies in Ontario. Canadian Partnership Against Cancer
5. Murphy G., Farah B., Wong W.W.L., Krahn M., Wells G., Chen L., Kelly S., Kaunelis D., Blouin J., Carrie A.. (2014). CADTH THERAPEUTIC REVIEW 7: Scientific Report: Direct Acting Antiviral Agents for Chronic Hepatitis C Genotype 1. Canadian Agency for Drugs and Technologies in Health, Ottawa.
Refereed conference proceedings
1. Wong WWL, Hamadeh A, Feng Z, Krahn M. (2018) Integrating 2017 model-based estimates of hepatitis C virus (HCV) prevalence into the evaluation of HCV screening cost effectiveness. 2018 CADTH Symposium, Halifax, Canada. Conference Abstract
2. Hamadeh A, Feng Z, Krahn M, Wong WWL. (2018) Estimation of Hepatitis C Prevalence in Canada Via a Two- Stage Back-Calculation Algorithm.7th Canadian Symposium On HCV, Toronto, Canada. Conference Abstract
3. Erman A, Wong WWL, Feld J, Grootendorst P, Krahn M. (2018) Identifying patients subgroups who bene t most from immediate vs. delayed treatment for chronic hepatitis C. 2018 Canadian Liver Meeting, Toronto, Canada. Conference Abstract
4. Mendlowitz A, Naimark D, Isaranuwatchai W, Wong WWL, Krahn M. (2018) An economic evaluation of emergency department population-based hepatitis C screening strategies in Canada. 2018 Canadian Liver Meeting, Toronto, Canada. Conference Abstract
5. Saeed Y, Bielecki J, Abrahamyan L, Pechlivanoglou P, Krahn M, Wong WWL. (2018) A meta-analysis of health utilities (preference-based quality of life) in chronic hepatitis C patients. 2018 Canadian Liver Meeting, Toronto, Canada. Conference Abstract
6. Farhang Zangneh H, Wong WWL, Sander B, Bell C, Mumtaz K, Kowgier M, van der Meer A, Cleary S, Janssen H, Chan K, Feld J. (2017) Cost-Effectiveness Analysis of Annual Versus Biannual Ultrasound Surveillance for Hepatocellular Carcinoma in Patients with Hepatitis C Related Cirrhosis after Sustained Viral Response.The 39th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA, U.S.A. Conference Abstract
7. Zargar M, McFarlane T, Chan K, Wong WWL. (2017) Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma in Canada. The 39th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA, U.S.A. Conference Abstract
Page 330 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
8. Mendlowitz A, Naimark D, Wong WWL, Isaranuwatchai W, Krahn M. (2017) Screening for Hepatitis C in the Emergency Department: A Cost-Effectiveness Analysis in Canada. The 39th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA, U.S.A. Conference Abstract
9. Erman A, Hansen T, Bielecki J, Feld J, Krahn M, Wong WWL, Grootendorst P, Thein HH. (2017) Estimation of Fibrosis Progression Rates for Chronic Hepatitis C: Updated Meta- Analysis and Meta-Regression.The 39th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA, U.S.A. Conference Abstract
10. Saeed Y, Phoon A, Wong J, Feld JJ, Wong D, Shah H, Mitsakakis N, Rac V, Ryan W, Bremner K, Krahn M, Wong WWL. (2017) Patient-Borne Costs Associated with Chronic Hepatitis C.The 39th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA, U.S.A, Pittsburgh, United States. Conference Abstract
11. Hamadeh A, Feng Z, Wong WWL. (2017) Estimation of Hepatitis C Prevalence in Canada Via a Two-Stage Back- Calculation Algorithm.The 39th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA, U.S.A, Conference Abstract
12. Wong WWL, Berry SR, Ko Y, Riesco-Martinez M, Chan K. (2017) Cost-effectiveness analysis of the first-line use of biologics for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC) based on primary tumor location.2017 Canadian Centre for Applied Research in Cancer Control (ARCC) Conference, Toronto, Canada. Conference Abstract
13. Saeed Y, Phoon A, Wong J, Feld J, Wong D, Shah H, Mitsakakis N, Rac V, Ryan W, Bremner K, Krahn M, Wong WWL. (2017) Health Utilities in Chronic Hepatitis C Patients With Decompensated Cirrhosis or Hepatocellular Carcinoma.2017 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Ottawa, Canada. Conference Abstract
14. Wong WWL, Erman A, Krahn M. (2017) Model-Based Projection of Health and Economic Effects of Screening Hepatitis C: Informing on Screening Recommendations in Canada.2017 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Ottawa, ON, Canada., Conference Abstract
15. Wong WWL, Lee KM, Singh S, Krahn M. (2016) Cost-Effectiveness Analysis of Drugs for Chronic Hepatitis C Infection: Informing on Listing Decisions in Canada. The 38th Annual Meeting of the Society for Medical Decision Making, Vancouver, Canada. Conference Abstract
16. Wong WWL. (2016) Is Very Early HTA Possible? A Mathematical Framework of Using Economic Evaluation Models to Influence the Direction of Drug Discovery. The 38th Page 331 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
Annual Meeting of the Society for Medical Decision Making, Vancouver, Canada. Conference Abstract
17. Saeed Y, Fried A, Alhokail M, Feld J, Wong D, Shah H, Bruneau J, Feng Z, Mitsakakis N, Powis J, Rac V, Bremner K, Krahn M, and Wong WWL. (2016) Health Utilities In Chronic Hepatitis C Patients With Late-Stage Liver Disease. The 38th Annual Meeting of the Society for Medical Decision Making, Vancouver, Canada. Conference Abstract
18. Saeed Y, Mason K, Chung S, Altenberg J, Powis J, Bruneau J, Feld J, Feng Z, Mitsakakis N, Rac V, Bremner K, Krahn M, Wong WWL.(2016) Socioeconomic Marginalization is Associated with Lower Health Utilities (Quality of Life) in Chronic Hepatitis C Patients. 5th Canadian Symposium on HCV, Montreal, Canada. Conference Abstract
19. Wong WWL, Feng Z, Thein HH. (2015) A parallel sliding region algorithm to make agent- based modeling possible for a large-scale simulation: modeling hepatitis C epidemics in Canada. The 5th International Conference on Infectious Disease Dynamics, Clearwater Beach, United States. Conference Abstract
20. Zangneh H.F., Wong W.W.L., Sander B., Bell C.M., Mumtaz K., Kowgier M., Janssen H.L.A., van der Meer A., Cleary S.P., Chan K., Feld J. (2015) Optimal age to start surveillance for hepatocellular carcinoma in patients with HCV-related cirrhosis after sustained virological response. American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting, San Francisco, United States. Conference Abstract
21. Saeed Y, Mason K, Chung S, Altenberg J, Powis J, Bruneau J, Feld J, Feng Z, Mitsakakis N, Rac V, Bremner K, Krahn M, Wong WWL.(2015) Health utilities in marginalized chronic hepatitis C patients participating in a community-based hepatitis C program. The 37th Annual Meeting of the Society for Medical Decision Making, St. Louis, United States. Conference Abstract
22. Wong WWL, Pechlivanoglou P, Erman A, Saeed Y, Younis M, Rayad N, Bielecki J, Rac V, Krahn M. (2015) Current treatment for chronic hepatitis B (CHB): A systematic review and a network meta-analysis. The 37th Annual Meeting of the Society for Medical Decision Making, St. Louis, United States. Conference Abstract
23. Wong W.W.L., Feld, J.,Krahn M. (2015) Cost-effectiveness of a one-time national hepatitis C screening program: impact of a selective drug reimbursement policy. Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Saskatoon, Canada. Conference Abstract
24. Zangneh HF, Wong WWL, Sander B, Mumtaz K, Van der Meer A, Chan K, Feld J. (2015)Cost effectiveness analysis of hepatocellular carcinoma surveillance in patients Page 332 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
with hepatitis C related cirrhosis after sustained virological response. European Association for the Study of the Liver (EASL) Meeting, Vienna, Austria. Conference Abstract
25. Zangneh HF, Wong WWL, Sander B, Mumtaz K, Van der Meer A, Chan K, Feld J. (2015) Cost-effectiveness analysis of hepatocellular carcinoma surveillance in patients with hepatitis C related cirrhosis after sustained virological response. Canadian Association for the Study of the Liver Winter Meeting, Banff, Canada. Conference Abstract
26. Wong W. W. L., Tu H-A., Feld J., Wong T., Krahn M. (2014) Cost-Effectiveness of Screening Hepatitis C in Canada. Drivers of Change: How HTA, Evidence and Policy Affect Perceptions of Value and Health Care Practice. Canadian Association for Population Therapeutics 2014, Toronto, Canada. Conference Abstract
27. Wong W.W.L, Hicks L.K., Tu H-A., Pritchard K.I., Krahn M, Feld J., Chan K.K. (2014) HBV screening before adjuvant chemotherapy in patients with early breast cancer: A cost- effectiveness analysis. American Society of Clinical Oncology (ASCO) Quality Symposium, Boston, United States. Conference Abstract
28. Wong W. W. L., Tu H-A., Feld J., Wong T., Krahn M. (2014) Cost-Effectiveness of Screening Hepatitis C in Canada. The 36th Annual Meeting of the Society for Medical Decision Making, Miami, United States. Conference Abstract
29. Wong W.W.L, Hicks L.K., Tu H-A., Pritchard K.I., Krahn M, Feld J., Chan K.K. (2014) Cost- Effectiveness of Hepatitis B Virus Screening Before Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer. The 36th Annual Meeting of the Society for Medical Decision Making, Miami, United States. Conference Abstract
30. Wijeysundera H, Wong WWL, Bennell M, Fremes SE, Radhakrishnan S, Peterson M, Ko DT. (2013) Impact of increasing wait times on the effectiveness of transcatheter aortic- valve replacement (TAVR) in high-risk and inoperable patients with severe aortic disease: a discrete event simulation model.The 35th Annual Meeting of the Society for Medical Decision Making, Baltimore, United States. Conference Abstract
31. Wong WWL, Tu HA, Chen W, Feld J, Chelak K, Lee K, Krahn M. (2013) The hepatitis C drug pipeline: Collaboration between academic and HTA agency partners to develop an early economic model. The 35th Annual Meeting of the Society for Medical Decision Making, Baltimore, United States. Conference Abstract
32. Pechlivanoglou P, Paulden M, Wong WWL, Bermingham S, Pham B. (2013) Using Projections of Life Expectancy in Economic Decision Making. The 35th Annual Meeting of the Society for Medical Decision Making, Baltimore, United States. Conference Abstract Page 333 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
33. Wong WWL. (2012) A Parallel Sliding Region Algorithm to Make Agent-based Modeling for Large Scale Simulation. The 34th Annual Meeting of the Society for Medical Decision Making, Phoenix, United States. Conference Abstract
34. Wong W.W.L., Thein H., Bayoumi A.M., and Krahn M. (2011) Developing a complex agent network model to predict HIV and HCV incidence in Canada.The 3rd International Conference on Infectious Disease Dynamics, Boston, United States. Conference Abstract
35. Wong W.W.L., Burkowski F.J. (2011) Kernel Alignment Feature Selection for Computational Drug Design. The International Conference on Advances in Probability and Statistics, Hong Kong, Hong Kong. Conference Abstract
36. Wong W.W.L., Thein H., Bayoumi A.M., and Krahn M. (2010) Developing a Complex Agent Network Model to Predict HIV and HCV Incidence in Canada. The 33rd Annual Meeting of the Society for Medical Decision Making, Chicago, United States. Conference Abstract
Presentations at conference
1. 2018, Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Halifax, NS, Canada. “Integrating 2017 model-based estimates of hepatitis C virus (HCV) prevalence into the evaluation of HCV screening cost effectiveness” Oral presentation
2. 2017, Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Ottawa, ON, Canada. “Model-Based Projection of Health and Economic Effects of Screening Hepatitis C: Informing on Screening Recommendations in Canada” Oral presentation
3. 2017, Canadian Centre for Applied Research in Cancer Control (ARCC) Conference, Toronto, ON, Canada. “Cost-effectiveness analysis of the first-line use of biologics for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC) based on primary tumor location” Poster presentation
4. 2016, The 38th Annual Meeting of the Society for Medical Decision Making, Vancouver, Canada. “Is Very Early HTA Possible? A Mathematical Framework of Using Economic Evaluation Models to Influence the Direction of Drug Discovery” Poster presentation
5. 2016, The 38th Annual Meeting of the Society for Medical Decision Making, Vancouver, Canada. “Cost-Effectiveness Analysis of Drugs for Chronic Hepatitis C Infection: Informing on Listing Decisions of Interferon-Free Direct-Acting Antiviral Regimens in Canada” Poster presentation Page 334 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
6. 2015, The 37th Annual Meeting of the Society for Medical Decision Making, St. Louis, MO, U.S.A. “Current treatment for chronic hepatitis B (CHB): A systematic review and a network meta-analysis” Oral Presentation.
7. 2015, Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Saskatoon, SK, Canada. “Cost-effectiveness of a one-time national hepatitis C screening program: impact of a selective drug reimbursement policy” Oral presentation.
8. 2015, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, U.S.A. "HBV screening before adjuvant chemotherapy in patients with early breast cancer: A cost-effectiveness analysis." Poster Presentation.
9. 2014, The 36th Annual Meeting of the Society for Medical Decision Making, Miami, FL, U.S.A. “Cost-Effectiveness of Screening Hepatitis C in Canada.” Poster Presentation.
10. 2014, The 36th Annual Meeting of the Society for Medical Decision Making, Miami, FL, U.S.A. “Cost-Effectiveness of Hepatitis B Virus Screening Before Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer.” Poster Presentation.
11. 2014, American Society of Clinical Oncology (ASCO) Quality Symposium, Boston, MA, U.S.A. "HBV screening before adjuvant chemotherapy in patients with early breast cancer: A cost-effectiveness analysis." Poster Presentation.
12. 2013, The 35th Annual Meeting of the Society for Medical Decision Making, Baltimore, MA, U.S.A. “The hepatitis C drug pipeline: Collaboration between academic and HTA agency partners to develop an early economic model.” Oral presentation.
13. 2012, The 34th Annual Meeting of the Society for Medical Decision Making, Phoenix, AZ, U.S.A. “A Parallel Sliding Region Algorithm to Make Agent-based Modeling for Large Scale Simulation.” Poster presentation.
14. 2011, The International Conference on Advances in Probability and Statistics, Hong Kong, China. “Kernel Alignment Feature Selection for Computational Drug Design.” Oral presentation.
15. 2011, The 3rd International Conference on Infectious Disease Dynamics, Boston, MA, U.S.A. “Developing a complex agent network model to predict HIV and HCV incidence in Canada.” Poster presentation
Page 335 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
16. 2011, The 33rd Annual Meeting of the Society for Medical Decision Making, Chicago, IL, U.S.A. “Developing a Complex Agent Network Model to Predict HIV and HCV Incidence in Canada.” Oral presentation.
17. 2011, The 33rd Annual Meeting of the Society for Medical Decision Making, Chicago, IL, U.S.A. “Disease Burden of Chronic Hepatitis B among Immigrants in Canada.” Poster presentation.
18. 2010, American Association for the Study of Liver Diseases (AASLD) – The liver meeting, Boston, MA, U.S.A. “Cost Effectiveness of Screening Immigrants for Hepatitis B.” Poster presentation.
19. 2010, The 32nd Annual Meeting of the Society for Medical Decision Making, Toronto, ON, Canada. “Cost Effectiveness of Screening Immigrants for Hepatitis B in Canada.” Poster presentation.
20. 2010, International Conference on Statistics and Society, Beijing, China. “Generalized Genetic Association Study with Samples of Related Individuals.” Oral presentation.
21. 2010, Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Halifax, NS, Canada. “Cost Effectiveness of Screening Immigrants to Canada for Hepatitis B.” Poster presentation. invited/keynote addresses
1. 2016, Canadian Task Force on Preventive Health Care Working Group Meeting, Ottawa, ON. “Model-based Projection of Health and Economic Effect of Screening Hepatitis C in Canada” Invited presentation
2. 2015, Canadian Agency for Drugs and Technologies in Health, Canadian Drug Expert Committee Meeting, Ottawa, Ontario, Canada. “Economic evaluation of drugs for chronic hepatitis C” Invited presentation
3. 2015, Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Saskatoon, SK. “Public Policy in the Post-Interferon Era: Can We Afford to Cure Hepatitis C?” Invited presentation
4. 2015, Public Health Agency of Canada Webinar Series, Ottawa, ON. “Cost-effectiveness of Screening for Hepatitis C in Canada” Invited presentation
Page 336 of 337
Curricula Vitae – Master of Pharmacy (Advanced Pharmacy Practice)
5. 2014, Canadian Agency for Drugs and Technologies in Health, Canadian Drug Expert Committee Meeting, Ottawa, Ontario, Canada. “Economic evaluation of direct-acting antiviral therapy for chronic hepatitis C Genotype 1.” Invited presentation
6. 2013, Public Health Agency of Canada: Hepatitis C Virus: Burden and Screening in Canada Workshop, Ottawa, Ontario, Canada. “Cost-Effectiveness of screening hepatitis C in Canada.” Invited presentation.
7. 2013, WHO technical consultation on the use of mathematical modelling for viral hepatitis programme planning, Geneva, Switzerland. “Two potential hepatitis C policy models in Canada.” Invited presentation.
Others (workshops presented)
1. 2017/02, Canadian Agency for Drugs and Technologies in Health (CADTH): An Introduction to Network Meta-Analysis – A Hands-On Workshop, Ottawa, ON.
DATE: April 2018
Page 337 of 337